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Summary 
Cardiovascular diseases (CVDs) including, hypertension, coronary heart disease 
and heart failure are the leading cause of death worldwide. Hypertension, a 
chronic increase in blood pressure above 140/90 mmHg, is the single main 
contributor to deaths due to heart disease and stroke. In the heart, hypertension 
results in adaptive cardiac remodelling, including LV hypertrophy to normalize 
wall stress and maintain cardiac contractile function. However, chronic 
increases in BP results in the development of hypertensive heart disease (HHD). 
HHD describes the maladaptive changes during cardiac remodelling which result 
in reduced systolic and diastolic function and eventually heart failure. This 
includes ventricular dilation due to eccentric hypertrophy, cardiac fibrosis which 
stiffens the ventricular wall and microvascular rarefaction resulting in a 
decrease in coronary blood flow albeit an increase in energy demand. Chronic 
activation of the renin-angiotensin-system (RAS) with its effector peptide 
angiotensin (Ang)II plays a key role in the development of hypertension and the 
maladaptive changes in HHD. Ang II acts via the angiotensin type 1 receptor 
(AT1R) to mediate most of its pathological actions during HHD, including 
stimulation of cardiomyocyte hypertrophy, activation of cardiac fibroblasts and 
increased collagen deposition. The counter-regulatory axis of the RAS which is 
centred on the ACE2/Ang-(1-7)/Mas axis has been demonstrated to counteract 
the pathological actions of Ang II in the heart and vasculature. Ang-(1-7) via the 
Mas receptor prevents Ang II-induced cardiac hypertrophy and fibrosis and 
improves cardiac contractile function in animal models of HHD. In contrast, less 
is known about Ang-(1-9) although evidence has demonstrated that Ang-(1-9) 
also antagonises Ang II and is anti-hypertrophic and anti-fibrotic in animal 
models of acute cardiac remodelling. However, so far it is not well documented 
whether Ang-(1-9) can reverse established cardiac dysfunction and remodelling 
and whether it is beneficial when administered chronically. Therefore, the main 
aim of this thesis was to assess the effects of chronic Ang-(1-9) administration on 
cardiac structure and function in a model of Ang II-induced cardiac remodelling. 
Furthermore, this thesis aimed to investigate novel pathways contributing to the 
pathological remodelling in response to Ang II.   
First, a mouse model of chronic Ang II infusion was established and characterised 
by comparing the structural and functional effects of the infusion of a low and 
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high dose of Ang II after 6 weeks. Echocardiographic measurements 
demonstrated that low dose Ang II infusion resulted in a gradual decline in 
cardiac function while a high dose of Ang II induced acute cardiac contractile 
dysfunction. Both doses equally induced the development of cardiac hypertrophy 
and cardiac fibrosis characterised by an increase in the deposition of collagen I 
and collagen III. Moreover, increases in gene expression of fibrotic and 
hypertrophic markers could be detected following high dose Ang II infusion over 
6 weeks. Following this characterisation, the high dose infusion model was used 
to assess the effects of Ang-(1-9) on cardiac structural and functional 
remodelling in established disease.   
Initially, it was evaluated whether Ang-(1-9) can reverse Ang II-induced cardiac 
disease by administering Ang-(1-9) for 2-4 weeks following an initial 2 week 
infusion of a high dose of Ang II to induce cardiac contractile dysfunction. The 
infusion of Ang-(1-9) for 2 weeks was associated with a significant improvement 
of LV fractional shortening compared to Ang II infusion. However, after 4 weeks 
fractional shortening declined to Ang II levels. Despite the transient 
improvement in cardiac contractile function, Ang-(1-9) did not modulate blood 
pressure, LV hypertrophy or cardiac fibrosis.  
To further investigate the direct cardiac effects of Ang-(1-9), cardiac contractile 
performance in response to Ang-(1-9) was evaluated in the isolated Langendorff-
perfused rat heart. Perfusion of Ang-(1-9) in the paced and spontaneously 
beating rat heart mediated a positive inotropic effect characterised by an 
increase in LV developed pressure, cardiac contractility and relaxation. This was 
in contrast to Ang II and Ang-(1-7). Furthermore, the positive inotropic effect to 
Ang-(1-9) was blocked by the AT1R antagonist losartan and the protein kinase A 
inhibitor H89.  
Next, endothelial-to-mesenchymal transition (EndMT) as a novel pathway that 
may contribute to Ang II-induced cardiac remodelling was assessed in Ang II-
infused mice in vivo and in human coronary artery endothelial cells (HCAEC) in 
vitro. Infusion of Ang II to mice for 2-6 weeks resulted in a significant decrease 
in myocardial capillary density and this was associated with the occurrence of 
dual labelling of endothelial cells for endothelial and mesenchymal markers. In 
vitro stimulation of HCAEC with TGFβ and Ang II revealed that Ang II 
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exacerbated TGF-induced gene expression of mesenchymal markers. This was 
not correlated with any changes in SMAD2 or ERK1/2 phosphorylation with co-
stimulation of TGFβ and Ang II. However, superoxide production was significantly 
increased in HCAEC stimulated with Ang II but not TGFβ.  
Finally, the role of Ang II in microvesicle (MV)-mediated cardiomyocyte 
hypertrophy was investigated. MVs purified from neonatal rat cardiac fibroblasts 
were found to contain detectable Ang II and this was increased by stimulation of 
fibroblasts with Ang II. Treatment of cardiomyocytes with MVs derived from 
Ang II-stimulated fibroblasts induced cardiomyocyte hypertrophy which could be 
blocked by the AT1R antagonist losartan and an inhibitor of MV synthesis and 
release brefeldin A. Furthermore, Ang II was found to be present in MVs isolated 
from serum and plasma of Ang II-infused mice and SHRSP and WKY rats. 
Overall, the findings of this thesis demonstrate for the first time that the actions 
of Ang-(1-9) in cardiac pathology are dependent on its time of administration 
and that Ang-(1-9) can reverse Ang II-induced cardiac contractile dysfunction by 
acting as a positive inotrope. Furthermore, this thesis demonstrates evidence for 
an involvement of EndMT and MV signalling as novel pathways contributing to 
Ang II-induced cardiac fibrosis and hypertrophy, respectively. These findings 
provide incentive to further investigate the therapeutic potential of Ang-(1-9) in 
the treatment of cardiac contractile dysfunction in heart disease, establish the 
importance of novel pathways in Ang II-mediated cardiac remodelling and 
evaluate the significance of the presence of Ang II in plasma-derived MVs.  
Chapter 1 – General Introduction 
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1.1 The heart 
The heart is a two-sided pump that operates in series to distribute blood across 
all organs. The right pump consists of the right atrium (RA) and ventricle (RV) 
which deliver blood into the pulmonary circulation for oxygenation. The 
oxygenated blood then enters the left atrium (LA) and is propelled through the 
systemic circulation via the left ventricle (LV) (the left pump). Cardiac 
contraction is initiated by electrical impulses from specialised cells residing in 
the sinoatrial node located in the RA. In a concerted manner, the impulse then 
travels through the cardiac muscle leading to cardiac contraction (Boulpaep, 
2009). The cardiac muscle is composed of cardiomyocytes, the primary 
contractile cells providing the mechanical force necessary for cardiac 
contraction. Although cardiomyocytes occupy the bulk volume of the entire 
myocardium, they only account for up to one third of the cell population in the 
adult human heart with cells such as fibroblasts, endothelial cells (ECs) and 
vascular smooth muscle cells (VSMC) accounting for the remainder (Vliegen et 
al., 1991). The cell populations in the heart are dynamically regulated by 
environmental factors and differ between species with larger animals proposed 
to have a smaller proportion of cardiomyocytes and a larger number of 
fibroblasts (Banerjee et al., 2007). As such the adult rat heart consists of 27 % 
cardiomyocytes, 63 % fibroblasts and 5 % other cell types (such as ECs and 
VSMCs) (Banerjee et al., 2007) while a recent study has demonstrated that the 
mouse heart contains 32 % cardiomyocytes, 12 % fibroblasts, 55 % ECs and 5% 
VSMCs (Pinto et al., 2016). Cardiac fibroblasts are the main cell type involved in 
the maintenance of the extracellular matrix (ECM) providing a structural 
network ensuring proper cardiac form and function (Souders et al., 2009). ECs 
and VSMCs form the network of coronary blood vessels which ensure adequate 
delivery of nutrients and oxygen to the cardiomyocytes. Due to its vital function 
in maintaining blood flow, oxygen and nutrient supply to all organs within the 
body, cardiovascular diseases (CVDs) with failure of the heart as a pump are 
some of the most common causes of morbidity and mortality. Understanding the 
physiological processes that maintain normal cardiac function and the 
pathophysiological processes contributing to CVDs is essential for developing 
novel therapies to maintain pump function.  
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1.2 Cardiovascular Disease 
In 2012, CVDs including coronary heart disease (CHD), cerebrovascular disease, 
hypertension and heart failure (HF) were the leading cause of death amongst 
non-communicable diseases (NCD) accounting for 46.2 % of all NCD deaths (WHO, 
2014b). Amongst CVDs, hypertension is one of the most common risk factors for 
premature death around the world. It is estimated that complications of 
hypertension accounted for approximately 45 % of deaths due to heart disease 
and stroke (WHO, 2013, WHO, 2014b). 
1.2.1 Hypertension  
Hypertension is defined as repeatedly elevated blood pressure (BP) above 
140/90 mmHg. New guidelines have classified the severity of hypertension into 
stages according to which treatment is administered: pre-hypertensive 
(>120/80 mmHg), Stage 1 (≥140/90 mmHg), Stage 2 (≥160/100 mmHg) and 
severe hypertension (≥180/110 mmHg). People diagnosed with stage 1 or stage 2 
hypertension generally require confirmation of BP via repeat measures and 
ambulatory monitoring before anti-hypertensive treatment is administered while 
patients with severe hypertension receive treatment at the time of presentation 
(Nadella and Howell, 2015). The World Health Organisation estimated that in 
2008 approximately 40 % of people aged over 25 were diagnosed with 
hypertension which was equivalent to approximately 1 billion people worldwide 
(WHO, 2013). World health statistics in 2014 estimated the global prevalence of 
hypertension as 23.4 % in men and 24 % in women (WHO, 2014a). Albeit the 
general notion that CVDs are diseases of high-income countries, hypertension is 
most prevalent in low- and middle-income countries where the risk of death due 
to CVDs is more than double that of high-income countries (WHO, 2014b). The 
prevalence of hypertension increases with age and it has been estimated that 
approximately 90 % of people who are normotensive at the age of 55-65 will 
develop hypertension by the age of 80-85 (Vasan et al., 2002, Burt et al., 1995).  
Hypertension is a multifactorial disease and depending on the underlying cause 
for high BP can be classified either as essential or secondary hypertension 
involving either primary largely unidentified genetic and environmental 
predispositions or secondary identifiable underlying causes. Essential 
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hypertension accounts for approximately 95 % of all cases of hypertension while 
hypertension secondary to other diseases accounts for the remainder. Essential 
hypertension is defined as hypertension of unknown cause and is thought to 
occur as a result of genetic predisposition and environmental factors such as 
obesity, high alcohol or salt intake, smoking, diabetes and aging (Carretero and 
Oparil, 2000). In most cases hypertension can be controlled effectively by non-
pharmacological methods such as changes in lifestyle and pharmacologically by 
anti-hypertensive medication. However, approximately 15-30 % of patients with 
hypertension suffer from resistant hypertension where BP remains uncontrolled 
despite extensive anti-hypertensive therapy (Pimenta and Calhoun, 2012). 
Resistant hypertension is defined as an increased BP above 140/90 mmHg 
despite treatment with at least three anti-hypertensive drugs which normally 
include an angiotensin converting enzyme-inhibitor (ACE-I) or angiotensin type 1 
receptor blocker (ARB) (Section 1.3.5), a calcium channel blocker and a thiazide 
diuretic (Myat et al., 2012). The risk of developing an adverse cardiovascular 
event is doubled in patients with resistant hypertension compared to patients 
with controlled BP highlighting the need for new anti-hypertensive strategies to 
tackle resistant hypertension in the population (Daugherty et al., 2012). Chronic 
elevations in BP lead to progressive development of end organ damage 
predominantly affecting the heart, kidney, brain, blood vessels and the eye and 
may result in severe consequences such as heart and renal failure (Nadella and 
Howell, 2015). In the heart, hypertension predisposes to the development of 
hypertensive heart disease (HHD) which contributes to the progression to HF.  
1.2.2 Hypertensive heart disease 
HHD describes the structural changes in the heart in response to chronic 
increases in BP. Classically, the development of HHD is thought of as the 
thickening of the LV wall and an increase in LV mass resulting in diastolic 
dysfunction. Subsequently, after a series of remodelling events in the heart, the 
LV dilates, ejection fraction (EF) decreases and HF develops (Drazner, 2011). 
However, it is now recognised that concomitant with an increase in LV mass 
during HHD there is a significant degree of cardiac fibrosis and microvascular 
disease resulting in increased cardiac stiffness, diastolic dysfunction and 
decreased coronary blood flow whilst there is an increase in cardiac oxygen 
demand (Frohlich et al., 1992, Frohlich, 1999). The adverse remodelling in 
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response to hypertension is equally influenced by haemodynamic and non-
haemodynamic factors which include genetic influences and neurohormonal 
systems. In particular, the renin-angiotensin-system (RAS) is of special interest 
due to the ability of pharmacological antagonists of the RAS to mediate 
regression of LV hypertrophy in HHD.  
The incidence of LV hypertrophy is directly related to the incidence of 
hypertension although only 15-20 % of hypertensive patients present with LV 
hypertrophy on echocardiographic assessment (Levy et al., 1990). Next to age, 
LV hypertrophy is a strong predictor of adverse cardiovascular outcomes in 
patients with hypertension. The Framingham study has demonstrated that the 
relative risk for development of subsequent CVD was 1.49 and 1.57 for every 
50 g/m increment in LV mass for men and women, respectively (Levy et al., 
1990). The risk of death due to CVD doubled in patients with LV hypertrophy and 
similarly, LV hypertrophy significantly increases the risk of ventricular 
arrhythmias, cerebrovascular disease and sudden death (Levy et al., 1990, 
Verdecchia et al., 2001, Levy et al., 1987). In particular, chronic untreated HHD 
is thought to predispose to the development of HF which may manifest as 
diastolic (congestive) or systolic HF, both of which have been demonstrated in 
advanced models of HHD (Brooks et al., 2010, Regan et al., 2015).  
1.2.3 Heart Failure 
HF is classically described as the inability of the heart to produce an adequate 
cardiac output for the perfusion of peripheral organs and the failure to 
accommodate venous return (Kemp and Conte, 2012). Compensatory 
mechanisms to maintain tissue perfusion include increasing cardiac output via 
the Frank-Starling mechanism, neurohormonal activation to increase mean 
arterial pressure (MAP) and cardiac remodelling to accommodate the increasing 
stresses on the heart. Although initially compensatory, these changes quickly 
become maladaptive and participate in a vicious cycle of worsening HF (Kemp 
and Conte, 2012). HF is associated with a poor prognosis with a 5-year mortality 
rate of approximately 65 % (Jhund et al., 2009). HF can be subdivided into two 
categories, systolic and diastolic HF which affects 60 % and 40 % of patients with 
HF, respectively (Federmann and Hess, 1994). Systolic HF and diastolic HF are 
predominantly distinguished by EF where an EF ≤40 % indicates systolic 
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dysfunction and an EF ›40 % may indicate diastolic dysfunction and describes HF 
patients with preserved EF (Kemp and Conte, 2012). Systolic HF is generally 
caused by the loss of functional myocardium usually seen in ischaemic heart 
disease or after a myocardial infarction (MI). This leads to a reduction in cardiac 
output and general hypoperfusion (Federmann and Hess, 1994). Additionally, due 
to impaired myocardial contraction, there is an increase in ventricular volume 
and LV end diastolic pressure (LVEDP) which in turn increases the pressure in the 
pulmonary capillaries resulting in pulmonary congestion and the typical signs of 
HF (Kemp and Conte, 2012). LV systolic dysfunction may also be a result of 
chronic uncontrolled BP although it has only been observed in late stage HHD 
(Vasan and Levy, 1996). In contrast, hypertension and HHD are a major cause of 
diastolic dysfunction and subsequent diastolic HF and can be found in 90 % of 
patients with LV hypertrophy (Mandinov et al., 2000). In diastolic HF, the passive 
stiffness of the ventricle is significantly increased resulting in impaired 
relaxation and early filling of the ventricle during diastole (Zile et al., 2004). 
This leads to a reduction in LV end diastolic volume with increased LVEDP 
resulting in a decreased stroke volume and decreased cardiac output. 
Additionally, atrial enlargement and impaired atrial contractile function further 
contribute to the reduction in cardiac output in advanced stages of the disease 
(Mandinov et al., 2000).  
1.3 The classical renin-angiotensin-system 
The classical RAS is an important endocrine system involved in the acute 
regulation of BP, renal function, fluid and electrolyte balance. Renin was first 
discovered more than 100 years ago as a heat labile substance in kidney extracts 
that led to a sustained increase in BP (Tigerstedt and Bergman, 1898). It was 
later identified that not renin but a pressor substance other than renin mediated 
acute increases in BP and this lead to the discovery of Angiotensin I (Ang I) and 
Ang II (then called hypertensin) in 1954 (Skeggs et al., 1954). The discovery of 
the enzyme responsible for Ang II formation, ACE, soon thereafter established 
the concept of the RAS as a single system involved in the regulation of BP and 
fluid balance (Skeggs et al., 1956). Since then our understanding of the RAS has 
expanded greatly and it is now recognised that next to its function in BP 
regulation, the RAS participates in numerous other physiological processes 
including digestive, neuronal, sensory, dermal and immune functions (Paul et 
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al., 2006). Next to its physiological actions, extensive research on the RAS and 
its effector Ang II has also documented its involvement in a wide range of 
diseases, particularly CVDs including hypertension, CHD, HF, MI and kidney 
disease (Nicholls and Robertson, 2000). In this aspect, the development of ARBs 
and ACE-I in the 1980s is termed as one of the greatest advances in 
cardiovascular medicine whose impact still persists until today (Ferrario, 2006). 
The classical enzymatic cascade of the endocrine RAS begins with the release of 
renin into the circulation from juxtaglomerular cells triggered in response to a 
decrease in renal perfusion pressure. Renin then cleaves liver-derived 
angiotensinogen to form the decapeptide Ang I which then in turn is cleaved by 
ACE predominantly located in the lung epithelium to form Ang II (Figure 1-1).  
The discovery of RAS components in various tissues, including the heart, kidney 
and brain have led to the characterisation of local tissue-specific RAS that acts 
independently of the endocrine systemic RAS (Paul et al., 2006). In this respect, 
independent Ang II forming systems involving cathepsin G, kallikrein and 
chymase have been described in tissues including the heart, kidney, blood 
vessels and immune cells which are distinct from the renin- and ACE-dependent 
systemic formation of Ang II in the regulation of BP (Urata et al., 1990b, Owen 
and Campbell, 1998, Rykl et al., 2006, Ihara et al., 1999, Sasaguri et al., 1995). 
Thus, for example, in human blood vessels it is estimated that 60 % of the 
generated Ang II is derived via non-ACE pathways and in the human heart, the 
serine protease chymase accounts for up to 80 % of the locally produced Ang II 
(Urata et al., 1990a, Urata et al., 1990b, Okunishi et al., 1993). 
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Figure 1-1. The classical and counter-regulatory RAS. 
In the classical RAS, renin converts angiotensinogen to Ang I which is then further cleaved by ACE to form Ang II. Ang II can then act either on the AT1R or the AT2R. 
In the counter-regulatory axis, ACE2 cleaves Ang I and Ang II to form Ang-(1-9) and Ang-(1-7), respectively. Ang-(1-7) binds the Mas receptor while Ang-(1-9) binds 
the AT2R. Alternative pathways for the production of Ang I, Ang-(1-7) and Ang-(1-9) exist. Ang-(1-7)= angiotensin-(1-7), Ang-(1-9)= angiotensin-(1-9), Ang I= 
angiotensin I, Ang II= angiotensin II, AT1R= angiotensin type 1 receptor, AT2R= angiotensin type 2 receptor, NEP= neprilysin, POP= prolyl endopeptidase, TOP= 
thimet oligopeptidase.
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1.3.1 ACE 
ACE was first isolated in 1956 and was then termed hypertensin converting 
enzyme (Skeggs et al., 1956). ACE is a zinc dipeptidyl carboxypeptidase and 
mediates the formation of Ang II from Ang I by the cleavage of the His-Leu 
dipeptide from the C-terminus. ACE is the major enzyme for the systemic 
conversion of Ang I to Ang II (Urata et al., 1990a), however, unlike renin, ACE is 
not substrate-specific and can cleave other substances such as bradykinin, β-
amyloid and gonadotropin-releasing hormone (Bernstein et al., 2013). Ang II is 
not cleaved further by ACE and acts as a natural inhibitor providing an additional 
regulatory mechanism to maintain adequate Ang II levels (Masuyer et al., 2012). 
In mammals, two distinct isoforms of ACE exist, the somatic tissue ACE (sACE) 
and germinal ACE (gACE) that is solely expressed in male testes. Although 
derived from the same gene, sACE has two active sites while gACE only consists 
of a single active site which is achieved by different promoter activities (Coates, 
2003). sACE is an ectoenzyme and is anchored to the plasma membrane via a C-
terminal transmembrane domain although ACE may also be shed from the plasma 
membrane by the action of secretases (Coates, 2003). ACE mRNA can be 
detected in all major tissues (Rivière et al., 2005); it is however particularly 
abundant in pulmonary ECs, the intestine and renal brush border membranes 
(Fuchs et al., 2008, Rivière et al., 2005). The two catalytic sites in sACE are 
formed by the N- and C-domains which share approximately 55 % sequence 
identity (Bernstein et al., 2013). Importantly, the enzymes differ in the 
substrate specificities. Both domains bind and hydrolyse bradykinin with equal 
efficiencies. Although both domains also bind Ang I with equal affinities, the C-
domain has a 3x higher catalytic activity making it the major site of Ang I 
conversion (Wei et al., 1991).  
1.3.2 Ang II 
Ang II is the octapeptide formed by the cleavage of the terminal His-Leu residues 
from Ang I via ACE. Circulating plasma Ang II levels in humans vary widely, 
ranging between 5-50 pg/mL (Roig et al., 2000, van Kats et al., 1997, Vilas-Boas 
et al., 2009). The half-life of Ang II is estimated to be 30 s, however Ang II can 
be accumulated in tissues such as the heart, kidney and adrenal glands and this 
prolongs its half-life to approximately 15 min due to protection from endothelial 
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proteases (van Kats et al., 1997). Ang II has pleiotropic effects in a variety of 
tissues that concertedly contribute to the physiological regulation of BP. When 
renal perfusion pressure falls, renin is released from the kidney to initiate the 
regulation of BP to normalise renal blood flow. Thus, in the vasculature, Ang II 
causes vasoconstriction of small arteries raising total peripheral resistance. In 
the kidney, Ang II stimulates increased renal sodium re-absorption via the 
release of aldosterone from the adrenal glands. Additionally, the Ang II-induced 
release of anti-diuretic hormone from the pituitary gland stimulates anti-diuresis 
(Kaschina and Unger, 2003). These concerted actions result in an increase in 
blood volume and BP which in turn normalises renal perfusion and decreases 
renin release, restoring homeostasis. In the heart, Ang II increases cardiac 
contractility and heart rate (HR), however, long term stimulation of 
cardiomyocytes by Ang II over days and weeks results in cardiac hypertrophy 
(Masaki et al., 1998, Gusev et al., 2009). Ang II mediates its effects by binding 
to two distinct receptors, the angiotensin type 1 receptor (AT1R) or the 
angiotensin type 2 receptor (AT2R). Both receptors are seven transmembrane G-
protein coupled receptors (GPCRs), however, they differ substantially in their 
signal transduction pathways and physiological outcomes (Sections 1.3.3& 1.3.4). 
Ang II mediates most of its physiological and pathological effects via the AT1R 
while signalling through the AT2R counteracts these responses (Table 1-1). 
 
Table 1-1.Physiological actions of the angiotensin receptors 
AT1R AT2R 
Vasoconstriction Vasodilation 
Salt/water retention Decreased proliferation 
Aldosterone release Apoptosis 
Sympathetic facilitation Natriuresis 
Cell growth/proliferation Cell differentiation 
Stimulation of thirst  
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1.3.3 Angiotensin type 1 receptor 
The AT1R is a 41 kDa seven-transmembrane GPCR located on chromosome 3 in 
humans (Dinh et al., 2001). In contrast, rodents possess two isoforms of the 
AT1R, the AT1R1A and the AT1R1B which are located on chromosome 17 and 2 
respectively and share 94 % sequence homology (Iwai and Inagami, 1992, Lewis 
et al., 1993). The AT1R1A is widely expressed in the kidney, lungs, heart, brain, 
vasculature and liver while the AT1R1B is confined to endocrine organs such as 
the adrenal gland, the pituitary gland and testes (Gasc et al., 1994, Martin et 
al., 1995). Pharmacologically, the two receptors are indistinguishable (Martin et 
al., 1995) and knockout experiments in vivo have demonstrated that the 
receptors may largely be functionally redundant although the AT1R1A is the 
predominant form involved in the regulation of BP (Chen et al., 1997, Ito et al., 
1995). Di-sulphide bridge formation between four cysteine residues in the 
extracellular domain of the receptor is crucial for the tertiary structure of the 
receptor and the transmembrane domain and extracellular loop are important 
for Ang II binding to the receptor (Dinh et al., 2001). The cytoplasmic tail 
contains numerous serine and threonine phosphorylation sites which play an 
important role in the modulation and internalisation of the AT1R. Like many 
other GPCRs, the AT1R is subject to desensitisation following stimulation. This 
process involves the phosphorylation of the AT1R by G protein kinases followed 
by the recruitment of β-arrestins (commonly β-arrestin 1 and β-arrestin 2) and 
the internalisation of the agonist-receptor complex into clathrin coated pits 
(Rajagopal et al., 2010). The AT1R is recycled back to the cell membrane while 
Ang II is targeted to lysosomes (Hein et al., 1997). Uncoupling of the receptor 
from G protein signalling occurs rapidly within seconds to minutes and following 
10 min Ang II stimulation, receptor density may decrease by 50 % before 
reaching a new steady-state (Hein et al., 1997, Guo et al., 2001). Expression of 
the AT1R is under tight regulation by its agonist Ang II and while acute 
stimulation may lead to an increase in AT1R expression, chronic Ang II 
stimulation leads to receptor down-regulation (Ichihara et al., 2001, Lassègue et 
al., 1995, Ichiki et al., 2001). Numerous growth factors and cytokines such as 
epidermal growth factor (EGF), Nitric oxide (NO), mineralocorticoids and low 
density lipoprotein have been shown to affect AT1R expression which may 
contribute to disease processes in various disorders (Kaschina and Unger, 2003).  
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Activation of the AT1R by Ang II results in the activation of signalling cascades 
that are either G protein dependent (Gq/11, Gi and G12/13) or G protein 
independent (Hunyady and Catt, 2006) (Table 1-2). However, as more data 
emerges distinctions between signalling pathways have become blurred 
highlighting the complex inter-related signalling cascades that are activated 
upon AT1R stimulation. Additionally, AT1R signal transduction and the resulting 
physiological and pathological effects have become increasingly complex with 
the characterisation of receptor transactivation cascades and homo- and 
heterodimer formation. In monocytes, Factor XIIIA transglutaminase mediates 
cross-linking of AT1R resulting in enhanced Ang II signal transduction which may 
contribute to atherosclerosis development (AbdAlla et al., 2004). In contrast, 
the formation of heterodimers with the AT2R counteracts Ang II signalling 
through the AT1R (AbdAlla et al., 2001). Heterodimer formation has also been 
reported with the bradykinin B2 receptor which enhanced AT1R G protein 
activation and has been suggested to contribute to hypersensitivity to the 
vasopressor effects of Ang II in various CVDs (AbdAlla et al., 2000). AT1R-β-
adrenergic receptor (βAR) complexes have also been observed and inhibition of 
either receptor with specific antagonists resulted in diminished responsiveness 
of either receptor (Barki-Harrington et al., 2003). Furthermore, in VSMC Ang II 
mediates the transactivation of EGF receptors (EGFR), platelet derived growth 
factor receptor (PDGFR) and Insulin-like growth factor 1 receptor (IGF-1R) and it 
has been demonstrated that their activation is indispensable for Ang II-induced 
VSMC proliferation, hypertrophy and redox-signalling (Kelly et al., 2004, Touyz 
et al., 2003, Bokemeyer et al., 2000, AbdAlla et al., 2005).  
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Table 1-2. AT1R signalling pathways.  
Target Second messenger Pathways Effect References 
PLC IP3, DAG, PKC, Ca
2+ 
MLCK phosphorylation 
Na+/H+ phosphorylation 
PI3K, ERK1/2 
c-fos, c-jun, c-myc, Egr-1 
Vasoconstriction 
Cell proliferation 
Cardiac contractility 
(Liang et al., 2010) 
(Kanaide et al., 2003)  
(Sadoshima and Izumo, 1993b) 
(Mehta and Griendling, 2007) 
(Olson et al., 2008) 
PLD 
phosphatidic acid, DAG, 
PKC,  
Ca2+ mobilisation 
NADPH oxidation 
Activation of tyrosine kinases 
Vasoconstriction 
VSMC proliferation 
Aldosterone secretion 
(Qin et al., 2010) 
(Touyz and Berry, 2002) 
PLA2 
AA, prostaglandins (PGI2, 
PGE2), ThxA2, PGH2 
MAPK activation 
Ca2+ mobilisation 
Vasodilation/Vasoconstriction 
Cell proliferation 
(Dulin et al., 1998) 
(Touyz and Berry, 2002) 
(Griendling et al., 1994) 
Nox (Nox1, Nox2, Nox4) ROS 
NO scavenger 
NFkb, AP1, Nrf2  
p38 MAPK/ERK/JNK  
Inflammation 
Hypertrophy 
(Drummond and Sobey, 2014) 
(Griendling et al., 1994) 
β-arrestins  Src/eNOS/MAPK 
 Blood pressure 
Cardiac contractility 
(Violin et al., 2010) 
(Tohgo et al., 2002) 
Tyrosine kinases (Src, FAK, 
Pyk2 PDGFR, EGFR, IGFR 
 
Ras/Raf/MAPK  
PLC  
Akt/PKB 
p38 MAPK 
Cytoskeletal reorganisation  
Focal adhesion formation  
Cell migration  
Cell proliferation 
(Hunyady and Catt, 2006) 
(Bokemeyer et al., 2000) 
(Kelly et al., 2004) 
Jak/STAT  
c-fos, c-jun, c-myc, Erg-1, 
VL-30 
Cardiac hypertrophy  
Inflammation  
VSMC proliferation 
Angiotensinogen synthesis 
(Marrero et al., 1995) 
(Booz et al., 2002) 
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1.3.4 Angiotensin type 2 receptor 
The AT2R is a 41 kDa seven transmembrane receptor encoded by the Agtr2 gene 
located on the X chromosome both, in humans and rodents (Dinh et al., 2001). 
The receptor binds Ang II with equal affinity to the AT1R (Flores-Muñoz et al., 
2011), however, it only shares 34 % sequence homology with the AT1R and 
belongs to the group of atypical seven transmembrane receptors that 
predominantly signal independently of G proteins (Mukoyama et al., 1993). The 
AT2R is highly expressed during foetal development but expression rapidly 
decreases postnatally and in the adult, AT2R can predominantly be detected in 
the heart, brain, adrenal glands and kidney (Mukoyama et al., 1993, Wang et 
al., 1998). AT2R expression is re-activated during cardiac pathology such as MI, 
HF and atherosclerosis (Nio et al., 1995, Tsutsumi et al., 1998, Sales et al., 
2005). Factors that may contribute to this upregulation are insulin and IGF while 
growth factors such as PDGF and EGF downregulate AT2R expression (Kambayashi 
et al., 1996). Similarly, Ang II negatively regulates AT2R expression (Ouali et al., 
1997). Unlike the AT1R, the AT2R does not get internalised upon agonist binding 
and can demonstrate constitutive activation (Hein et al., 1997, Widdop et al., 
2002). The physiological actions of the AT2R antagonise Ang II signalling through 
the AT1R and as such it has been demonstrated to mediate vasodilation, 
natriuresis, negative inotropic and chronotropic effects (Castro-Chaves et al., 
2008, Kemp et al., 2014, Tsutsumi et al., 1999). The signalling cascades 
activated by the AT2R are diverse but are so far not well understood. Three main 
signalling cascades have been proposed to be activated by the receptor: NO 
release and cyclic guanosine monophosphate (cGMP) formation, phospholipase A2 
(PLA2) stimulation and protein phosphatase activation (Table 1-3). In similarity 
to the AT1R, the AT2R has also been demonstrated to form heterodimers with the 
B2 receptor which modulates phosphoprotein signalling leading to an 
enhancement of NO and cGMP synthesis (Abadir et al., 2006). Heterodimer 
formation with the AT1R inhibits AT1R signalling and decreased heterodimer 
formation correlates with an increase in Ang II sensitivity (AbdAlla et al., 2001). 
Investigations of Ang II binding to the AT2R revealed that Ang II binding is not 
dependent on specific ligand-receptor interactions and the receptor exists in a 
“relaxed” state suggestive of a constitutively active receptor (Miura and Karnik, 
1999). This was confirmed in VSMC and epithelial cells where AT2R expression 
mediated cellular apoptosis independently of Ang II (Miura and Karnik, 2000). 
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Despite the demonstration that activation of the AT2R antagonises the 
pathological signalling of Ang II at the AT1R, the role of the AT2R in CVD remains 
unclear as studies investigating the loss or gain of function of AT2R have 
demonstrated controversial results. Thus, ventricular specific overexpression of 
the AT2R induced dilated cardiomyopathy characterised by a decrease in cardiac 
contractile function, significant chamber dilation and cardiomyocyte 
hypertrophy (Yan et al., 2003). This was found to be due to the chronic 
activation of signalling pathways involved in pathological hypertrophy and HF, 
including protein kinase c (PKC)-α, PKC-β, extracellular signal-regulated kinase 
(ERK)1/2 and p70s6k (Yan et al., 2003). Additionally, isolated cardiomyocytes 
showed a significant depression in fractional shortening (FS) concomitant with a 
decrease in peak Ca2+ amplitude which was accompanied by a significant 
increase in phospholamban (PLB) expression and a decrease in the 
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA)/PLB ratio (Nakayama et al., 
2005). Cardiomyocytes of AT2R overexpressing mice are generally found to be 
larger compared to those of wildtype littermates (Nakayama et al., 2005, Yan et 
al., 2003). In vitro overexpression of the AT2R in neonatal cardiomyocytes using 
adenoviral-mediated gene transfer caused constitutive growth of cardiomyocytes 
in the absence of ligand that was resistant to inhibition by the AT2R antagonist 
PD123319 or the mitogen-activated protein kinase (MAPK) inhibitor PD98059 
(D'Amore et al., 2005). Previously, Senbonmatsu et al. (2003) proposed a novel 
AT2R signalling pathway mediating cardiomyocyte hypertrophy in vivo and in 
vitro (Senbonmatsu et al., 2003). This involves the activation of the 
promyelocytic zinc finger protein by the AT2R which results in the increased 
expression of p85α, phosphoinositide 3-kinase (PI3K) and p70s6k (Senbonmatsu et 
al., 2003). A role for the AT2R in cardiac hypertrophy was also confirmed in 
Agtr2 knockout mice which failed to increase cardiomyocyte size following 
chronic pressure overload and Ang II infusion potentially through a decrease in 
p70s6k (Senbonmatsu et al., 2000, Ichihara et al., 2001). Interestingly, cardiac 
fibrosis was also absent in Agtr2-/Y mice, suggesting a role for the AT2R in 
collagen deposition.  
In contrast, in a different strain of mice with cardiac specific overexpression of 
the AT2R, the AT2R abolished Ang II-induced cardiac fibrosis but not cardiac 
hypertrophy via activation of the bradykinin-NO system (Kurisu et al., 2003). 
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Similarly, lentiviral-mediated overexpression of the AT2R postnatally prevented 
Ang II-mediated increases in ventricular wall thickness and interstitial fibrosis 
while the fibrotic response to aortic banding was exacerbated in Agtr2-/y mice 
(Falcón et al., 2004, Akishita et al., 2000). Similar observations were made in 
the model of MI where deletion of the AT2R exacerbated the progression to HF 
and significantly decreased survival (Adachi et al., 2003) while lentiviral gene 
transfer or moderate transgenic AT2R overexpression prevented HF progression 
post-MI by reducing post-myocardial remodelling and improving contractile 
function in a mechanism involving increased endothelial nitric oxide synthase 
(eNOS) expression and downregulation of NADPH oxidase (Nox) 2 (Metcalfe et 
al., 2004, Xu et al., 2014). Interestingly, in AT2R transgenic mice it was noted 
that the resulting cardiac phenotype was directly related to the degree of 
transgene expression (Xu et al., 2014, Nakayama et al., 2005, Yan et al., 2003). 
Thus, for example, in MI, moderate AT2R expression improved functional 
outcomes while high expression of the transgene worsened recovery (Xu et al., 
2014). Similarly, myocyte contractile dysfunction was worst at the highest level 
of transgene expression (Nakayama et al., 2005). This suggest that the 
contrasting reports on the role of the AT2R in CVD is in part due to the 
experimental approaches to manipulate the AT2R in vivo and highlights that the 
cardiovascular outcome of AT2R activation may be largely governed by its 
relative expression levels in relation to other RAS components.  
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Table 1-3. AT2R signalling pathways 
Target Second messenger Pathways Effect References 
NO/cGMP Bradykinin 
Caspase 3 
NHE3 internalisation 
Na+/H+ exchanger inhibition 
Vasodilation 
Apoptosis 
Blood pressure  
 Natriuresis 
Angiogenesis 
 Contractility 
(Kemp et al., 2014) 
(Castro-Chaves et al., 2008) 
(Munk et al., 2007) 
(Dimmeler et al., 1997) 
(Tsutsumi et al., 1999) 
PLA2 
AA, 11,12-
epoxyeicosatrienoic acid 
Erk, IL-6, NFkb, KCa 
Natriuresis 
Inflammation 
Vasodilation 
(Rompe et al., 2010) 
(Arima et al., 1997) 
Phosphatases MKP-1, PP2A, SHP-1 
ERK, JNK 
BCL-2 dephosphorylation 
Ito inhibition 
 
cell proliferation, 
apoptosis 
APD prolongation 
(Bedecs et al., 1997) 
(Horiuchi et al., 1997) 
(Caballero et al., 2004) 
Gi/o cAMP Akt, eNOS, MKP-1 
endothelial migration/ tube 
formation 
apoptosis 
,fibrosis 
(Benndorf et al., 2003) 
(Yamada et al., 1996) 
(Mifune et al., 2000) 
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1.3.5 ACE inhibitors and angiotensin type 1 receptor blockers 
The first natural ACE-I was isolated in the 1960s from the venom of the Brazilian 
arrowhead viper and this led to the development of synthetic peptides inhibiting 
ACE (Ferreira, 1965). Captopril was the first ACE-I to be introduced in 1981 and 
since then 17 ACE-I were licensed for clinical use (Zaman et al., 2002). In 
contrast, with the release of losartan in 1995, ARBs are one of the newest 
classes of drugs available for the treatment of hypertension and CVDs (Ripley 
and Hirsch, 2010). To date, eight ARBs have been licenced for clinical use, the 
most recent one being azilsartan medoxomil in 2011 (Paulis et al., 2012). ACE-I 
act by binding to the catalytic site of ACE and thereby preventing hydrolysis of 
its substrates. The prevention of Ang I cleavage to form Ang II following acute 
administration of ACE-I significantly reduces the plasma levels of Ang II and 
aldosterone while plasma renin activity and Ang I are increased due to the loss 
of negative feedback (Chen et al., 2010, Juillerat et al., 1990). In contrast, ARBs 
act by blocking the binding of Ang II to the AT1R and thereby prevent 
pathological signalling through the AT1R (Ripley and Hirsch, 2010). Despite 
different modes of action, both drugs mediate their BP lowering activity by 
decreasing vasopressin release, sympathetic activation, total peripheral 
resistance and increasing renal blood flow thereby promoting sodium and water 
excretion (Atlas, 2007).  
Several large clinical trials have demonstrated that ACE-I and ARB therapy 
significantly improves symptoms and cardiac function while dramatically 
reducing morbidity and mortality in patients with hypertension, HF, post-MI 
cardiac dysfunction and CHD (Zaman et al., 2002, Yusuf et al., 2000). Next to 
the haemodynamic alterations, both, ARBs and ACE-I have also been 
demonstrated to mediate regression of LV hypertrophy and cardiac fibrosis in 
animal models of hypertension and small short-term clinical studies (Kim et al., 
1995, Brilla, 2000, Lip, 2001, Schwartzkopff et al., 2000, Boldt et al., 2006, 
Tokuda et al., 2004, Devereux et al., 2004, López et al., 2001, Díez et al., 2002, 
Kawasaki et al., 2007, Kawano et al., 2005a). However, data from large scale 
long-term studies are lacking to identify the physiological relevance of this 
observation. Nevertheless, this suggests that ACE-I and ARB may be beneficial in 
targeting cardiac remodelling in CVD.  
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In recent years, research has focussed on the development of novel ACE-I and 
ARBs. This includes the development of C-selective ACE-I such as lisW-S which 
reduces side effects due to inhibition of bradykinin degradation (Burger et al., 
2014) and ARBs with selective agonism on the AT1R such as TRV120027. 
TRV120027 selectively activates β-arrestin signalling at the AT1R thereby 
increasing cardiac contractile performance and mediating cardioprotection 
(Violin et al., 2010, Kim et al., 2012, Boerrigter et al., 2011, Boerrigter et al., 
2012). Additionally, a novel approach is suggesting to harness the beneficial 
effects of the counter-regulatory RAS in the treatment of CVDs with 
development of AT2R agonists to engage counter-regulatory signalling pathways. 
Compound (C)21 was the first non-peptide agonist synthesised for the AT2R in 
2004 and has been extensively employed to assess the physiological functions of 
the AT2R (Steckelings et al., 2011). Although no clear evidence has been 
published on the anti-hypertensive actions on C21 (Kemp et al., 2014, Bosnyak 
et al., 2010, Rehman et al., 2012) it has been demonstrated to preserve cardiac 
function post-MI by reducing infarct size and prevent adverse cardiac 
remodelling (Kaschina et al., 2008, Lauer et al., 2014). Specifically, C21 has 
been demonstrated to significantly improve cardiac EF, contractility and 
relaxation by preventing cardiac dilatation, the development of severe cardiac 
fibrosis and normalising the expression of markers of inflammation (Lauer et al., 
2014, Kaschina et al., 2008, Rehman et al., 2012). This data highlights C21 and 
the engagement of the AT2R in general as a potential new therapeutic target for 
the treatment of adverse cardiac remodelling. A clinical trial to investigate the 
potential of C21 in pulmonary fibrosis is to get underway this year (Pharma, 
2016) and another AT2R agonist MP-157 developed by a Japanese company is 
currently being tested in a Phase I clinical trial for its safety and tolerability 
(NHS, 2011).  
1.4 Cardiac remodelling in CVD 
1.4.1 Cardiac hypertrophy  
Cardiac hypertrophy is an adaptive mechanism of the heart to compensate for 
increased cardiac wall stress due to increased cardiac workload. It can be 
classed as physiological when it occurs in healthy individuals in response to 
exercise or pregnancy and is not associated with cardiac damage or scarring. In 
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contrast, pathological hypertrophy results, for example, from chronic pressure 
or volume overload and MI. Unlike physiological hypertrophy, pathological 
hypertrophy is associated with the re-expression of foetal genes [e.g. β-myosin 
heavy chain (βMHC), atrial natriuretic peptide (ANP) and brain natriuretic 
peptide (BNP)], alterations in the proteins required for excitation-contraction 
(EC) coupling and changes to the energetic and metabolic state of the cell 
(Kehat and Molkentin, 2010). There are two types of hypertrophy, concentric 
and eccentric hypertrophy (Figure 1-2). Eccentric hypertrophy is usually 
associated with chronic volume overload or ventricular remodelling following MI 
(Chen et al., 2011). It is characterised by an increase in the internal LV diameter 
and concomitant wall thinning. Cardiomyocyte contractile units are assembled in 
series leading to an increase in cell length while cell width remains unchanged 
or decreases. This increases the shortening capacity of cardiomyocytes and helps 
maintain ventricular function (Kehat and Molkentin, 2010). In contrast, 
concentric hypertrophy usually occurs in response to chronic pressure overload 
(Izumiya et al., 2006). Macroscopically, concentric hypertrophy is characterised 
by an increase in LV wall thickness without a change in LV chamber size. 
Microscopically, cardiomyocyte contractile units are assembled in parallel 
leading to a net increase in cell width. Concentric hypertrophy may progress to 
eccentric hypertrophy in the progression towards HF (Kehat and Molkentin, 
2010).  
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Figure 1-2. Patterns of cardiac hypertrophy.  
Concentric hypertrophy is characterised by an increased left ventricular wall thickness without an 
increase in chamber size. Microscopically, cardiomyocytes increase in width by assembly of new 
contractile units in parallel. Eccentric hypertrophy is characterised by dilatation of the heart where 
the internal diameter of the ventricle increases to a greater degree than wall thickness. 
Microscopically, cardiomyocytes assemble new contractile units in series resulting in a greater 
increase in cell length than cell width. 
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1.4.1.1 Molecular mechanisms of cardiomyocyte hypertrophy  
Since cardiomyocytes are terminally differentiated, cardiomyocytes respond to 
hypertrophic stimuli with an increase in protein synthesis which increases cell 
size and the re-expression of foetal genes that adjust cardiomyocyte function to 
the altered workload (Sadoshima and Izumo, 1993a). Broadly, there are two 
types of hypertrophic stimuli, mechanical and neurohormonal factors (e.g. Ang 
II, endothelin-1 [ET-1], growth factors) which induce a spectrum of intracellular 
signalling pathways that either stimulate or inhibit pro-hypertrophic gene 
expression (Figure 1-3). 
Cardiomyocytes directly respond to increased myocardial stretch via an internal 
sensory apparatus. Although not well characterised this is thought to involve cell 
surface β-integrins and its effector kinase focal adhesion kinase (FAK), the β1-
integrin interacting protein melusin and the Z-disc protein muscle LIM protein 
(MLP) which transduce changes in cell stretch to the intracellular cytoskeleton 
and mediate hypertrophic gene expression (Shai et al., 2002, Peng et al., 2006, 
Heineke and Molkentin, 2006, Brancaccio et al., 2003, Knöll et al., 2002). 
Additionally, stretch-induced ion channels have also been suggested to 
participate in the activation of hypertrophic signalling pathways by increasing 
intracellular Ca2+ and activating the sodium hydrogen exchanger (NHE) leading to 
MAPK activation (Tatsukawa et al., 1997, Yamazaki et al., 1998).  
Pro-hypertrophic neurohormonal factors mediate their effects by binding to 
seven-transmembrane GPCRs coupled to the Gq/11 subclass of G proteins. 
Activation of the Gq/11 subunit has been demonstrated to be a necessary event 
for the induction of pathological hypertrophy (Heineke and Molkentin, 2006). 
This subunit couples to the activation of phosphoplipase C (PLC) β which 
mediates the formation of diacylglycerol (DAG) and inositol-1,4,5-trisphosphate 
(IP3) (Heineke and Molkentin, 2006). IP3 mediates the release of Ca2+ from 
internal calcium stores by binding to the IP3 receptor. This has been associated 
with the activation of the calcineurin-nuclear factor of activated T-cells (NFAT) 
pathway and calcium-calmodulin kinase II (CaMKII)-dependent inactivation of 
histone deacetylase (HDAC) II and activation of the transcription factor myocyte 
enhancer factor 2 (MEF-2) (Wu et al., 2006). DAG participates in the activation 
of PKC and especially PKCε has been demonstrated to play a role in pathological 
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cardiac hypertrophy (Dorn and Force, 2005). Additionally, PKC can activate 
protein kinase D (PKD) which phosphorylates HDAC II and results in its nuclear 
export thereby disinhibiting hypertrophic gene expression (Vega et al., 2004).  
The MAPK pathway is a central pathway involved in cardiac hypertrophy (Mutlak 
and Kehat, 2015). MAPK signalling pathways consist of a series of kinases that 
lead to the phosphorylation of the effector kinases p38, ERK1/2 and c-jun N-
terminal kinase (JNK) (Heineke and Molkentin, 2006). ERK1/2 signalling in 
particular has been demonstrated to be important for concentric hypertrophy by 
enhancing transcriptional activation of NFAT, AP-1 and GATA-4 (Sanna et al., 
2005, Bueno et al., 2000). In contrast, overexpression of ERK5 in mice 
precipitated ventricular dilatation and eccentric cardiac remodelling suggesting 
that the type of cardiac hypertrophy is in part regulated by specific MAPK 
activation (Nicol et al., 2001).  
Hypertrophic signalling is counteracted in part by activation of p38, JNK and 
glycogen synthase kinase (GSK)-3β which phosphorylate NFAT and other 
transcription factors and prevent nuclear translocation (Heineke and Molkentin, 
2006). In particular, inhibition of GSK-3β is a convergence point for many 
hypertrophic signalling pathways induced by a variety of stimuli (Dorn and Force, 
2005). Additionally, the natriuretic peptides ANP and BNP are natural inhibitors 
of cardiac hypertrophy and are increased in response to pathological 
hypertrophy in an attempt to counteract detrimental remodelling. ANP and BNP 
bind to natriuretic peptide receptors (NPRs) which are linked to activation of 
guanylyl cyclase and the formation of cGMP. Increases in cGMP have been 
suggested to activate protein kinase G (PKG) 1 which inhibits L-type Ca2+ 
channels thereby blocking calcineurin-dependent activation of NFAT (Barry et 
al., 2008).   
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Figure 1-3. Hypertrophic signalling pathways. 
Cardiac hypertrophy can be induced by a variety of signals at the cell membrane resulting in the 
activation of the nuclear pro-hypertrophic transcription factors MEF-2, NFAT, GATA4 and AP-1. 
This includes G-protein coupled receptors signalling via Gq/11 and Phospholipase C to mediate the 
nuclear export of HDAC disinhibiting MEF-2 transciptional activity. Similarly, AT1R-, receptor 
tyrosine kinase or G-protein mediated activation of the MAP kinase pathway, specifically ERK1/2 
and ERK5 can activate pro-hypertrophic gene expression. Furthermore, cellular stretch may 
activate hypertrophic signalling either indirectly via AT1R activation or directly by increasing 
intracellular calcium and promoting the nuclear localisation of NFAT. Cellular hypertrophy can be 
inhibited by promoting the cytoplasmic retention of transcription factors such as NFAT. This is 
mediated by natriuretic peptide mediated activation of PKG, activation of the MAP kinases JNK or 
p38 and GSK-3β. Especially inhibition of GSK-3β via PKA or PKC is a main convergence point of 
pro- hypertrophic signalling pathways. AP-1= activator protein 1, AT1R= angiotensin type 1 
receptor, CaM= calmodulin, CaMK II= calcium calmodulin kinase II, DAG= Diacylglycerol, ERK= 
extracellular signal regulated kinase, GPCR= G protein coupled receptor, GSK-3β= glycogen 
synthase kinase 3β, HDAC= histone deacetylase, IP3= inositol-1,4,5-trisphosphate, JAK= janus 
kinase, JNK= c-jun N-terminal kinase, MEF-2= myocyte enhancer factor 2, MEK= mitogen-
activated protein kinase, NFAT= nuclear factor of activated T-cells, NPR= Natriuretic peptide 
receptor, PKC= protein kinase C, PKD= protein kinase D, PLC= phospholipase C, RTK= receptor 
tyrosine kinase, STAT= signal transducers and activators of transcription. Red lines with filled circle 
indicate inhibition. Black arrows indicate activation. Adapted from Heineke & Molkentin (2006), 
Dorn & Force(2005) and Shah & Mann (2011). 
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1.4.1.2 Role of Ang II in cardiomyocyte hypertrophy 
Ang II signalling is one of the main mediators of cardiac hypertrophy in CVDs. 
Evidence demonstrates that Ang II mediates a direct pro-hypertrophic effect on 
the heart which is independent of its pressor effect (Gusev et al., 2009). Ang II 
stimulation of cardiomyocytes directly induces early response genes such as c-
fos, c-jun, c-myc and Egr-1 which precede the re-expression of foetal genes such 
as β-MHC, BNP, ANP and skeletal actin within 24 h (Kim et al., 1995). During 
Ang II infusion in vivo, cardiomyocyte hypertrophy is evident in as little as three 
days when hypertension is not yet fully developed highlighting the potent pro-
growth effect of Ang II on cardiomyocytes (Kim et al., 1995). The signalling 
pathways involved in Ang II-induced hypertrophy have been widely studied 
unravelling a complex signalling network that involves the cross-activation of 
various other growth factor pathways including transforming growth factor 
(TGF)β, ET-1, EGF, interleukin (IL)-6 and aldosterone (Figure 1-4). Pro-
hypertrophic signalling pathways activated by Ang II binding to the AT1R include 
Gq mediated activation of PLC, PLD, PLA2 and the subsequent activation of PKC, 
Rho/ Rock, c-Src, MAPKs and Nox (Sadoshima and Izumo, 1993b, Peng et al., 
2016, Nakagami et al., 2003, Aoki et al., 2000, Bendall et al., 2002). 
Additionally, mechanical stretch has also been shown to induce the autocrine 
release of Ang II and ET-1, and it has also been demonstrated that signalling at 
the AT1R can be activated by mechanical stretch in the absence of its ligand 
highlighting that mechanical stretch synergistically induces hypertrophic 
signalling via conventional receptor-mediated pathways and cytoskeletal 
mechanosensors (Zou et al., 2004). 
The dependency for cross-activation of growth factor signalling pathways in Ang 
II-induced cardiac hypertrophy has been demonstrated in TGFβ1 knockout mice 
where chronic Ang II infusion failed to elicit cardiac remodelling and cardiac 
dysfunction observed in wildtype mice (Schultz et al., 2002). Similarly inhibition 
of the TGFβ receptor I (TGFβRI) completely abolished the hypertrophic response 
to Ang II stimulation (Watkins et al., 2012). Ang II stimulates TGFβ mRNA in 
isolated cardiomyocytes and fibroblasts which acts in an autocrine and paracrine 
mechanism to stimulate cardiomyocyte growth by activating TGFβ activated 
kinase 1 (TAK1) (Gray et al., 1998, Everett et al., 1994, Koitabashi et al., 2011). 
Similarly, it has been demonstrated that Ang II stimulates the autocrine and 
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paracrine release of IL-6 from cardiomyocytes and fibroblasts which activates 
the cardiomyocyte Janus kinase/ signal transducers and activators of 
transcription (JAK/STAT) pathway leading to cell growth (Sano et al., 2000b, 
Sano et al., 2000a). Additionally, it has been demonstrated that Ang II 
stimulation induces the release of ET-1 from ECs, fibroblasts and cardiomyocytes 
in a PKC-dependent manner and Ang II-induced protein synthesis can be blocked 
by the addition of an ETA receptor antagonist (Ito et al., 1993). Interestingly, the 
hypertrophic response to Ang II infusion is blunted in mice with endothelial-
specific ET-1 deletion indicating an important paracrine role of non-myocyte 
cells in Ang II induced-hypertrophy (Adiarto et al., 2012). A role for EGFR 
transactivation was demonstrated in a transgenic mouse model expressing an 
AT1R incapable of transactivating EGFR (Zhai et al., 2006). Ang II-induced 
phosphorylation of EGFR failed to induce cardiomyocyte hypertrophy and 
induction of foetal genes via the activation of Erk1/2 and Akt (Zhai et al., 2006, 
Peng et al., 2016). Aldosterone has also been suggested to participate in Ang II-
induced cardiac hypertrophy which is demonstrated by the ability of aldosterone 
antagonists to inhibit cardiomyocyte growth (Matsui et al., 2004). Stimulation of 
cardiomyocytes with aldosterone revealed a potent pro-hypertrophic effect that 
is mediated by the activation of ERK1/2, PKC and JNK (Okoshi et al., 2004).  
Ang II has also been increasingly linked to the induction of oxidative stress via 
the activation of Nox. Reactive oxygen species (ROS) have been demonstrated to 
play a role in Ang II-induced cardiac hypertrophy as induction of the foetal gene 
program can be prevented by antioxidants. In mice with deletion of gp91phox 
(Nox2), Ang II fails to induce cardiac hypertrophy (Byrne et al., 2003, Bendall et 
al., 2002). The activation of Nox by Ang II is likely due to pathways involving 
Rho/Rock and ERK1/2 (Higashi et al., 2003, Nakagami et al., 2003, Laplante et 
al., 2003), however, downstream mechanisms of ROS-mediated induction of 
cardiac hypertrophy need to be elucidated but this is likely to involve Akt and 
nuclear factor (NF)κb activation (Higuchi et al., 2002, Hingtgen et al., 2006). 
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Figure 1-4. Hypertrophic signalling pathways activated by Ang II.  
Ang II mediated cellular hypertrophy is complex and involves the cross-activation of various other 
growth factor pathways. Direct activation of the AT1R by AngII can result in the activation of the 
phospholipase C and D pathways resulting in the release of intracellular Ca2+ and PKC activation 
which in turn activate the early response genes c-fos, c-jun, c-myc and Egr-1. Furthermore, AT1R 
mediated activation of Rho/Rock and increased Nox activity can promote pro-hypertrophic gene 
expression via Akt and NFκb signalling. AT1R activation mediates the cross-activation of the EGFR 
via c-src and promotes the release of IL-6, ET-1, aldosterone and TGFβ which in turn contribute to 
pro-hypertrophic signalling by activation of the JAK/STAT pathway, ERK1/2, JNK and TAK1. α/β-
MHC= α/β myosin heavy chain, ANP= atrial natriuretic peptide, AT1R= angiotensin type 1 receptor, 
BNP= brain natriuretic peptide, DAG= diacylglycerol, EGFR= epidermal growth factor receptor, 
ERK1/2= extracellular signal regulated kinase, ETA= endothelin receptor A, ET-1= endothelin-1, 
IP3= inositol-1,4,5-trisphosphate, JAK/ STAT= janus kinase/ signal transducers and activators of 
transcription, JNK= c-jun N-terminal kinase, MR= mineralocorticoid receptor, NFκB= nuclear factor 
κB, PKC= protein kinase C, PLC= phospholipase C, PLD= phospholipase D, TAK1= TGFβ 
activated kinase 1, TGFβR= TGFβ receptor. 
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1.4.2 Fibrosis 
1.4.2.1 The extracellular matrix and the role of cardiac fibroblasts 
The cardiac ECM comprises approximately 20 % of the total cardiac volume in 
humans and provides a highly organised 3 dimensional network surrounding and 
connecting individual cardiomyocytes (Vliegen et al., 1991, Porter and Turner, 
2009). Its main function is to provide mechanical support for cardiomyocytes and 
assist in the distribution of mechanical forces; however, the ECM has also been 
demonstrated to harbour a variety of growth factors, cytokines and chemokines 
(Souders et al., 2009). The ECM predominantly consists of fibrillar collagens with 
collagen type I (80 %) and type III (10 %) being the most abundant (Brown et al., 
2005). Less abundant ECM molecules include collagen type IV which forms the 
cardiomyocyte basement membrane, collagen type V, type VI, laminin and 
fibronectin. Fibrillar collagens are synthesised as pro-collagens which are 
secreted into the ECM and proteolytically cleaved to remove the N- and C-
terminal domains forming mature collagen which is then incorporated into 
collagen fibrils (Bishop and Laurent, 1995). Type I collagen predominantly forms 
large thick parallel fibres and has a tensile strength as high as steel (Collier et 
al., 2012). In contrast, collagen type III forms thin fibrillar networks with lower 
stiffness and contributes to tissue elasticity (Collier et al., 2012). The 
myocardial collagen network is organised in a hierarchical order containing 1) 
the endomysium, an intricate network of small fibrils surrounding individual 
cardiomyocytes; 2) the perimysium, collagen sheaths surrounding bundles of 
cardiomyocytes and collagen struts that connect individual cardiomyocytes and 
blood vessels; and 3) the epimysium which encapsulates entire muscle bundles 
(Brown et al., 2005). Especially the organisation of the perimysial collagen fibres 
in parallel to the cardiomyocytes serves to prevent overstretching of the 
cardiomyocytes and contributes to the elastic recoil during diastole facilitating 
ventricular filling (Janicki and Brower, 2002). Due to the high tensile strength of 
fibrillar collagen and its close contact with cardiomyocytes, it is thought that 
the collagen network contributes to the maintenance of the size and shape of 
the cardiac chambers and directly impacts cardiac contractile performance 
(Janicki and Brower, 2002). This is exemplified in MI where the near complete 
loss of the collagenous membrane in the scar weakens the scar and makes it 
susceptible to spontaneous rupture as it cannot withstand the increase in 
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pressure during systole (Fang et al., 2008, Heymans et al., 1999). Additionally, a 
clear link has been established between cardiac collagen content and the 
passive stiffness of the heart which thereby impacts on cardiac relaxation and 
diastolic filling (Badenhorst et al., 2003, Kitamura et al., 2001, Jalil et al., 
1989). Maintenance of the ECM is therefore of special significance in CVDs which 
are associated with a dysregulation of ECM homeostasis and may directly 
contribute to disorganisation of cardiac structure and impaired contractile 
function. 
Fibroblasts are the main connective tissue cell found in the heart and are 
responsible for the deposition and maintenance of the cardiac ECM. In the mouse 
heart it has been suggested that fibroblasts constitute approximately 12-26 % of 
the cardiac cell population while in rats this has been demonstrated to be as 
high as 70 % (Banerjee et al., 2007, Pinto et al., 2016). In humans, comparable 
studies are missing, however it has previously been estimated that connective 
tissue cells constitute approximately 70 % of cells within the heart (Vliegen et 
al., 1991). Cardiac fibroblasts are identified by their flat spindle-shaped cell 
morphology and are distinguished from other cell types within the heart by their 
lack of a basement membrane (Souders et al., 2009). In the myocardium, 
fibroblasts are located in the endomysium surrounding cardiomyocytes and are 
organised into three-dimensional networks forming connections with other 
fibroblasts, the ECM and cardiomyocytes (Goldsmith et al., 2004). This 
arrangement allows fibroblasts to contract the endomysial collagen network 
thereby exerting mechanical force on cardiomyocytes (Souders et al., 2009). 
Although fibroblasts have usually been viewed as a homogeneous cell type with 
similar functions in all tissues, it has emerged that fibroblasts form a 
heterogeneous cell population with different phenotypes and functions across 
different tissues (Souders et al., 2009). In the heart, fibroblasts can be primarily 
be identified by their expression of discoid domain receptor 2 (DDR2) and the 
calcium binding protein S100A4 (fibroblast specific protein 1;FSP1) (Goldsmith et 
al., 2004, Strutz et al., 1995).  
The key function of cardiac fibroblasts in the normal heart is the maintenance of 
the ECM and to preserve a tight balance between synthesis and degradation of 
the collagen matrix (Porter and Turner, 2009). In response to stimulation with 
growth factors such as TGFβ and Ang II, fibroblasts increase their synthesis of 
Chapter 1  30 
 
 
fibrillar collagen (Kawano et al., 2000, Leivonen et al., 2005). In contrast, 
matrix degradation is regulated by the expression of matrix metalloproteinases 
(MMPs) and tissue inhibitors of metalloproteinases (TIMPs). Cardiac fibroblasts 
express the collagenases MMP1 and MMP13, the gelatinases MMP2 and MMP9 and 
a membrane-bound MMP which can be activated in response to chemical, 
physical or environmental signals to regulate collagen matrix degradation (Porter 
and Turner, 2009, Stacy et al., 2007). TIMP1 and TIMP2 are primarily expressed 
in cardiac fibroblasts and oppose the actions of MMPs (Min et al., 2004, Porter 
and Turner, 2009). The balance of MMP:TIMP ratio is an important determinant 
of ECM homeostasis and disturbance of this balance during cardiac disease 
contributes to disease progression (Martos et al., 2007, López et al., 2006).  
In addition to its key role in ECM homeostasis, cardiac fibroblasts can actively 
contribute to cardiac electrophysiology. In the myocardium, cardiac fibroblasts 
couple to cardiomyocytes through connexin-43 (Cx-43) and connexin-45 (Cx-45) 
allowing the transduction of electrical signals between the two cells (Goldsmith 
et al., 2004). Although fibroblasts are electrically inactive, they are excellent 
conductors and it has been suggested that fibroblasts form bridges between 
myocytes that would otherwise be separated and thereby synchronise the 
spontaneous activity in distant cardiomyocytes (Gaudesius et al., 2003). This 
may have important implications in CVDs where enhanced coupling between 
fibroblasts and myocytes predisposes to severe cardiac arrhythmias (Miragoli et 
al., 2007).  
1.4.2.2 Mechanisms of cardiac fibrosis 
A hallmark of cardiac remodelling is an alteration in myocardial stiffness which 
has been attributed to cardiac fibrosis (Badenhorst et al., 2003, Jalil et al., 
1989). In animal models an increase in myocardial collagen has been 
demonstrated to contribute to diastolic dysfunction and eventually culminate in 
diastolic HF (Mukherjee and Sen, 1993, Kitamura et al., 2001, Doering et al., 
1988, Westermann et al., 2011). In contrast, the degradation of the collagen 
matrix has been associated with chamber dilatation and progression to systolic 
HF (Martos et al., 2007, Iwanaga et al., 2002, López et al., 2006). Pathological 
fibrosis in patients is characterised by widespread deposition of collagenous ECM 
equally affecting the non-hypertrophic RV and the hypertrophied LV (Berk et al., 
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2007). Fibrotic lesions can either be characterised as scars resulting from 
myocyte necrosis and concomitant reparative (replacement) fibrosis or as 
perivascular and interstitial collagen deposits which present a type of reactive 
fibrosis with the increased deposition of collagen fibres in the myocardium in the 
absence of myocyte necrosis (Weber et al., 1989).  
Perivascular and interstitial fibrosis arises from the transient infiltration of 
leukocytes into the adventitia of coronary arterioles resulting in the activation 
of local myofibroblasts and the deposition of dense collagen fibres around the 
vessel. Myofibroblasts are characterised by the expression of the contractile 
protein α-smooth muscle actin (SMA) which corresponds with the acquisition of a 
proliferative, pro-migratory and secretory phenotype (Porter and Turner, 2009). 
The extensive remodelling eventually ensnares neighbouring cardiomyocytes 
which undergo load-dependent atrophy (Figure 1-5)(Xia et al., 2009).  
Myocyte necrosis in the hypertensive heart is a leading cause of replacement 
fibrosis and scarring resulting in impaired cardiac contractile function and 
diastolic stiffness (Weber et al., 2013). In animal models of hypertension, such 
as the Goldblatt model of renovascular hypertension or Ang II infusion, myocyte 
necrosis occurs acutely and is visible as early as 2 days following hypertensive 
stimulation (Tan et al., 1991, Brilla et al., 1990). In hypertensive hearts, 
cardiomyocyte necrosis occurs as a result of Ca2+ overload due to the persistent 
activation of βAR or other cytotoxic factors such as Ang II, triggering the opening 
of the mitochondrial permeability transition pore and subsequent necrotic cell 
death (Whelan et al., 2010). The rupture of cardiomyocytes and the spillage of 
intracellular contents into the extracellular space releases damage-associated 
molecular patterns which lead to the activation of the innate immune system, 
subsequent infiltration of immune cells, and myofibroblast activation (Figure 
1-5) (Campbell et al., 1995, Zhang et al., 2015). Activated macrophages engulf 
the necrotic myocytes and are a major source of pro-fibrotic mediators such as 
Ang II and TGFβ1 at the sight of injury which mediate the activation of 
fibroblasts to myofibroblasts (Kitazono et al., 1995, Assoian et al., 1987, 
Westermann et al., 2011, Bai et al., 2013).  
In the diseased heart, myofibroblasts are the major cell type involved in the 
turnover of the collagen matrix. Myofibroblasts are important in the normal 
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wound repair process as they contribute to the contraction of the wound edges, 
promote scarring and maintain the integrity of the healing scar (Gabbiani, 2003). 
Once the scar has matured myofibroblasts usually undergo apoptosis, however, 
activated myofibroblasts persist in the remodelled myocardium and fail to 
undergo apoptosis which contributes to progressive cardiac fibrosis and 
transition to HF (Desmoulière et al., 1995, Willems et al., 1994). Myofibroblasts 
contribute to the pro-fibrotic remodelling by an increase in the synthesis and 
deposition of collagen and by altering the turnover of the ECM. In the initial 
stages of cardiac remodelling, increased synthesis of ECM proteins is the 
predominant process leading to fibrotic deposits within the heart (Berk et al., 
2007). In response to TGFβ1, myofibroblasts increase the synthesis of collagen 
type I and III which leads to the de novo deposition of collagens in the ECM 
contributing to scar formation (Wang et al., 2006). Additionally, in later stages 
of remodelling, matrix degradation may occur in response to increased ECM 
synthesis. This is mediated by altering the balance between MMPs and TIMPs 
secreted by myofibroblasts and this may in itself contribute to excess fibrosis by 
activating a cycle of degradation and repair within the myocardium (Berk et al., 
2007). Most importantly, the new collagen matrix differs from the native ECM 
with highly cross-linked collagen I ,as it is deposited in hypertensive hearts, 
being degraded at a slower rate than collagen III favouring the net accumulation 
of a stiffer collagen matrix (Rucklidge et al., 1992). A critical role for MMPs is 
demonstrated in the observation that mice deficient in MMP2 or MMP9 are 
protected against adverse cardiac remodelling following pressure overload 
(Matsusaka et al., 2006, Heymans et al., 2005). Increased circulating MMP2 and 
MMP9 levels have been correlated with deterioration of heart function and the 
transition to HF highlighting the therapeutic potential for altering ECM 
degradation to treat adverse cardiac remodelling (Martos et al., 2007, Iwanaga 
et al., 2002, López et al., 2006).  
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Figure 1-5. Fibrotic remodelling in the hypertensive heart.  
Schematic of the stages of fibrotic remodelling in the heart leading to perivascular/ interstitial and 
replacement fibrosis. Perivascular fibrosis (left) results from the transient infiltration of leukocytes 
into the adventitia and the subsequent activation of resident fibroblasts to myofibroblasts. 
Replacement fibrosis (right) occurs as a result of cardiomyocyte necrosis, the subsequent 
infiltration of macrophages and activation of fibroblasts to myofibroblasts replacing cardiomyocytes 
with collagen fibres. Ang II= angiotensin II, TGFβ= transforming growth factor β.  
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1.4.2.3 Role of Ang II in cardiac fibrosis 
Ang II is one of the main orchestrators of fibrotic signalling in the heart and has 
been demonstrated to induce fibroblast differentiation, proliferation and 
collagen secretion (Porter and Turner, 2009).  
In vivo the fibroproliferative response to Ang II infusion peaks within 2-4 days of 
infusion and correlates with the early occurrence of cardiomyocyte necrosis 
although fibroblast proliferation may persist for up to 2 weeks (Campbell et al., 
1995, McEwan et al., 1998). Activation of fibroblasts to myofibroblasts by Ang II 
occurs rapidly and involves activation of PKC and Nox (Bai et al., 2013) (Figure 
1-6). Additionally, in isolated cardiac fibroblasts Ang II is a potent mitogen and 
mediates an increase in DNA and protein synthesis within 24 h (Schorb et al., 
1993). This is mediated by an increase in AP-1 mediated transcription and 
increased DNA binding activity of c-jun and c-fos heterodimers (Sadoshima and 
Izumo, 1993a, Puri et al., 1995, Crabos et al., 1994). MAPK activity is one of the 
main signalling molecules involved in the increased protein and DNA synthesis in 
response to Ang II (Grohé et al., 1998). Pathways involved in activating the MAPK 
pathway have been shown to involve PLC-mediated activation of PKC, ROS-
mediated activation of PKC and tyrosine kinases and EGFR transactivation 
(Crabos et al., 1994, Olson et al., 2008, Chintalgattu and Katwa, 2009, Seta and 
Sadoshima, 2003). Additionally, Ang II has been demonstrated to mediate 
prepro-ET-1 mRNA synthesis in isolated fibroblasts and ET-1 can act in an 
autocrine manner to increase fibroblast proliferation via the ETA receptor 
(Fujisaki et al., 1995) (Figure 1-6).  
Although the effects of Ang II on fibroblast proliferation and differentiation are 
directly mediated by Ang II signalling in the heart, Ang II-induced ECM expression 
is largely mediated by the autocrine and paracrine release of connective tissue 
growth factor (CTGF) and TGFβ1 (Kupfahl et al., 2000, Che et al., 2008).  
TGFβ1 is the major cytokine mediating tissue fibrosis and directly induces the 
expression of collagen type I and type III by nuclear translocation of 
SMAD2/SMAD3. The TGFβ superfamily consists of over 30 members including the 
TGFβs, BMPs, activins, inhibins, nodal, myostatin, growth/ differentiation 
factors and anti-Müllerian hormone (Leask and Abraham, 2004). TGFβ1, TGFβ2 
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and TGFβ3 are the prototypes of the TGFβ superfamily and play a key role in 
wound healing and fibrotic processes in the adult. TGFβ receptors consist of a 
heteromeric complex consisting of one of seven TGFβ type I (the activator) and 
one of five TGFβ type II receptor (the propagator) (Massagué, 2012). TGFβs 
exclusively binds to the type I receptor TGFBR1 (also known as ALK5) and the 
type II receptor TGFBR2. This results in the phosphorylation of SMAD2/SMAD3 
and their translocation to the nucleus where they activate pro-fibrotic gene 
expression (Figure 1-7). TGFβ-induced ECM expression in fibroblasts is largely 
dependent on the activation of SMAD3 as TGFβ1 fails to induce collagen I 
expression in the absence of SMAD3 (Chen et al., 1999). However, it has been 
demonstrated that TGFβ-induced ECM expression may additionally require the 
activation of p38, ERK1/2 or PKC highlighting the complexity in TGFβ-mediated 
transcriptional responses (Figure 1-7) (Sato et al., 2002, Leivonen et al., 2005, 
Mulsow et al., 2005).  
Stimulation of fibroblasts with Ang II leads to the upregulation of CTGF and TGFβ 
mRNA within 1 h of stimulation which involves EGFR transactivation, RhoA, Nox, 
ERK1/2 and PKC activation leading to c-fos, Egr-1 and AP-1 mediated 
transcription (Kawano et al., 2000, Moriguchi et al., 1999, Tang et al., 2009, 
Rupérez et al., 2003, Che et al., 2008, Iwanciw et al., 2003). Autocrine TGFβ 
signalling in fibroblasts furthermore induces the secretion of tumour necrosis 
factor (TNF)α and IL-6 which synergistically exacerbate Ang II-induced collagen 
secretion (Sarkar et al., 2004). In VSMC, a TGFβ-independent pathway of 
collagen synthesis has also been demonstrated where Ang II mediates the early 
phosphorylation of SMAD2/3 independent of TGFβ signalling (Wang et al., 2006). 
Additionally, Ang II drives excess collagen deposition by modulating collagenase 
activity in the heart. Thus, it has been demonstrated that Ang II decreases the 
activity of MMP-1, MMP-2 and MMP-9 while increasing TIMP-1 thereby leading to 
a net increase in interstitial collagen (Brilla et al., 1994, Min et al., 2004, Stacy 
et al., 2007) (Figure 1-6).  
Next to the effects of Ang II on resident fibroblasts, it has also been 
demonstrated that Ang II can mediate the recruitment of various fibroblast 
precursors from the circulation and the myocardium itself. CD133+ 
hematopoietic progenitor cells were detected in the myocardium within 1 day of 
Ang II infusion preceding the excess deposition of ECM (Sopel et al., 2011). 
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Additionally, CD43+/CD45+ monocytic fibroblasts were detected in hearts from 
Ang II-infused mice (Haudek et al., 2006). The appearance of these cells was 
dependent on monocyte chemoattractant protein (MCP)-1 expression and 
deletion of MCP-1 prevented CD34+/CD45+ fibroblast accumulation and cardiac 
fibrosis in response to Ang II infusion (Haudek et al., 2006). Furthermore, TGFβ 
is a main mediator of endothelial-to-mesenchymal transition (EndMT) during 
which ECs transdifferentiate into mesenchymal cells such as fibroblasts and 
VSMCs (Garside et al., 2013). In the heart this process has been demonstrated to 
contribute up to 30 % of activated fibroblasts in the heart (Zeisberg et al., 
2007b). A role for Ang II is emerging in the process which is addressed in detail in 
Section 5. Overall, this demonstrates the importance of blood-borne and bone-
marrow derived fibroblasts in the pathogenesis of Ang II-induced cardiac fibrosis.  
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Figure 1-6. Fibrotic signalling pathways activated by Ang II in cardiac fibroblasts. 
Activation of the AT1R in cardiac fibroblasts directly mediates fibroblast activation and 
differentiation via the activation of PKC and Nox signalling. In contrast, activation of the 
phospholipase C pathway with the activation of Erk1/2 and PKC results in the activation of early 
response genes (c-fos, c-jun, c-myc, Egr-1) and fibroblast proliferation. Collagen synthesis and 
deposition in response to Ang II signalling is indirectly mediated via the release of TGFβ and CTGF 
mediated by cross-activation of the EGFR, Erk1/2 and early response genes. TGFβ mediates the 
activation of Smad2/3 and thereby directly affects matrix gene expression and cellular fibrosis. 
Alternatively, AT1R signalling can regulate fibrosis via the alteration in the gene expression of 
MMPs and TIMPs in cardiac fibroblasts. AT1R= angiotensin type 1 receptor, CTGF= connective 
tissue growth factor, DAG= diacylglycerol, EGFR= epidermal growth factor receptor, ERK1/2= 
extracellular signal regulated kinase 1/2, ET-1= endothelin 1, IP3= inositol-1,4,5-trisphosphate, 
MMP= matrix metalloproteinase, PKC= protein kinase C, PLC= phospholipase C, TGFβ= 
transforming growth factor β, TIMP= tissue inhibitor of metalloproteinase 1. Broken lines indicate 
incomplete pathway. 
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Figure 1-7. TGFβ signalling pathway for matrix gene synthesis.  
TGFβs are synthesised as inactive precursors bound to latent TGFβ binding protein (LTBP) 
sequestered in the ECM and are activated by proteolytic cleavage of LTBP by MMPs, plasmin or 
thrombospondin-1. Upon binding of TGFβ to the type II receptor, phosphorylation of the type I 
receptor allows phosphorylation of SMAD transcription factors. Once phosphorylated, they form a 
trimeric complex with the common mediator SMAD4 and translocate to the nucleus to activate 
matrix gene expression. SMADs themselves are weak transcriptional activators and form 
complexes with other co-factors such as p300. SMAD signalling is terminated by phosphorylation 
by GSK-3β which targets SMADs for ubiquitination. Inhibitory SMAD7 competes with SMAD4 for 
SMAD2/3 binding and promotes TGFBR1 receptor degradation thereby inducing negative 
feedback. Erk1/2= extracellular signal regulated kinase 1/2, LTBP= latent TGFβ binding potein, 
MEK1= mitogen activated protein kinase 1, MMP= matrix metalloproteinase, PKC= protein kinase 
C, TGFβRI= type I TGFβ receptor, TGFβRII= type II TGFβ receptor, Tsp-1= thrombospondin-1. 
Broken lines indicate incomplete pathway. 
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1.5 The counter-regulatory renin-angiotensin-system 
The discovery of a novel ACE-homologue, ACE2, which can hydrolyse Ang I and 
Ang II to biologically active peptides that can counteract Ang II signalling has 
built the basis for the characterisation of the counter-regulatory axis of the RAS 
(Figure 1-1) (Donoghue et al., 2000, Tipnis et al., 2000). The counter-regulatory 
RAS is predominantly defined by the ACE2/Angiotensin-(1-7)/Mas axis where 
ACE2 mediates the conversion of Ang II to Angiotensin-(1-7) [Ang-(1-7)] which 
binds to Mas to mediate its biological effects. Additionally, ACE2 hydrolyses 
Ang I to form Angiotensin-(1-9) [Ang-(1-9)] which can be further broken down to 
Ang-(1-7) by ACE (Donoghue et al., 2000, Tipnis et al., 2000). Ang-(1-9) has 
recently been demonstrated to be an active peptide and mediate its effects by 
binding to the AT2R (Flores-Muñoz et al., 2011). Ang-(1-9) may also be formed 
from Ang I via the actions of carboxypeptidase A or cathepsin A while 
prolylendopeptidase (POP), neutral endopeptidase (neprilysin, NEP) and thimet 
oligopeptidase (TOP) can convert Ang I directly to Ang-(1-7) (McKinney et al., 
2014).  
Increasing evidence suggests a beneficial role of the counter-regulatory RAS not 
only in curtailing Ang II signalling but also to counteract pathological remodelling 
in a broad range of CVDs (Iwai and Horiuchi, 2009). The discovery of additional 
new Ang II metabolites with biological function forms an increasingly complex 
regulatory network of cardiovascular homeostasis. 
1.5.1 ACE2  
ACE2 was first described in 2000 by two independent research groups (Donoghue 
et al., 2000, Tipnis et al., 2000). ACE2 is a zinc metalloproteinase which shares 
40 % sequence homology with the N- and C- terminal domains of ACE (Tipnis et 
al., 2000). Additionally, ACE2 has a 48 % sequence homology in its cytoplasmic 
and transmembrane domains with the non-catalytic protein collectrin which has 
been demonstrated to play a role in the kidney and pancreas (Lambert et al., 
2008). In humans as well as in rodents, the Ace2 gene is localised on the X 
chromosome (Tipnis et al., 2000). ACE2 has one catalytic domain that functions 
as a carboxypeptidase by cleaving a single carboxyl-residue from its substrates 
and which is insensitive to ACE-I (Donoghue et al., 2000). ACE2 cleaves Ang II to 
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Ang-(1-7) at very high efficiency and to a lesser extent Ang I to Ang-(1-9) despite 
a 5x lower affinity for Ang I than ACE (Rice et al., 2004). Additionally, ACE2 has 
been demonstrated to cleave neurotensin, kinetensin, and des-Arg-bradykinin 
but not bradykinin itself (Donoghue et al., 2000). ACE2 expression is highly 
confined to the heart, kidney and testes and small amounts can be detected in 
the liver and digestive tract (Donoghue et al., 2000, Tipnis et al., 2000, Rivière 
et al., 2005). In the heart, ACE2 expression is mainly found in the ECs of intra-
cardiac vessels, however, expression on cardiomyocytes and fibroblasts 
susceptible to cardiac pathology has also been demonstrated (Donoghue et al., 
2000, Gallagher et al., 2008, Goulter et al., 2004). The high expression of ACE2 
in the heart together with its ability to degrade Ang II and generate Ang-(1-7) 
has been demonstrated to counteract Ang II in the heart and vasculature 
suggesting a crucial role for ACE2 in cardiovascular homeostasis. This is 
confirmed by the observation of severely impaired cardiac contractile function 
in ace2-/- mice that can be rescued by deletion of ACE suggesting a crucial role 
for Ang II imbalance in the pathology of ace2-/- mice (Crackower et al., 2002). 
Further evidence has been presented where lentiviral-mediated overexpression 
of ACE2 in cardiomyocytes prevented cardiac dysfunction and cardiac 
remodelling in the SHRSP and following MI (Der Sarkissian et al., 2008, Díez-
Freire et al., 2006). Interestingly, transgenic or adeno-associated viral-mediated 
cardiomyocyte-specific overexpression of ACE2 has also been demonstrated to 
result in severe cardiac fibrosis, cardiac conduction abnormalities and sudden 
death (Masson et al., 2009, Donoghue et al., 2003). While this may in part be 
due to the artificial increase in ACE2 in cells that usually have low ACE2 levels, 
this suggests that that the role of ACE2 in the heart is complex and likely 
dependent on other factors in the RAS.  
Since ACE2 is found downregulated in many CVDs, a new strategy in the 
development of novel treatments for CVDs suggests that the enhancement of 
ACE2 activity may harbour beneficial effects. This has been approached by the 
use of recombinant human (rh)ACE2 and ACE2 activators. Animal studies with 
rhACE2 demonstrated prevention of adverse remodelling in response to Ang II 
infusion and a partial rescue of cardiac function, reversal of cardiac hypertrophy 
and fibrosis and prevention of ventricular dilatation in a model of pressure-
overload induced HF suggesting therapeutic potential of rhACE2 in CVD (Zhong et 
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al., 2010). The ACE2 activator xanthenone was demonstrated to decrease BP and 
increase cardiac contractility and relaxation and reduce cardiac fibrosis in the 
SHR and streptozotocin-induced diabetic rats equally either via oral 
administration or minipump infusion (Hernández Prada et al., 2008, Murça et 
al., 2012). The beneficial effects of increased ACE2 activity may be due to the 
decrease in plasma Ang II levels and an increase in Ang-(1-7) formation which has 
been observed in plasma and interstitial and perivascular fibroblasts (Lo et al., 
2013, Ferreira et al., 2011) highlighting their therapeutic potential. However, 
little is yet known about ACE2 biology and the safety of these applications. As 
such, infusion of rhACE2 in mice resulted in the formation of antibodies (Wysocki 
et al., 2010) although this was not observed in humans (Haschke et al., 2013). 
Furthermore, it has been demonstrated that xanthenone fails to activate ACE2 in 
vivo and in vitro and that it mediates similar anti-hypertensive effects in ACE2-
null mice (Haber et al., 2014) 
1.5.2 Ang-(1-7) 
Ang-(1-7) is a heptapeptide that is generated by the cleavage of the terminal 
phenylalanine residue from Ang II by ACE2 (McKinney et al., 2014). Ang II 
hydrolysis is the major pathway involved in Ang-(1-7) formation in the human 
heart with an approximate production rate of 2718 pg/mL which can be 
completely abolished by the administration of ACE-I (Zisman et al., 2003). 
Alternatively, Ang-(1-7) may also be produced via hydrolysis of Ang-(1-9) by ACE 
or directly from Ang I via the actions of POP, NEP and TOP (Santos et al., 1992, 
Yamamoto et al., 1992, Pereira et al., 2013). Plasma Ang-(1-7) levels in healthy 
individuals have been estimated to range between 17.1-25.5 pg/mL and these 
may increase up to 3-fold during disease (Vilas-Boas et al., 2009, Yamada et al., 
1998a). The half-life of Ang-(1-7) in the circulation is estimated to be 10 s 
before it is further metabolised to the inactive peptide Ang-(1-5) by ACE 
(Yamada et al., 1998a). Hence, treatment with ACE-I and ARBs can significantly 
increase Ang-(1-7) levels and this property has been suggested to contribute to 
the beneficial effects of ACE-I and ARBs in CVD (Ishiyama et al., 2004). Ang-(1-7) 
signalling antagonises most actions of Ang II in various tissues by inhibiting cell 
proliferation, migration, vasoconstriction and inflammation (Iwai and Horiuchi, 
2009). Originally, it was thought that these effects were mediated through 
angiotensin receptors, however, binding studies demonstrated that Ang-(1-7) has 
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very low binding affinities for the AT1R and AT2R, although at high 
concentrations it shows functional selectivity for the AT2R (Rowe et al., 1995, 
Bosnyak et al., 2011). Using ligand-binding studies, it was demonstrated that the 
orphan GPCR Mas functions as the receptor for Ang-(1-7) and mediates its 
beneficial effects in the vasculature and kidney (Santos et al., 2003). Mas 
expression can be detected in the heart, kidney, testes, brain, vasculature, liver 
and adipose tissue correlating with the beneficial effects of Ang-(1-7) observed 
in these tissues (Alenina et al., 2008, Passos-Silva et al., 2013). Mice lacking Mas 
demonstrate impaired endothelial function, hypertension, impaired cardiac 
contractile function and increased cardiac ECM deposition highlighting an 
important role in cardiovascular homeostasis (Rabelo et al., 2008, Xu et al., 
2008, Santos et al., 2006). Despite the well described biological actions of Ang-
(1-7), the underlying signalling pathways still remain elusive. It has been widely 
demonstrated that Ang-(1-7) activates the PI3K-Akt pathway in vivo and in vitro 
coupling to an increase in eNOS activity and NO generation (Sampaio et al., 
2007b, Dias-Peixoto et al., 2008). Additionally, Ang-(1-7) inhibits the growth 
promoting MAPK pathway and thereby may antagonise the pathological effects of 
Ang II (Sampaio et al., 2007a).  
The effects of Ang-(1-7) in the cardiovascular system have been extensively 
studied. In a model of MI, Ang-(1-7) has been shown to be increasingly produced 
in the peri-infarct region and the degree of Ang-(1-7) significantly correlated 
with the rise in LVEDP (Averill et al., 2003). Continuous intravenous infusion of 
Ang-(1-7) following MI for 8 weeks attenuated the development of HF by 
improving cardiac contractile function and normalising coronary flow by 
improving endothelial function (Loot et al., 2002). The cardioprotective effect 
of Ang-(1-7) has been mainly attributed to its anti-hypertrophic and anti-fibrotic 
properties. Thus, Grobe et al. (2007) showed that the co-infusion of Ang-(1-7) 
with Ang II via subcutaneous osmotic minipumps in rats for 4 weeks prevented 
the development of Ang II-induced cardiac hypertrophy and interstitial fibrosis 
independent of an effect on BP (Grobe et al., 2007). In a similar manner, the 
cardiac specific overexpression of Ang-(1-7) via an Ang-(1-7) fusion protein 
strategy in transgenic rats (VII-7) was able to prevent cardiac hypertrophy, 
fibrosis and downregulate the expression of molecular markers of cardiac 
remodelling (ANP, BNP, TGFβ) (Mercure et al., 2008). This protective effect was 
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attributed to an increase in cardiac phosphatase activity by up-regulation of 
SHP-2 and dual specific phosphatase-1 which decreased mitogenic signalling 
pathways including ERK1/2, c-src kinase and p38 (Mercure et al., 2008, 
McCollum et al., 2012a). In deoxycorticosterone acetate (DOCA)-salt loaded rats 
expressing an Ang-(1-7) fusion protein (TG(A1-7)3292), Ang-(1-7) preserved 
cardiac contractile function by preventing the downregulation of SERCA2A and 
inhibiting the excessive dephosphorylation of PLB by protein phosphatase (PP)1 
thereby increasing Ca2+ transient amplitude (de Almeida et al., 2015). These 
beneficial effects generally occur in the absence of a hypotensive effect 
although some studies demonstrate BP lowering effects of Ang-(1-7). Thus, for 
example, intravenous infusion of Ang-(1-7) in the SHR but not Wistar Kyoto rat 
(WKY) decreased plasma vasopressin levels and induced natriuresis and diuresis 
thereby lowering BP (Benter et al., 1995). Similarly, in fructose-fed rats, Ang-(1-
7) infusion for 2 weeks reversed cardiac remodelling and normalised BP, an 
effect that was associated with a reduction in the phosphorylation of ERK1/2, 
JNK1/2 and p38 (Giani et al., 2010). In vitro experiments confirm the direct 
anti-hypertrophic and anti-fibrotic actions of Ang-(1-7) on cardiomyocytes and 
fibroblasts where Ang-(1-7) decreases growth factor-induced 3H-thymidine 
incorporation by downregulating MAPK signalling and up-regulating dual-specific 
phosphatase-1 (Tallant et al., 2005, Iwata et al., 2005, McCollum et al., 2012b). 
Additionally, Ang-(1-7) modulates the tissue expression and activity of mitogen-
activated MMPs and TIMPs in vivo and in vitro favouring collagen degradation 
and preventing adverse cardiac remodelling (Pei et al., 2010, Pan et al., 2008). 
The vast array of studies highlights the important role of Ang-(1-7) as a regulator 
of pathological cardiac remodelling which harbours potential as a new target in 
the treatment of hypertension and HF (Lee et al., 2013).  
As a result, a recent strategy is investigating the potential to directly deliver 
Ang-(1-7) to confer cardioprotection. So far this strategy has been hampered by 
the short half-life of Ang-(1-7) in the circulation. The development of a cyclic 
form of Ang-(1-7) where a thioether bridge links the amino acids 4-7 was largely 
protected against degradation by ACE and other proteases in vivo and in vitro 
while retaining its functional activity even when applied orally (Kluskens et al., 
2009, de Vries et al., 2010, Durik et al., 2012). In a similar manner, an oral 
formulation of Ang-(1-7) encapsulated in hydroxylprolyl β-cyclodextrin conferred 
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cardioprotective effects in a model of MI and improved indices of cardiac 
function and ventricular geometry (Marques et al., 2012). Although this study did 
not investigate the stability of encapsulated Ang-(1-7) in the circulation these 
data indicate that the direct delivery of modified counter-regulator peptides 
with enhanced half-life may hold therapeutic potential in the treatment of 
adverse cardiac remodelling.  
1.5.3 Ang-(1-9) 
Ang-(1-9) is a decapeptide that is generated by the cleavage of the terminal 
leucine residue from Ang I by ACE2 (Tipnis et al., 2000, Donoghue et al., 2000). 
Alternatively, in heart homogenates, Ang-(1-9) may also be generated via 
carboxypeptidase A/ cathepsin A-dependent hydrolysis of Ang I (Jackman et al., 
2002, Kokkonen et al., 1997, Garabelli et al., 2008). Cathepsin A is more 
abundant in atria whereas in ventricles carboxypeptidase A has been suggested 
to contribute up to 80 % of the Ang-(1-9) forming activity (Jackman et al., 2002, 
Garabelli et al., 2008). In fact, in heart homogenates of wildtype mice, Ang-(1-
9) was the major metabolite of Ang I conversion and in failing human hearts 85 % 
of Ang I is metabolised to equivalent levels of Ang-(1-9) and Ang II (Kokkonen et 
al., 1997). Ang-(1-9) can be further metabolised to Ang-(1-7) by ACE and it was 
originally thought that Ang-(1-9) mediates its beneficial effects in the 
vasculature by conversion to Ang-(1-7). However, Ang-(1-9) has been suggested 
to act as an endogenous inhibitor of ACE because it is a substrate of ACE itself 
(Donoghue et al., 2000). ACE binds Ang-(1-9) and Ang I with similar affinities 
(Rice et al., 2004), however, the catalytic efficacy of ACE at Ang-(1-9) is low and 
it has been demonstrated that Ang-(1-9) is hydrolysed 18x slower than Ang I 
supporting endogenous ACE inhibition by Ang-(1-9) that has also been observed 
in cardiac homogenates (Rice et al., 2004, Chen et al., 2005, Kokkonen et al., 
1997).  
In contrast to Ang-(1-7), Ang-(1-9) was recognised as an active peptide only very 
recently and its functional effects are only just emerging. One of the first 
studies to demonstrate that Ang-(1-9) is an active peptide and acts 
independently of Ang-(1-7) investigated the role of Cathepsin A in the release of 
Ang-(1-7) and Ang-(1-9) from heart homogenates (Jackman et al., 2002). In this 
study, the authors demonstrated that Cathepsin A is a major enzyme involved in 
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the formation of Ang-(1-9) from Ang I. Additionally, they demonstrated that in 
the presence of ACE, Ang-(1-9) potentiated the effect of bradykinin at the B2 
receptor and significantly increased the release of NO and arachidonic acid (AA). 
This effect was more pronounced with Ang-(1-9) and because the concentrations 
of Ang-(1-9) employed were below concentrations that would significantly inhibit 
ACE and increase bradykinin it was concluded that Ang-(1-9) is active per se and 
not broken down to Ang-(1-7) (Jackman et al., 2002). In a later study this 
observation was extended to show that Ang-(1-9) was more potent than Ang-(1-
7) to promote the re-sensitisation of the B2 receptor which was thought to be 
due to allosteric modulation of the ACE-B2 receptor complex by Ang-(1-9) (Chen 
et al., 2005). A first functional link between Ang-(1-9) and cardiac function was 
that 1 week following MI in rats, the levels of ACE and ACE2 activity significantly 
increased concomitant with a significant elevation of circulating Ang II and Ang-
(1-9) levels (Ocaranza et al., 2006). Following 8 weeks however, ACE2 and Ang-
(1-9) were significantly decreased and this could be prevented by treatment 
with the ACE-I enalapril which significantly elevated the bioavailable Ang-(1-9) 
but not Ang-(1-7), suggesting that Ang-(1-9) partially mediated the preservation 
of cardiac function with enalapril treatment following MI (Ocaranza et al., 
2006). The authors extended this finding in one of the first studies to 
demonstrate a direct effect of Ang-(1-9) on cardiac remodelling in vivo and in 
vitro (Ocaranza et al., 2010). Continuous administration of Ang-(1-9) via osmotic 
minipumps for 2 weeks following MI prevented ventricular dilatation, preserved 
cardiac function and inhibited the development of cardiomyocyte hypertrophy 
(Ocaranza et al., 2010). The anti-hypertrophic actions of Ang-(1-9) were 
corroborated in vitro where Ang-(1-9) dose-dependently prevented hypertrophy 
of neonatal rat cardiomyocytes stimulated with either norepinephrine or IGF-1. 
This effect was not blocked by the Mas receptor antagonist A779 further 
confirming that Ang-(1-9) is not broken down to Ang-(1-7) and that the actions of 
Ang-(1-9) are independent of the Mas receptor (Ocaranza et al., 2010).  
A subsequent study clearly separating the actions of Ang-(1-7) and Ang-(1-9) was 
the identification of the receptor for Ang-(1-9) (Flores-Muñoz et al., 2011). Using 
radioligand binding, it was demonstrated that Ang-(1-9) was able to compete 
with radiolabelled Ang II at the AT2R albeit at a lower overall affinity than Ang II 
(Flores-Muñoz et al., 2011). Using H9c2 cardiomyocytes this observation was 
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confirmed and demonstrated that Ang-(1-9) prevented Ang II-induced 
cardiomyocyte hypertrophy and this effect could be blocked by the AT2R 
antagonist PD123319. More importantly, although Ang-(1-7) and Ang-(1-9) have 
been demonstrated to mediate similar anti-hypertrophic effects, this study 
provided a clear delineation of the actions of Ang-(1-7) and Ang-(1-9) (Flores-
Muñoz et al., 2011). First, the addition of the ACE-I captopril did not abolish the 
anti-hypertrophic effect of Ang-(1-9), indicating that its actions are independent 
of its breakdown to Ang-(1-7). Second, this study demonstrated that Ang-(1-7) 
and Ang-(1-9) engaged their anti-hypertrophic effects via distinct receptors with 
the effects of Ang-(1-7) being inhibited by the Mas receptor antagonist A779 but 
not the AT2R antagonist PD123319 while the effects of Ang-(1-9) were insensitive 
to A779. Additionally, the anti-hypertrophic actions of Ang-(1-7) were partially 
mediated via bradykinin while those of Ang-(1-9) were not (Flores-Muñoz et al., 
2011).  
Despite the identification of the AT2R as the receptor for Ang-(1-9), the 
mechanism by which Ang-(1-9) mediates beneficial effects remains elusive. In 
the stroke prone spontaneously hypertensive rat (SHRSP), Flores-Muñoz et al. 
(2012) demonstrated that the infusion of Ang-(1-9) over 4 weeks via osmotic 
minipumps at the pre-hypertensive stage improved aortic endothelial function 
due to an increased NO bioavailability (Flores-Munoz et al., 2012). Similarly 
direct application of Ang-(1-9) to pre-contracted aortic rings elicited a 
vasodilatory response at picomolar concentrations of Ang-(1-9) and this was 
inhibited by the NOS inhibitor L-NAME (Ocaranza et al., 2014). It is possible that 
this effect is mediated by potentiation of bradykinin as seen in cardiac 
homogenates (Jackman et al., 2002), however, Ang-(1-9) has also been linked to 
an increase in Nox4 which can induce vasodilation via hydrogen peroxide release 
(Flores-Munoz et al., 2012). In atrial preparations Ang-(1-9) has been 
demonstrated to enhance stretch induced ANP release via the AT2R-PI3K-Akt-
eNOS-GC pathway (Cha et al., 2013). This presents one possible pathway by 
which Ang-(1-9) may mediate its anti-hypertrophic actions in vivo and in vitro. 
Next to its anti-hypertrophic actions, Flores-Muñoz et al. (2012) also 
demonstrated that Ang-(1-9) prevented the development of cardiac fibrosis in 
the SHRSP which was due to a reduction in collagen I gene expression by Ang-(1-
9) (Flores-Munoz et al., 2012). Additionally, Ang-(1-9) could directly inhibit 
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serum-induced cardiac fibroblast proliferation and reduce collagen I gene 
expression below that of unstimulated cells suggesting that Ang-(1-9) may 
improve cardiac remodelling via its actions on various cell types in the heart 
(Flores-Munoz et al., 2012).  
In a recent study by Ocaranza et al. (2014) the authors induced hypertension in 
rats either via Ang II infusion or renal artery clipping for two to four weeks prior 
to the administration of Ang-(1-9) via osmotic minipumps for a further 2 weeks 
(Ocaranza et al., 2014). In this study design, the authors for the first time 
demonstrated an anti-hypertensive effect of Ang-(1-9) which was mediated via 
the AT2R. Furthermore, Ang-(1-9) was able to reverse established cardiac 
hypertrophy and fibrosis in both models of hypertension, although whether this 
is due to a reduction in BP or directs actions of Ang-(1-9) on the heart was not 
addressed in this study (Ocaranza et al., 2014). In a second study by Zheng et al. 
(2015) Ang-(1-9) was administered to streptozotocin-induced diabetic rats which 
had normal BP but developed cardiomyopathy (Zheng et al., 2015). Untreated 
rats had significant cardiac hypertrophy and fibrosis while treatment with Ang-
(1-9) reversed cardiac remodelling and significantly decreased markers of 
cardiac fibrosis (TGFβ, collagen I) and cardiac hypertrophy (β-MHC, BNP). 
Furthermore, Ang-(1-9) was shown to directly affect cardiac function and 
preserved indexes of cardiac contractility and relaxation, normalised LVEDP and 
EF. The authors hypothesised that this was due to a reduction in Nox activity, a 
decrease in inflammatory markers (NFkB, TNFα, IL-1β) and ACE inhibition with 
reduced Ang II levels further strengthening the counter-regulatory actions of 
Ang-(1-9) (Zheng et al., 2015).  
Interestingly, despite the beneficial effects of Ang-(1-9) in the heart and 
vasculature, one study has reported that Ang-(1-9) through the AT1R mediates 
pro-thrombotic effects on platelets and this is dependent on the conversion of 
Ang-(1-9) to Ang II via a yet unknown carboxypeptidase (Kramkowski et al., 
2010, Drummer et al., 1988). This highlights that further research is needed to 
understand the extensive physiological actions of the counter-regulatory RAS in 
order to modulate therapeutic approaches. Overall, these data demonstrate that 
Ang-(1-9) mediates beneficial effects on acute cardiac remodelling in various 
models of cardiac disease and suggests that it would be a good new therapeutic 
target for the treatment of adverse cardiac remodelling in CVD. However, 
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clinically relevant longitudinal data on the effects of Ang-(1-9) in established 
cardiac disease still needs to be established.  
1.6 Hypothesis and aims 
The counter-regulatory RAS axis peptide Ang-(1-9) demonstrates therapeutic 
potential in the treatment of CVDs. So far, studies have only investigated acute 
reversal or prevention of adverse cardiac remodelling by Ang-(1-9). Whether 
Ang-(1-9) is beneficial when administered chronically is unknown.  
Therefore, it was hypothesised that chronic administration of Ang-(1-9) to a 
mouse model of Ang II-induced cardiac remodelling and dysfunction would 
attenuate adverse cardiac remodelling and improve cardiac function by a direct 
effect on the heart.  
The principal aim of this thesis was to assess the effects of chronic Ang-(1-9) 
delivery on cardiac functional and structural parameters in a model of Ang II-
induced cardiac remodelling and to investigate novel pathways by which Ang II 
contributes to adverse cardiac remodelling. This was addressed by the following 
experimental aims: 
1) Develop a mouse model of chronic Ang II-infusion and characterise 
associated cardiac structural and functional parameters. 
2) Assess the changes in structural and functional parameters with Ang-(1-9) 
infusion in the Ang II-infusion model and identify direct effects of Ang-(1-
9) on cardiac contractility in the isolated rat heart 
3) Identify new mechanisms of Ang II-induced cardiac remodelling by 
investigating the role of Ang II in EndMT and defining the role of 
microvesicles in Ang II-induced hypertrophy.  
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2.1 Solutions and buffers 
ADS buffer, pH 7.35 (in mM): 116 NaCl, 20 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 1 NaH2PO4, 5.5 Glucose, 5 KCl, 0.8 MgSO4 
Krebs-Henseleit solution, pH 7.4 (in mM): 120 NaCl, 20 HEPES, 5.4 KCl, 0.52 
NaH2PO4, 3.5 MgCl2-6H2O, 20 taurine, 10 creatine, 11.1 glucose anhydrous.  
10x Phosphate-buffered saline (PBS), pH 7.4 (in mM): 1370 NaCl, 27 KCl, 100 
Na2HPO4, 18 KH2PO4  
ROS phosphate buffer, pH 7.4 (in mM): 50 KH2PO4, 1 ethylene glycol tetraacetic 
acid (EGTA), 150 sucrose. 
ROS lysis buffer, pH 7.4 (in mM): 50 KH2PO4, 1 EGTA, 150 sucrose, 153 x 10-6 
aprotinin, 2.1 x 10-3 leupeptin, 1.46 x 10-3 pepstatin, 1 PMSF.  
Sodium citrate buffer, pH 6 (in mM); 11.4 Tri-sodium citrate, 500 μL Tween-
20/L. 
10x Tris-buffered saline (TBS), pH 7.4 (in mM): 1369 NaCl, 27 KCl, 247 Tris base 
Tyrode’s solution (in mM): 116 NaCl, 20 NaHCO3, 0.4 Na2HPO4, 1 MgSO4-7H2O, 5 
KCl, 11 glucose anhydrous, 1.8 CaCl2. 
Western lysis buffer (in mM): 50 Tris-HCl pH7.4, 50 NaF, 1 Na4P2O7, 1 EGTA, 1 
Ethylenediaminetetraacetic acid (EDTA), 1 % (v/v) Triton-X 100, 1 DTT, 1 
Na3VO4, 0.1 PMSF, 250 mM mannitol, 1 x complete mini protease inhibitor 
cocktail tablet (for 10 mL solution) (Roche, Burgess Hill, UK), 1 x phosSTOP 
phosphatase inhibitor cocktail tablet (for 10 mL solution) (Roche, Burgess Hill, 
UK). 
Western transfer buffer (in mM): 192 Glycine, 25 Tris base, 0.01 % SDS, 200 mL 
Methanol/L 
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2.2 Cell culture 
All cell culture was performed aseptically in sterile class II laminar flow hoods 
(Thermo Fisher, Paisley, UK) and cells were maintained in humidified incubators 
at 37 ºC and 5 % CO2/95 % O2. All tissue culture reagents were purchased from 
Gibco (Thermo Fisher, Paisley, UK) unless otherwise indicated.  
H9c2 cells are an immortalised cell line of cardiomyoblasts derived from BDIX 
embryonic rat heart tissue (Hescheler et al., 1991). H9c2 cells were purchased 
from Public Health England (Salisbury, UK). Cells were maintained in T150 cm2 
cell culture flasks in minimum essential media (MEM) supplemented with 10 % 
(v/v) fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin and 
100 μg/mL streptomycin and sub-cultured at 60-70 % confluence.  
Primary human coronary artery endothelial cells (HCAEC) are derived from the 
right and left coronary artery of a single donor. As important regulators of 
coronary blood flow, they are especially useful for in vitro studies of 
atherosclerosis and hypertension. Cryopreserved HCAEC were purchased from 
PromoCell (Heidelberg, Germany) and maintained in T75 cm2 cell culture flasks 
in Endothelial Cell Medium MV (PromoCell, Heidelberg, Germany) supplemented 
with 100 U/mL penicillin and 100 μg/mL streptomycin and the provided 
supplement mix containing 5 % (v/v) fetal calf serum, 0.4 % (v/v) endothelial 
cell growth supplement, 10 ng/mL recombinant human EGF, 90 μg/mL heparin 
and 1 μg/mL hydrocortisone. Cells were sub-cultured when reaching 90-100 % 
confluence. Experiments were performed in basal growth medium (endothelial 
cell medium MV with 2mM L-glutamine, 100 U/mL penicillin, 100 μg/mL 
streptomycin and 1 mM sodium pyruvate). Cells were used between passages 2-
10.  
2.2.1 Cell subculture 
Once cells reached the desired confluence, cells were passaged. After removal 
of medium from a confluent flask, cells were washed twice with sterile 1x PBS 
before the addition of 1x trypsin-EDTA and incubation at 37 ºC for approximately 
5 min or until cells were detached. Once detached, approximately 8-10 mL of 
complete media was added to the flask to neutralise the trypsin and prevent 
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over-digestion of the cells. The flask was washed several times with the media 
before transferring it to a sterile tube and centrifugation at 480 g for 5 min. The 
supernatant was decanted and the pellet re-suspended in fresh media before 
plating in new flasks. Primary neonatal fibroblasts were usually split 1:2- 1:3 
while H9c2 cells were sub-cultured 1:3-1:8. HCAEC were seeded at a density of 
7.5x 105 cells in a T75 cm2 flask.  
In order to seed cells at a specified density, cells were counted after re-
suspension. For this, 10 μL of the suspension were added into a haemocytometer 
and the cells were counted in the 4 quadrants made up of 16 squares each to 
determine the mean number of cells across all 4 quadrants. Since each of the 
quadrants measures 1 mm x 1 mm and the distance between the coverslip is 
0.1 mm, one quadrant fits a volume of 0.1 μL. Therefore, the number of cells is: 
cells
mL
= mean of 4 quadrants x 10
4
 
To determine the volume of cell suspension required for the desired seeding 
density, the following formula was used: 
required volume (μL)= 
required density
number of cells per μL
. 
2.2.2 Cryopreservation 
For cryopreservation and long-term storage, cells were prepared as outlined in 
section 2.2.1. After centrifugation and removal of the supernatant, cells were 
re-suspended in an appropriate volume of complete cell culture media 
supplemented with 10 % (v/v) dimethyl sulfoxide (DMSO) to achieve an 
approximate density of 1x 106 cells/mL. The media was then aliquoted into 1 mL 
cryopreservation tubes which were placed into a freezing container filled with 
100 % isopropanol and placed into a -80 ºC freezer for 24 h. This method allows a 
cooling rate of approximately -1 ºC/minute to -80 ºC and prevents cell rupture 
by rapid freezing. After 24 h, frozen cells were transferred to liquid nitrogen 
storage tanks for long term storage.  
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To recover cells from liquid nitrogen, cells were rapidly defrosted by placing into 
a water bath at 37 ºC. The cell suspension was then transferred into a flask 
containing fresh pre-warmed cell culture medium and incubated for 24 h at 
37 ºC and 5 % CO2 to allow cells to adhere to the culture plastic. The cell culture 
medium was then replaced to remove residual DMSO.  
2.2.3 Neonatal rat cardiomyocyte and fibroblast isolation and 
culture 
Neonatal rat cardiomyocytes (NRCM) and fibroblasts (NRCF) were isolated from 
3-7 day old WKY rats by enzymatic digestion. This is a two-step process where 
hearts are initially subjected to enzymatic digestion to free cardiac myocytes 
and fibroblasts. The isolated cells are then purified by differential plating on 
different substrates; poly-L-lysine for fibroblasts and gelatin for cardiomyocytes. 
Neonatal rat pubs were killed by decapitation and hearts were quickly excised 
via thoracotomy and placed into cold sterile ADS buffer (Figure 2-1 A-C). The 
hearts were then transferred into a sterile laminar flow hood where the lungs, 
surrounding connective tissue and atria were dissected and the ventricles were 
placed into a Petri dish with ADS buffer. Using fine scissors, hearts were cut into 
small pieces until homogenised (Figure 2-1 D). The pieces were then drawn up 
with a Pasteur pipette and transferred into a sterile 100 mL Duran bottle. The 
ADS buffer was carefully removed by tapping the bottle against the bench to 
collect the heart pieces at the bottom. For the first digestion, 10 mL of enzyme 
mix containing pancreatin (Sigma, Dorset, UK) and collagenase type II 
(Worthington Chemicals, US) at a final concentration of 0.6 mg/mL was added to 
the heart pieces and incubated in a shaking water bath at 37 ºC and 
180 strokes/min for 5 min. This initial digestion allows the breakdown of excess 
connective tissue to release the cells (Louch et al., 2011). After 5 min of 
digestion, the enzyme was removed and discarded. Stepwise enzymatic digestion 
was then performed as laid out in Table 2.1. After each digestion, the digestion 
mix was removed from the heart pieces, transferred to a sterile falcon tube 
containing 2 mL of FBS and centrifuged at 210 g for 5 min to pellet the released 
cells and remove the enzyme. The supernatant was decanted and the pellet 
carefully re-suspended in 4 mL of FBS by gentle tapping. The cell suspensions 
from every digestion step were pooled in one Falcon tube which was placed into 
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the incubator at 37 ºC and 5 % CO2 after every step. The lid was loosened to 
allow gas exchange. After the final digestion, the digestion mix was directly 
added to the falcon tube containing the cell suspension and centrifuged at 210 g 
for 6 min to pellet the cells. This pellet contains a mixture of cardiac cells that 
were isolated by the enzymatic digestion but the biggest fraction is made up of 
cardiomyocytes and fibroblasts. To remove adherent, non-myocytes from the 
cells suspension and isolate cardiac fibroblasts, the cells were pre-plated on 
poly-L-lysine (Sigma, Dorset, UK) coated 100 mm cell culture dishes. For this, 
the pellet was re-suspended in an appropriate volume of plating media (Table 
2.2) and 1 mL of cell suspension was added to each dish to make up a total 
volume of 10 mL. Generally, one dish was used for every two hearts in the initial 
digestion. The plates were then placed into the incubator at 37 ºC and 5 % CO2 
for 90 min to allow adhesion of cardiac fibroblasts (Figure 2-1 E). 
Once fibroblasts adhered to the dish, each dish was gently washed using a 
Pasteur pipette to remove the non-adherent cells. The supernatant was 
collected in a 50 ml Falcon tube and 5 ml of plating media was added to each 
dish. The wash step was repeated and the supernatant transferred into the 50 ml 
falcon tube. If a significant number of floating cells could still be seen under the 
microscope, the wash step was repeated for a third time. After the final wash, 
10 mL of plating media was added to each dish and cardiac fibroblasts incubated 
at 37 ºC and 5 % CO2.  
To count the number of cardiomyocytes in the supernatant, 10 μL of the 
suspension was added to a haemocytometer and counted as described in Section 
2.2.1. Since neonatal cardiomyocytes do not proliferate (Ahuja et al., 2007), 
cells cannot be sub-cultured and need to be plated out directly for use. For 
experimentation, cardiomyocytes were plated out at an assay dependent density 
into 1 % gelatin coated cell culture plates and allowed to adhere overnight at 
37 ºC and 5 % CO2. The next day, most of the cardiomyocytes will have adhered 
to the dish and can be seen beating (Figure 2-1 F). The plating media was 
removed and cells were washed with 1x PBS to remove further cell debris before 
proceeding with the experimental protocol.  
For long-term storage, the cardiomyocytes were plated into 60 mm cell culture 
dishes coated with 1 % gelatin at a density of 6-7 x 106 in a final volume of 4 mL 
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and allowed to attach overnight at 37 ºC and 5 % CO2. The next day, the plating 
media was removed and cells were washed with 1x PBS before the addition of 
maintenance media (Table 2.3). Maintenance media contains no serum to reduce 
the growth of contaminating fibroblasts. After a further day in maintenance 
media, cardiomyocytes were then trypsinized and frozen for long-term storage 
as outlined in section 2.2.2.   
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Figure 2-1. Neonatal cardiomyocyte and fibroblast isolation experimental setup and heart 
preparation. 
(A) Setup of the isolation reagents and equipment under the laminar flow hood. (B, C) Image of the 
excision of the neonatal heart. (D) Mincing of the hearts using fine scissors. Example images of (E) 
NRCF and (F) NRCM after 24 h in culture. 
Table 2.1 Digestion steps 
Digest Volume of enzyme mix (mL) Time (min) Strokes/min 
1 10 5 180 
2 10 20 160 
3 8 25 150 
4 8 25 150 
5 6 15 160 
6 6 10 150 
 
Table 2.2 Plating media composition 
 mL/500mL Final concentration 
DMEM 340 68 % (v/v) 
M199 85 17 % (v/v) 
Horse serum 50 10 % (v/v) 
FBS 25 5 % (v/v) 
Penicillin/ 
Streptomycin 
5 
100 U/mL / 
100 μg/mL 
 
Table 2.3 Maintenance media composition 
 mL/500mL Final concentration 
DMEM 400 80 % (v/v) 
M199 100 20 % (v/v) 
Penicillin/ 
Streptomycin 
5 
100 U/mL / 
100 μg/mL 
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2.3 Endothelial-to-Mesenchymal Transition 
For induction of EndMT, HCAEC were plated into fibronectin-coated cell culture 
plates at 3x 105 cells/well and 6.4x 104 cells/well for 6-well and 12-well plates, 
respectively. 6-well plates were used for protein extraction and 12-well plates 
were used for RNA analysis. Cells were allowed to attach overnight and were 
then starved in 0.5 % FBS (v/v) basal growth medium for 24 h. Cells were then 
stimulated with 10 ng/mL TGFβ1 or TGFβ2 (Peprotech, London, UK), 100 nM or 
1 μM Ang II (Sigma, Dorset, UK) alone or in combination in 2 % FBS (v/v) basal 
growth medium for up to 15 days. Medium was re-placed every second day and 
cells were re-stimulated. AT1R, AT2R and SMAD2/3 were blocked by addition of 
1 μM losartan (Sigma Dorset, UK), 500 nM PD123319 (Sigma, Dorset, UK) or 1 μM 
SB525334 (Tocris, Bristol, UK) 15 min prior to stimulation. At the end of the 
protocol, cells were lysed for protein and RNA extraction as outlined in Section 
2.8 and 2.9.  
2.3.1 Time-course stimulations 
For assessment of signalling pathways, HCAEC were plated into fibronectin 
coated cell culture plates at a density of 3x 105 cells/well and allowed to adhere 
overnight. Cells were then starved in serum free basal growth medium for 24 h 
and then stimulated with 10 ng/mL TGFβ1 or 1 μM Ang II alone or in combination 
for 5, 15, 30 and 60 min and lysed for protein extraction as described in Section 
2.9. Unstimulated cells served as control.  
For analysis of superoxide production, HCAEC were plated into fibronectin 
coated cell culture plates at a density of 2x 105 cells/well and allowed to adhere 
overnight. Cells were starved in 0.5 % FBS (v/v) basal growth medium overnight. 
The next day, cells were stimulated with 10 ng/mL TGFβ1 or 1 μM Ang II alone or 
in combination in serum free basal growth medium for 1, 5 and 30 min. 
Inhibitors of Rac1/2 (EHT1864, 10 μM; Tocris, Bristol, UK), Nox1 (ML171, 1 μM; 
Tocris, Bristol, UK) and Nox1/4 (GKT137831, 1 μM; provided by GenKyotex, 
Geneva, Switzerland) were added 30 min prior to stimulation. Following 
stimulation, cells were placed on ice and washed twice in ice-cold PBS. Cells 
were then lysed in 80 μL ROS Lysis buffer using a cell scraper and the lysate was 
kept on ice until use.  
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2.3.2 Lucigenin assay 
Prior to use, the Orion Microplate Luminometer (Titertek Berthold, Pforzheim, 
Germany) was pre-heated to 37 ºC. In a white 96-well plate, 50 μL sample was 
combined with 100 μL ROS buffer and 75 μL 16.6 μM Lucigenin (Sigma, Dorset 
UK). The plate was read in the luminometer for basal luminescence. Each well 
was read 30x 1 s. 25 μL 1 mM NADPH (Tocris, Bristol, UK) were then added to 
each well and the plate read again to determine NOX activity levels. Protein 
concentration was determined in the remaining (10 μL) sample using the BCA 
assay (Section 2.9.2). Relative superoxide production was then determined with 
the following calculation: 
O2
-  production = 
mean activity luminescence - mean basal luminescence
μg protein in 50 μL 
 
2.4 Microvesicles 
2.4.1 Microvesicle conditioned medium 
NRCF were isolated and cultured as outlined in Section 2.2.3. 2-3 flasks of NRCF 
cultured in a 150 cm2 cell culture flask were passaged at a ratio of 1:3 or 1:2, 
respectively, into six 150 cm2 cell culture flasks. Once confluent, cells were 
placed into a total of 18 mL serum free Dulbecco's Modified Eagle Medium 
(DMEM), supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin. 
Three flasks were then stimulated with 1 μM Ang II while the other three flasks 
were left untreated (control) for 48 h. To inhibit microvesicle (MV) secretion, 
Brefeldin A (BFA) was used as an inhibitor of the endosomal secretory pathway 
(Islam et al., 2007). Due to its global effect on cellular secretion, BFA is 
cytotoxic over long term and only allows stimulation for a maximum of 24 h. 
Thus, NRCF were treated with 5 μg/mL BFA in the presence or absence of 1 μM 
Ang II and stimulated for 24 h.  
In a similar manner, H9c2 cells were cultured as outlined in Section 2.2. One 
flask of H9c2 cells was passaged 1:6 into six 150 cm2 cell culture flask. Once 70 % 
confluence was reached, cells were placed into 18 mL serum free MEM, 
supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin and three 
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flasks were stimulated with 1 μM Ang II while the other three were left 
untreated for 48 h.  
2.4.2 Microvesicle isolation 
Serial centrifugation and ultracentrifugation is the most common procedure 
employed for the isolation of MVs and exosomes in currently published literature 
(Pironti et al., 2015, Lyu et al., 2015). This method is based on the knowledge 
that the larger the size of a particle, the lower the centrifugation speed needed 
to sediment the particle. Therefore, by increasing centrifugation speed, 
particles are gradually excluded from the preparation. Initially, cells, debris and 
large apoptotic bodies are removed by low-speed centrifugation before pelleting 
larger MVs commonly called microparticles by centrifugation speeds between 
10,000–20,000 g (Witwer et al., 2013). Alternatively, the preparation may be 
clarified by passing it through, for example, a 0.2 μm filter and exclude vesicles 
by size (Théry et al., 2006). Once cleared of cell debris and other contaminating 
vesicles, small MVs can then be pelleted by ultracentrifugation with speeds 
ranging between 100,000–120,000 g. While ultracentrifugation is a cost effective 
way to purify MVs, it fails to achieve an absolutely pure MVs population as the 
size and density of vesicles is largely dependent on their cargo and small vesicles 
may pellet at low speeds if they are located near the bottom of the tube 
(Witwer et al., 2013). Furthermore, due to their lipophilic nature, MVs tend to 
aggregate which interferes with separation by vesicle size and the high speeds of 
centrifugation tends to sediment protein aggregates and other contaminants. To 
further purify the MV population from contaminants, vesicles can be floated on a 
30 % sucrose gradient which will effectively separate protein to the bottom of 
the tube while MVs float on the gradient (Witwer et al., 2013, Théry et al., 
2006).  
2.4.2.1 Ultracentrifugation 
MVs from cell culture media were isolated by serial centrifugation and 
ultracentrifugation as previously described (Théry et al., 2006). A workflow of 
the MV purification procedure is outlined (Figure 2-2). Briefly, the MV 
conditioned medium was removed and transferred into 25 mL universal cell 
culture tubes and subjected to centrifugation at 850 g for 5 min to remove cell 
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debris and then passed through a 0.2 μm sterile filter to remove any particles 
≥ 200 nm in size. The cleared medium was then transferred into Ultra-Clear, 
open-top thin-walled 16 x 102 mm ultracentrifuge tubes (Beckman Coulter, High 
Wycombe, UK) and then subjected to ultracentrifugation at 110,000 g at 4 ºC for 
90 min in a Beckman Coulter SW 32.1 Ti swinging-bucket rotor in a pre-cooled 
Beckman Coulter L-80XP ultracentrifuge. The supernatant was decanted and the 
MVs were washed by resuspension in 1 mL ice-cold PBS. The tube was filled 
completely with PBS and the centrifugation step repeated. A small white pellet 
was visible after this centrifugation step and the MV pellet was re-suspended in 
100 μL PBS and stored at -20ºC until further use.  
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Figure 2-2. Workflow for microvesicle isolation by ultracentrifugation. 
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2.4.2.2 Proteinase K treatment 
To remove proteins attached to the surface of MVs, MVs were treated with 
Proteinase K as previously described (Montecalvo et al., 2012, Melo et al., 
2014). Proteinase K is a serine protease that can cleave proteins over a broad 
spectrum and allows the breakdown of proteins contained on the vesicular 
surface while leaving proteins contained in the vesicular lumen intact (Shelke et 
al., 2014, Gupta and Knowlton, 2007). Proteinase K treatment was performed 
after the first ultracentrifugation step by resuspending the MV pellet in 
500 μg/mL proteinase K followed by incubation for 1 h at 37ºC. Proteinase K was 
then inactivated by placing the tubes into a water bath heated to 60ºC for 
10 min. Following this, ultracentrifugation was performed as described above. 
2.4.2.3 Microvesicle isolation from serum and plasma 
Next to ultracentrifugation, MVs and exosomes can be isolated using 
commercially available isolation reagents. Isolation reagents work on the basis of 
tying up water molecules and thereby force the less-soluble lipophilic 
components such as the MVs out of solution which can then be pelleted by a 
brief centrifugation step. Studies comparing ultracentrifugation against isolation 
reagents have shown that isolation reagents tend to result in a higher yield of 
MVs from any given volume but do not affect the cargo itself (Rekker et al., 
2014). 
MVs were isolated from serum of Ang II-infused mice using the total exosome 
isolation reagent (from serum) (Thermo Fisher, Paisley, UK) according to the 
manufacturer’s instructions. Briefly, serum was thawed at 25ºC in a water bath 
and then centrifuged at 2,000 g for 30 min to clear the serum of cells and other 
debris. 200–400 μL of clarified serum was transferred to a new tube and 
0.2 volumes (i.e. 40–80 μL) of total exosome isolation reagent was added to the 
sample and mixed well by vortexing. Next, the sample was incubated at 4ºC for 
30 min and then subjected to centrifugation at 10,000 g for 10 min at room 
temperature to pellet the MVs. The MV depleted supernatant was removed and 
stored separately and the MV pellet was resuspended in 100–200 μL PBS and 
stored at -20ºC until further use.  
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MVs were isolated from the plasma of WKY and SHRSP rats using the total 
exosome isolation reagent (from plasma) (Thermo Fisher, Paisley, UK) according 
to the manufacturer’s instructions without proteinase K treatment. Briefly, 
plasma was defrosted at 25ºC in a water bath and then centrifuged at 2,000 g for 
20 min to remove cellular debris. The supernatant was then clarified by a 
further centrifugation step at 10,000 g for 20 min. To dilute the plasma, 100 μL 
of PBS was added to 200 μL of plasma and mixed well by vortexing. Next, 
0.2 volumes (60 μL) of total exosome isolation reagent was added to the sample, 
vortexed and incubated for 10 min at room temperature. Next, sample was 
centrifuged at 10,000 g for 5 min at room temperature to pellet the MVs. The 
plasma supernatant was removed and stored separately. The MV pellet was 
resuspended in 100 μL PBS and stored at -20ºC until further use.  
2.4.3 Nanoparticle tracking analysis 
Nanoparticle tracking analysis (NTA) is a light-scattering method for the real-
time visualisation and quantification of nanoparticles in solution. It employs a 
focussed laser beam that is passed through the solution to illuminate the 
particles (Figure 2-3). The light scattered by the particles can then be visualised 
microscopically by a conventional microscope with a 20x objective. The 
microscope is connected to an electron multiplying charged coupled device 
camera that allows the capture of a video at 30 frames per second (Wright, 
2012). The movement of particles in solution is based on the Brownian motion 
and the NTA software identifies and tracks each particle in each frame of a 30–
60 s video (Gardiner et al., 2013). Using the determined mean distance of 
particle movement in x and y, particle size can be calculated for a known 
temperature (T) and solvent viscosity (η) using a variation of the Stokes-Einstein 
equation: 
(𝑥, 𝑦)̅̅ ̅̅ ̅̅ ̅2
4
= 𝐷𝑡 =  
𝐾𝐵𝑇
3𝜋𝜂𝑑
 
Where Dt is the particle diffusion coefficient, KB the Boltzmann’s constant and d 
the particle hydrodynamic diameter (Wright, 2012).  
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MVs purified from cell culture medium or animal serum and plasma were 
quantified using NTA. In brief, 5–10 μL of the re-suspended MVs were diluted in 
1 mL PBS. Using a 1 mL syringe the sample was loaded into the sample chamber 
of a LM14C controller unit connected to an Andor DL-658-OEM-630 camera 
(Nanosight, Malvern Instruments, Malvern, UK). Videos of 60 s were recorded in 
duplicate for each sample. Videos were analysed using the accompanying 
Nanosight NTA 2.0 software with a minimal particle size of 30 nm and the gain 
and detection threshold adjusted accordingly to detect all particles. The 
determined concentration was adjusted for sample dilution and the total volume 
of MV suspension was noted to calculate the total number of MVs.  
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Figure 2-3. Schematic of the setup for nanosight tracking analysis. 
Microvesicles in solution are placed into the sample chamber which is placed under the 
microscope. A laser beam is shown through the sample and the light reflected by the vesicles is 
captured by a 20 x microscope objective. An attached electron multiplying charged coupled device 
camera (EmCCD) camera captures a video of the particles moving in solution under Brownian 
motion and using the accompanying NTA software, the particle motion is tracked (red traces). 
Schematic adapted from Wright (2012). 
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2.4.4 Hypertrophy model 
H9c2 cells were plated at a density of 1x 105 cells/well onto glass coverslips 
placed in 6-well cell culture plates and allowed to adhere overnight. The cells 
were then placed into 2 mL serum free MEM and were either left untreated or 
stimulated with 100 nM Ang II for 96 h to stimulate cardiomyocyte hypertrophy. 
H9c2 cells were treated with NRCF-derived MVs by dissolving MVs in 2 mL of 
serum free MEM followed by sterile filtration through a 0.2 μm filter. The sterile 
solution was then added onto H9c2 cells for 96 h. The AT1R antagonist losartan 
(Sigma, Dorset, UK) was used to block the AT1R receptor and was added at a 
concentration of 1 μM. In a similar manner, NRCM isolated and cultured as 
described in Section 2.2.3 were plated at a density of 1x 106 cells/well onto 1 % 
gelatin-coated coverslips. The next day, cells were placed into maintenance 
media and stimulated for hypertrophy as described above. 
At the end of the protocol, cells were lysed for RNA extraction (Section 2.8) or 
stained with phalloidin (Section 2.5.1).  
2.4.5 Labelling of NRCF with fluorescent DiI 
Labelling of cells with a fluorescent dye provides an effective method for the 
investigation of cell proliferation, migration and adhesion (Tian et al., 2013b, 
Progatzky et al., 2013). DiI (1,1'-Dioctadecyl-3,3,3',3'-
Tetramethylindocarbocyanine Perchlorate) is a member of the highly lipophilic 
carbocyanine dyes that exhibit strong fluorescence when incorporated into 
membranes (Progatzky et al., 2013). When applied to the cell, the dyes diffuse 
laterally within the cell membrane staining the entire cell while exhibiting very 
low cell toxicity.  
NRCF were labelled with DiI using the Vybrant DiI cell-labelling solution (Thermo 
Fisher, Paisley, UK) according to the manufacturer’s instructions. Briefly, NRCF 
were trypsinised and centrifuged in a 15 mL falcon tube as described in Section 
2.2.1. The cells were then resuspended in 1 mL serum free DMEM and 5 μL of 
Vybrant DiI labelling solution was added to the medium. Following gentle mixing, 
cells were incubated for 30 min at 37 ºC and 5 % CO2. Using Fluorescence-
activated cell sorting, this was determined to result in ≥ 90 % labelling of NRCF 
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which was retained over 48 h. Cells were then pelleted by centrifugation at 
480 g for 5 min and washed in PBS prior to plating. 
2.4.6 Fibroblast– cardiomyocyte transwell co-culture 
MV exchange between fibroblasts and cardiomyocytes was assessed by transwell 
co-culture. Transwell cell culture inserts consist of a 10 μm microporous 
polycarbonate membrane separating the top and bottom chamber and allowing 
the exchange of cellular signals or the migration of cells depending on pore size. 
A pore size of 0.4 μm prevents the migration of cells but allows the transfer of 
substances ≤ 400 nm, including MVs. 
H9c2 cells were plated at a density of 4x 104 cells/well onto round glass 
coverslips in a 12-well plate and allowed to adhere overnight. Similarly, DiI-
labelled NRCF were seeded onto the poly-L-lysine coated microporous membrane 
of a transwell at a density of 2x 104 cells. The next day, the culture media of 
H9c2 cells and NRCF was replaced by serum free medium and the transwell with 
the NRCF in the top chamber was moved over the H9c2 cells to allow MV 
exchange. After 48–96 h, the cells were fixed with 4 % paraformaldehyde (PFA) 
(Section 2.5) and mounted with Prolong Gold+ DAPI on microscope slides. MV 
transfer was assessed by confocal microscopy (Section 2.6) at 40x magnification 
and 0.7x zoom using the HeNe543 and Diode405–30 lasers to visualise DiI and 
DAPI, respectively. Post-processing of images was performed in Zen 2 lite black. 
2.4.7 Detection of Ang II in microvesicles 
2.4.7.1 Ang II ELISA 
The Angiotensin II EIA Kit was purchased from Bertin Pharma (Montigny le 
Bretonneux, France). The ELISA is based on immobilised antigen technology 
which increases its sensitivity to concentrations as low as 1–2 pg/mL. Following 
reaction of Ang II in the sample with the monoclonal anti-angiotensin II antibody 
immobilised on the plate, the bound Ang II is covalently linked to the antibody 
by glutaraldehyde. Bound Ang II then reacts with acetylcholine esterase-
conjugated anti-angiotensin II antibody and Ang II content is visualised using 
Ellman’s reagent as substrate.  
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The Ang II EIA Kit was used according to the manufacturer’s instructions. Briefly, 
8 standards were prepared by serial dilution ranging from 125–0.98 pg/mL and 
100 μL of standard, purified mouse serum and MVs were added to the pre-coated 
anti-Angiotensin II IgG plate. Sample less than 100 μL were adjusted to 100 μL 
with PBS. Untreated wells served as negative controls while a quality control of 
known Ang II concentration supplied with the assay served as positive control. 
The plate was then incubated for 1 h at room temperature with gentle agitation. 
Glutaraldehyde [0.5 % (v/v)] was prepared by the addition of 100 μL 
glutaraldehyde to 1x wash buffer and 50 μL of glutaraldehyde was added to each 
well and incubated with gentle agitation for 5 min. Next, borane trimethylamine 
was reconstituted in 5 mL 2 N HCl/Methanol (50/50, v/v) and 50 μL were added 
to each well and incubated for 5 min to inactivate glutaraldehyde. The plate was 
then washed 5 times before the addition of 100 μL anti-Angiotensin II IgG tracer. 
The plate was covered with a plate seal and incubated at 4ºC overnight. The 
tracer was then removed and the plate washed 5x prior to a 10 min incubation in 
300 μL wash buffer and a further five washes with wash buffer. Next, 200 μL 
Ellman’s reagent was added to the plate and incubated in the dark under gentle 
agitation for 30 min to allow colour development. Absorbance was measured at 
405 nm using a Dynex plate reader (Dynex Technologies, Worthing, UK) and the 
supplied software Revelation 4.25. For the determination of sample 
concentration, the blanking value (Ellman’s reagent only) was subtracted from 
all measurements and a standard curve with origin at x= 0 and a linear trendline 
was plotted. Using the linear equation, sample concentration was calculated and 
corrected for sample dilution if necessary. For samples with a negative 
concentration as determined from the standard curve Ang II concentration was 
assumed to be 0 pg/mL. Mean Ang II concentration was calculated by averaging 
all individual sample readouts measured across different ELISA plates.   
2.4.7.2 Tracking of fluorescent Ang II in microvesicles 
Fluorescently-labelled Ang II has previously been employed to visualise Ang II-
receptor interactions and track its recycling within the cell (Hunyady et al., 
2002, Hein et al., 1997) making it a useful tool to determine the loading of 
exogenous Ang II into MVs. 
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NRCF were labelled with Vybrant DiI as described in Section 2.4.5 and cultured 
in 150 cm2 cell culture flasks until confluent. MVs were isolated from 
conditioned medium of NRCF stimulated with 1 μM Fluorescein amidite (FAM)-
labelled Ang II (Anaspec Inc., Seraing, Belgium) (Section 2.4.1, 2.4.2.1). H9c2 
cells were plated at full confluence onto round coverslips in a 12-well plate. The 
next day, MVs from control and Ang II-stimulated NRCF were added onto H9c2 
cells in serum free medium. The cells were then placed on ice for 30 min. This 
reduces cellular metabolism but allows MVs to settle on the cells without being 
bound and internalised at the cell membrane. Subsequently, the cells were 
reheated by placing them at 37ºC and 5 % CO2 for 30 min to allow MVs to bind 
and fuse to the cell membrane. Cells were then washed 3x in PBS prior to 
fixation with 1 % PFA for 20 min. Following a wash in PBS 3x, coverslips were 
then mounted with Prolong Gold+DAPI onto microscope slides. Slides were 
imaged by confocal microscopy (Section 2.6) at a magnification of 40x with a 1-
1.7x zoom using a C-Apochromat 40x/1.2 x W corr lens and the Argon/2 (488), 
HeNe543 and Diode405-30 lasers for the detection of FAM, DiI and DAPI, 
respectively. Images were subsequently processed in Zen 2 lite black.  
2.5 Immunocytochemistry 
Immunocytochemistry (ICC) is the analysis of specific anatomical structures and 
localisation of proteins in isolated single cells. It differs thereby from 
immunohistochemistry (described in 2.7.3) which is the analysis of tissue 
specimens. Immunocytochemical staining involves the fixation, permeabilisation 
and the subsequent staining of cells with specific antibodies.  
Prior to ICC, cells were cultured on coverslips as outlined in Section 2.2 and 
treated according to the specified experimental conditions. At the endpoint, 
culture medium was removed from the cells and washed with PBS three times. 
Cells were then fixed in 4 % paraformaldehyde for 15 min followed by 3 washes 
with PBS. At this stage, fixed cells could be stored at 4 ºC in PBS for later 
analysis. Cells were then permeabilised with 0.1 % (v/v) Triton X-100 (Sigma, 
Dorset, UK) in PBS for 5 min at room temperature before washing with PBST 3x 
5 min. Cells were then blocked in either 10 % goat serum in PBST for single stains 
or 20 % goat serum in PBST for dual stains for 30 min. For this, coverslips were 
transferred onto a dry surface (usually the plate lid) and 150 μL blocking solution 
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was added to each coverslip. Coverslips were then transferred back into the 
culture plate and 150 μL of the appropriate antibody made up in blocking buffer 
(Table 2.4) was added and incubated at 4ºC overnight. Coverslips were washed 
3x 5 min in PBST at room temperature and transferred back onto a dry surface 
before incubation with the appropriate secondary antibody made up in blocking 
buffer (Table 2.5) at room temperature in the dark for 1 h. Coverslips were 
washed 3x 5 min in PBST and mounted with Prolong Gold+DAPI (Thermo Fisher, 
Paisley, UK) onto glass microscope slides. Slides were allowed to dry overnight in 
the dark prior to imaging by confocal microscopy (Section 2.6).  
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Table 2.4 Primary antibodies for ICC 
Antigen Manufacturer 
Host 
Species 
Concentration Dilution Buffer 
CD31 DAKO (JC70A) Mouse  1:20 
Blocking 
buffer 
S100A4 
Abcam 
(ab27957) 
Rabbit 0.72 mg/mL 1:100 
αSMA 
Abcam 
(ab5694) 
Rabbit 0.2 mg/mL 1:50 
 
Table 2.5 Secondary antibodies for ICC 
Antigen 
Secondary 
antibody 
Manufacturer Concentration Dilution  Buffer 
CD31 
Goat anti-
mouse IgG 
Alexa Fluor 
546  
Thermo 
Scientific 
(A11030) 
2 mg/mL 1:500 
Blocking 
buffer S100A4 Goat anti-
rabbit IgG 
Alexa Fluor 
488 
Thermo 
Scientific 
(A11008)  
2 mg/mL 1:500 
αSMA 
 
  
Chapter 2  72 
 
 
2.5.1 Phalloidin stain 
Phalloidin is a phallotoxin found in Amanita phalloides (death cap mushroom). It 
acts by binding and stabilising filamentous (F-) actin and prevents its 
depolymerisation. Due to its high selectivity for F-actin, fluorescently labelled 
phalloidin is widely used to visualise and investigate cytoskeletal architecture.  
Prior to phalloidin stain, cells were fixed with 4 % PFA as previously described in 
Section 2.5. Cells were then permeabilised in 0.1 % (v/v) Triton X-100 in PBS for 
10 min and washed with PBS three times. Cells were then stained with 5 μg/mL 
fluorescein isothiocyanate (FITC) labelled phalloidin (Sigma, Dorset, UK) 
prepared with 1 % bovine serum albumin (BSA) in PBS at room temperature in 
the dark for 1 h. Cells were then washed three times with PBS and the coverslips 
mounted with Prolong Gold+DAPI (Thermo Fisher, Paisley, UK) onto glass 
microscope slides. 
Images were captured by confocal imagining (Section 2.6) at 25x magnification 
with a 0.7x zoom and the Argon/2 and Diode405-30 to visualise phalloidin and 
DAPI, respectively. Images were captured from five fields of view per coverslip 
and care was taken to capture images where cell boundaries were clearly 
visible. Image analysis was performed using ImageJ. The scale was manually 
adjusted with a pre-defined macro and using the polygon lasso tool, individual 
cells were outlined as regions of interest and surface area was measured. Mean 
cell size was calculated across all measurements per treatment.  
2.6 Confocal Microscopy 
Confocal microscopy is a microscopy technique that allows the creation of true 
three-dimensional images of a sample. This is achieved by illuminating the 
sample with a laser beam and excluding out-of-focus reflected light.  
The working principle of confocal microscopy is illustrated in Figure 2-4. In the 
confocal microscope, the sample is illuminated by a fine laser beam. The beam 
is passed through a pinhole and then reflects off a dichroic mirror which reflects 
light shorter than a certain wavelength and passes light at longer wavelength. 
The beam is then focussed on a small spot (1 pixel) in the sample by the 
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microscope objective. The emitted light passes through the dichroic mirror and 
is focused on a detector pinhole. The light passing through the pinhole is 
measured by the photomultiplier tube detector and transferred into a visual 
image of the section in the sample. Out-of-focus light does not enter the pinhole 
and therefore is eliminated. In this way, an image is generated only from the 
point of focus and the sample can be sectioned at multiple planes.  
Confocal microscopy was carried out on a LSM 510 Meta laser scanning confocal 
microscope and the accompanying LSM510 software (Zeiss, Cambridge, UK). 
Specimens were imaged at either 25x or 40x magnification with variable zoom 
using a LCI Plan-neofluar 25x/ 0.8 mm KorrPh2 and C-Apochromat 40x/1.2 W 
corr water immersion lens, respectively. Green, red and blue flourescence were 
visualised using an Argon/2– 458/477/488/514 (excitation of e.g. FITC), HeNe543 
(excitation of e.g. WGA) and Diode 405-30 (excitation of DAPI) laser, 
respectively. Images were exported as LSM files and post-processing was 
performed in either Zen 2 lite black (Zeiss, Cambridge, UK) or ImageJ.  
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Figure 2-4. Working schematic of confocal microscopy.  
The laser beam is passed through a pinhole and reflected by the dichromatic mirror before being 
focused on one focal plane by the objective. The reflected light is passed through the dichromatic 
mirror and a detection pinhole and detected by the photomultiplier. Out of focus light from other 
focal planes does not pass through the pinhole and is therefore discarded from the image 
acquisition.  
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2.7 Histology 
2.7.1 Processing, sectioning and re-hydration 
Prior to processing, fixed tissue was transferred into Shandon biopsy cassettes 
(Thermo Scientific, Paisley, UK) and then processed in a Shandon Excelsior tissue 
processor (Thermo Scientific, Paisley, UK) according to the sequence shown in 
Table 2.6. Once infiltrated in wax, the tissue was embedded on a Shandon 
Histocentre 3 (Thermo Scientific, Paisley, UK). Hearts were orientated 
longitudinally to visualise the full myocardial architecture. For sectioning, heart 
tissue blocks were chilled on ice and then sectioned on a Shandon Finesse 325 
microtome (Thermo Scientific, Paisley, UK). Initially, tissue blocks were peeled 
in to visualise the entire cardiac chamber from which point on 5 μm serial 
sections were taken for staining. The sections were transferred to a waterbath 
at 40 ºC to flatten the tissue section before mounting on Tissue-Tek silanized 
microscope slides (Sakura Finetek, Thatcham, UK) and placing at 60 ºC overnight 
to dry the tissue.  
Prior to histological staining, sections were de-paraffinised and re-hydrated by 
passing through histoclear and a gradient of alcohol as outlined in Table 2.7. 
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Table 2.6 Processing sequence for paraffin-embedded tissue sections 
Solvent Time (min) 
70 % Ethanol 30 
95 % Ethanol 30 
100 % Ethanol 30 
100 % Ethanol 30 
100 % Ethanol 45 
100 % Ethanol 45 
100 % Ethanol 60 
Xylene 30 
Xylene 30 
Xylene 30 
Paraffin wax 30 
Paraffin wax 30 
Paraffin wax 45 
 
Table 2.7 Re-hydration sequence for histology 
Solution Time (min) 
Histoclear 7 
Histoclear 7 
100 % Ethanol 7 
90 % Ethanol 7 
70 % Ethanol 7 
Water 5 
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2.7.2 Picrosirius Red  
Picrosirius red is one of the most commonly used histological stains to assess 
collagen deposition in a variety of tissues. The stain is comprised of a solution of 
yellow picric acid which is a small anionic and hydrophobic dye and sirius red, a 
large hydrophilic acid dye which penetrate the tissue at different rates. This 
property leads to the characteristic stain where collagenous tissue is stained 
bright red and remaining tissue yellow.  
After re-hydration, sections were placed into Weigert’s haematoxylin (prepared 
by mixing equal volumes of reagent A and B) (TCS Bioscience, Buckingham, UK) 
for 10 min to stain the nuclei before washing under running tap water for a 
further 10 min. Slides were then stained in a 0.1 % sirius red solution in 
saturated picric acid (Pricrosirius red (F3BA)) (Sigma, Dorset, UK) in the dark for 
90 min. Slides were then briefly washed in two changes of 0.01 N HCl (acidified 
water) by quickly dipping 3 times before de-hydration in two changes of 100 % 
ethanol for 3 min and two changes in histoclear for 7 min. Sections were then 
mounted in DPX mountant (Sigma, Dorset, UK) and dried overnight at room 
temperature.  
2.7.3 Immunohistochemistry 
Immunohistochemistry allows the detection of specific antigens in tissue sections 
by using antigen-specific antibodies which are then visualised by secondary 
enzymatic reactions or fluorescence. A workflow diagram of the steps involved 
in the histological staining process is shown in Figure 2-5. All incubations were 
performed in humidified chambers in the dark to prevent evaporation. 
  
Chapter 2  78 
 
 
 
Figure 2-5. Workflow of immunohistochemical staining.  
In paraffin embedded section, the antigen is unmasked by enzymatic or heat-mediated antigen 
retrieval. This is followed by blocking and incubation with antigen-specific primary antibody. 
Primary antibodies are visualised by either using fluorescently-conjugated or enzyme-conjugated 
secondary antibodies (raised against the host species of the primary antibody). 
  
Chapter 2  79 
 
 
Prior to histological staining, tissue was processed, cut and re-hydrated as 
described (Section 2.7.1 and Table 2.7). This was followed by sodium citrate 
mediated antigen retrieval which involves boiling the sections in an acidic 
solution to unfold the antigen masked by the protein cross-links of the formalin 
fixation. Slides were placed into pre-heated sodium citrate solution and boiled 
for 10 min and allowed to cool for a further 20 min to allow correct re-folding of 
the antigen. Slides were then rinsed under running tap water for 5 min followed 
by two washes in 1x PBS for 5 min. Endogenous biotin activity was quenched by 
incubation in 3 % H2O2 in distilled H2O for 15 min at room temperature followed 
by a 5 min wash in 1x PBS. Sections were then blocked in the appropriate 
blocking solution for 30-60 min as indicated (Table 2.8). Following the removal 
of the blocking solution by gentle tapping, sections were incubated with primary 
antibody prepared at the appropriate dilution in modified blocking solution at 
4 ºC overnight (Table 2.8). Appropriate IgG at equal concentration was used as a 
negative control. For secondary enzymatic detection, sections were washed 
three times in PBS for 5 min followed by incubation with the appropriate 
secondary antibody (Table 2.9). For collagen I, enzymatic detection by 3,3’-
Diaminobenzidine (DAB) staining was performed directly by using a horse radish 
peroxidase (HRP)–linked secondary antibody which provides a near 1:1 signal 
ratio to the antibody bound. For collagen III and CD31, a biotinylated secondary 
antibody was used and the signal was amplified by attaching HRP-linked avidin-
biotin complex. Avidin has four high affinity binding sites for biotin and by 
binding the biotinylated secondary antibody at its unoccupied sites, the avidin-
biotin complex amplifies the signal several-fold. For avidin-biotin signal 
amplification, the Vectastain ABC Kit (VectorLabs, Peterborough, UK) was used 
according to the manufacturer’s instructions. Briefly, 2 drops of reagent A were 
mixed with 2 drops of reagent B in 5 mL PBS and incubated for 30 min at 4 ºC to 
allow the avidin-biotin complexes to form before applying to the tissue sections 
for 30 min at room temperature. Prior to colour detection with DAB, sections 
were washed 3x 5 min in PBS.  
DAB builds the substrate for the HRP linked to the secondary antibody complex 
and when oxidised forms a brown precipitate at sites of primary-secondary 
antibody interactions. DAB was prepared according to the manufacturer’s 
instructions of the DAB Peroxidase substrate kit (VectorLabs, Peterborough, UK). 
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Briefly, 2 drops of buffer, 4 drops of DAB and 2 drops of H2O2 were mixed in 
distilled water and the prepared mix was added to one slide. A stopwatch was 
started and the colour reaction was monitored under a microscope. Once dark 
brown staining was evident, the reaction was stopped by placing the slide in 
water. All other slides were developed according to the same protocol. Slides 
were then washed under running tap water before counterstaining nuclei with 
Harris haematoxylin (Sigma, Dorset, UK) for 30 s. Slides were rinsed for a further 
5 min in tap water and then dehydrated using the reverse sequence of the re-
hydration protocol (Table 2.7). Sections were mounted in DPX mountant and 
dried overnight.  
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Table 2.8 Primary antibodies for IHC 
Antigen Manufacturer 
Host 
Species 
Concentration Dilution Buffer Blocking Buffer and time 
CD31 Dianova (SZ31) Rat 0.2 mg/mL 1:20 2 % rabbit serum in PBST 15 % rabbit serum PBST, 30 min 
Collagen I 
Abcam 
(ab34710) 
Rabbit 1 mg/mL 1:200 
4 % goat serum in 1 % 
BSA/PBS 
6 % goat serum in 1 % BSA/PBS, 60 
min 
Collagen 
III 
Abcam (ab7778) Rabbit 1 mg/mL 1:1000 2 % goat serum in PBST 15 % goat serum in PBST, 30 min 
 
Table 2.9 Secondary antibodies for IHC 
Antigen Secondary antibody Manufacturer Concentration Dilution  Buffer Incubation time 
CD31 Biotinylated rabbit anti-rat VectorLabs (BA-4000) 1.5 mg/mL 1:500 PBST 30 min 
Collagen I HRP goat anti-rabbit DAKO (PO448) 0.25 mg/mL 1:100 1 % BSA/PBS 45 min 
Collagen III Biotinylated goat anti-rabbit VectorLabs (BA-1000) 1.5 mg/mL 1:500 PBST 30 min 
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2.7.4 Imaging and analysis 
Sections stained for picrosirius red, collagen I, collagen III and CD31 were 
imaged on the EVOS FL Imaging system (Thermo Scientific, Paisley, UK) or an 
Olympus BX41 microscope connected to a QImaging Go-3 CMOS camera. Per 
section, 5 fields of view around the entire myocardium were captured as 8-bit 
TIFF files. 
Picrosirius red, collagen I and collagen III staining was analysed using Image-Pro 
Analyzer 7.0 (MediaCybernetics, Rockville, USA). The scale was set manually 
using a predefined macro. In all cases, the count/size menu was used to specify 
and select the colour and intensity of the stain and stained area was expressed 
as percent of total area.  
CD31 staining was analysed using ImageJ (National Institute of Health, US). The 
scale was set manually using a predefined macro and the image was subdivided 
into 6 squares. Capillaries and nuclei were counted manually using the cell 
counter in each individual square. For capillary/cardiomyocyte ratio, the ratios 
of capillaries/nuclei in each individual square were averaged. For 
capillaries/mm2: 
capillaries
mm2
= (
sum of capillaries in all squares
area of squares 
)  x 106 
2.7.5 Dual Immunofluorescence 
Immunofluorescence provides an alternative to enzymatic detection in paraffin 
embedded tissue sections and due to the variety of fluorophore colours greatly 
facilitates multiplexing, especially when co-localisation of certain antigens is to 
be determined.  
Tissue sections were prepared and re-hydrated as outlined previously (Section 
2.7.1 and Table 2.7) followed by antigen retrieval in 10 mM sodium citrate for 
10 min as described previously (Section 2.7.3). Sections were then washed under 
running tap water for 10 min followed by 3x 2 min washes in TBS. Sections were 
blocked in TBST with 15 % goat serum for 30 min before incubation with CD31 
and S100A4 or CD31 and αSMA as outlined (Table 2.10) at 4 ºC overnight. 
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Sections were washed 3x 5 min with TBS and then incubated with secondary 
antibody for 2 h at room temperature (Table 2.11). Slides were washed 3x 5 min 
in TBS in the dark and then treated with 0.1 % sudan black for 10 min at room 
temperature to remove lipofuscin-mediated autofluorescence. Sudan black was 
removed in three 5 min washes of TBS before staining sections with 10 μg/mL 
DAPI (Sigma, Dorset, UK) for 10 min. DAPI was quickly washed off in TBS before 
sections were mounted with Prolong Gold+DAPI (Thermo Scientific, Paisley, UK) 
and allowed to dry overnight. Images were captured by confocal microscopy 
(Section 2.6). 
Co-localisation was assessed using ImageJ with the plugin Just another Co-
localisation Plugin (JACoP). In both, the green and the red channel, the 
thresholds were manually adjusted to exclude background fluorescence and the 
Pearson’s coefficient R and Mander’s M1 and M2 coefficients were calculated. 
Pearson’s R value is a measure of a linear relationship between both channels 
and ranges between -1 to +1 where -1 indicates negative correlation and 1 
positive correlation or co-localisation. Mander’s M1 and M2 coefficients calculate 
the ratio of overlap between the two channels and range from 0 to 1 (Bolte and 
Cordelières, 2006).  
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Table 2.10 Primary antibodies for immunofluorescence 
Antigen Manufacturer 
Host 
Species 
Concentration Dilution Buffer 
CD31 Dianova (SZ31) Rat 0.2 mg/mL 1:20 
10 % goat 
serum in TBST 
S100A4 
Abcam 
(ab27957) 
Rabbit 0.72 mg/mL 1:200 
αSMA 
Abcam 
(ab5694) 
Rabbit 0.2 mg/mL 1:100 
 
Table 2.11 Secondary antibodies for immunofluorescence 
Antigen 
Secondary 
antibody 
Manufacturer Concentration Dilution  Buffer 
CD31 
Goat anti-rat 
IgG Alexa Fluor 
488 
Thermo 
Scientific 
(A11006) 
2 mg/mL 1:500 
TBST 
S100A4 Goat anti-rabbit 
IgG Alexa Fluor 
546 
Thermo 
Scientific 
(A11010)  
2 mg/mL 1:500 
αSMA 
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2.7.6 Wheat Germ Agglutinin 
Wheat Germ Agglutinin (WGA) is a plant lectin found in Triticum vulgaris 
(wheat) which preferentially binds to sugars with N-acetylglucosamine and N‑
acetylneuraminic  acid (sialic acid) residues commonly found in membrane 
glycoproteins (Wright, 1984). In the myocardium, N-acetylglucosamine and sialic 
acid are especially abundant in the cardiomyocyte membrane and the t-tubular 
structures and in cardiac histology, fluorescently-labelled WGA is widely used to 
visualise the cardiomyocyte membrane and determine cardiomyocyte cross-
sectional area (Savio-Galimberti et al., 2008, Tsukamoto et al., 2013, Bueno et 
al., 2000). 
Sections were de-paraffinised and re-hydrated as described previously (Table 
2.7) before sodium citrate-mediated antigen retrieval as described previously 
(Section 2.7.3). Slides were allowed to cool for 20 min and washed under running 
tap water for 5 min followed by 1x PBS for another 5 min. Sections were blocked 
in 1x PBS with 1 % BSA and 5 % goat serum (VectorLabs, Peterborough, UK) for 
1 h at room temperature before being incubated with 10 μg/mL Alexa Fluor 555 
conjugated WGA (Thermo Scientific, Paisley, UK) prepared in the blocking 
solution for 1 h. Following incubation, sections were washed twice in 1x PBS for 
5 min and mounted in Prolong Gold+DAPI (Thermo Scientific, Paisley, UK). Slides 
were protected from light and allowed to dry overnight prior to imaging by 
epifluorescence using an Olympus BX40 microscope connected to a QiCam 12-bit 
Mono Fast 1394 Cooled camera or confocal microscopy (Section 2.6). 
Images were taken from 5 fields of view from each section and were analysed in 
ImageJ. The scale was set using a predefined macro. Cardiomyocyte cross-
sectional area was measured using the region of interest tool to trace individual 
cardiomyocytes (Figure 2-6 B). Twenty-five cardiomyocytes were measured per 
image. Cardiomyocyte diameter was measured across the widest point of the 
cross-section of a cardiomyocyte (Figure 2-6 B). Forty cardiomyocytes were 
measured per image. Cardiomyocyte length was measured in longitudinal images 
and length was measured across the length of the cardiomyocyte (Figure 2-6 A). 
Up to ten cardiomyocytes were measured per image. Mean cell size and length 
was determined as the average of all measurements across all five images.  
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Figure 2-6. Measurements of cardiomyocyte size. 
Cardiac sections were stained with wheat germ agglutinin and images were taken from longitudinal 
and cross-sectional cardiomyocytes and analyised using ImageJ. (A) Cell length was measured by 
measuring the longest part of the cell from intercalated disk to intercalated disk of adjacent 
cardiomyocytes (indicated by white line). (B) Cell cross-sectional area was measured by tracing the 
perimeter of individual cardiomyocytes (indicated by white line) and measuring cell area. Cell 
diameter was measured across the widest point of a cardiomyocyte cross-section (indicated by 
white line). Scale bar: 100 μm. 
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2.8 Gene expression analysis 
Gene expression is the process by which the information on a gene is transcribed 
for the synthesis of proteins. In scientific investigations it is usually employed to 
assess increases or decreases in the expression of certain genes associated with 
specific treatment conditions or to verify the active expression of certain genes 
in a sample. The analysis of the mRNA profile in a sample is a multistep process 
which involves RNA purification and quantification before its reverse 
transcription to cDNA and subsequent analysis by quantitative polymerase chain 
reaction (qPCR). 
2.8.1 RNA purification 
High quality RNA extracts without genomic DNA contamination are needed for 
downstream applications such as qPCR and microarray analysis and may not be 
achieved by standard RNA extraction protocols. The miRNeasy Mini Kit 
(Qiagen,Manchester, UK) combines QIAzol based lysis with membrane based RNA 
purification to yield molecular biology grade RNA ranging from 18 nucleotides 
upward for downstream analysis.  
2.8.1.1 Cell/Tissue lysis 
QIAzol is a phenol/guanidine thiocyanate based lysis reagent that is optimised 
for lysis of fatty tissues and inhibits RNases to stabilise the RNA product. Organic 
extraction with QIAzol efficiently removes genomic DNA contamination.  
Cells cultured as described in Section 2.2 were washed in PBS twice before 
addition of 700 μL QIAzol to each well for lysis. Cells were scraped with the 
rubber bung of a 1 mL syringe for optimal lysis and the solution was transferred 
to 1.5 mL RNase free tubes (Thermo Scientific, Paisley, UK). Samples were 
vortexed briefly for complete homogenisation. Samples were then processed as 
described in Section 2.8.1.2 or stored at -80 ºC for later analysis.  
For RNA extraction from tissue, 10-30 mg of tissue sample (heart) was weighed 
out into 2 mL RNase free tubes on dry ice followed by the addition of 700 μL 
QIAzol and a 5 mm stainless steel bead (QIAgen, Manchester, UK). The tissue was 
then lysed in a tissue lyser (Qiagen, Manchester, UK) at 25 Hz for 4x 30 s for 
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complete homogenisation of the tissue. The homogenate was immediately 
processed and RNA extracted as outlined in Section 2.8.1.2.  
2.8.1.2 Extraction 
RNA extraction from QIAzol lysed cell or tissue samples was performed using the 
miRNeasy mini kit (QIAgen, Manchester, UK) according to the manufacturer’s 
instructions.  
Following lysis the homogenate was placed on the benchtop for 5 min at room 
temperature to promote dissociation of nucleoprotein complexes. This was 
followed by the addition of 140 μL chloroform and samples were shook vigorously 
for 15 s for complete mixing of the suspension. The samples were then incubated 
on the benchtop at room temperature for 3 min and then spun at 12,000 x g at 
4 ºC for 15 min. This organic extraction step efficiently removes genomic DNA 
and protein from the sample by separating the solution into three phases: a 
lower red organic phase which contains protein; a white interphase consisting of 
genomic DNA and the upper colourless aqueous phase which contains RNA. The 
aqueous phase (usually 200 μL) was transferred to a new tube and 525 μL 100 % 
ethanol was added. The sample was then pipetted into a spin column and 
centrifuged at 8000 x g for 15 s to bind the RNA to the silica membrane in the 
spin column. At this step, on-column DNase digestion was performed to remove 
any residual contaminating genomic DNA. 
Briefly, the column was washed with 350 μL of the ethanol based wash buffer 
RWT. A stock of DNase I was prepared as per the manufacturer’s instructions 
(Qiagen, Manchester, UK) where per tube 10 μL of DNase I was mixed with 70 μL 
RDD buffer. 80 μL of prepared DNase I was added directly onto the column 
membrane and incubated at room temperature for 15 or 30 min for cell and 
tissue lysates, respectively. The DNase was removed by washing the column with 
350 μL RWT buffer.  
Following DNase I digestion, the column was washed twice with 500 μL of the 
ethanol based wash buffer RPE for 15 s and 2 min, respectively. The column was 
then placed in a new 2 mL collection tube and subjected to centrifugation at 
16,100 g for 2 min to dry the membrane and remove carryover of RPE buffer. 
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The RNA was then eluted from the column by the addition of 30-50 µL of RNase 
free water directly on the membrane and spinning at 8000 g for 1 min. To 
increase RNA yield and concentration, the elute was passed through the column 
again. RNA concentration and quality was then assessed by nanodrop as 
described in Section 2.8.1.3. 
2.8.1.3 RNA quantification 
Purified RNA was quantified using the Nanodrop 1000 Spectrophotometer 
(Thermo Scientific, Paisley, UK). The Nanodrop allows the measurement of 
nucleic acid as well as protein concentration in a sample volume as small as 1 μL 
by using a novel sample retention system. It works by applying 1-2 μL of sample 
to a pedestal which will form a liquid column once the upper arm is lowered on 
the sample. A xenon light will pulse a light near 260 nm through the specimen, 
the absorption of which is measured by the CCD detector in the bottom and from 
which the concentration is calculated with a modification of the Beer-Lambert 
equation: 
C=
(A x ε)
b
 
where C is the concentration of the sample in ng/μL, A the absorbance measured 
at 260 nm, ε the wavelength dependent extinction coefficient (for RNA 40 ng-
cm/μL) and b the path length in cm (for the Nanodrop 1000 this is 0.2 and 1 mm) 
(Gallagher and Desjardins, 2006). Since ssDNA, dsDNA and RNA all absorb at 
260 nm their purification is therefore essential prior to spectrophotometric 
quantification. 
Since RNA absorbs at 260 nm but not 280 nm, the 260/280 absorbance ratio was 
used to determine the purity of RNA and an absorbance ratio from 1.8– 2.2 was 
considered as pure. Lower absorbance ratios indicate a contamination of protein 
or phenol or other substance that absorb at 280 nm.  
2.8.2 Real time quantitative reverse transcription PCR 
Real time qPCR is a method by which expression of specific genes of interest can 
be measured in a complex sample. It is one of the most sensitive methods for 
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gene expression analysis and measures the PCR reaction as it occurs which 
allows later quantification of the starting concentration and copy number. This 
is in contrast to less sensitive endpoint methods (such as Northern blots or 
standard PCR) where gene quantification is not possible (Schmittgen et al., 
2000). Real time qPCR is based on the use of fluorescent reporters that allow 
monitoring of the amplification reaction as it occurs. Two chemistries have been 
developed for use in real time qPCR: TaqMan and SYBR Green I dye. TaqMan 
chemistry is based on the use of Taq DNA polymerase which has intrinsic 5’ 
nuclease activity and dual labelled hydrolysis probes. Such probes have a 
fluorescent reporter (FAM) located at the 5’ end and a quencher (MGB) in the 
minor groove at the 3’ end. The proximity of the MGB moiety in the intact probe 
significantly reduces the fluorescence of the reporter (Figure 2-7 A). When 
combined with cDNA product, the probe will anneal to its target sequence and 
as Taq polymerase extends the strand, it cleaves the probe at the 5’ end and 
thereby separates the fluorescent reporter from the probe and significantly 
increases the fluorescent signal. Additionally, the probe will now be removed 
from the target strand and allows complete target strand extension (Figure 2-7 
A). As the reaction progresses, more probe will be cleaved and the increase in 
fluorescent signal is directly proportional to the amount of amplicon (Heid et 
al., 1996). In contast, SYBR Green I dye is based on its ability to bind double 
stranded (ds) DNA. When bound to dsDNA, SYBR Green emits fluorescence and 
hence, the more the target sequence is amplified, the higher the fluorescence 
emitted by the dye (Figure 2-7 B). However, since SYBR Green binds all dsDNA, it 
bears the risk of amplifying non-specific targets and protocols are lengthened by 
the analysis of melt curves to assess for primer-dimers in the reaction.  
A PCR reaction consists of 3 phases: The exponential phase where there is exact 
doubling of PCR product due to high abundance of reagents; the linear phase 
where exact doubling of product no longer occurs due to depletion of reagents; 
and the plateau phase where the reaction is stopped as all reagents have been 
used up. This is usually measured in end-point assays of gene expression. In real 
time qPCR the threshold, the intensity of fluorescence above background, is set 
when the reaction enters its exponential phase and where variability is the 
lowest. The cycle at which a sample crosses this threshold is defined as the Ct 
and used for later quantitative analysis. Real time qPCR reactions can be 
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performed in one step where the reverse transcription and the PCR are 
performed in one system or as a two-step procedure where reverse transcription 
is carried out separately from the PCR reaction as outlined below. 
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Figure 2-7. Working principle of TaqMan and SYBR Green gene expression analysis.  
(A) The close proximity of the Quencher (Q) to the reporter dye (R) in the TaqMan probe quenches 
baseline fluorescence. Upon transcription and elongation of the DNA strand by Taq polymerase, 
the reporter is cleaved from the quencher which now exhibits bright fluorescence. (B) SYBR green 
probes exhibit strong fluorescence when bound to double-stranded DNA. Upon depolymerisation, 
there is a net decrease in fluorescence. As new strands are extended, fluorescence increases and 
once polymerisation is complete there is a net increase in fluorescence. Adapted from Applied 
Biosystems (2010). 
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2.8.2.1 Reverse transcription 
Reverse transcription was performed using Taqman reverse transcription 
reagents (Thermo Fisher, Paisley, UK) according to the manufacturer’s 
instructions. The reactions were prepared in a 96-well PCR plate (Starlab, Milton 
Keynes, UK). In brief, for a 20 μL reaction, reagents were prepared as follows: 
2 μL 10 x RT buffer, 4.4 μL 25mM MgCl2, 4 μL 10 mM dNTPs, 1 μL 50 μM random 
hexamers, 0.4 μL RNase Inhibitor (20 U/μL), 0.5 μL Multiscribe reverse 
transcriptase (50 U/μL) and 7.7 μL of RNA pre-diluted in RNase-free water. For 
gene expression analysis in cell culture samples, RNA was pre-diluted to the 
lowest concentration in the sample set (ranging between assay-dependent 
concentrations of 20-200 ng/μL). For tissue samples, samples were pre-diluted 
to 200 ng/μL and 5 μL was added to give a final amount of 1 μg RNA in the cDNA 
reaction. A negative reaction where only H2O was added served as negative 
control for specific amplification. The plate was sealed with an adhesive sheet 
and briefly centrifuged to mix the components in the bottom of the plate. The 
plate was placed on a PCR block set up for the cycling conditions indicated 
(Table 2.12). Samples were stored at -20ºC until required. 
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Table 2.12 Cycling conditions for reverse transcription 
Step Temperature (ºC) Time (min) 
1 25 10 
2 48 30 
3 95 5 
4 4 infinite 
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2.8.2.2 Quantitative PCR 
qPCR was performed in 384-well MicroAmp optical PCR plates (Thermo Fisher, 
Paisley, UK) with a total reaction volume of 10 μL. For 1 reaction, 5 μL of 
TaqMan master mix II (Thermo Scientific, Paisley, UK) containing AmpliTaq Gold 
DNA polymerase, dNTPs, ROX passive reference and buffer was combined with 
0.5 μL of the appropriate TaqMan assay containing the specific primer 
components (Table 2.13, Table 2.14, Table 2.15), 1.5 μL of the RT product and 
made up with RNase free H2O to 10 μL. In certain circumstances where 
expression of the target gene was low, the volume of RT product was increased 
to load a maximum of 100 ng cDNA in the reaction. Reactions were performed in 
duplicate and the cDNA negative and H2O served as negative controls. The plate 
was sealed with an optical adhesive sheet and centrifuged to mix the 
components and remove any air bubbles in the sample. qPCR was performed 
either on a 7900HT Fast or a Quantstudio 12K Flex Real Time PCR System with 
the accompanying software (Thermo Fisher, Paisley, UK). To reduce variability, 
the PCR system used was kept consistent for related data sets. The cycling 
conditions used are shown (Table 2.16). Cycle threshold (Ct) was determined as 
the cycle where the reaction entered the exponential phase. Data were 
expressed as relative quantity (RQ) according to the 2-ΔΔCt method (Schmittgen 
and Livak, 2008) where 
ΔΔCt=(Ct gene of interest(A)-Ct internal control(A)) 
 - (Ct gene of interest(B)-Ct internal control(B)) 
with A = sample of interest and B = reference sample (i.e. control). 
In tissue samples, Ppib (Peptidylprolyl Isomerase B), a cyclosporine-binding 
protein involved in the celluar secretory pathways, was selected as 
housekeeping gene as it has been verified to be stable across all treatment 
groups in previous investigations using an endogenous control assay. For cell 
culture samples, GAPDH was verified as stable housekeeping gene.  
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Table 2.13 Mouse TaqMan probes 
Gene Assay ID 
Reference 
Sequence 
Label 
ACE Mm00802048_m1 NM_001281819.1 FAM/MGB 
ACE2 Mm01159003_m1 NM_001130513.1 FAM/MGB 
ACTA2 Mm00725412_s1 NM_007392.3 FAM/MGB 
Agtr1a Mm00616371_m1 NM_177322.3 FAM/MGB 
Agtr2 Mm01341373_m1 NM_007429.5 FAM/MGB 
Col1a1 Mm00801666_g1 NM_007742.3 FAM/MGB 
Col3a1 Mm01254476_m1 NM_009930.2 FAM/MGB 
MYH7 Mm01319006_g1 NM_080728.2 FAM/MGB 
Nppa Mm01255747_g1 NM_008725.2 FAM/MGB 
Nppb Mm01255770_g1 NM_001287348.1 FAM/MGB 
Ppib Mm00478295_m1 NM_011149.2 FAM/MGB 
S100A4 Mm00803372_g1 NM_011311.2 FAM/MGB 
TGFβ1 Mm01178820_m1 NM_011577.1 FAM/MGB 
 
Table 2.14 Human TaqMan probes 
Gene Assay ID 
Reference 
Sequence 
Label 
ACTA2 Hs00426835_g1 NM_001141945.1 FAM/MGB 
Cdh5 Hs00901463_m1 NM_001795.3 FAM/MGB 
CNN1 Hs00154543_m1 NM_001299.4 FAM/MGB 
Col1a1 Hs00164004_m1 NM_000088.3 FAM/MGB 
GAPDH 4326317E NM_002046.3 VIC/MGB 
PECAM1 Hs00169777_m1 NM_000442.4 FAM/MGB 
S100A4 Hs00243202_m1 NM_002961.2 FAM/MGB 
Smad4 Hs00929647_m1 NM_005359.5 FAM/MGB 
Smad7 Hs00998193_m1 NM_001190821.1 FAM/MGB 
SNAI1 Hs00195591_m1 NM_005985.3 FAM/MGB 
SNAI2 Hs00950344_m1 NM_003068.4 FAM/MGB 
TAGLN Hs01038777_g1 NM_001001522.1 FAM/MGB 
TGFβ Hs00998133_m1 NM_000660.4 FAM/MGB 
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Table 2.15 Rat TaqMan probes 
Gene Assay ID 
Reference 
Sequence 
Label 
ACE Rn00561094_m1 NM_012544.1 FAM/MGB 
ACE2 Rn01416293_m1 NM_001012006.1 FAM/MGB 
Agtr1a Rn02758772_s1 NM_030985.4 FAM/MGB 
Agtr2 Rn00560677_s1 NM_012494.3 FAM/MGB 
CTGF Rn01537279_g1 NM_022266.2 FAM/MGB 
Mas Rn00562673_s1 NM_012757.2 FAM/MGB 
Nppa Rn00664637_g1 NM_012612.2 FAM/MGB 
Nppb Rn00676450_g1 NM_031545.1 FAM/MGB 
Ppib Rn00574762_m1 NM_022536.2 FAM/MGB 
 
Table 2.16 Cycling conditions for qPCR 
Step Temperature (ºC) Time 
1 95 10 min 
2 95 15 s 
Repeat 40x 
3 60 1 min 
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2.9 Protein expression analysis 
2.9.1 Protein extraction 
Protein extraction is the process by which individual cellular proteins are 
isolated from the intact cells and tissue. Cell lysis is the first step in the process 
of protein extraction and is normally achieved by the physical disruption of cell 
in conjunction with detergent-based lysis buffers. Such lysis buffer are 
physiological buffers containing detergents (e.g. Triton-X, sodium dodecyl 
sulphate) for membrane disruption, protease inhibitors (e.g. PMSF, EDTA, EGTA) 
to stabilise the cellular proteins and protect them from degradation by activated 
endogenous proteases as well as inhibitors of phosphatases (e.g. NaF, Na3VO4) to 
maintain the protein in its current state and prevent de-phosphorylation.  
Cells cultured in 6-well plates and treated according to the experimental 
outline, were washed twice with cold PBS before the addition of 100 μL Western 
lysis buffer. Cells were disrupted with a cell scraper and the cell lysate 
transferred to an Eppendorff tube. The lysate was then freeze-thawed on dry ice 
to increase cell lysis. The sample was then sonicated at 20 Hz for 5 s using a 
Sonic Dismembrator (Fisher Scientific, Loughborough, UK) before centrifugation 
at 16,100 g for 10 min at 4 ºC to remove any cellular debris. The supernatant 
was then transferred to a fresh tube, protein concentration determined by BCA 
assay (Section 2.9.2) and the sample stored at -20 ºC until use.  
For tissue, 10-30 mg of tissue sample (heart) was weighed out into 2 mL 
Eppendorffs containing 5 mm stainless steel beads on dry ice followed by the 
addition of 10x volume of lysis buffer (i.e. for 20 mg, 200 μL lysis buffer was 
added). The tissue was then lysed in a tissue lyser (Qiagen, Manchester, UK) at 
25 Hz for 4x 30 s for complete homogenisation of the tissue and subsequently 
processed as described above for cell lysate. 
2.9.2 The bicinchoninic acid assay 
The bicinchoninic acid (BCA) assay is a colorimetric assay for the detection and 
quantification of total protein in a sample. It is based on the biuret reaction 
where Cu2+ is reduced to Cu1+ by protein in an alkaline medium to develop a 
purple colour on reaction with BCA which exhibits a strong absorbance at 
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562 nm. The colour development is highly proportional to the concentration of 
protein in the assay and using standards of common proteins such as BSA with 
known concentration allows the construction of a standard curve from which 
unknown protein concentration can be determined. The BCA assay has the 
advantage that unlike other protein assay formulations it is compatible with a 
wide variety of detergents and denaturing reagents found in common protein 
lysis buffers (Walker, 1994).   
The BCA assay was performed using the Pierce BCA Protein Assay Kit (Thermo 
Scientific, Paisley, UK) according to manufacturer’s instructions for the micro-
well procedure. The assay was performed in a clear 96-well flat bottom plate. 
Briefly, 9 standard dilutions of known concentration were prepared using the 
provided BSA stock solution as outlined (Table 2.17) and 25 μL of prepared 
standards were pipetted in duplicate into the micro-well plate. Protein sample 
was diluted 1:5 or 1:2.5 by adding 20 μL or 15 μL of PBS to each well and adding 
5 μL or 10 μL of sample, respectively. Samples were prepared in duplicate unless 
starting sample volume was low. The BCA working reagent was then prepared by 
mixing the required volume of Reagent A with 50 parts of Reagent B and 200 μL 
of the resulting green mixture was added to each well. The plate was mixed 
briefly and then incubated at 37ºC for 30 min. Following incubation, absorbance 
was then read at 562 nm using a SpectraMax Spectrophotometer and the 
accompanying software. Using Microsoft Excel, a standard curve was then 
prepared by blotting the mean absorbance of each standard on the X-axis and 
the corresponding amount of BSA in each well on the Y-axis. A best fit linear 
trendline was added and linearity was verified by an R2 ≥ 0.98. Using the 
provided linear equation, the amount of protein in the sample was calculated by 
solving the equation for Y using the determined absorbance values. Protein 
concentration was then calculated: 
Protein concentration (
μg
μL
) = 
Amount of protein (μg)
Volume of protein sample added into reaction (μL)
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Table 2.17 BSA protein standards for the BCA assay 
Standard BSA concentration (μg/mL) Amount of BSA in a well (μg) 
A 2000 50 
B 1500 37.5 
C 1000 25 
D 750 18.75 
E 500 12.5 
F 250 6.25 
G 125 3.125 
H 25 0.625 
I 0 0 
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2.9.3 Western blotting 
2.9.3.1 SDS-Page 
Protein samples prepared as outlined previously (Section 2.9.1 and 2.9.2) were 
diluted to an equal amount of 15-20 μg in a total volume of 11.25 μL PBS with 
3.75 μL of 4x NuPAGE LDS sample buffer (Thermo Scientific, Paisley, UK) to 
make up the volume to 15 μL. This sample buffer contains lithium dodecyl 
sulphate at pH 8.4 which allows for optimal denaturing and reducing conditions 
needed for protein preparation for electrophoresis. The added coomassie dye 
furthermore allows for the visualisation of the progress of the electrophoresis 
along the gel. Prepared samples were heated to 70ºC for 10 min on a heat block 
to denature the protein. In the meantime, 1 L of 1x MES SDS running buffer 
(Thermo Scientific, Paisley, UK) was prepared. Pre-cast NuPAGE Novex Bis-Tris 
gels with a polyacrylamide gradient of 4-12 % (Thermo Scientific, Paisley, UK) 
and the appropriate number of wells were set up in a XCell SureLock Mini gel 
tank (Thermo Scientific, Paisley, UK) and the combs removed. These gels are 
made up of a low acrylamide (4 %) density stacker gel and a running gel with an 
acrylamide gradient (4-12%). Due to the low density of acrylamide and the 
resulting large pores, the stacking gel does not separate the protein but allows 
its concentration into a thin band (Mahmood and Yang, 2012). In the running gel, 
the increasing concentration of acrylamide separates the proteins by size with 
smaller proteins migrating faster than larger ones. Running buffer was added to 
the gel tank to cover the electrodes and the system was checked for leaks. Next, 
the heated protein samples were loaded in the wells and note was taken of the 
order of loading. A pre-stained molecular weight marker (Amersham ECL 
Rainbow Molecular Marker, GE Healthcare Life Sciences, Little Chalfont, UK) was 
loaded into one well for reference. The electrophoresis was run on ice for 45-
60 min at 200 V until the loading dye reached the end of the gel for maximum 
protein separation. 
2.9.3.2 Transfer 
Following electrophoresis as described (Section 2.9.3.1), the gel was transferred 
onto a membrane to allow the detection of protein with antibodies. During 
electrophoresis, transfer buffer was prepared by diluting 10x Western running 
buffer in 20 % (v/v) methanol in distilled H2O. The pre-cut 0.2 μm pore size 
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nitrocellulose membrane (GE Healthcare Life Sciences, Little Chalfont, UK) was 
wetted in distilled H2O before being soaked in transfer buffer for at least 
10 min. Similarly, 6 pre-cut filter papers were soaked in transfer buffer. After 
electrophoresis, the gel was carefully removed from the cassette and placed on 
top of a pre-wetted sponge and 3 pieces of filter paper. The nitrocellulose 
membrane was carefully placed on top of the gel, followed by 3 pieces of filter 
paper and a sponge. A blotting roller was used to ensure no air bubbles were 
trapped in this sandwich. The blotting cassette was then transferred into the 
transfer tank and filled with transfer buffer. Care was taken to ensure that the 
membrane was facing the anode to allow protein to migrate out of the gel and 
onto the membrane. Current was applied at 100 V and run for 90 min at 4 ºC. 
2.9.3.3 Detection 
Following transfer, the membrane was removed from the transfer cassette and 
washed with PBS for 5 min. Successful transfer was verified by the transfer of 
the pre-stained protein ladder. The membrane was then blocked in 30 % Sea 
Block (Thermo Scientific, Paisley, UK) in TBST for 1 h at room temperature. Sea 
block contains steelhead salmon serum in PBS and provides an alternative to 
milk and BSA as blocking reagents. It is especially useful in detection that 
involves mammalian samples as it has less specific binding interactions with 
antibodies and other proteins that usually occur with standard blocking reagents, 
thereby significantly reducing background. Following blocking, the membrane 
was incubated with the appropriate primary antibody (Table 2.18) made up in 
blocking buffer at 4 ºC overnight. As fluorescent detection was used, antibodies 
were multiplexed when possible. The following day, the antibody was removed 
and frozen at -20 ºC for re-use. The membrane was washed 3x 10 min in TBST 
before incubation in the appropriate secondary antibody (Table 2.19) made up in 
blocking buffer. As fluorescent antibodies were used, all further steps were 
performed in the dark. The secondary antibody was removed and frozen at -
20 ºC for re-use and the membrane was washed 3x 10 min in TBST. The 
membrane was then placed in PBS until being scanned on an Odyssey Sa Infrared 
Imaging System (Licor, Cambridge, UK) and the accompanying Odyssey Sa 
software.  
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For quantification, scans were imported into Image Studio Lite version 5.2.5 
(Licor, Cambridge, UK) and using the analysis tool, rectangles were placed 
automatically around each individual band. The background method was set to 
median with a border width of 3. The abundance of the protein of interest was 
then expressed relative to the housekeeper GAPDH: 
relative abundance= 
signal intensity of protein of interest
signal intensity of GAPDH
 
In the case of phospho-proteins, abundance was expressed relative to the total 
abundance of the protein. 
For the analysis of several proteins on the same membrane when antibodies 
cannot be multiplexed, it is necessary to strip and reprobe the membrane. 
Stripping removes bound primary antibody but carries the risk of releasing 
protein from the membrane and decreasing sensitivity. Several different 
stripping options exist with harsh buffers using heat and detergent and milder 
approaches using low or high pH. Here, membranes were stripped using high pH 
and agitated in 0.2 M NaOH for 15 min. Residual NaOH was then washed off with 
TBST for 10 min. The membrane was then re-blocked and protein detection was 
performed as described above.  
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Table 2.18 Primary antibodies for Western blotting 
Antigen Manufacturer 
Host 
Species 
Concentration Dilution 
GAPDH Abcam (6C5) Mouse 2 mg/mL 1:5000 
GAPDH 
Cell Signalling 
(14C10) 
Rabbit n/a 1:1000 
Phospho-PKA C (Thr 197) 
Cell Signalling 
(D45D3) 
Rabbit n/a 1:500 
PKA C alpha 
Cell Signalling 
(#4782) 
Rabbit n/a 1:1000 
Phospho-Smad2 (Ser 
465/467) 
Cell Signalling 
(138D4) 
Rabbit n/a 1:500 
Smad2 
Cell Signalling 
(D43B4) 
Rabbit n/a 1:500 
Phospho-p44/42 MAPK 
(Erk1/2) 
(Thr202/Tyr204) 
Cell Signalling 
(#9109) 
Rabbit n/a 1:1000 
p44/42 MAPK (Erk1/2) 
Cell Signalling 
(#9102) 
Rabbit n/a 1:1000 
Human CD31 DAKO (JC70A) Mouse 515 mg/mL 1:500 
αSMA Abcam (ab5694) Rabbit 0.2 mg/mL 1:500 
 
Table 2.19 Secondary antibodies for Western blotting 
Secondary antibody Manufacturer Concentration Dilution  
Donkey anti-mouse IRDye 
680RD 
Licor (926-68072) 1 mg/mL 1:15000 
Goat anti-mouse IgG Alexa 
Fluor 700 
Thermo Scientific 
(A21036) 
2 mg/mL 1:15000 
Goat anti-rabbit IgG Alexa 
Fluor 790 
Thermo Scientific 
(A11367)  
2 mg/mL 1:15000 
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2.10 Adult mouse cardiomyocyte isolation 
Mouse ventricular cardiomyocytes were isolated from adult C57BL/6 mice by 
Langendorff perfusion with collagenase enzyme.  
Mice were killed by cervical dislocation and the heart was rapidly removed and 
cannulated (Section 2.11.1). The heart was then perfused at a constant flow 
rate of 4 mL/min with Krebs-Henseleit (KH) solution to clear the heart of 
residual blood. Once the perfusate was clear, collagenase type I (Worthington 
Chemicals, USA) and protease XIV (Sigma, Dorset, UK) were added to the 
perfusion solution at a final concentration of 0.7 mg/mL and 0.06 mg/mL, 
respectively. The heart was digested for 6 min 15 s prior to perfusion with 0.5 % 
BSA in KH buffer for a further 4 min to de-activate the enzyme. The heart was 
then removed from the cannula, the RV removed and the LV was cut into small 
pieces which were transferred into a 15 mL falcon tube with fresh 10 mL BSA-KH 
buffer. The heart pieces were agitated with a flame-blunted Pasteur pipette to 
release cells from the tissue. Once the solution appeared cloudy, the remaining 
heart pieces were allowed to settle and 5 mL supernatant was transferred into a 
fresh tube. Fresh BSA-KH was added and the process repeated for a further 2-3 
times. Visual inspection confirmed the presence of viable rod-shaped 
cardiomyocytes. Next, the calcium concentration of the cell suspension was 
gradually increased to 1 mM by incremental addition of 1 μL of 100 mM CaCl2 per 
1 mL cell suspension every 5 min. This limits rapid Ca2+ influx and 
hypercontraction of cardiomyocytes.  
2.10.1 Cardiomyocyte stimulation  
The cardiomyocytes were pelleted using a hand-operated centrifuge and re-
suspended in 8 mL KH buffer containing 1.8 mM Ca2+. The cell solution was 
distributed into 8 individual falcon tubes and cells were stimulated with 1 μM 
Ang-(1-9), 1 μM Ang-(1-7) (Phoenix Pharmaceuticals, Karlsruhe, Germany) or 1 
μM forskolin in duplicate for 15 min. Untreated cell served as time matched 
control. The cells were then pelleted and lysed in protein lysis buffer for 
Western blotting of (phospho-)PKA as described in Section 2.9. 
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2.11 Ex vivo Langendorff perfusion 
Ex vivo Langendorff perfusion of rat hearts was carried out by perfusion of the 
heart with Tyrode’s solution at a constant flow of 10 mL/min which was found to 
be optimal in this experimental system (Figure 2-8 A).  
 
 
Figure 2-8. Constant flow Langendorff perfusion. 
(A) Schematic of the Langendorff perfusion system with constant flow. (B - C) Cannula setup for 
measurement of LVP with the attached balloon prepared out of clingfilm. 
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2.11.1 Harvesting and cannulating the heart 
Adult Wistar rats (Envigo, UK) weighing between 200–250 g were killed by 
concussion with subsequent cervical dislocation. The skin was incised at the 
xyphoid-sternum and the incision continued left and right through the ribs to 
expose the heart. Using blunt forceps and fine curved scissors the heart was 
excised by cutting the ascending aorta at the thymus level. The excised heart 
was immediately transferred to ice cold Ca2+-free Tyrode solution, gently 
squeezed to expel residual blood and transferred into fresh ice cold Tyrode 
solution. Extra-cardiac tissue was quickly removed to dissect the aorta. Next, 
the heart was transferred onto the cannula while perfusate was dripping from 
the cannula to minimise the transfer of air emboli and was secured in place with 
a bulldog clip and then two secure sutures. Care was taken to not insert the 
cannula too deep into the aorta resulting in occlusion of coronary arteries or 
damage of the aortic valves leading to inadequate cardiac perfusion. To allow 
drainage of the perfusate, a small incision was made into the pulmonary artery. 
After successful cannulation, the heart will start beating within seconds, 
however, it may take up to 20 min for normal steady-state contractile function 
to be re-established. For successful and reliable measurements of cardiac 
function, the time from removal of the heart to cannulation and perfusion must 
be kept as short as possible and should not exceed 5 min.  
2.11.2 Instrumentation of the heart 
To measure LV pressure, a fluid-filled balloon connected to a pressure 
transducer is inserted into the LV. This allows the measurement of force 
development within the whole LV and derivation of indices of systolic and 
diastolic function in the heart preparation. The ideal balloon should be infinitely 
thin, flexible and non-elastic while being compatible with biological tissues 
(Skrzypiec-Spring et al., 2007). Commercially available latex balloons do not 
meet all of these criteria and a previous investigation (unpublished) has 
identified that the use of latex balloons resulted in unstable readings of LVEDP 
and LV end systolic pressure (LVESP) over the course of a perfusion protocol. 
This was attributed to the high compliance of the latex balloon which may lead 
to slower relaxation and contraction than the myocardium itself. In contrast, 
balloons prepared out of cling film resulted in stable measurements of LVEDP 
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and LVESP with measurements close to reported values of cardiac function in 
vivo. 
A balloon was prepared out of ordinary cling film (Figure 2-8 C). The LV end 
diastolic volume in rats is approximately 200 μL and the ideal balloon should 
have an approximate volume of 100 μL giving an optimal size for the 
measurement of LV pressure (LVP). The balloon was attached on a 1.5 mm metal 
cannula connected to a haemostasis valve connected to a Hamilton syringe 
(Figure 2-8 B-C). The system was primed with double distilled H2O and all air 
bubbles were eliminated. This is important as air is compressible and would 
falsify pressure measurements. The balloon was then deflated and inserted into 
the LV by removal of the left atrial appendage to visualise the entry into the LV. 
Once positioned correctly, a solid state pressure transducer (Scisense, London, 
Canada) was inserted into the balloon. The balloon was then slowly inflated 
using the Hamilton syringe to give an LVEDP of approximately 3 mmHg which was 
found to be optimal in this preparation. When pacing was required, 2 electrodes 
were attached to the RA connected to a voltage stimulator with delay generator 
(Digitimer Ltd., Welwyn Garden City, UK). The heart was then stimulated at 
5.3 Hz (320 bpm) with 2 ms duration and voltage approximately 1.5x above 
threshold.  
2.11.3 Perfusion Protocols 
Once the heart was cannulated and instrumented, it was allowed to reach a 
steady pressure before pacing (if required) was initiated. The perfusion solution 
was then switched over to a bottle with a fixed volume of perfusion solution to 
start the experiment according to the perfusion protocols for spontaneously 
beating and paced hearts (Figure 2-9). In all cases, the heart was allowed to 
reach a steady state for 10 min. One set of time-matched control hearts where 
equal volumes of Tyrode’s were added at 0 and 10 min was used for comparison 
of all treatments (Figure 2-9 A-B). 
At the end of the perfusion protocol, hearts were rapidly removed from the 
perfusion system and frozen at -80ºC for further analysis.   
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Figure 2-9. Langendorff perfusion protocols. 
Hearts were allowed to reach a steady pressure before the beginning of the perfusion protocol. (A) 
Perfusion protocols in spontaneously beating hearts. Hearts were perfused for 10 min to reach a 
steady state before being perfused for 20 min 1) as control hearts with the addition of Tyrode’s 
solution; 2) with increasing doses of Ang II (1 µM, 3 µM), Ang(1-9) or Ang-(1-7) (1 µM, 10 µM); 3) 
pre-perfusion with 1 µM PD123319 for 10 min prior to the addition of 1 µM Ang-(1-9); 4) a 
combination of Ang II and Ang-(1-9) (both 1 µM); or 5) pre-perfusion with 1 µM Ang II for 10 min 
prior to the addition of 1 µM Ang-(1-9) (B) Perfusion protocols in hearts paced at 320 bpm. Hearts 
were paced at 320 bpm and allowed to reach a steady state for 10 min before being 1) perfused as 
control hearts with the addition of tyrodes solution for 20 min; 2) perfused with 1 µM Ang II or Ang-
(1-9) for 10 min; 3) pre-perfused with 1 µM PD123319 or 10 µM Losartan for 10 min prior to the 
addition of 1 µM Ang-(1-9) for a further 10 min; 4) pre-perfused with 1 µM H89 or 2.5 µM K93 for 
10 min prior to the addition of 1 µM Ang-(1-9) for a further 10 min.  
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2.11.4 Data acquisition and analysis 
The pressure transducer was connected to a Millar MPVS-400 pressure-volume 
loop system (Millar, Houston, Texas) and the LVP trace was recorded using 
LabChart 7.0 (ADInstruments, Oxford, UK). Using the in-built blood pressure 
module, LVESP, LVEDP, LV developed pressure (LVDP), the first derivative of LV 
developed pressure (dP/dtmax and dP/dtmin) and the exponential decay of LV 
pressure (tau) were fitted and calculated (Figure 2-10). Tau was calculated by 
fitting a mono-exponential decay to an asymptote pressure to the decaying 
portion of the pressure curve using the formula 
P(t)=A e(-t tau⁄ )+ B 
where P is the pressure, t is the time in seconds from the start of the fitted 
region and A, B and tau are fitted parameters. The fitting range was set to start 
at the steepest negative slope (dP/dtmin) and end after 5 mmHg change from the 
LVEDP. 
To determine baseline steady state parameters, LV function parameters were 
averaged across 2 min prior to the perfusion with peptide or inhibitors. 
Subsequently, LV parameters were sampled by averaging 10 s in 2 min intervals. 
In case of an arrhythmia at a sampling point that distorts the measurements, the 
sampling point was shifted maximally by 30 s prior or after the arrhythmia.  
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Figure 2-10. Cyclic measurements of LVP. 
A = End diastolic pressure/ minimum pressure (LVEDP), B = dP/dtmax, C = end systolic pressure/ 
maximum pressure (LVESP), D = dP/dtmin, E = tau.   
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2.12 The mouse model of Ang II infusion 
All surgical procedures were performed in accordance with the Animals Scientific 
Procedures Act (1986) and were approved by the University of Glasgow Ethical 
Review Panel and the UK Home Office. Male C57BL/6 mice were obtained from 
Envigo (UK) at 11 weeks of age and housed under controlled environmental 
conditions (12 hr light/dark cycle at ambient temperature and humidity) and 
maintained on a standard chow diet. Animals were allowed one week 
acclimatisation period before being used for procedure at 12 weeks of age.  
2.12.1 Osmotic minipump preparation 
To deliver Ang II and Ang-(1-9), subcutaneously implanted osmotic minipumps 
(Alzet, CA, USA) of the models 1002, 1004 or 2006 were used. Osmotic 
minipumps operate on the basis of an osmotic pressure difference between the 
pump compartment and the tissue environment. The pump consists of fluid 
reservoir which is encapsulated by an osmotic layer surrounded by a semi-
permeable membrane (Figure 2-11). The high osmolality in the osmotic layer 
results in water influx from the surrounding tissue. This leads to compression of 
the reservoir chamber within the pump and the graded continuous delivery of 
the solution at a predetermined rate that is specific to each pump model 
(Theeuwes and Yum, 1976) (Figure 2-11).  
Minipumps were prepared to deliver Ang II (Sigma, Dorset, UK) and/ or Ang-(1-9) 
(Phoenix Pharmaceuticals, Karlsruhe, Germany) at the predetermined rates 
shown in Table 2-20. To determine the concentration Cd required for delivery of 
the required dose, the following formula was used: 
ko=Q x Cd 
Where Q is the flow rate of the pump (μL/hr) (Table 2-21), Cd is the 
concentration of the drug solution (μg/μL) and ko is the mass delivery rate 
(μg/hr) determined for a mouse weighing 28.2 g which is the average weight of a 
C57BL/6 mouse at 12 weeks by using the following equation:  
mass delivery rate (
μg
hr
) = dosage (
μg
kg
hr
)  x 0.0282 kg. 
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All drugs were prepared 2x concentrated in sterile dH2O and diluted 1:2 upon 
filling of the pump. This allowed the combination of several drugs in one pump.  
The pump was filled using the provided filling unit equivalent to a 25 gauge 
needle and a 1 mL syringe. Care was taken to prevent any air bubbles in the 
filling reservoir that may impede drug release.  
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Figure 2-11. Design and working principle of osmotic minipumps.  
The osmotic minipump consists of a drug reservoir which is encapsulated by an osmotic layer 
within a semipermeable membrane. Diffusion of water from the surrounding tissue through the 
semipermeable membrane expands the osmotic layer. This compresses the drug reservoir and 
leads to release of the drug at a predefined constant rate. The flow moderator prevents 
interference of air bubbles and leakage of drug.  
 
Table 2-20. Doses of Ang II and Ang-(1-9) used in in vivo studies 
Drug Dose (μg/kg/hr) 
Ang II 24 
Ang II  48 
Ang-(1-9) 48 
 
Table 2-21. Osmotic minipump specifications 
Pump model Flow rate (μL/hr) Pump volume (μL) 
1002 0.25 100 
1004 0.11 100 
2006 0.15 200 
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2.12.2 Minipump implantation 
Subcutaneous implantation of minipumps was performed under sterile 
technique. Prior to surgery, each animal received a subcutaneous injection of 
0.125 mg carprofen (Rimadyl) in 250 μL 5 % sterile saline.  
To anaesthetise the animal, the induction box was filled with 5 % isoflurane in 
oxygen at a flow rate of 1 mL/min and the animal was placed into the box. Once 
induction was confirmed, the animal was placed on a face mask delivering 3 % 
isoflurane in oxygen (flow rate 1 mL/min) and the hair was removed from the 
neck and between the shoulder blades with a hair trimmer. Residual hair was 
removed diligently by the use of Vetasept chlorhexidine surgical disinfectant. 
Using sharp surgical scissors a small horizontal incision was made in the neck 
anterior to the scapulae (Figure 2-12 A). Using blunt, straight dissection forceps 
a pocket was created under the skin for the placement of the minipump (Figure 
2-12 B). Next the minipump was inserted into the subcutaneous pocket with the 
flow regulator pointing away from the incision site (Figure 2-12 C). The incision 
was closed using 6-0 Vicryl suture (Ethicon, Norderstedt, Germany) and sterilised 
with Vetasept (Figure 2-12 D). Isoflurane levels were reduced to 0 % and the 
animal was monitored until signs of recovery became visible. The animal was 
placed into a pre-heated cage with soft food readily available. Following 
surgery, the animal was checked and weighed twice daily for 1 week and was 
then checked once a day thereafter.  
Overall mortality following minipump implantation and infusion was 12.7 %. This 
was solely due to adverse effects caused by Ang II infusion (irrespective of 
dosage or addition of Ang-(1-9)) where mortality amounted to 19.2 % (Figure 
2-12 E). A thoracic or abdominal haemorrhage was present in 70 % of cases and 
was attributed to the rupture of an aortic aneurysm (Figure 2-12 F). Other 
causes of death included post-operative complications and other unknown 
causes.  
Ang II infusion in mice results in the development of hypertension as measured 
by telemetry (Flores-Munoz and Nicklin, unpublished) and tail cuff 
plethysmography (Figure 2-12 G-H). The time period over which hypertension 
developed varied between low (24 μg/kg/hr) and high (48 μg/kg/hr) doses with 
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the low dose causing a gradual rise in BP by 14 % to 142 mmHg at one week 
which further increased to 147 mmHg after 2 weeks (Figure 2-12 G) while high 
dose Ang II caused a rapid increased in BP by 35 % to 152 mmHg after one week 
before levelling off (Figure 2-12 H), in agreement with previous observations 
(Kawada et al., 2002). 
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Figure 2-12. Implantation of subcutaneous osmotic minipumps for infusion of Ang II.  
(A-D) A midline incision was made near the scapulae and a subcutaneous pocket was formed. The 
minipump was placed into the pocket with the flow regulator facing away from the incision. The 
incision was closed using 6-0 Vicryl suture and the animal was allowed to recover. (E) Mortality for 
animals receiving either H2O or Ang II irrespective of dose or Ang-(1-9) addition. (F) Percentage 
incidence for causes of death in Ang II-infused mice. (G) Blood pressure was measured in mice 
receiving either H2O or 24 μg/kg/hr Ang II over 2 weeks by radiotelemetry. n= 6. Data generated by 
and used with permission of Dr Monica Flores-Munoz. (H) Blood pressure was measured in mice 
receiving either H2O or 48 μg/kg/hr Ang II by tail cuff plethysmography. n= 6 for control and n= 10 
for Ang II.   
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2.12.3 Minipump replacement 
For the replacement of the minipump as required in the reversal study, animals 
were prepared and anesthetised as outlined (Section 2.12.2). A horizontal 
incision was made at the original incision site which will have formed a 
collagenous scar. The existing minipump was removed from the subcutaneous 
pocket and the new minipump was inserted. To facilitate healing of the 
remodelled scar, the wound edges were refreshed by scraping off connective 
tissue with a sharp scalpel blade until a light capillary bleed was apparent. The 
incision was then closed with 6-0 Vicryl suture. As previously described, the 
animals were recovered in a pre-heated cage with soft food and monitored twice 
daily for 1 week and then once daily thereafter.  
2.12.4 Sacrifice & tissue collection 
Mice were anaesthetised in an induction box with 5 % isoflurane in oxygen at a 
flow of 1 mL/min. Following induction, the animal was placed on a face mask 
delivering 3 % isoflurane in oxygen (flow 1 mL/min). A midline incision was made 
along the abdomen and chest to visualise the ribcage and heart. Animals were 
then euthanized by exsanguination via cardiac puncture. Death was confirmed 
by cessation of the circulation. Using a fine needle, PBS was then circulated via 
the apex of the heart to flush out residual blood from the organs. The liver, 
kidneys, lungs, spleen, heart and aorta were removed, placed into PBS, weighed 
and then trimmed for sampling. The heart was cut longitudinally at the angle of 
the RV. One half was snap frozen in liquid nitrogen and then stored at -80ºC until 
further use. The other half was placed into 10 % neutral buffered formalin 
(Cellstor, CellPath, Newton, UK) for fixation for at least 24 h and was then 
processed for histological staining as outlined previously (Section 2.7).  
The collected blood was transferred into a 1.3 mL serum microtube (Sarstedt, 
Nümbrecht, Germany) and allowed to clot at room temperature for several 
hours. The serum was then purified by centrifugation at 16,000 x g for 10 min, 
aliquoted and sorted at -80ºC until further use.  
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2.13 Echocardiography  
Echocardiography is useful tool for the investigation of cardiovascular structure 
and function and is the gold standard for the assessment of cardiac morphology 
in humans. The main benefits of echocardiography are its portability, the facility 
for real-time imaging, non-invasiveness and the possibility to carry out serial 
measurements over time (Ram et al., 2011).  
For echocardiography, the animals were placed into an induction box and 
anesthetised at 5 % isoflurane in oxygen with a flow of 1 mL/min. Once induction 
was complete, the animals were placed on a face mask delivering the same 
isoflurane combination and isoflurane content was gradually reduced to 1.5 %. 
Throughout the procedure temperature was controlled by placing the animals on 
a heat mat and monitoring body temperature with a rectal thermometer 
(Harvard Apparatus, Kent, UK). To remove interference, the chest was shaven 
and hair removed with Vetasept. Echocardiographic images were acquired with a 
Siemens Acuson Sequoia 512 ultrasound machine and a 15L8 probe set to a 
frequency of 14 MHz. For imaging, ultrasound gel was applied on the probe 
which was placed at the correct angle on the animal’s chest to capture images in 
the longitudinal and transverse axis (Figure 2-13 A). M-mode images were 
captured at the same region in all animals with measurements taken just above 
the papillary muscle. For Doppler flow measurements, a four chamber view was 
achieved by placing the probe at a 45º angle below the animal’s diaphragm. 
Mitral valve inflow was located by colour-flow mapping and a series of images 
were taken. Accompanying 2-lead electrocardiographic (ECG) measurements 
were made via placement of subdermal electrodes at each front paw and the 
corresponding earthing electrode into the right hind leg.  
Analysis was performed in ImageJ. Mean data of echocardiographic indices was 
determined by analysing a maximum of 4 images per animal with three 
consecutive beats being analysed per image. Images were chosen on the basis of 
pre-determined criteria that 1) measurements were taken immediately above 
the papillary muscle; 2) the walls have to be clearly distinguishable; 3) wall 
contraction was synchronous. Consecutive beats were measured in-between 
breaths where wall movement was in steady-state. The scale was manually set 
using the scale provided on the image. Measurements of LV dimensions, 
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including LV end diastolic and end systolic dimensions (LVEDD, LVESD), LV free 
wall thickness during diastole and systole (LVFWd, LVFWs) and interventricular 
septum thickness during diastole and systole (IVSd, IVSs), were made as shown 
(Figure 2-13 B). HR was estimated by counting the QRS complexes in one sweep 
of the accompanying ECG. Fractional shortening (FS) was calculated as 
FS (%)= (
LVEDD-LVESD
LVEDD
) x 100 
where LVEDD= LV end diastolic dimension and LVESD= LV end systolic dimension. 
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Figure 2-13. Echocardiography B-mode and M-mode analysis. 
(A) Example diagram for the positioning of the probe (indicated by arrow) to obtain (i) long-axis 
view and (ii) short-axis view. LV= Left ventricle, LA= Left atrium, Ao= Aorta, RVOT= Right 
ventricular outflow tract. (B) Example M-mode image taken at baseline demonstrating the 
measurements of cardiac morphology performed for each image. LVEDD= Left ventricular end-
diastolic dimension, LVESD= Left ventricular systolic dimension, IVSd= Interventricular septum 
diastole, IVSs= Interventricular septum systole, LVFWd= Left ventricular free wall diastole, 
LVFWs= Left ventricular free wall systole.  
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2.14 Tail cuff plethysmography 
Tail cuff plethysmography is the most commonly employed non-invasive 
approach for the determination of BP in conscious experimental animals. It 
works on the same basis as the sphygmomanometer in humans and utilises a tail 
cuff placed around the proximal portion of the tail to occlude blood flow. During 
controlled deflation of the cuff a distal BP sensor will measure pulse, the systolic 
and diastolic BP. There are three types of BP sensors: photoplethysmography, 
piezoplethysmography and volume pressure plethysmography.  
Tail cuff plethysmography was carried out with a Visitech BP-2000 Series II BP 
analysis system (Figure 2-14 A). This system uses transmission 
photoplethysmography where the variation of transmitted light through 
vasodilation and constriction in response to every heart beat is measured 
through the tail and used as signal for the determination of BP. This approach 
has previously shown to correlate well with direct intra-arterial BP 
measurements (Krege et al., 1995). Upon inflation of the cuff, the diastolic 
pressure is determined as the point where the pulse rate waveform decreases 
and the systolic pressure as the point where the waveform has reached a steady 
state. Prior to measurements, the system was pre-heated to 37 ºC and assessed 
for leaks in the pressure cuffs.  
Prior to the start of the experimental protocol animals were trained for tail cuff 
plethysmography to improve result reproducibility. During the experimental 
period, measurements were carried out once a week at the same time of the day 
to remove circadian variation. The animals were placed into a restraining 
chamber onto a pre-heated surface to maintain body temperature. The tail was 
fed through the cuff which was positioned at the proximal end. The distal end 
was placed into the V-shaped sensor groove (Figure 2-14 B). Six animals were 
measured in parallel. The system was configured to carry out 5 preliminary 
recordings with subsequent 20 recordings for averaging. The standard time 
between measurements was 2.5 s and the upper pressure limit was set to 
250 mmHg. In-built statistical analysis allowed the removal of outliers due to 
excess movement and other confounding factors.   
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Figure 2-14. Tail cuff plethysmography setup.  
(A) Setup of the BP-2000 system with blood pressure measurements made in parallel in 6 animals. 
(B) Magnification of the individual components of the tail cuff plethysmography system. A= heated 
undercover, B= Restraining chamber, C= Tail cuff, D= Sensor chamber. 
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2.15 Statistical Analysis 
Data are expressed as mean± standard error of the mean (SEM) unless otherwise 
stated. Statistical analysis was performed using GraphPad Prism Version 4. 
Unpaired Student’s t-test was performed when comparing two samples of a data 
set and a one-way ANOVA with Tukey’s or Dunnett’s post-hoc correction was 
employed for multiple comparisons as indicated. For traces of LV functional 
parameters and echocardiography, a Students’s t-test was used to determine 
statistical significance between individual data points of one time-point when 
comparing two traces and a one-way ANOVA with Tukey’s or Dunnett’s post-hoc 
correction was employed as indicated when several traces were compared. Equal 
variance was confirmed by Brown-Forsythe test. In the case of unequal variance, 
the Welch’s correction was applied for Student’s t-test while for one-way 
ANOVA, data was logged prior to analysis. A p-value <0.05 was termed 
statistically significant.  
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Chapter 3 – Characterisation of a mouse model of 
chronic Ang II infusion and assessment of the 
effects of Ang-(1-9) on Ang II-induced cardiac 
pathology 
  
  
Chapter 3  126 
 
 
3.1 Introduction 
3.1.1 The Ang II-infusion model 
Chronic Ang II infusion is a well-recognised experimental model of hypertension 
and cardiac remodelling in HHD (Simon et al., 1995). The dosage of Ang II during 
chronic infusion determines the rate at which BP and subsequent cardiac 
remodelling increase.  
High dose Ang II infusion (≥ 24 μg/kg/hr in mouse) has a pressor effect and 
triggers an acute increase in BP within minutes/ hours of infusion (Kawada et 
al., 2002, Suo et al., 2002, Broomé et al., 2001). The acute increase in Ang II 
causes hypersecretion of aldosterone, ANP and vasopressin which remain 
elevated while plasma Ang II levels are elevated (Simon et al., 1995). This is 
accompanied by a significant degree of salt and water retention and expansion 
of the extracellular fluid with a shift of the pressure-natriuresis curve to higher 
pressures (Simon et al., 1995). Additionally, baroreceptors are reset to higher 
pressures which results in an increase in sympathetic output at inappropriately 
high arterial pressures (Brooks et al., 1993). During acute infusion of high doses 
of Ang II, plasma Ang II levels may acutely increase up to 171-fold and 
chronically remain elevated during the perfusion period (Broomé et al., 2001) 
Infusion of low doses of Ang II (≤ 24 μg/kg/hr in mouse) have no acute effect on 
BP and lead to a slow pressor response with a gradual rise in BP over 7 days 
peaking at around 2 weeks (Von Thun et al., 1994, Kawada et al., 2002). 
Hypertension in response to low dose Ang II infusion occurs in the absence of 
renal dysfunction or significant sodium and water retention (Kawada et al., 
2002, Von Thun et al., 1994, Brown et al., 1981). Similarly, plasma aldosterone 
levels remain largely unchanged (Kisch et al., 1976). Despite the slow onset 
hypertension, cardiac hypertrophy and phenotypic modulation is evident 3 days 
after low dose Ang II infusion (Kim et al., 1995). The mechanisms contributing to 
the slow onset hypertension by low dose Ang II infusion are not fully understood. 
A role for vasoconstriction, oxidative stress, and activation of the central RAS 
has been suggested (Hood et al., 2007, Ortiz et al., 2001, Baltatu et al., 2000). 
During chronic low dose Ang II infusion, plasma Ang II levels may be elevated 2-
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5-fold and significant intrarenal Ang II accumulation has been observed (Von 
Thun et al., 1994, Ocaranza et al., 2014).  
3.1.1.1 Cardiac remodelling in the Ang II infusion model 
Despite the different phenotypes in hypertension development with low or high 
dose Ang II infusion, cardiac remodelling in Ang II-infused mice proceeds in a 
similar manner irrespective of dosage. Ang II mediates a direct pro-hypertrophic 
effect in cardiomyocytes by activating complex signalling cascades (Section 
1.4.1.2). The development of cardiac hypertrophy with an increase in cardiac 
mass is evident as early as 3-7 days following Ang II infusion while the gene 
expression of markers of hypertrophy such as ANP and βMHC may already 
increase within 24 h of Ang II infusion (Kim et al., 1995, Sopel et al., 2011). 
Although no time-course studies of cardiac hypertrophy in Ang II-infused mice 
beyond one week have been carried out, the degree of cardiac hypertrophy 
reported in mice infused with Ang II for 2-6 weeks was comparable (Kurisu et al., 
2003, Matsui et al., 2004, Tsukamoto et al., 2013), suggesting that cardiac 
hypertrophy in response to Ang II infusion plateaus early during progression of 
cardiac remodelling. Maladaptive remodelling and exhaustion of the 
hypertrophic reserve is a major contributor to cardiac contractile dysfunction 
during Ang II infusion (Hermans et al., 2014, Domenighetti et al., 2005). 
Although cardiac hypertrophy is primarily described as an adaptive response to 
normalise wall stress in settings of increased BP (Heineke and Molkentin, 2006), 
the early hypertrophic response to Ang II infusion was demonstrated to be BP 
independent and could not be inhibited by administration of hydralazine (Kim et 
al., 1995). This is further supported by the observation that transgenic mice with 
cardiac-specific elevation of Ang II production develop cardiac hypertrophy and 
cardiac contractile dysfunction (Domenighetti et al., 2005).  
Infusion of Ang II causes early cardiomyocyte apoptosis and in rats and rabbits 
infused acutely with high doses of Ang II intravenously, multifocal lesions are 
evident as early as 4 hours (Gavras et al., 1971, Gavras et al., 1975, Giacomelli 
et al., 1976). Whereas this was initially attributed to the hypertension caused by 
Ang II infusion, low dose infusion of Ang II has demonstrated that cardiomyocyte 
necrosis in response to Ang II occurs independent of a hypertensive response. In 
this model, antimyosin labelling of cardiomyocytes (an indicator of abnormal 
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sarcolemmal permeability) is visible as early as 24 h of low dose Ang II infusion 
while myocytolysis is clearly evident microscopically after 2 days (Tan et al., 
1991).Furthermore, regulation of BP with hydralazine does not abrogate fibrotic 
remodelling in Ang II-infused rats (Kim et al., 1995). Interestingly, mice with 
cardiac specific elevation of Ang II production do not present cardiomyocyte 
necrosis and do not develop cardiac fibrosis despite significant cardiac 
hypertrophy and contractile dysfunction (Domenighetti et al., 2005), suggesting 
that cardiomyocyte necrosis is a driving factor of Ang II-induced fibrotic 
remodelling. Myocyte necrosis triggers reparative fibrosis and this corresponds 
with the infiltration of immune cells (macrophages, lymphocytes and 
neutrophils) and the occurrence of myofibroblasts within 2 days of Ang II infusion 
(Campbell et al., 1995). The temporal development of histological fibrotic 
lesions in Ang II-infused mice has been well characterised and demonstrate that 
fibrotic lesions develop early during Ang II infusion (Campbell et al., 1995) 
(Figure 3-1). Within 4 days early focal and perivascular scarring is visible in 
hearts of Ang II-infused rats which develops into extensive interstitial and 
perivascular fibrosis within 2 weeks of infusion before plateauing at 4-6 weeks 
after which fibrosis may worsen with disease progression (Campbell et al., 
1995). Myocardial fibrotic lesion in response to Ang II infusion are predominantly 
formed by the deposition of collagen I and collagen III, the expression of which 
increases within 3 days of Ang II infusion and is preceded by increases in TGFβ1 
and CTGF (Kim et al., 1995, Sopel et al., 2011, Haudek et al., 2006). The 
fibrotic remodelling in response to Ang II infusion is caused by the activation of 
complex signalling cascades by Ang II in fibroblasts in which it directly increases 
proliferation and myofibroblast transition (Section 1.4.2.3).  
  
Chapter 3  129 
 
 
 
Figure 3-1. Histological changes in the development of cardiac fibrosis with Angiotensin II 
infusion.  
Cardiomyocyte necrosis in response to Ang II infusion occurs rapidly within one day of infusion and 
subsides after three days. This triggers the transient infiltration of lymphocytes (1-5 days) and the 
more prolonged infiltration of activated macrophages (up to 2 weeks) to the site of necrosis. The 
immune response leads to the activation of fibroblasts to myofibroblasts and the gradual deposition 
of collagen fibres leading to increased cardiac fibrosis.  
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3.2 Aims 
1) Establish and characterise a chronic model of Ang II-induced cardiac 
remodelling and dysfunction using low and high doses. 
2) Determine the cardiac effects of Ang-(1-9) infusion in healthy 
normotensive mice. 
3) Investigate the potential of Ang-(1-9) to reverse established Ang II-
induced cardiac dysfunction and remodelling. 
3.3 Results 
3.3.1 Model characterisation 
In order to assess the effects of Ang-(1-9) on chronic cardiac disease, a chronic 
model of Ang II infusion was developed and characterised. Mice were implanted 
with osmotic minipumps delivering either a low (24 μg/kg/hr) or high 
(48 μg/kg/hr) dose of Ang II and cardiac function and remodelling was assessed 
at 6 weeks. Animals implanted with minipumps releasing H2O served as control. 
Cardiac function was measured every fortnight by echocardiography and cardiac 
fibrosis and hypertrophy were quantified post-mortem by immunohistochemistry. 
3.3.1.1 Cardiac function 
At baseline, echocardiography indices of cardiac structure and function did not 
significantly differ between treatment groups (Table 3-1). FS remained 
unchanged in control infused mice over the 6 week period, however, infusion of 
24 and 48 μg/kg/hr Ang II was associated with chronic (24 μg/kg/hr) and acute 
(48 μg/kg/hr) reduction in FS. At 2 weeks Ang II infusion there was a significant 
30 % drop (p<0.05) in FS from 47.2 ± 2.2 % in control mice to 33.1 ± 3.2 % in mice 
infused with 48 μg/kg/hr Ang II but not 24 μg/kg/hr Ang II (44.4 ± 2.6 %) (Figure 
3-2 A-B). The significant reduction in FS with 48 μg/kg/hr Ang II was maintained 
at 4 weeks and similarly FS was significantly reduced in animals receiving 
24 μg/kg/hr Ang II (control 49.3 ± 2.5 %, 24 μg/kg/hr Ang II 36.5 ± 2.5 %, 
48 μg/kg/hr Ang II 34.1 ± 3.9 %, n= 3-11, p<0.05). After 6 weeks, the reduction 
in FS was maintained in both groups resulting in a FS of 31.0 ± 2.1 % (p<0.05) and 
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36.6 ± 4.2 (p>0.05) in mice receiving 24 and 48 μg/kg/hr Ang II, respectively 
(Figure 3-2 B). The decrease in FS with Ang II infusion at either dose was 
associated with a gradual increase in LVESD but not LVEDD (Figure 3-2 C-D). In 
control animals, LVEDD and LVESD were not significantly different at any time-
point (Figure 3-2 D). Only small changes in LVFWd and LVFWs thickness could be 
observed with Ang II infusion and LVFWd and LVFWs were significantly increased 
by 31 % and 14 % (p<0.05), respectively at 2 weeks with 24 μg/kg/hr Ang II 
(Figure 3-2 E-F). 
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Table 3-1. Echocardiography parameters in mice at baseline and 6 weeks. 
 Baseline 
 
6 weeks 
 
Control  
24 μg/kg/hr 
Ang II 
48 μg/kg/hr 
Ang II 
 
Control  
24 μg/kg/hr 
Ang II 
48 μg/kg/hr 
Ang II 
Body weight (g) 28.96 ± 0.46 28.35 ± 0.37 29.12 ± 0.20 
 
30.96 ± 0.36 30.51 ± 0.64 29.80 ± 0.33 
Heart rate (bpm) 496 ± 8 496 ± 9 480 ± 23 
 
476 ± 13 472 ± 14 470 ± 10 
FS (%) 48.4 ± 1.8 51.2 ± 2.3 45.9 ± 1.0 
 
45.5 ± 1.8 31.0 ± 2.1* 36.6 ± 4.2 
LVEDD (mm) 3.31 ± 0.09 3.10 ± 0.13 3.48 ± 0.12 
 
3.60 ± 0.08 3.56 ± 0.17 3.53 ± 0.13 
LVESD (mm) 1.72 ± 0.09 1.53 ± 0.12 1.89 ± 0.10 
 
1.67 ± 0.23 2.48 ± 0.18* 2.25 ± 0.41 
LVFWd (mm) 1.10 ± 0.04 1.05 ± 0.05 1.03 ± 0.05 
 
1.16 ± 0.07 1.42 ± 0.09 1.25 ± 0.05 
LVFWs (mm) 1.58 ± 0.05 1.53 ± 0.03 1.71 ± 0.04 
 
1.57 ± 0.05 1.71 ± 0.11 1.61 ± 0.02 
*p<0.05 vs. Control; FS= Fractional shortening; LVEDD= Left ventricular end-diastolic dimension; LVESD= Left ventricular 
systolic dimension; LVFWd/LVFWs= Left ventricular free wall thickness during diastole and systole 
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Figure 3-2. Cardiac function in Ang II-infused mice. 
(A) Example M-mode images for mice receiving H2O (control) (n= 11), 24 μg/kg/hr (24 μg Ang II, n= 
10) or 48 μg/kg/hr (48 μg Ang II, n= 3) Ang II at week 0, 2, 4 and 6 weeks. Scale= 5 mm and 
200 ms. Serial measurements of (B) FS, (C) LVEDD, (D) LVESD, (E) LVFWd and (F) LVFWs from 
longitudinal M-mode images for each treatment group over 6 weeks. Data are presented as mean 
± SEM. FS= Fractional shortening; LVEDD= Left ventricular end-diastolic dimension; LVESD= Left 
ventricular systolic dimension; LVFWd/LVFWs= Left ventricular free wall thickness during diastole 
and systole *p<0.05 vs. control (ANOVA with Tukey post-hoc analysis).  
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3.3.1.2 Hypertrophy 
There was a significant increase in heart weight/ tibia length (HW/TL) in animals 
which received 24 and 48 μg/kg/hr Ang II (control 10.01 ± 0.29 mg/mm, 
24 μg/kg/hr Ang II 11.39 ± 0.42 mg/mm, 48 μg/kg/hr Ang II 12.24 ± 
0.31 mg/mm, n= 3-11, p<0.05) (Figure 3-3 A i-ii). To determine cardiomyocyte 
hypertrophy, WGA staining was used to determine cardiomyocyte cross-sectional 
area, diameter and length (Figure 3-3 B-C). Cardiomyocyte cross-sectional area 
was significantly increased in the 24 μg/kg/hr Ang II group compared to control 
and similarly, cross-sectional area tended to be increased with 48 μg/kg/hr Ang 
II, despite non-significant (control 268.88 ± 7.23 μm2, 24 μg/kg/hr Ang II 373.34 
± 17.77 μm2, 48 μg/kg/hr Ang II 321.85 ± 23.17 μm2, n= 3-11, p<0.05) (Figure 3-3 
B i-ii). Similarly, cardiomyocyte diameter was significantly increased by 15 % and 
19 % (p<0.05) with 24 and 48 μg/kg/hr Ang II compared to control (Figure 3-3 B 
iii). Cell length was not significantly different with Ang II infusion, however, in 
the 24 μg/kg/hr Ang II group cardiomyocyte length tended to be increased by 
11 % (p>0.05) (Figure 3-3 C i-ii). 
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Figure 3-3. Effects of chronic Ang II infusion on cardiac hypertrophy. 
(A i) Example images of hearts from animals receiving H2O (control), 24 μg/kg/hr (24 μg Ang II) or 
48 μg/kg/hr (48 μg Ang II) Ang II at 6 weeks. Scale= 10 mm. (ii) Heart weight/ tibia length (HW/TL) 
for control (n= 11), 24 and 48 μg Ang II (n= 10 and 3, respectively) after 6 weeks. Heart sections 
were stained with wheat germ agglutinin to visualise both, transverse (B i) and longitudinal (C i) 
sections of cardiomyocytes. The cardiomyocyte membrane is stained red and nuclei blue. The 
inset represents a magnification of the area within the white square. Scale= 100 μm. (B ii) Cell 
cross-sectional area, (B iii) cell diameter and (C ii) cell length were determined in control (n= 11), 
24 and 48 μg Ang II (n= 10 and 3, respectively). Data are presented as mean ± SEM. *p<0.05 vs. 
control (ANOVA with Tukey post-hoc anlysis). 
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3.3.1.3 Fibrosis 
Total fibrosis measured by picrosirius red staining was significantly increased in 
Ang II-infused animals compared to control (Figure 3-4 A i, B i). Infusion of 
48 μg/kg/hr Ang II significantly exacerbated total fibrosis compared to 
24 μg/kg/hr Ang II (control 2.35 ± 0.54 %, 24 μg/kg/hr Ang II 5.34 ± 0.36 %, 
48 μg/kg/hr Ang II 12.05 ± 1.61 %, n= 3-11, p<0.05). The increase in fibrosis was 
due to the deposition of collagen I and collagen III which were both significantly 
increased by 75 % and 81 % (p<0.05), respectively in animals receiving 
24 μg/kg/hr Ang II (Figure 3-4 A ii-iii, B ii-iii). In animals receiving 48 μg/kg/hr 
Ang II, collagen I was increased by 56 % while collagen III increased by 136 % 
compared to control (p<0.05) (Figure 3-4 A ii-iii, B ii-iii). The collagen I/ 
collagen III ratio was 1.95 ± 0.29 in control animals and this was not significantly 
changed by Ang II infusion (Figure 3-4 B iv). 
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Figure 3-4. Effects of chronic Ang II infusion on cardiac fibrosis. 
(A) Heart sections of animals receiving H2O (control), 24 μg/kg/hr (24 μg Ang II) or 48 μg/kg/hr 
(48 μg Ang II) Ang II for 6 weeks were stained with (i) picrosirius red, (ii) collagen I and (iii) collagen 
III. The inset represents a magnification of the area within the black square. Scale= 100 μm. (B i) 
Total cardiac fibrosis, (ii) the collagen I and (iii) collagen III fractions as well as the (iv) collagen I/ 
collagen III ratio were determined for control (n= 11), 24 and 48 μg Ang II (n= 10 and 3, 
respectively). Data are presented as mean ± SEM. *p<0.05 vs. control. † p<0.05 vs. 24 μg Ang II 
(ANOVA with Tukey post-hoc analysis). 
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3.3.1.4 Gene expression analysis 
qRT-PCR analysis was performed to investigate the expression of components of 
the RAS as well as markers of fibrosis and hypertrophy. Expression of the RAS 
components Agtr1a (AT1R), Agtr2 (AT2R), Mas1, Ace and Ace2 were not 
significantly altered between Ang II infusion and control (Figure 3-5 A i-v). 
Col1A1, Col3A1 and ACTA2 (αSMA) gene expression were significantly increased 
with 48 μg/kg/hr Ang II compared to control and 24 μg/kg/hr Ang II (RQ: 1.50 ± 
0.21, 1.52 ± 0.17 and 2.48 ± 0.71, respectively, p<0.05) (Figure 3-5 B i-ii, vi). 
Expression of TGFβ1, Ctgf and S100A4 were unchanged across all treatment 
groups (Figure 3-5 B iii-v). Gene expression of the hypertrophy markers Nppa 
(ANP) and Nppb (BNP) were not significantly altered across any group (Figure 3-5 
C i-ii). However, expression of Myh7 (βMHC) was significantly increased with 
48 μg/kg/hr Ang II compared to control (RQ: control 1.0 ± 0.31, 24 μg/kg/hr Ang 
II 1.01 ± 0.59, 48 μg/kg/hr Ang II 4.09 ± 1.21, n= 3-6, p<0.05) (Figure 3-5 C iii). 
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Figure 3-5. Effects of Ang II infusion on the gene expression of RAS components, 
hypertrophic and fibrotic markers.  
Gene expression analysis was carried out in cardiac homogenates of mice receiving H2O (control), 
24 μg/kg/hr (24 μg Ang II) or 48 μg/kg/hr (48 μg Ang II) Ang II for 6 weeks for (A) the RAS 
components (i) Agtr1a, (ii) Agtr2, (iii) Mas1, (vi) Ace and (v) ACE2; (B) fibrosis makers (i) Col1A1, 
(ii) Col3A1, (iii) TGFβ1, (vi) Ctgf, (v) S100A4, (vi) Acta2; and (C) hypertrophy markers (i) Nppa, (ii) 
Nppb and (iii) Myh7. Gene expression was normalised to the housekeeper Ppib and expressed as 
the relative quantity (RQ) ± rqmax of control which was set as RQ= 1. n= 6, 4 and 3 for control, 
24 and 48 μg Ang II, respectively. *P<0.05 vs. control. † p<0.05 vs. 24 μg Ang II (ANOVA with 
Tukey’s post-hoc analysis). 
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3.3.2 Effects of Ang-(1-9) on cardiac structure and function 
Next the cardiac effects of chronic Ang-(1-9) infusion in healthy normotensive 
mice were assessed. Mice were implanted with minipumps delivering 
48 μg/kg/hr Ang-(1-9) for 6 weeks and cardiac function was assessed by 
echocardiography at fortnightly intervals. The effects of Ang-(1-9) were 
compared to control mice infused with H2O (Section 3.3.1). 
Example M-mode images from Ang-(1-9)-infused mice at all time-points are 
shown in Figure 3-6 A. Infusion of Ang-(1-9) had no effect on any 
echocardiographic indices of cardiac function (FS) and morphology (LVEDD, 
LVESD, LVFWd, LVFWs) at all time-points (Figure 3-6 B-F).  
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Figure 3-6. Effects of Ang-(1-9) on cardiac function.  
(A) Example M-mode images for mice receiving 48 μg/kg/hr Ang-(1-9) (n= 4) at week 0, 2, 4 and 6. 
Scale= 5 mm and 200 ms. Serial measurements of (B) FS, (C) LVEDD, (D) LVESD, (E) LVFWd 
and (F) LVFWs from longitudinal M-mode images over 6 weeks for animals receiving Ang-(1-9) 
compared to control (n= 11) previously presented in Figure 3-2. Data are presented as mean ± 
SEM. FS= Fractional shortening; LVEDD= Left ventricular end-diastolic dimension; LVESD= Left 
ventricular systolic dimension; LVFWd/LVFWs= Left ventricular free wall thickness during diastole 
and systole *p<0.05 vs. control (Student’s t-test).  
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At necropsy, HW/TL of mice infused with Ang-(1-9) was not significantly 
different to control hearts (p>0.05) (Figure 3-7 A i-ii). A lack of an effect on 
cardiomyocyte hypertrophy was confirmed by WGA staining (Figure 3-7 B-C). 
Total fibrosis as measured by picrosirius red, collagen I and collagen III staining 
as well as the collagen I/ collagen III ratio was not significantly different 
between Ang-(1-9)- and control-infused mice (Figure 3-7 D-E).  
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Figure 3-7. Effects of Ang-(1-9) infusion on cardiac hypertrophy and fibrosis. 
(A i) Example image of a heart from a mouse receiving H2O (control) or 48 μg/kg/hr Ang-(1-9). 
Scale= 10 mm. (ii) Heart weight/tibia length (HW/TL) at 6 weeks for Ang-(1-9) (n= 4) compared to 
control (n= 11) previously presented in Figure 3-3. Example images of wheat germ agglutinin 
staining in both, (B i) transverse and (C i) longitudinal sections of cardiomyocytes in Ang-(1-9)-
infused mice. The cardiomyocyte membrane is stained red and nuclei blue. The inset represents a 
magnification of the area within the white square. Scale= 100 μm. (B ii) Cell cross-sectional area, 
(B iii) cell diameter and (C ii) cell length were determined in the Ang-(1-9) group (n= 4) and 
compared to control (n= 11). (D) Example images of (i) picrosirius red, (ii) collagen I and (iii) 
collagen III staining in hearts of Ang-(1-9)-infused mice. The inset represents a magnification of the 
area within the black square. Scale= 100 μm. (E i) Total cardiac fibrosis, (ii) the collagen I and (iii) 
collagen III fractions and the (iv) collagen I/ III ratio were determined for Ang-(1-9)-infused mice (n= 
4) and compared to control (n= 11). Data are presented as mean ± SEM. *p<0.05 vs. control 
(Student’s t-test with Welch’s correction for cardiomyocyte cross-sectional area and cell diameter).   
Chapter 3  144 
 
 
3.3.3 Assessment of reversal of Ang II-induced cardiac disease by 
Ang-(1-9) 
To assess whether Ang-(1-9) can reverse established Ang II-induced cardiac 
remodelling and contractile dysfunction a reversal model was developed (Figure 
3-8). At 12 weeks of age, mice were implanted with osmotic minipumps 
delivering either H2O as control or 48 μg/kg/hr Ang II for 2 weeks to induce 
cardiac contractile dysfunction. Minipumps were then replaced and animals were 
either maintained on H2O and 48 μg/kg/hr Ang II or received a combination of 
48 μg/kg/hr Ang II and 48 μg/kg/hr Ang-(1-9) for a further 2 or 4 weeks (i.e. 4 
and 6 weeks in total, respectively). BP and cardiac function were assessed by 
tail cuff plethysmography and echocardiography, respectively.  
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Figure 3-8. Study outline for the assessment of the role of Ang-(1-9) in established Ang II-
induced cardiac pathology. 
Minipumps were implanted in male C57BL/6J mice at 12 weeks of age (week O) to deliver either 
H2O (control) or 48 μg/kg/hr Ang II for 2 weeks. Minipumps were then replaced and Ang II-infused 
animals were randomised to either be maintained on 48 μg/kg/hr Ang II alone or receive a 
coinfusion of 48 μg/kg/hr Ang II with 48 μg/kg/hr Ang-(1-9) for a further 2-4 weeks. Control animals 
received a further infusion of H2O. Cardiac function and blood pressure were assessed by 
echocardiography and tail cuff plethysmography in fortnightly intervals. 
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3.3.3.1 Blood pressure 
BP was assessed by tail cuff plethysmography. Baseline measurements of BP 
were not significantly different between animal groups (Table 3-2). Systolic and 
diastolic BP were increased by 15 % and 33 % in the Ang II group at 2 weeks 
(p<0.05) and this was maintained over the course of the infusion peaking at 6 
weeks with 153 ± 6 mmHg and 81 ± 9 mmHg for systolic and diastolic BP, 
respectively (p<0.05) (Figure 3-9 A-B). Infusion of Ang-(1-9) did not alter Ang II-
induced increases in systolic and diastolic BP (Figure 3-9 A-B). Similarly, mean 
BP was significantly increased with Ang II at 2 weeks (control 74 ± 2 mmHg vs. 
Ang II 91 ± 3 mmHg, n= 6-10, p<0.05) which was maintained at 4 and 6 weeks 
(Figure 3-9 C). Ang-(1-9) did not alter Ang II-induced increases in mean BP 
(Figure 3-9 C). At 2 weeks, the pulse rate was significantly decreased by Ang II 
(control 594 ± 17 bpm vs. Ang II 492 ± 14 bpm, n= 6-10, p<0.05) (Figure 3-9 D). 
This returned to control values by 4 weeks and was not altered by Ang-(1-9) 
(Figure 3-9 D).  
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Table 3-2. Functional indices measured by tail cuff plethysmography and echocardiography. 
 Baseline 
 
2 weeks 
 
4 weeks 
 
6 weeks 
 
Control  Ang II 
 
Control  Ang II 
 
Control  Ang II 
Ang II+ 
Ang-(1-9)  
 
Control  Ang II 
Ang II+ 
Ang-(1-9)  
MAP (mmHg) 75 ± 3 76 ± 2  74 ± 2 90 ± 3*  78 ± 3 92 ± 7 100 ± 5  70 ± 2 105 ± 7* 91 ± 9 
SBP (mmHg) 113 ± 5 117 ± 2  117 ± 5 135 ± 4*  118 ± 4 139 ± 9 156 ± 6  108 ± 3 153 ± 6* 142 ± 10 
DBP (mmHg) 55 ± 3 55 ± 2  51 ± 3 68 ± 4*  55 ± 3 69 ± 7 71 ± 6  51 ± 2 81 ± 9* 66 ± 9 
Pulse (bpm) 636 ± 15 619 ± 13  594 ± 17 492 ± 14*  635 ± 15 625 ± 27 630 ± 37  627 ± 15 565 ± 39 562 ± 20 
FS (%) 
52.26 ± 
2.03 
51.30 ± 
1.09 
 
54.82 ± 
3.00 
35.47 ± 
1.87* 
 
50.48 ± 
2.17 
33.56 ± 
1.88* 
43.98 ± 
3.54† 
 
49.28 ± 
5.24 
35.02 ± 
1.60 
33.17 ± 
0.55 
LVEDD (mm) 
3.41 ± 
0.15 
3.43 ± 
0.08 
 
3.39 ± 
0.12 
3.34 ± 
0.09 
 
3.56 ± 
0.10 
3.25 ± 
0.21 
3.39 ± 
0.15 
 
3.64 ± 
0.28 
3.54 ± 
0.26 
3.17 ± 
0.12 
LVESD (mm) 
1.63 ± 
0.14 
1.67 ± 
0.07 
 
1.56 ± 
0.16 
2.16 ± 
0.11* 
 
1.78 ± 
0.11 
2.17 ± 
0.18 
1.93 ± 
0.19 
 
1.88 ± 
0.33 
2.28 ± 
0.13 
2.12 ± 
0.10 
LVFWd (mm) 
0.84 ± 
0.04 
0.87 ± 
0.03 
 
0.84 ± 
0.05 
1.40 ± 
0.07* 
 
0.90 ± 
0.05 
1.16 ± 
0.09 
1.29 ± 
0.10 
 
0.85 ± 
0.15 
1.02 ± 
0.07 
1.69 ± 
0.19 † 
LVFWs (mm) 
1.45 ± 
0.03 
1.43 ± 
0.03 
 
1.44 ± 
0.01 
1.79 ± 
0.06* 
 
1.37 ± 
0.07 
1.50 ± 
0.08 
1.75 ± 
0.11 
 
1.49 ± 
0.13 
1.57 ± 
0.14 
2.00 ± 
0.20 
*p<0.05 vs. Control, † p<0.05 vs. Ang II. DBP= diastolic blood pressure; FS= Fractional shortening; MAP= Mean arterial pressure; SBP= Systolic blood pressure; 
LVEDD= Left ventricular end-diastolic dimension; LVESD= Left ventricular systolic dimension; LVFWd/LVFWs= Left ventricular free wall thickness during diastole and 
systole 
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Figure 3-9. Effects of Ang-(1-9) on Ang II-induced hypertension. 
Mice were infused with H2O (control) or 48 μg/kg/hr Ang II (48 μg Ang II) for 2 weeks and 
minipumps were replaced to deliver H2O, 48 μg/kg/hr Ang II or 48 μg/kg/hr Ang II+48 μg/kg/hr Ang-
(1-9) for a further 4 weeks. (A) Systolic BP, (B) diastolic BP, (C) mean BP and (D) pulse rate were 
determined by tail cuff plethysmography. n= 6 and 10 for control and 48 μg Ang II, respectively at 
week 0 and 2 and n= 6, 5, and 5 for control, 48 μg Ang II and 48 μg Ang II+Ang-(1-9), respectively 
at week 4 and 6. Data are presented as mean ± SEM. *p<0.05 vs. control (ANOVA with Dunnett’s 
post-hoc analysis).  
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3.3.3.2 Cardiac function 
At baseline, measurements of cardiac structure and function did not significantly 
differ between groups (Table 3-2). After 2 weeks Ang II infusion, FS was 
significantly decreased from 54.82 ± 3.00 % in control animals to 35.47 ± 1.87 % 
(p<0.05) (Figure 3-10 A-B). This was maintained at 4 and 6 weeks where FS 
measured 33.56 ± 1.88 % and 35.02 ± 1.60 %, respectively (Figure 3-10 B). 
Infusion of Ang-(1-9) for 2 weeks (i.e. at week 4), significantly improved FS 
compared to Ang II (Ang II 33.56 ± 1.88 % vs. Ang II+Ang-(1-9) 43.98 ± 3.54 %, n= 
6-8, p<0.05) (Figure 3-10 B). However, after 4 weeks of Ang-(1-9) addition (i.e. 
at 6 weeks) FS was not significantly different compared to Ang II (p>0.05) (Figure 
3-10 B). LVEDD remained unchanged in all treatment groups at all timepoints 
(Figure 3-10 C). However, the reduction in FS with Ang II infusion was associated 
with a significant increase in LVESD. Infusion of Ang-(1-9) at 4 and 6 weeks did 
not significantly alter Ang II-induced changes in LVESD (Figure 3-10 D). At 2 
weeks, LVFWd and LVFWs were significantly increased by 67 % and 24 %, 
respectively with Ang II compared to control (p<0.05) (Figure 3-10 E-F). Ang-(1-
9) significantly increased LVFWd after 4 weeks of co-infusion with Ang II 
compared to Ang II alone (p<0.05) but did not affect LVFWs (Figure 3-10 E-F).  
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Figure 3-10. Effects of Ang-(1-9) on established Ang II-induced cardiac dysfunction. 
(A) Example M-mode images for mice receiving H2O (control), 48 μg/kg/hr Ang II (48 μg Ang II) or 
48 μg/kg/hr Ang II+48 μg/kg/hr Ang-(1-9) at week 0, 2, 4 and 6 weeks. Scale= 5 mm and 200 ms. 
Serial measurements of (B) FS, (C) LVEDD, (D) LVESD, (E) LVFWd and (F) LVFWs from 
longitudinal M-mode images for each treatment group over 6 weeks. n= 8 and 14 for control and 
48 μg Ang II, respectively at 0 and 2 weeks. n= 8, 6 and 8 for control, 48 μg Ang II and 48 μg Ang 
II+Ang-(1-9), respectively at 4 weeks. n= 4, 3 and 3 for control, 48 μg Ang II and 48 μg Ang II+Ang-
(1-9), respectively at 6 weeks (data produced by Lauren Wills). FS= Fractional shortening; 
LVEDD= Left ventricular end-diastolic dimension; LVESD= Left ventricular systolic dimension; 
LVFWd/LVFWs= Left ventricular free wall thickness during diastole and systoleData are presented 
as mean ± SEM. *p<0.05 vs. control. † p<0.05 vs. 48 μg Ang II (ANOVA with Dunnett’s post-hoc 
analysis).  
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3.3.3.3 Hypertrophy 
Hearts dissected from mice after 4 and 6 weeks infusion of Ang II irrespective of 
Ang-(1-9) treatment were visibly larger than hearts from control animals (Figure 
3-11 A). At 4 weeks, despite being non-significant, HW/TL tended to be 
increased with Ang II. Infusion of Ang-(1-9) in the last 2 weeks did not 
significantly alter Ang II-induced hypertrophy (control 10.36 ± 0.30 mg/mm, Ang 
II 11.75 ± 0.36 mg/mm, Ang II+Ang-(1-9) 12.90 ± 0.60 mg/mm, n= 6, p>0.05) 
(Figure 3-11 B). At 6 weeks, HW/TL was significantly increased by Ang II from 
10.86 ± 0.38 mg/mm in control animals to 13.34 ± 0.60 mg/mm with Ang II 
infusion (p<0.05) (Figure 3-11 B). The addition of Ang-(1-9) to Ang II infusion in 
the last four weeks did not alter the Ang II induced increase in HW/TL (13.49 ± 
0.74, p>0.05) (Figure 3-11 B). 
Cardiomyocyte size was assessed by WGA staining in heart tissue sections (Figure 
3-12 A i-B i). Cardiomyocyte cross-sectional area was significantly increased by 
40 % and 28 % (p<0.05) in Ang II-infused mice at 4 and 6 weeks, respectively and 
this was not reversed by the infusion of Ang-(1-9) (Figure 3-12 A ii). Cell 
diameter was significantly increased by 13 % and 19 % in the Ang II group at 4 
and 6 weeks, respectively (p<0.05) (Figure 3-12 A iii). The addition of Ang-(1-9) 
after 2 weeks of Ang II-infusion did not reverse Ang II-induced increases in cell 
diameter (p>0.05) (Figure 3-12 A iii). Measurements of cell length revealed no 
significant difference in cell length between control, Ang II and Ang II+Ang-(1-9) 
at 4 weeks (p>0.05) (Figure 3-12 B ii). At 6 weeks, cell length was significantly 
increased by 16 % with Ang II (p<0.05), however, Ang-(1-9) did not alter the Ang 
II-induced increase in cell length (p>0.05) (Figure 3-12 B ii). 
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Figure 3-11. Effects of Ang-(1-9) on established Ang II-induced cardiac hypertrophy.  
Mice were infused with either H2O (control) or 48 μg /kg/hr Ang II (48 μg Ang II) for 2 weeks when 
minipumps were replaced and animals were infused with H2O, 48 μg /kg/hr Ang II or 48 μg /kg/hr 
Ang II+48 μg /kg/hr Ang-(1-9) for a further 2-4 weeks. (A) Example images of hearts from control, 
48 μg Ang II and 48 μg Ang II+Ang-(1-9) after 4 and 6 weeks. Scale= 10 mm. (B) Heart weight/tibia 
length (HW/TL) for control, 48 μg Ang II and 48 μg Ang II+Ang-(1-9) after 4 and 6 weeks. n= 6 for 
all groups at 4 weeks and n= 10, 8 and 8 for control, 48 μg Ang II and 48 μg Ang II+Ang-(1-9), 
respectively at 6 weeks (n= 4 and 3 for control and 48 μg Ang II±Ang-(1-9) at 6 weeks, respectively 
produced by Lauren Wills). Data are presented as mean ± SEM. *p<0.05 vs. control (ANOVA with 
Dunnett’s post-hoc analysis). 
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Figure 3-12. Effects of Ang-(1-9) on established Ang II-induced cardiomyocyte hypertrophy.  
Example images of wheat germ agglutinin staining in both, (A i) transverse and (B i) longitudinal 
sections of hearts from mice infused with H2O (control), 48 μg/kg/hr Ang II (48 μg Ang II) and 
48 μg/kg/hr Ang II+48 μg/kg/hr Ang-(1-9) for 4 and 6 weeks. The cardiomyocyte membrane is 
stained red and nuclei blue. The inset represents a magnification of the area within the white 
square. Scale= 100 μm. (A ii) Cell cross-sectional area, (A iii) cell diameter and (B ii) cell length 
were determined in control, 48 μg Ang II and 48 μg Ang II+Ang-(1-9) at 4 and 6 weeks. n= 6 for all 
groups at 4 weeks and n= 10, 8 and 8 for control, 48 μg Ang II and 48 μg Ang II+Ang-(1-9), 
respectively at 6 weeks (n= 4 and 3 for control and 48 μg Ang II±Ang-(1-9) at 6 weeks, respectively 
produced by Lauren Wills). Data are presented as mean ± SEM. *p<0.05 vs. control, † p<0.05 vs. 
48 μg Ang II (ANOVA with Dunnett’s post-hoc analysis).    
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3.3.3.4 Fibrosis 
Total cardiac fibrosis as assessed by picrosirius red staining (Figure 3-13 A) 
revealed a significant increase in cardiac fibrosis with Ang II compared to control 
at 4 weeks (control 0.94 ± 0.16 % vs. Ang II 9.26 ± 2.05 %, n= 6, p<0.05) (Figure 
3-13 B). Infusion of Ang-(1-9) did not significantly change Ang II-induced cardiac 
fibrosis (p>0.05) (9.07 ± 1.89 %, n=6). Similarly, at 6 weeks, cardiac fibrosis was 
significantly increased by 285 % in the Ang II group compared to control (p<0.05) 
and infusion of Ang-(1-9) for the last 4 weeks did not affect Ang II-induced 
cardiac fibrosis (p>0.05) (Figure 3-13 B).  
Collagen I deposition revealed a significant increase in cardiac collagen I content 
with Ang II by 124 % and 50 % at 4 and 6 weeks, respectively (p<0.05) and 
infusion of Ang-(1-9) for 2 or 4 weeks did not reduce Ang II-induced collagen I 
deposition (p>0.05) (Figure 3-14 A-B). 
At 4 weeks, cardiac collagen III content was significantly increased by Ang II and 
this was not altered by the addition of Ang-(1-9) (control 1.94 ± 0.22 %, Ang II 
4.07 ± 0.38 %, Ang II + Ang-(1-9) 3.01 ± 0.92 %, n= 6, p<0.05) (Figure 3-15 A-B). 
At 6 weeks, collagen III content was increased by 87 % with Ang II infusion 
compared to control (p<0.05) (Figure 3-15 B). Infusion of Ang-(1-9) for the last 4 
weeks did not significantly alter Ang II-induced collagen III deposition (p>0.05) 
(Figure 3-15 B). Infusion of Ang II in the presence of absence of Ang-(1-9) for 4 to 
6 weeks did not significantly alter the collagen I/ III ratio (Figure 3-15 C).  
  
Chapter 3  155 
 
 
 
Figure 3-13. Effects of Ang-(1-9) on established Ang II-induced cardiac fibrosis.  
(A) Cardiac section from mice infused with H2O (control), 48 μg/kg/hr Ang II (48 μg Ang II) or 
48 μg/kg/hr Ang II+48 μg/kg/hr Ang-(1-9) for 4 or 6 weeks were stained with picrosirius red. The 
inset represents a magnification of the area within the black square. Scale= 100 μm. (B) Total 
cardiac fibrosis was determined. n= 6 for all groups at 4 weeks and n= 10, 8 and 8 for control, 
48 μg Ang II and 48 μg Ang II+Ang-(1-9), respectively at 6 weeks (n= 4 and 3 for control and 48 μg 
Ang II±Ang-(1-9) at 6 weeks, respectively produced by Lauren Wills). Data are presented as mean 
± SEM. *p<0.05 vs. control (ANOVA with Dunnett’s post-hoc analysis).  
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Figure 3-14. Effects of Ang-(1-9) on established Ang II-induced collagen I deposition. 
(A) Cardiac section from mice infused with H2O (control), 48 μg/kg/hr Ang II (48 μg Ang II) or 48 
μg/kg/hr Ang II+48 μg/kg/hr Ang-(1-9) for 4 or 6 weeks were stained for collagen I. The inset 
represents a magnification of the area within the black square. Scale= 100 μm. (B) Mean collagen I 
content was determined. n= 6 for all groups at 4 weeks and n= 10, 7 and 8 for control, 48 μg Ang II 
and 48 μg Ang II+Ang-(1-9), respectively at 6 weeks (n= 4 and 3 for control and 48 μg Ang II±Ang-
(1-9) at 6 weeks, respectively produced by Lauren Wills). Data are presented as mean ± SEM. 
*p<0.05 vs. control (ANOVA with Dunnett’s post-hoc analysis).  
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Figure 3-15. Effects of Ang-(1-9) on established Ang II-induced collagen III deposition.  
(A) Cardiac section from mice infused with H2O (control), 48 μg/kg/hr Ang II (48 μg Ang II) or 
48 μg/kg/hr Ang II+48 μg/kg/hr Ang-(1-9) for 4 or 6 weeks were stained for collagen III. The inset 
represents a magnification of the area within the black square. Scale= 100 μm. (B) Mean collagen 
III content and (C) the collagen I/ III ratio was determined. n= 6 for all groups at 4 weeks and n= 10, 
8 and 8 for control, 48 μg Ang II and 48 μg Ang II+Ang-(1-9), respectively at 6 weeks (n= 4 and 3 
for control and 48 μg Ang II±Ang-(1-9) at 6 weeks, respectively produced by Lauren Wills). Data 
are presented as mean ± SEM. *p<0.05 vs. control (ANOVA with Dunnett’s post-hoc analysis).  
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3.3.3.5 Gene expression analysis 
qRT-PCR analysis of RAS components and markers of fibrosis and hypertrophy 
revealed no significant changes in the expression of Agtr1a, Agtr2, Mas1, Ace2, 
Col1A1, Col3A1, S100A4, ACTA2 and Nppa between control, Ang II and Ang 
II+Ang-(1-9) at either 4 or 6 weeks (p>0.05) (Figure 3-16 A-C). Ang II infusion 
significantly increased the expression of CTGF (RQ: 2.03 ± 0.54, p<0.05), Nppb 
(RQ: 2.80 ± 0.51, p<0.05) and Myh7 (RQ: 3.11 + 0.87, p<0.05) at 4 and 6 weeks, 
respectively (Figure 3-16 B-C). This was not altered by co-infusion of Ang-(1-9). 
In contrast, Ang-(1-9) co-infusion with Ang II for 2-4 weeks induced the gene 
expression of ACE (RQ: 2.47 ± 0.41, p<0.05), TGFβ1 (RQ: 1.83 ± 0.16, p<0.05) 
and Ctgf (RQ: 4.81 ± 1.30, p<0.05), respectively which remained unchanged with 
Ang II alone (Figure 3-16 A-B).  
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Figure 3-16. Effects of Ang-(1-9) on Ang II-induced gene expression of RAS components, 
fibrotic and hypertrophic markers.  
Gene expression analysis was performed in the cardiac homogenates of mice infused with H2O 
(control), 48 μg/kg/hr Ang II (48 μg Ang II) or 48 μg/kg/hr Ang II+48 μg/kg/hr Ang-(1-9) for 4 to 6 
weeks for (A) the RAS components (i) Agtr1a, (ii) Agtr2, (iii) Mas1, (vi) Ace and (v) ACE2; (B) 
fibrosis makers (i) Col1A1, (ii) Col3A1, (iii) TGFβ1, (vi) Ctgf, (v) S100A4, (vi) Acta2; and (C) 
hypertrophy markers (i) Nppa, (ii) Nppb and (iii) Myh7. Gene expression was normalised to the 
housekeeper Ppib and expressed as the relative quantity (RQ) ± rqmax of the time-matched control 
which was set as RQ= 1. n= 6 for all groups. *p<0.05 vs. control. † p<0.05 vs 48 μg Ang II (ANOVA 
with Dunnett’s post-hoc analysis). 
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3.4 Discussion 
Here, a chronic model of Ang II infusion using either high or low doses of Ang II 
was characterised for both, its functional effects and its effects on cardiac 
remodelling to allow assessment of the role of Ang-(1-9) in the context of Ang II-
induced cardiac remodelling. The main findings of this study are summarised in 
Table 3-3. The data shows that Ang II infusion leads to adverse changes in 
cardiac function with associated cardiac remodelling while Ang-(1-9) infusion 
alone has no effect on cardiac function and remodelling. 
Table 3-3. Summary of pathological changes observed in Ang II and Ang-(1-9)-infused mice. 
Treatment 
Contractile 
Function 
Hypertrophy Fibrosis 
   Collagen I 
Collagen 
III 
24 μg/kg/hr Ang II 
Gradual decline, 
dysfunction at 6 
weeks 
+ + + 
48 μg/kg/hr Ang II 
Acute dysfunction 
at 2 weeks 
+ + + 
Ang-(1-9) — — — — 
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It has previously been demonstrated that the infusion of 24 μg/kg/hr Ang II leads 
to the development of hypertension within 2 weeks (Flores-Munoz et al., 2013). 
Here, it was demonstrated that a high dose of Ang II (48 µg/kg/hr) leads to the 
development of sustained hypertension within 1 week of infusion as previously 
described (Suo et al., 2002, Lakó-Futó et al., 2003). Interestingly, Ang II infusion 
leads to a significant decrease in HR in the first two weeks of infusion. This is in 
contrast to the positive chronotropic actions that have been described for Ang II 
in isolated hearts and cardiomyocytes (Masaki et al., 1998, Lambert, 1995). 
Similar observations on a reduction in HR have previously been made with Ang II 
infusion (Suo et al., 2002, Lakó-Futó et al., 2003, Földes et al., 2001). However, 
these effects occurred acutely only over the first 3 days of Ang II infusion before 
HR normalised or increased (Suo et al., 2002, Lakó-Futó et al., 2003, Földes et 
al., 2001). This response has been attributed to the inhibition of sympathetic 
outflow and parasympathetic activation by the baroreceptors in response to the 
sudden increase in BP (Suo et al., 2002). With a gradual loss in baroreceptor 
sensitivity the release of norepinephrine from cardiac nerve terminals is 
facilitated and HR begins to normalise (Suo et al., 2002). 
Echocardiography was used to assess the functional consequences of chronic Ang 
II infusion on the heart. Baseline echocardiographic measurements of cardiac 
function and morphology were in the range previously reported for C57BL/6 
mice (Ram et al., 2011, Rottman et al., 2007). The infusion of a low dose of Ang 
II in mice over 6 weeks led to a gradual reduction in FS with a depression clearly 
visible at 4 weeks. In contrast, infusion of a high dose Ang II resulted in severe 
depression in FS within 2 weeks indicating distinct dose-dependent response 
profiles to Ang II infusion (Simon et al., 1995). FS is a measure of LV systolic 
function and together with indices of LV dimension, LVEDD and LVESD, allows 
the determination of overall LV structure and function (Ram et al., 2011). 
LVESD, a measure of systolic function where an increase indicates impaired 
contractile function, followed the trend observed in FS further indicating that LV 
systolic function is impaired in Ang II-infused mice. LVEDD, a measure of LV 
chamber size at diastole and an indicator of diastolic function, in contrast, 
remained unchanged suggesting that no chamber dilation was evident. Cardiac 
fibrosis and hypertrophy occur within one week of Ang II infusion at similar doses 
employed here (Wang et al., 2014, Kim et al., 1995, Sopel et al., 2011) and 
Chapter 3  162 
 
 
evidence from our lab has also shown the presence of cardiac fibrosis and 
hypertrophy with 24 μg/kg/hr Ang II after 2 weeks (Flores-Munoz et al., 2013). 
Since cardiac remodelling is well established at 2 weeks of 24 μg/kg/hr Ang II 
but FS remains normal, this indicates that the heart is in an adaptive and 
compensated stage of cardiac remodelling where cardiac contractile function 
and output are maintained by the adaptive thickening and stiffening of the heart 
to withstand the increase in BP and maintain cardiac output (Legault et al., 
1990). After 4 weeks, FS is significantly reduced, indicating systolic dysfunction. 
This suggests that the heart may be in the decompensated maladaptive phase of 
cardiac remodelling where excessive cardiac hypertrophy and fibrosis impede 
normal cardiac contraction (Diwan and Dorn, 2007). In contrast, animals 
receiving 48 μg/kg/hr Ang II entered the decompensated phase as early as 2 
weeks. This may be due to the significant extracardiac effects of high doses of 
Ang II resulting in additional volume overload and an exaggerated process of 
cardiac remodelling (Simon et al., 1995). The significant decrease in cardiac 
contractile function with either dose of Ang II is in contrast to previous studies 
using similar experimental protocols: Previously, the infusion of low and high 
doses of Ang II for 2-6 weeks in mice and rats either led to no change or an 
increase in FS while LVFW thickening was clearly evident (Izumiya et al., 2003, 
Ocaranza et al., 2014, Kawano et al., 2005b, Hermans et al., 2014, Suo et al., 
2002, Matsui et al., 2004, Tsukamoto et al., 2013, Peng et al., 2011). The 
discrepancies of these studies to the results presented here are unclear. It has 
previously been demonstrated that the genetic background of various mouse 
strains can significantly impact basal cardiovascular function and the 
cardiovascular phenotypes developed by Ang II infusion and chronic pressure 
overload (Peng et al., 2011, Gao et al., 2011, Shah et al., 2010, Barnabei et al., 
2010, Garcia-Menendez et al., 2013). This may be one factor contributing to the 
different observations made. However, so far no other study has characterised in 
detail and directly compared the acute and chronic cardiac effects of a low and 
high dose of Ang II and this is the first study to present the distinct temporal 
effects of two doses of Ang II infusion on cardiac function.  
Development of cardiac hypertrophy is one of the major phenotypes that occur 
early during Ang II infusion (Kim et al., 1995). The extend of cardiac hypertrophy 
was not significantly different between infusion of a low or high dose of Ang II 
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although dose-dependent effects of Ang II on cardiac hypertrophy have been 
reported at lower doses of Ang II where a BP response was absent (Kawano et 
al., 2005b). Cardiac hypertrophy was found to be already fully developed after 4 
weeks of Ang II infusion and previous studies have demonstrated a similar degree 
of cardiac hypertrophy after 1 week of high dose Ang II infusion (Wang et al., 
2014). This suggests that cardiac hypertrophy plateaus early during cardiac 
remodelling before the heart gradually decompensates correlating with a 
decrease in FS (Legault et al., 1990). Sizing of cardiomyocytes revealed that 
cardiomyocyte hypertrophy induced by a low dose of Ang II was largely due to 
concentric hypertrophy associated with the thickening of cardiomyocytes and to 
a lesser extent eccentric hypertrophy and lengthening of cardiomyocytes. In 
contrast, utilising a high dose of Ang II infusion, additional lengthening of 
cardiomyocytes could be observed. Concentric hypertrophy is usually observed in 
models of chronic pressure overload, including the Ang II-infusion model 
(Hermans et al., 2014, Heineke and Molkentin, 2006). This form of hypertrophy 
is typically associated with the functionally compensated phase of cardiac 
remodelling while progression to an eccentric phenotype is linked to 
decompensation and increased mortality (Domenighetti et al., 2005). 
Interestingly, more recently, it has been demonstrated that the delivery of a 
high dose of Ang II for 4 weeks in mice induced a mixed cardiac phenotype with 
concentric or eccentric hypertrophy involving aortic valve insufficiency and 
chronic volume overload (Hermans et al., 2014). A similar phenotype has been 
observed in transgenic mice with elevated cardiac Ang II (Domenighetti et al., 
2007). This correlates with the observation of an increase in cell length after 
chronic high dose Ang II infusion in mice which enter the decompensated phase 
within 2 weeks of infusion while at a low dose, decompensation only occurs 
within 4-6 weeks and eccentric remodelling may not yet be evident.  
Despite the obvious development of cardiac hypertrophy in mice receiving Ang II 
infusion, gene expression of the hypertrophy markers ANP and BNP were 
unchanged with Ang II infusion. Previous studies using comparable doses of Ang II 
have demonstrated increases in the mRNA and protein levels of ANP and BNP 
after 1-4 weeks of Ang II infusion (Izumiya et al., 2003, Yang et al., 2013b) while 
no change in ANP and BNP was detected after a 6 week high dose of Ang II 
(Tsukamoto et al., 2013) correlating with observations made here. Discrepancies 
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in ANP and BNP gene expression were previously demonstrated in other models 
of chronic pressure overload where ANP and BNP either remained unchanged or 
increased (Suo et al., 2002, Marttila et al., 1996, Yokota et al., 1995). In a study 
of Ang II infusion in rats over 2 weeks, Suo et al. (2002) demonstrated that BNP 
mRNA is dynamically regulated and increases within 2 h of Ang II infusion, 
peaking within 12 h before it gradually decreases to baseline levels after 1 week 
while plasma BNP levels remain elevated (Suo et al., 2002). Similarly, in 
transgenic rats overexpressing human renin, BNP mRNA levels remained 
unchanged despite established hypertension and cardiac hypertrophy (Marttila et 
al., 1996). In a mouse model of Ang II infusion, ANP similarly tended to be 
increased after 2 days but returned to basal levels after 2 weeks (Cardin et al., 
2014). Additionally, increases in ANP and BNP tended to initially occur in the 
atria which were not assessed here (Marttila et al., 1996, Luchner et al., 1998). 
Overall, this suggests a mismatch between ANP and BNP protein and gene 
expression which was suggested to be due to post-translation regulation (Suo et 
al., 2002). This may in part explain the current observation on ANP and BNP 
gene expression, however, ANP and BNP protein levels were not assessed here to 
confirm this hypothesis.  
The re-expression of the foetal isoform of myosin heavy chain, βMHC, is defined 
as a classical marker for pathological hypertrophy. In isolated cardiomyocytes, 
Ang II directly induces an increase in βMHC without affecting αMHC (Shalitin et 
al., 1996), however, here, βMHC was only found to be elevated after 
administration of a high dose but not a low dose of Ang II. This has previously 
been observed by others suggesting that βMHC is not exclusively coupled to 
cardiac hypertrophy (Schultz et al., 2002, Matsumoto et al., 2013). Recent 
evidence has demonstrated that βMHC expression is not uniform across the heart 
but rather tends to be localised in perivascular and fibrotic regions and is not 
always associated with cardiac hypertrophy (Pandya et al., 2006, Schiaffino et 
al., 1989, López et al., 2011). Hence, it has been suggested that βMHC is instead 
a marker of cardiac fibrosis (Pandya et al., 2006) and this correlates with the 
exacerbated degree of cardiac fibrosis induced by a high dose compared to a low 
dose of Ang II observed here.  
The significant cardiac dysfunction induced by Ang II infusion after 4 and 6 
weeks was associated with a significant increase in cardiac fibrosis 
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predominantly characterised by the increased deposition of collagen I and 
collagen III. Collagen I and collagen III are the main collagens in the heart with 
abundance of 85 and 10-15 % respectively (Weber et al., 2013) and in line with 
this, LV collagen I content was always higher than collagen III. Basal collagen 
content in the adult myocardium is estimated to be between 1-4 % and basal 
values of collagen content reported here in control mice are in line with these 
observations (Brower et al., 2006, Izumiya et al., 2003, Peng et al., 2011, 
Ichihara et al., 2001).  
Cardiac ECM content has been shown to directly impact cardiac contractile 
function with a strong relationship between the cardiac collagen fraction and 
diastolic and systolic function and overall chamber stiffness (Kitamura et al., 
2001, Doering et al., 1988, Jalil et al., 1989, Brower et al., 2006, Weber et al., 
1988, Badenhorst et al., 2003). This link persisted irrespective of cardiac 
hypertrophy, strengthening the notion of a direct influence of the ECM on 
cardiac contractile properties (Brower et al., 2006). Here, after chronic Ang II 
infusion for 4-6 weeks, both, collagen I and collagen III fractions were 
significantly increased while collagen I content was higher than collagen III. An 
increase in ECM deposition, especially collagen I, is part of the initial adaptive 
response to hypertension to account for changes in ventricular filling and 
maintain cardiac contractile function (reactive fibrosis) (Brower et al., 2006, 
Weber et al., 1989) and interference with collagen deposition during pressure 
overload reduces cardiac function (Baicu et al., 2003). Collagen I forms thick 
collagen fibres and provides rigidity to tissues such as ligaments, tendons and 
scars (Burgess et al., 1996). It has a high elastic recoil and therefore a greater 
ability to resist stretch which is advantageous in situations with increased 
afterload such as hypertension (Collier et al., 2012). Previous evidence from our 
lab has shown that collagen I deposition in hearts of Ang II-infused mice 
precedes collagen III at 2 weeks (Flores-Munoz et al., 2013) correlating with the 
compensated phase and maintenance of cardiac contractile function. However 
the excessive deposition of collagen I has been associated with myocardial 
stiffness (Jalil et al., 1989, Doering et al., 1988, Díez et al., 2002) eventually 
resulting in impaired diastolic and systolic function that developed over longer 
Ang II perfusion times. Collagen III forms thin fibres and provides compliance to 
tissues such as the skin. It is less stiff and has a lower elastic recoil and is 
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increased in situations of increased strain which occur in the decompensated 
phase of hypertensive cardiac remodelling (Collier et al., 2012, Vanderheyden et 
al., 2004). Due to its high compliance, the excessive deposition of collagen III 
predisposes the heart to chamber dilation and worsens outlook (Kitamura et al., 
2001). The ratio of type I collagen to type III collagen (or vice versa) is thought 
to be an important determinant of the stiffness/ elasticity of the heart and has 
been reported to be increased in experimental hypertension and dilated 
cardiomyopathy correlating with a decrease in cardiac function (Burgess et al., 
1996, Mukherjee and Sen, 1993, Marijianowski et al., 1995). Here, the collagen 
I/ collagen III ratio was unchanged following a low dose of Ang II infusion, but 
the collagen I/collagen III ratio tended to be decreased by 48 μg/kg/hr Ang II 
after 6 weeks. This was likely due to a decrease in collagen I rather than an 
increase in collagen III. The relative increase in collagen III may therefore 
contribute to cardiac dysfunction in the decompensated phase and together with 
the eccentric remodelling of cardiomyocytes participate in the progression from 
a concentric to an eccentric phenotype.  
While collagen I and collagen III deposition was clearly visible on histological 
assessment, gene expression analysis of collagen I and collagen III revealed an 
up-regulation only at 6 weeks in the 48 μg/kg/hr Ang II group. This mismatch in 
protein and gene expression may be explained by the dynamic nature of collagen 
synthesis in the heart. Cardiac collagen deposition occurs early during Ang II 
infusion and this is correlated with an increase in collagen I and collagen III 
mRNA (Kim et al., 1995, Sopel et al., 2011, Izumiya et al., 2003). However, as 
fibrosis becomes established and reaches a plateau, a new steady state may be 
reached where de novo collagen synthesis decreases and ECM content is 
maintained by the actions of MMPs and TIMPs (López et al., 2006). The 
continued elevation in collagen I and collagen III mRNA with 48 μg/kg/hr Ang II is 
also seen in other studies using chronic high dose Ang II infusion (Matsui et al., 
2004, Tsukamoto et al., 2013) and suggests that de novo collagen synthesis is 
still ongoing and this may be the result of excessive cardiomyocyte necrosis 
occurring in the decompensated phase of cardiac remodelling. CTGF has been 
postulated as a downstream mediator of the pro-fibrotic actions of TGFβ1 and 
more recently also Ang II (Iwanciw et al., 2003, Finckenberg et al., 2003, Che et 
al., 2008). Here TGFβ1 remained unchanged with either dose of AngII and this 
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correlates with reports that TGFβ1 and CTGF mRNA increase within 24 h of Ang II 
infusion (Kim et al., 1995, Sopel et al., 2011) but decrease thereafter and no 
changes can be detected after 2-6 weeks following Ang II infusion (Sopel et al., 
2011, Tsukamoto et al., 2013, Cardin et al., 2014). CTGF was found to be 
increased with 48 μg/kg/hr Ang II after 4 weeks correlating with the persistent 
increase in collagen I and collagen III which is in line with the role of CTGF in 
Ang II-mediated collagen deposition. S100A4 and αSMA are commonly used 
markers of fibroblasts and myofibroblasts, respectively and an increase in their 
expression may suggest an increase in the fibroblast population as a result of 
fibrotic signalling (Swaney et al., 2005, Zeisberg et al., 2007b, Strutz et al., 
1995). Here, S100A4 was unchanged by treatment with either dose of Ang II over 
4-6 weeks. While this may suggest the absence of an S100A4-positive fibroblast 
population in the heart, it however also coincides with the relative decrease in 
the fibroblast number reported in Ang II-infused rats at such time points 
(Campbell et al., 1995). However, this was not investigated further in this study. 
αSMA mRNA was found to be increased after 6 weeks infusion of Ang II at a high 
dose. This may suggest an increase in the myofibroblast population in the heart 
either through the activation of resident fibroblasts or EndMT which has been 
shown to occur in the hearts of Ang II-infused mice (Section 5). Additionally, it 
has been shown that the Acta2 gene can be re-activated as part of the foetal 
gene programme strongly correlating with the development of cardiac 
hypertrophy (Black et al., 1991) and it cannot be excluded that the increase in 
Acta2 mRNA is of cardiomyocyte origin. This would be of interest for further 
investigations.   
Expression of RAS components has been shown to be dynamically regulated in 
the development of cardiac hypertrophy and the transition to HF: The AT1R was 
shown to be upregulated during the development of cardiac hypertrophy in the 
SHR and 2K1C hypertension with increased Ang II levels (Suzuki et al., 1993). 
Similarly, AT1R expression tended to be increased in a model of pressure 
overload while no change was detected following chronic volume overload (Wolf 
et al., 1996, Iwai et al., 1995). In patients with HF, ventricular AT1R levels were 
significantly lower compared to non-failing hearts suggesting the dynamic 
expression of AT1R with disease progression (Haywood et al., 1997). Here, Agtr1a 
expression following chronic Ang II infusion was similar to control animals and 
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differs from observations made in other models of chronic cardiac hypertrophy 
described above. This is most likely due to regulation of AT1R by Ang II as it has 
previously been demonstrated that in a mouse model of low dose Ang II infusion 
AT1R mRNA transiently increased after 3 days before it decreased to baseline 
within 7 days possibly due to a negative feedback loop (Ichihara et al., 2001).  
The tissue expression of Agtr2 is very low in the adult heart but increases in 
pathophysiological conditions as part of the foetal gene program (Dinh et al., 
2001). As such, a significant upregulation of Agtr2 mRNA has been demonstrated 
post-MI and in 2K1C rats (Nio et al., 1995, Suzuki et al., 1993). Here, Agtr2 
expression was unchanged by chronic Ang II infusion. Although this contrasts with 
the reports that the AT2R increases during cardiac pathology, Agtr2 expression 
has previously been demonstrated to remain unchanged in pressure overloaded 
rats and in patients with HF despite significant expression of βMHC and ANP, 
indicating foetal gene expression (Wolf et al., 1996, Haywood et al., 1997). 
Furthermore, Ang II has been demonstrated to downregulate Agtr2 expression 
(Ouali et al., 1997). Decreased Agtr2 is observed in cardiomyocytes from 
patients with HF while cardiac fibroblasts from patients with interstitial fibrosis 
selectively re-express the AT2R (Tsutsumi et al., 1998, Matsumoto et al., 2000). 
Thus, it cannot be excluded that any cell-specific changes in Agtr2 expression 
were diluted in the gene expression analysis of total ventricular tissue.  
ACE and ACE2 are found up-regulated in human heart disease and experimental 
models of HF (Iwai et al., 1995, Weinberg et al., 1997, Studer et al., 1994, 
Serneri et al., 2001, Goulter et al., 2004) and ACE expression has been 
demonstrated to correlate with the extent of cardiac hypertrophy (Weinberg et 
al., 1997, Iwai et al., 1995). Here, neither dose of Ang II induced significant 
changes in ACE and ACE2 expression. This discrepancy may result from a 
differential regulation of the RAS in the Ang II infusion model compared to 
models of chronic pressure and volume overload (Brilla et al., 1990, Ruzicka et 
al., 1995). In the rat Ang II-infusion model, it was demonstrated that Ang II 
increases cardiac ACE activity, however, ACE mRNA levels were not measured 
(Ocaranza et al., 2014).  
Here, two protocols were employed to assess the cardiac effects of Ang-(1-9) in 
the healthy and diseased heart. The main findings are 1) chronic Ang-(1-9) 
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infusion into healthy normotensive mice has no effect on cardiac contractile 
function, fibrosis or hypertrophy; 2) the co-infusion of Ang-(1-9) after the 
induction of cardiac contractile dysfunction with a high dose of Ang II for 2 
weeks (reversal study) transiently reversed systolic dysfunction after 4 weeks 
independent of any anti-hypertensive, anti-hypertrophic and anti-fibrotic 
effects. These results highlight the complexity of Ang-(1-9) signalling in the 
heart. 
So far only one other study has presented data on the cardiac effects of Ang-(1-
9) infusion in the healthy heart (Zheng et al., 2015). In this study, rats were 
infused with Ang-(1-9) for 4 weeks and no significant changes were detected in 
measures of cardiac contractile function and remodelling (Zheng et al., 2015). 
This correlates with data presented here where it was demonstrated that Ang-
(1-9) does not significantly modulate cardiac systolic and diastolic function or 
cardiac remodelling. However, when Ang-(1-9) was co-infused with Ang II into 
mice with established Ang II-induced cardiac dysfunction, Ang-(1-9) transiently 
improved cardiac systolic function after 4 weeks before it declined to levels 
similar to Ang II infusion at 6 weeks. This may suggest that Ang-(1-9) has a direct 
effect on cardiac contraction (investigated in Section 4). The functional recovery 
was independent of any anti-hypertensive or anti-fibrotic actions by Ang-(1-9) 
and in fact Ang-(1-9) may exacerbate Ang II-induced cardiac hypertrophy at this 
stage. Cardiomyocytes possess an intrinsic hypertrophic reserve which was 
demonstrated to differ between males and females (Tamura et al., 1999, Brower 
et al., 2006). Whether Ang-(1-9) may trigger an additionally hypertrophic 
reserve or whether the exacerbation of Ang II-induced hypertrophy by Ang-(1-9) 
is secondary to effects on contraction induced by Ang-(1-9) is unknown. At 6 
weeks, cardiac function declined to levels seen in Ang II-infused mice and the 
hearts began to transition from a concentric to an eccentric phenotype as 
evidenced by the increase in cell length. This remodelling process corresponded 
with the significant increase in the gene expression of collagen I, TGFβ1, CTGF, 
BNP and βMHC. It can be hypothesised that the rapid decompensation after 
functional recovery is partially due to the uncontrolled hypertension and cardiac 
remodelling which results in an already structurally remodelled and stiffer heart 
having to work against an increased afterload which over long term becomes 
unsustainable and the heart begins to fail. Using a similar study design, Ocaranza 
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et al. (2014) recently demonstrated that Ang-(1-9) reverses established Ang II-
induced cardiac pathology in rats by decreasing BP and reversing established 
cardiac remodelling (Ocaranza et al., 2014). This is in contrast to the results 
presented here where Ang-(1-9) normalised cardiac function independent of an 
effect on BP and cardiac remodelling. The anti-hypertensive effects of Ang-(1-9) 
observed in the published report may in part contribute to the regression of 
cardiac remodelling (Ocaranza et al., 2014). However, the dose of Ang II was 
half that employed here with a 1.5:1 ratio of Ang-(1-9) to Ang II compared to the 
1:1 ratio employed here. Since it has been identified that there are dose-
dependent differences in the cardiac phenotype of Ang II-infused mice, it cannot 
be excluded that dosage-specific differences as well as species-specific 
differences contribute to the contrasting results. 
Here, Ang-(1-9) did not alter Ang II-induced hypertension and this supports 
previous findings in the SHRSP (Flores-Munoz et al., 2012) and Ang II-infused 
mice (Flores-Munoz et al., 2013). Conversely, the data presented here do not 
suggest any effect on cardiac fibrosis and hypertrophy presented in other 
studies. Flores-Munoz et al. (2012) demonstrated that Ang-(1-9) prevents the 
development of cardiac fibrosis in the SHRSP (Flores-Munoz et al., 2012) and 
inhibits cardiomyocyte hypertrophy in vitro (Flores-Muñoz et al., 2011). Similar 
observations were made in a rat model of streptozotocin-induced diabetes 
where Ang-(1-9) reversed cardiac remodelling and improved cardiac contractile 
function (Zheng et al., 2015). Additionally, in a rat model of MI, Ang-(1-9) 
prevented chamber dilatation and wall thinning and was highly correlated to the 
regression of LV hypertrophy (Ocaranza et al., 2010). However, these studies 
investigated the effects of Ang-(1-9) acutely at 2 weeks or in models that lack 
chronic hypertension. Hence, it cannot be excluded that Ang-(1-9) may acutely 
alter cardiac hypertrophy and fibrosis during acute hypertension which disappear 
when BP is chronically increased.  
To-date, no other studies have directly associated Ang-(1-9) with improved 
cardiac function in the absence of an anti-remodelling effect. In vitro and in 
vivo evidence suggests that Ang-(1-9) signals via the AT2R to mediate its 
beneficial effects in the heart and activation of the AT2R has been linked to 
improved cardiac contractile function (Flores-Muñoz et al., 2011, Flores-Munoz 
et al., 2012, Lauer et al., 2014). Although Ang-(1-9) has so far not been 
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implicated in the modulation of cardiac contractility prior evidence has shown 
that Ang-(1-7) can improve cardiac function in animal models of HF by direct 
actions on cardiomyocyte calcium handling (Zhou et al., 2015, de Almeida et al., 
2015). Similarly, ACE2 has been implicated in the modulation of cardiac 
contractility and ACE2 deficient mice suffer from serve cardiac contractile 
dysfunction in the absence of cardiac remodelling (Crackower et al., 2002). 
Overall this suggests a role for the counter-regulatory RAS in the direct 
modulation of cardiac contractile function. Although Ang-(1-9) has been 
demonstrated to mediate biological effects independent of its conversion to 
Ang-(1-7), given their overlapping biological actions, effects on cardiac 
contractility may be mediated by similar mechanisms.  
3.5 Summary 
In summary, these data demonstrate that the chronic Ang II infusion model is a 
valid model of Ang II induced cardiac remodelling which presented with 
measurable changes in LV contractile function, hypertrophy and fibrosis 
comparable to previously reported studies. Additionally, these data confirm the 
previously reported temporal and pathophysiological differences in disease 
development reported with the infusion of low and high doses of Ang II.  
Furthermore, the results demonstrate the complex nature of the cardiovascular 
effects of Ang-(1-9) and it can be hypothesised that the state of the heart, time 
of administration, disease model and stimulus largely determine the cardiac 
response to Ang-(1-9). While systemic delivery of Ang-(1-9) alone had no 
significant effect on cardiac function and remodelling in the healthy heart, it 
was demonstrated that the administration of Ang-(1-9) to animals with 
established Ang II-induced cardiac pathology transiently improved cardiac 
contractile function independently of an effect on BP or cardiac remodelling. 
These data suggest that Ang-(1-9) may have beneficial effects in improving 
cardiac contractile function in the diseased heart with adequate BP control. 
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Chapter 4 – Assessment of the direct cardiac 
effects of Ang-(1-9) in the isolated rat heart 
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4.1 Introduction 
4.1.1 Cardiomyocyte excitation-contraction-coupling 
Cardiomyocytes are the contractile cells of the heart and perform two major 
functions: initiation and conduction of an electrical impulse and contraction. 
Cardiac EC coupling is the process by which the electrical stimulation of the 
cardiac muscle by an action potential is converted into contraction of the 
myofibrils of the cardiac muscle resulting in the expulsion of blood into the 
circulation. As a direct activator of myofilament crosslinking and contraction, 
the second messenger Ca2+ is the essential mediator of cardiac EC coupling and 
alterations in Ca2+ handling forms the basis of many CVDs with cardiac 
contractile dysfunction (Bers, 2002).  
Cardiac EC coupling is initiated by the cardiac action potential which is distinct 
from fast action potentials observed in neurons and is characterised by a plateau 
phase mediated by influx of Ca2+ through the L-type Ca2+ channels (Figure 4-1 A). 
The resting membrane potential in atrial and ventricular cardiomyocytes is 
governed by a small potassium current Ik1 (the inward rectifier) and lies at 
approximately -90 mV. The arrival of an action potential from nearby cells or the 
sinoatrial node which increases membrane potential above the -70 mV threshold 
triggers the opening of voltage gated, fast sodium channels (INa) that rapidly 
inactivate giving rise to a sharp increase in membrane potential to just above 
0 mV. Opening of transient outward rectifier potassium channels (Ito) partially 
repolarise the membrane. This is followed by a plateau phase mediated by influx 
of Ca2+ through the L-type Ca2+ channels. This plateau phase is unique to 
cardiomyocytes and is an important determinant of cardiac contraction by 
directly influencing the strength of contraction and preventing early re-
activation of cardiomyocytes by another action potential. The slow de-activation 
of the L-type Ca2+ current leads to the opening of a delayed rectifier potassium 
current (IKs, IKr, IK1) which repolarises the membrane This plateau phase prevents 
early re-activation of cardiomyocytes by another action potential and allows for 
adequate cardiac contraction and relaxation. (Camm and Bunce, 2009) 
A schematic of cardiac EC-coupling is shown in Figure 4-1 B. During systole, the 
cardiac action potential leads to the opening of T-tubular L-type Ca2+ channels 
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and influx of Ca2+ into the sarcoplasm. The increase in [Ca2+]i  which can rise up 
to 50 μM locally leads to the opening of the sarcoplasmic reticulum Ca2+ release 
channel, the ryanodine receptor (RyR), to mediate Ca2+ induced Ca2+ release 
(CICR) (Bers, 2002). The global increase in Ca2+ allows the binding of Ca2+ to the 
regulatory myofilament protein troponin C allowing crossbridge formation 
between actin and myosin resulting in contraction. Cardiac contractile force is a 
function of [Ca2+]i and a rise of [Ca2+]i from 150 nM to approximately 600 nM is 
required for half-maximal activation of contractile force (Bers, 2000). 
For relaxation to occur, [Ca2+]i must decrease to basal levels to allow 
dissociation of Ca2+ from the contractile apparatus (Figure 4-1 B right). Extrusion 
of Ca2+ from the cytosol occurs via four different mechanisms: SERCA, the 
sarcolemmal sodium-calcium exchanger (NCX), the sarcolemmal Ca2+-ATPase and 
the mitochondrial Ca2+ uniporter. The contribution of each system to the 
removal of cytosolic Ca2+ varies between species. Thus, for example, in rabbit, 
70 % of Ca2+ is extruded by SERCA, 28 % via NCX and 1 % by other mechanisms 
such as the Ca2+ ATPase in the sarcolemma and the mitochondrial Ca2+ uniporter. 
In contrast, in rats, SERCA accounts for 92 % of Ca2+ removal while NCX 
contributes 7 % and other systems 1 % (Bers, 2000). Ca2+ handling in mice is 
similar to rat whereas in humans Ca2+ fluxes are more similar to the rabbit (Bers, 
2002).   
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Figure 4-1. The cardiac action potential and excitation-contraction coupling. 
(A) The cardiac action potential with the associated currents. IK1= inward rectifier K+ current, Ito= 
transient outward K+ current, INa= rapid Na+ current, ICa= L-type Ca2+ current, IKs= slow delayed 
rectifier K+ current, IKr= rapid delayed rectifier K+ current. (B) Schematic of EC coupling in 
cardiomyocytes. The arrival of an action potential triggers the opening of the L-type Ca2+ channel. 
The increase in intracellular Ca2+ results in the opening of the RyR and Ca2+-induced Ca2+ release. 
The free Ca2+ interacts with troponin C and allows cardiomyocyte contraction to occur. For 
relaxation to occur during diastole, the intracellular Ca2+ concentration is decreased by the actions 
of SERCA, NCX and the sarcolemmal Ca2+ ATPase. Cardiac excitation-contraction coupling is 
regulated by the two kinases PKA and CaMKII both of which can phosphorylate the L-type Ca2+ 
channel and increase Ca2+ flux, the RyR to increase opening probability and phosphlamban to 
disinhibit SERCA. Additionally, PKA phosphorylates troponin C and thereby increases Ca2+ 
dissociaton for relaxation to occur. CaMKII= Calcium Calmodulin Kinase II, NCX= Sodium-calcium 
exchanger, PKA= Protein Kinase A, PLB= Phospholamban, RyR= Ryanodine receptor, SR= 
Sarcoplasmic reticulum, SERCA= sarcoplasmic reticulum Ca2+ ATPase. 
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4.1.2 RAS and EC coupling 
Activation of the RAS has also been linked to the modulation of EC coupling 
affecting various components of the Ca2+ handling mechanisms in the cell. In 
vivo modulation of EC coupling by Ang II has been assessed in detail in the 
TG1306/1R transgenic mice which express several copies of the rat 
angiotensinogen gene under the αMHC promoter resulting in increased cardiac 
Ang II levels without systemic increases in BP (Domenighetti et al., 2005, Gusev 
et al., 2009). These mice progressively develop cardiac dysfunction and cardiac 
remodelling with concentric and dilated hypertrophy associated with 
dysregulation of Ca2+ handling proteins (Domenighetti et al., 2005, Gusev et al., 
2009). In the initial adaptive phase, an increase in NCX and INCX was observed 
which is thought to be a compensatory mechanism to cellular hypertrophy, a 
reduction in Ca2+ transient amplitude and SERCA2 expression. Progression to 
decompensated cardiac remodelling resulted in a decrease in NCX current which 
was suggested to protect the reduced sarcoplasmic reticulum (SR) [Ca2+] and 
hypersensitivity of CICR resulting in cardiac contractile dysfunction 
(Domenighetti et al., 2005, Gusev et al., 2009). Similarly, in mice 
overexpressing the AT1R, expression of SERCA2 and NCX were significantly 
reduced resulting in an increase in the Ca2+ decay rate, prolonging relaxation 
(Rivard et al., 2011).  
Increased cardiac Ang II levels result in QT prolongation due to the lengthening 
of action potential duration and thereby increased susceptibly for fatal 
arrhythmias (Domenighetti et al., 2007). This was demonstrated to be a result of 
a decrease in the expression of Kir2.1 and Kir2.2 which encode subunits for the 
Ik1-related potassium channel. Similarly, in mice with cardiomyocyte specific 
overexpression of the AT1R which develop cardiac dysfunction at an early age 
independent of cardiac hypertrophy, action potential duration was nearly 
doubled at a young age compared to wild type littermates (Rivard et al., 2008). 
This was due to a significant decrease in the total potassium current of the 
action potential and includes a decrease in Ito, Ikur and Ik1 whose channels were 
significantly downregulated. Furthermore, cell shortening was significantly 
reduced as a result of a decrease in the L-type Ca2+ channel current and Ca2+ 
transient amplitude (Rivard et al., 2011).  
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In vitro positive inotropic actions of Ang II have been associated with an increase 
in L-type Ca2+ channel current which is thought to be due to PKC-dependent 
modulation of the channel gating properties (Aiello and Cingolani, 2001, Salas et 
al., 2001, Liang et al., 2010). However, in rat and mouse cardiomyocytes it has 
also been demonstrated that Ang II modulates the L-type Ca2+ channel as well as 
INa in a Nox2 and PKA-sensitive manner (Wagner et al., 2014). In chick 
ventricular cardiomyocytes, Ang II increased nuclear and cytosolic Ca2+ wave 
frequency and this was due to activation of the AT1R and AT2R (Bkaily et al., 
2005). In rabbit cardiomyocytes, Ang II signalling led to a biphasic change in the 
Ca2+-dependent Cl- current which was decreased acutely but increased following 
prolonged incubation coinciding with an increase in action potential duration 
(Morita et al., 1995). An increase in action potential duration has also been 
associated with Ang II-mediated inhibition of Ito. Interestingly, in rat myocytes, 
Ito inhibition was due to an AT2R mediated activation of PP2A (Caballero et al., 
2004). In contrast, in endocardial canine cardiomyocytes, AngII modulated Ito in 
an AT1R-dependent manner to reduce density and slow recovery from 
inactivation thereby prolonging action potential duration. Treatment of 
epicardial cardiomyocytes which have high Ito density, with losartan transformed 
Ito characteristics and action potential wave form to those of endocardial cells, 
suggesting differential modulation of the RAS in cardiomyocytes across different 
regions of the heart (Yu et al., 2000). In contrast, in guinea pig atrial 
cardiomyocytes, Ang II-AT1R signalling increased IKs via PKC thereby shortening 
action potential duration (Zankov et al., 2006).  
Overall, these studies highlight the complex role of the classical RAS in the 
regulation of various components of the cardiac contractile machinery and how 
the RAS can influence cardiac contractile function acutely and chronically to 
mediate cardiac contractile dysfunction. However, few studies so far have 
investigated the counter-regulatory RAS in the modulation of EC coupling and 
cardiac contractility (De Mello, 2004, Zhou et al., 2015, de Almeida et al., 
2015). In a model of ischaemia-reperfusion injury in rat hearts it was 
demonstrated that administration of Ang-(1-7) to RV muscle sections following 
ischaemia hyperpolarises the muscle thereby restoring impulse conduction (De 
Mello, 2004). This was found to be due to stimulation of the Na+/K+ ATPase by 
Ang-(1-7) (De Mello, 2004). More recently, it was reported that Ang-(1-7) 
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increased L-type Ca2+ currents in isolated cardiomyocytes from rats with HF but 
not control rats via a mechanism involving the NO/bradykinin pathway (Zhou et 
al., 2015). Additionally, Ang-(1-7) increased Ca2+ transient amplitude by 
preventing the downregulation of SERCA and PLB dephosphorylation in 
cardiomyocytes from DOCA-salt loaded rats (de Almeida et al., 2015). The 
stimulation of Ca2+ fluxes by Ang-(1-7) may be due to the activation of PKA that 
has been demonstrated by the intracellular application of Ang-(1-7) in isolated 
rat cardiomyocytes (De Mello, 2015). This demonstrates that the counter-
regulatory RAS may beneficially modulate cardiomyocyte EC coupling in CVD, 
however, so far, no studies have investigated whether Ang-(1-9) can modulate 
EC coupling and cardiac contractility.  
4.1.3 The RAS in the isolated Langendorff heart 
Studies in the isolated Langendorff-perfused heart have contributed significantly 
to the understanding of the cardiac actions of Ang II and the cardiac RAS as a 
whole. Using a modulation of the Langendorff-perfused rat heart de Lannoy et 
al. (1997) and Müller et al. (1998) demonstrated the presence of Ang I and Ang II 
in the coronary effluent of renin-perfused rat hearts confirming the production 
of Ang I and Ang II from local angiotensinogen and strengthening the notion of a 
tissue RAS (de Lannoy et al., 1997, Müller et al., 1998). While renin has been 
shown to be present in cardiac tissue it was largely unclear whether this was due 
to expression of renin in the heart. In the absence of perfusion with renin 
however, little angiotensinogen was converted to Ang I (de Lannoy et al., 1997) 
confirming that cardiac renin is largely derived from exogenous diffusion of 
plasma renin into the tissue, while ACE is present locally to mediate the 
formation of Ang II (Müller et al., 1998, de Lannoy et al., 2001). Perfusion of 
Ang II in isolated heart preparations mediates dose- and time-dependent 
chronotropic and inotropic effects within minutes of perfusion which is largely 
dependent on activation of the AT1R (Aplin et al., 2007, van Esch et al., 2010, 
Masaki et al., 1998). However, using [3H] phenylalanine, it was shown that 
within 60 min of perfusion, Ang II can also mediate a 3.9-fold increase in protein 
synthesis independent of induction of the proto-oncogenes c-fos and c-jun and 
demonstrating the direct actions of Ang II on cardiomyocyte growth independent 
of systemic changes in cardiac loading (Schunkert et al., 1995).  
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Perfusion of Ang II in the mouse and rat heart results in coronary 
vasoconstriction, decreasing coronary flow and increasing perfusion pressure 
that are manifested in a reduction in cardiac contractile performance (van Esch 
et al., 2010). Using mice with genetic deletions of the AT1aR, AT1bR and AT2R, 
van Esch et al. (2010) demonstrated that this effect is solely due to the 
activation of AT1aR in the coronary vasculature (van Esch et al., 2010). Perfusion 
of hearts with losartan in the absence of Ang II increases coronary flow and 
improves cardiac contractile function suggesting a tonic constrictor response via 
the AT1R in coronary vessels (Paz et al., 1998). In contrast, Ang-(1-7) was 
demonstrated to mediate coronary vasodilation and potentiate bradykinin-
mediated vasorelaxation (Almeida et al., 2000) while vessel resistance was 
increased in mice with genetic deletion of the Mas receptor (Santos et al., 
2006).  
Using the Langendorff model of global ischaemia-reperfusion, the AT1R was 
demonstrated to be acutely upregulated in the rat LV after 40 min ischaemia 
and 30 min reperfusion correlating with the development of post-ischaemic 
cardiac dysfunction that could be abolished by losartan (Yang et al., 1997). More 
widely investigated however is the effect of reducing Ang II in ischaemia 
reperfusion injury using ARBs and ACE-Is. Perfusion of an ACE-I, ARB or renin 
inhibitor prior to ischaemia reduced the incidence of reperfusion arrhythmias 
and improved post-ischaemic recovery of cardiac contractile function 
(Fleetwood et al., 1991, Chen et al., 2001, Paz et al., 1998) suggesting that 
local production of Ang II by renin and ACE participates in the development of 
potentially fatal reperfusion arrhythmias and impaired recovery of post-
ischaemic cardiac contractile function. In this regard, administration of the Ang-
(1-7) during reperfusion period mediated an anti-arrhythmic effect compared to 
the pro-arrhythmic actions of Ang II (Ferreira et al., 2001). Furthermore, 
perfusion of Ang-(1-7) preserved systolic and diastolic tension and the rate of 
contractility and relaxation post-ischaemia and this was absent in mice lacking 
Mas or mice treated with A779 or indomethacin suggesting a role for 
prostaglandins (Castro et al., 2006, Ferreira et al., 2002). However, the 
underlying mechanism remains elusive and whether Ang-(1-9) mediates similar 
effects in ischaemia-reperfusion injury has so far not been investigated.  
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4.2 Aims 
4) Establish the effects of Ang-(1-9) and Ang II on cardiac contractile 
function in the isolated Langendorff-perfused rat heart 
5) Determine the role of angiotensin receptors in the cardiac response to 
Ang-(1-9) perfusion 
6) Investigate downstream signalling pathways activated by Ang-(1-9). 
4.3 Results 
4.3.1 Spontaneously beating hearts  
4.3.1.1 Ang II perfusion 
Ang II has previously been shown to modulate cardiac contractility in the 
isolated Langendorff perfused mouse and rat heart. Additionally, it has been 
demonstrated that chronic Ang II infusion in mice in vivo results in cardiac 
contractile dysfunction (Section 3). Therefore, to determine the effects of Ang II 
on cardiac contractility in the present model of rat Langendorff perfusion, rat 
hearts were perfused with increasing doses of Ang II as outlined in protocol 2 
(Figure 2-9 A) and LV contractile parameters measured (Figure 4-2). Addition of 
an equal volume of Tyrodes to the perfusion solution served as control in time-
matched perfused hearts. 
An example trace of Ang II perfusion in the isolated rat heart is shown (Figure 
4-2 A). Baseline parameters of Ang II-infused hearts were not significantly 
different from control-perfused hearts (Table 4-1). HR significantly increased 
within 2 min of perfusion with 1 μM Ang II and peaked after 6 min with 106.70 ± 
2.14 % (p<0.05) (Figure 4-2 B). Increasing concentration to 3 μM had no further 
effect on HR (Figure 4-2 B). Perfusion of rat hearts with Ang II at either 1 or 3 μM 
did not alter LVDP (Figure 4-2 C). Similarly, 1 μM Ang II did not affect the 
maximal rate of pressure change dP/dtmax (Figure 4-2 D). However, increasing 
Ang II concentration to 3 μM significantly increased dP/dtmax after 6 min of 
perfusion (control 97.18 ± 1.51 % vs. Ang II 103.35 ± 1.68 %, n= 7, p<0.05) and 
remained elevated over the length of the perfusion protocol (Figure 4-2 D). 
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Perfusion with 1 μM Ang II caused a significant peak in dP/dtmin at 4 min of 
perfusion (control 98.40 ± 1.02 % vs. Ang II 102.00 ± 1.12 %, n= 7, p<0.05) before 
decreasing to control levels (Figure 4-2 E). Similar to dP/dtmax, 3 μM Ang II 
significantly elevated dP/dtmin after 8 min of perfusion (control 90.00 ± 2.88 % 
vs. Ang II 99.34 ± 1.83 %, n= 7, p<0.05) which remained elevated for the 
remainder of the protocol (Figure 4-2 E). Tau was significantly decreased 6 min 
after the addition of 1 μM Ang II (control 101.23 ± 2.41 % vs. Ang II 93.67 ± 
1.88 %, n= 7, p<0.05) (Figure 4-2 F). This effect was maintained after increasing 
Ang II concentration to 3 μM with a maximum decrease to 89.68 ± 2.48 % at 
18 min. (Figure 4-2 F).  
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Table 4-1. Baseline steady state parameters in spontaneously beating Langendorff-perfused rat hearts. 
 
n LVDP (mmHg) dP/dtmax (mmHg/s) dP/dtmin (mmHg/s) Tau (ms) Heart rate (bpm) 
Control 7 124.98 ± 10.48 3429.10 ± 250.61 -2352.30 ± 168.59 30.69 ± 2.24 251.20 ± 12.89 
Ang-(1-9) 6 117.28 ± 7.77 3249.20 ± 206.42 -2291.96 ± 138.31 28.46 ± 0.78 260.44 ± 11.47 
PD123319 + Ang-(1-9) 7 131.30 ± 4.89 3702.14 ± 98.50 -2529.21 ± 93.33 29.34 ±1.39 261.50 ± 5.28 
Ang II 7 129.71 ± 6.09 3537.58 ± 147.59 -2721.90 ± 137.14 26.87 ± 1.56 278.58 ± 11.82 
Ang II + Ang-(1-9) (co-infusion) 6 137.01 ± 3.70 3883.66 ± 95.70 -2689.07 ± 136.85 29.06 ± 1.14 273.08 ± 9.94 
Ang II + Ang-(1-9) (pre-infusion) 3 137.64 ± 3.05 3907.35 ± 207.42 -2673.51 ± 88.09 27.29 ± 2.13 278.62 ± 10.58 
Ang-(1-7) 7 130.73 ± 4.36 3718.07 ± 123.39 -2612.91 ± 112.34 29.17 ± 2.39 277.41 ± 12.19 
LVDP= Left ventricular developed pressure; dP/dtmax/min= rat of left ventruclar pressure rise and fall; Tau= exponential decay of left ventricular pressure fall 
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Figure 4-2. Ang II perfusion in spontaneously beating hearts. 
Rat hearts were perfused according to the Langendorff method. After reaching maximal pressure, 
the heart was allowed to reach a steady state for 10 min prior to the perfusion with 1 μM Ang II for 
10 min. The concentration was then increased to 3 μM Ang II for a further 10 min. Time-matched 
perfused hearts served as control. (A) Example left ventricular pressure (LVP) trace of Ang II 
perfusion in the isolated rat heart. (B) Heart rate, (C) left ventricular developed pressure (LVDP), 
(D) dP/dtmax, (E) dP/dtmin and (F) tau were measured using a fluid filled balloon connected to a 
pressure transducer and changes were expressed as percent-change compared to steady state. 
Data are presented as mean ± SEM. n= 7. p<0.05 vs. control (Student’s t-test).  
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4.3.1.2 Ang-(1-9) perfusion 
To investigate the effects of Ang-(1-9) on cardiac contractility in spontaneously 
beating hearts, rat hearts were perfused with increasing doses of Ang-(1-9) as 
outlined in protocol 2 in Figure 2-9 A. LVDP and contractile parameters 
calculated in 2 minute intervals were expressed as percent-change from steady 
state prior to the addition of Ang-(1-9) (Figure 4-3). Time-matched perfused 
hearts with the addition of Tyrodes solution as shown in Figure 4-2 served as 
control. 
An example LVP trace of Ang-(1-9) perfusion in the isolated rat heart is shown in 
Figure 4-3 A. Baseline steady state parameters of cardiac function were not 
significantly different between control and Ang-(1-9)-perfused rat hearts (Table 
4-1). HR significantly decreased within 2 min of 1 μM Ang-(1-9) perfusion (control 
100.94 ± 0.23 % vs. Ang-(1-9) 98.36 ± 1.20 %, n= 6-7, p<0.05) before increasing 
above control levels, despite being non-significant (Figure 4-3 B). Increasing Ang-
(1-9) concentration to 10 μM significantly increased HR within 4 min to 104.25 ± 
1.61 % (p<0.05) and remained elevated for the length of the perfusion protocol 
(Figure 4-3 B). Perfusion of 1 μM Ang-(1-9) caused a significant increase in LVDP 
within 2 min of perfusion and peaked after 4 min at 105.03 ± 1.99 % (p<0.05) 
(Figure 4-3 C). This effect was transient and LVDP returned to control level after 
8 min of perfusion. Increasing Ang-(1-9) concentration to 10 μM had no further 
effect on LVDP (Figure 4-3 C). In a similar manner, dP/dtmax and dP/dtmin 
transiently increased within the first 6 min of perfusion of 1 μM Ang-(1-9) and 
peaked at 4 min (dP/dtmax: control 99.92 ± 0.63 % vs. Ang-(1-9) 106.61 ± 1.77; 
dP/dtmin: control 98.40 ± 1.02 % vs. Ang-(1-9) 104.26 ± 2.03 %; n= 6-7, p<0.05) 
(Figure 4-3 D,-E). While dP/dtmax tended to stay elevated compared to control, 
dP/dtmin returned to control values and 10 μM Ang-(1-9) did not significantly 
alter dP/dtmax and dP/dtmin, In contrast, the isovolumic relaxation constant tau 
remained unchanged during perfusion with either dose Ang-(1-9) (Figure 4-3 F). 
Overall, this data suggests that Ang-(1-9) is acting as a positive inotrope. 
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Figure 4-3. Ang-(1-9) perfusion in spontaneously beating hearts. 
Rat hearts were perfused according to the Langendorff method. After reaching maximal pressure, 
the heart was allowed to reach a steady state for 10 min prior to the perfusion with 1 μM Ang-(1-9) 
for 10 min. The concentration was then increased to 10 μM Ang-(1-9) for a further 10 min. Time-
matched perfused hearts presented in Figure 4-2 served as control. (A) Example left ventricular 
pressure (LVP) trace of Ang-(1-9) perfusion in the isolated rat heart. (B) Heart rate, (C) left 
ventricular developed pressure (LVDP), (D) dP/dtmax, (E) dP/dtmin and (F) tau were measured using 
a fluid filled balloon connected to a pressure transducer and changes were expressed as percent-
change compared to steady state. Data are presented as mean ± sem. n= 7 for control and n= 6 for 
Ang-(1-9). Data are presented as mean ± SEM. *p<0.05 vs. control (Student’s t-test).  
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Ang-(1-9) has been shown to mediate its anti-hypertrophic effects in 
cardiomyocytes by binding the AT2R (Flores-Muñoz et al., 2011). To investigate 
the role of the AT2R in the transient inotropic effect observed by perfusion with 
Ang-(1-9), rat hearts were perfused with 1 μM of the AT2R antagonist PD123319 
for 10 min prior to the addition of 1 μM Ang-(1-9) for a further 10 min (Protocol 
3, Figure 2-9 A) (Figure 4-4).  
Perfusion with PD123319 did not alter cardiac contractile function compared to 
control (Table 4-1). In the presence of PD123319, Ang-(1-9) induced a significant 
increase in HR as early as 2 min (control 98.79 ± 0.94 % vs. PD123319+Ang-(1-9) 
102.48 ± 1.41 %, n= 7, p<0.05) and this remained elevated throughout the 
perfusion protocol, peaking at 107.13 ± 2.34 % (p<0.05) (Figure 4-4 A). The 
presence of PD123319 however seemed to completely abolish the increase in 
LVDP, dP/dtmax and dP/dtmin observed with Ang-(1-9) while tau remained 
unchanged (Figure 4-4 B-E).  
To further elucidate the effect of PD123319 in the inotropic response to Ang-(1-
9), HR, LVDP, dP/dtmax and dP/dtmin measured at 4 min of perfusion with Ang-(1-
9) (where the increase in LVDP with Ang-(1-9) perfusion was maximal) in the 
presence and absence of PD123319 were directly plotted against each other with 
their time-matched control and analysed by one-way ANOVA (Figure 4-5). At 4 
min, Ang-(1-9) had no effect on HR but this tended to be increased in the 
presence of PD123319 (control 1 101.30 ± 0.38 %, control 2 99.46 ± 0.93 %, Ang-
(1-9) 101.72 ± 1.14 %, PD123319+Ang-(1-9) 104.69 ± 2.44 %, n= 6-7, p>0.05) 
(Figure 4-5 A). Ang-(1-9) significantly increased LVDP to 105.03 ± 1.99 % and 
despite being a non-significant change, this tended to be decreased in the 
presence of PD123319 (99.31 ± 1.95 %) (Figure 4-5 B). Similarly, dP/dtmax was 
significantly increased by Ang-(1-9) and this was abolished by PD123319 (control 
1 99.92 ± 0.63 %, control 2 98.86 ± 0.76 %, Ang-(1-9) 106.61 ± 1.77 %, 
PD123319+Ang-(1-9) 100.44 ± 1.83 %, n= 6-7, p<0.05) (Figure 4-5 C). dP/dtmin was 
elevated to 104.26 ± 2.03 % with Ang-(1-9) perfusion and PD123319 reduced this 
to 98.55 ± 1.71 % (p>0.05) (Figure 4-5 D). Overall, these results demonstrate an 
inhibitory effect of PD123319 on the positive inotropic effect induced by Ang-(1-
9).  
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Figure 4-4. Role of the AT2R in Ang-(1-9)-induced positive inotropy.  
Rat hearts were perfused according to the Langendorff method. After reaching maximal pressure, 
the heart was allowed to reach a steady state for 10 min prior to the perfusion with 1 μM PD123319 
for 10 min at which point 1 μM Ang-(1-9) was added to the perfusate for a further 10 min. Time-
matched control hearts presented in Figure 4-2 served as control. (A) Heart rate, (B) left ventricular 
developed pressure (LVDP), (C) dP/dtmax, (D) dP/dtmin and (E) tau were measured using a fluid 
filled balloon connected to a pressure transducer and changes were expressed as percent-change 
compared to steady state prior to the addition of Ang-(1-9). Data are presented as mean ± SEM. n= 
7. *p<0.05 vs. control (Student’s t-test). 
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Figure 4-5. PD123319 in Ang-(1-9)-induced inotropy. 
(A) Heart rate, (B) left ventricular developed pressure (LVDP), (C) dP/dtmax and (D) dP/dtmin at 4 
min perfusion with 1 μM Ang-(1-9) in the presence or absence of 1 μM PD123319. Time-matched 
control hearts presented in Figure 4-2 served as control. Data are presented as mean ± SEM. n= 6 
for Ang-(1-9) and n= 7 for control and PD123319+Ang1-9. *p<0.05 vs. control. † p<0.05 vs Ang-(1-
9) (ANOVA with Tukey’s post-hoc analysis). 
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4.3.1.3 Crosstalk between Ang-(1-9) and Ang II 
Since it has been observed that Ang-(1-9) can reverse Ang II-induced cardiac 
contractile dysfunction in vivo (Section 3.3.3) and that Ang-(1-9) acts as a 
positive inotrope in the isolated rat heart (Section 4.3.1.2), next it was assessed 
whether Ang-(1-9) modulates the actions of Ang II on cardiac contractile 
function. Mimicking in vivo protocols, rat hearts were either perfused with a 
combination of Ang II and Ang-(1-9) (Figure 4-6) or pre-perfused with Ang II prior 
to the addition of Ang-(1-9) (Figure 4-7) as outlined in protocols 3 and 4 (Figure 
2-9 A). Control data presented previously served as control (Figure 4-2). 
Baseline parameters between control and Ang II+Ang-(1-9)-perfused hearts were 
not significantly different (Table 4-1). HR was significantly increased within 
2 min of perfusion of Ang II+Ang-(1-9) and peaked with 107.62 ± 1.90 % at 16 min 
similar to Ang II alone (Figure 4-6 A). Co-perfusion with Ang II and Ang-(1-9) over 
20 min did not alter LVDP and the inotropic effect observed with Ang-(1-9) alone 
at 2 and 4 min of perfusion was absent (Figure 4-6 B). Similarly, dP/dtmax, 
dP/dtmin were unaffected by Ang II+Ang-(1-9) co-infusion and the increases in 
dP/dtmax and dP/dtmin with Ang-(1-9) were absent (Figure 4-6 C-D). Similar to 
perfusion with Ang II alone, tau was significantly decreased to 91.70 ± 2.01 % 
(p<0.05) at 8 min and this was maintained throughout the perfusion protocol 
(Figure 4-6 E). 
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Figure 4-6. Ang II and Ang-(1-9) co-infusion in spontaneously beating hearts. 
Rat hearts were perfused according to the Langendorff method. After reaching maximal pressure, 
the heart was allowed to reach a steady state for 10 min prior to the co-perfusion with 1 μM Ang II 
and 1μM Ang-(1-9) for 20 min. Time-matched perfused hearts presented in Figure 4-2 served as 
control. (A) Heart rate, (B) left ventricular developed pressure (LVDP), (C) dP/dtmax, (D) dP/dtmin 
and (E) tau were measured using a fluid filled balloon connected to a pressure transducer and 
changes were expressed as percent-change compared to steady state. Data are presented as 
mean ± SEM. n= 7 for control and n= 6 for Ang II+Ang-(1-9). *p<0.05 vs. control (Student’s t-test). 
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When Ang II was pre-perfused for 10 min, as previously observed, Ang II induced 
a significant increase in HR with a maximum increase of 107.20 ± 2.36 % (p<0.05) 
and this was unaffected by addition of Ang-(1-9) (Figure 4-7 A). Addition of Ang-
(1-9) to the perfusate after 10 min pre-perfusion of Ang II did not alter LVDP and 
Ang-(1-9) failed to induce an inotropic response (Figure 4-7 B). In a similar 
manner, addition of Ang-(1-9) failed to induce an increase in dP/dtmax and 
dP/dtmin in the presence of Ang II (Figure 4-7 C-D). Ang II induced a transient 
increase in tau at 2 min to 105.52 ± 1.88 % (p<0.05) which returned to control 
values (Figure 4-7 F). Addition of Ang-(1-9) did not significantly alter tau but tau 
was significantly decreased at the end of the perfusion protocol (control 108.00 
± 3.93 vs. Ang II+Ang-(1-9) 92.87 ± 1.81 %, n= 3-7, p<0.05) (Figure 4-7 F).  
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Figure 4-7. Effects of Ang-(1-9) in Ang II-perfused spontaneously beating hearts.  
Rat hearts were perfused according to the Langendorff method. After reaching maximal pressure, 
the heart was allowed to reach a steady state for 10 min prior to the perfusion with 1 μM Ang II for 
10 min. 1 μM Ang-(1-9) was then added for a further 10 min. Time-matched perfused hearts 
presented in Figure 4-2 served as control. (A) Heart rate, (B) left ventricular developed pressure 
(LVDP), (C) dP/dtmax, (D) dP/dtmin and (E) tau were measured using a fluid filled balloon connected 
to a pressure transducer and changes were expressed as percent-change compared to steady 
state. Data are presented as mean ± SEM. n= 7 for control and n= 3 for Ang II+Ang-(1-9). *p<0.05 
vs. control (Student’s t-test). 
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4.3.1.4 Ang-(1-7) perfusion 
Ang-(1-9) can be broken down to Ang-(1-7) by ACE and Ang-(1-7) has previously 
been shown to improve cardiac contractile function in models of cardiac disease 
(Zhou et al., 2015, de Almeida et al., 2015). Therefore, to determine whether 
the actions of Ang-(1-9) may be through breakdown to Ang-(1-7), rat hearts were 
perfused with increasing doses of Ang-(1-7) as per protocol 2 (Figure 2-9 A) and 
its effects on cardiac function were assessed (Figure 4-8). Time-matched 
controls served as control (Figure 4-2). 
Baseline steady state parameters of cardiac contractile function were not 
significantly different between control and Ang-(1-7)-perfused hearts (Table 
4-1). An example LVP of Ang-(1-7) perfusion in the isolated rat heart is shown 
(Figure 4-8 A). Perfusion with either 1 or 10 μM Ang-(1-7) had no effect on HR, 
LVDP, dP/dtmax or dP/dtmin (Figure 4-8 B-E). Tau was significantly decreased 
after 10 min of perfusion with either 1 μM or 3 μM Ang-(1-7) to 94.40 ± 1.54 % 
and 95.62 ± 3.29 % (p<0.05), respectively (Figure 4-8 F). Overall, this suggests 
that Ang-(1-9) is not broken down to Ang-(1-7).  
  
Chapter 4   194 
 
 
 
Figure 4-8. Ang-(1-7) in spontaneously beating hearts.  
Rat hearts were perfused according to the Langendorff method. After reaching maximal pressure, 
the heart was allowed to reach a steady state for 10 min prior to the perfusion with 1 μM Ang-(1-7). 
After 10 min, the concentration was increased to 10 μM and the hearts perfused for a further 
10 min. Time-matched perfused hearts presented in Figure 4-2 served as control. (A) Example left 
ventricular pressure (LVP) trace from an Ang-(1-7) perfused rat heart. (B) Heart rate, (C) left 
ventricular developed pressure (LVDP), (D) dP/dtmax, (E) dP/dtmin and (F) tau were measured using 
a fluid filled balloon connected to a pressure transducer and changes were expressed as percent-
change compared to steady state. Data are presented as mean ± SEM. n= 7. *p<0.05 vs. control 
(Student’s t-test). 
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4.3.2 Paced Hearts 
Since investigations of Ang-(1-9) and Ang II in unpaced, spontaneously beating 
hearts revealed significant effects on HR and HR has previously been shown to 
mask changes in other cardiac function parameters (Derumeaux et al., 2008), 
the effects of Ang-(1-9) and Ang II were also assessed in paced Langendorff-
perfused rat hearts. Hearts were paced at 320 bpm which was approximately 
20 bpm above the maximum increase in HR measured by 1 μM Ang II (296.53 ± 
10.88 bpm). This was determined to be optimal to prevent the occurrence of 
arrhythmias in response to the chronotropic effects of Ang II. A set of hearts 
perfused over 20 min with the addition of equal volumes of Tyrodes solution 
served as time-matched controls for the data presented below (Protocol 1, 
Figure 2-9 B).  
4.3.2.1 Ang II perfusion 
Paced rat hearts were perfused with 1 μM Ang II for 10 min as outlined (protocol 
2, Figure 2-9 B). Baseline steady-state parameters of cardiac function did not 
differ between control and Ang II-perfused hearts (Table 4-2). Over 10 min of 
perfusion, LVDP pressure loss in control hearts was approximately 3 % (Figure 4-9 
B). Ang II caused a transient significant increase in LVDP at 4 min of perfusion 
(control 98.71 ± 0.46 vs. Ang II 100.55 ± 0.41, n= 5-6, p<0.05) which 
subsequently returned to control levels. dP/dtmax and dP/dtmin were unaffected 
by Ang II perfusion, even though an initial drop could be observed at 2 min 
although this did not reach significance (Figure 4-9 C-D). Similarly, Ang II 
perfusion did not alter tau, despite an initial increase observed at 2 min 
perfusion (Figure 4-9 E).  
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Figure 4-9. Ang II in paced Langendorff-perfused rat hearts. 
Rat hearts were perfused according to the Langendorff method. After reaching maximal pressure, 
hearts were paced at 320 bpm and allowed to reach a steady state for 10 min prior to the perfusion 
with 1 μM Ang II for 10 min. Time-matched perfused hearts served as control. (A) Example left 
ventricular pressure (LVP) trace of Ang II perfusion in a paced rat heart. (B) left ventricular 
developed pressure (LVDP), (C) dP/dtmax, (D) dP/dtmin and (E) tau were measured using a fluid 
filled balloon connected to a pressure transducer and changes were expressed as percent-change 
compared to steady state. n= 5 for control and n= 6 for Ang II. Data are presented as mean ± SEM. 
*p<0.05 vs. control (Student’s t-test). 
Table 4-2. Baseline cardiac function parameters in paced rat hearts.  
 
n LVDP (mmHg) dP/dtmax (mmHg/s) dP/dtmin (mmHg/s) Tau (ms) 
Control 5 138.84 ± 2.12 3811.10 ± 106.67 -2654.61 ± 102.23 26.67 ± 1.05 
Ang-(1-9) 6 125.64 ± 3.20 3756.27 ± 107.14 -2599.57 ± 107.20 26.67 ± 1.12 
Ang II 6 128.01 ± 3.25 3759.65 ± 102.27 -2760.33 ± 130.48 24.79 ± 1.53 
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4.3.2.2 Ang-(1-9) perfusion 
Next, the effect of Ang-(1-9) on cardiac contractile function was assessed in 
paced Langendorff-perfused rat hearts (Figure 4-10). Time-matched control 
perfused hearts presented in Section 4.3.2.1 served as control.  
Steady state characteristic of cardiac function did not differ between control 
and Ang-(1-9)-perfused hearts (Table 4-2). Perfusion with 1 μM Ang-(1-9) induced 
a sustained increase in LVDP within 2 min of perfusion which reached statistical 
significance at 4 min (control 98.71 ± 0.46 % vs. Ang-(1-9) 103.20 ± 1.46 %, n= 5-
6, p<0.05) and this was maintained throughout the perfusion period (Figure 4-10 
A-B). dP/dtmax remained stable in control perfused hearts and perfusion with 
Ang-(1-9) induced an elevation of dP/dtmax which was significant at 6 min of 
perfusion (control 99.99 ± 0.87 % vs. Ang-(1-9) 104.02 ± 1.07 %, n= 5-6, p<0.05) 
(Figure 4-10 C). In contrast, dP/dtmin was unaffected by perfusion with Ang-(1-9) 
(Figure 4-10 D). However, Ang-(1-9) induced a significant and sustained increase 
in tau within 2 minutes of perfusion which peaked at 6 min at 114.08 ± 2.58 % 
(p<0.05) (Figure 4-10 E), contrary to observations in spontaneously beating 
hearts (Section 4.3.1.2). This data confirms that Ang-(1-9) is a positive inotrope 
but also a negative lusitrope in paced Langendorff-perfused rat hearts. 
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Figure 4-10. Ang-(1-9) in paced Langendorff-perfused rat hearts. 
Rat hearts were perfused according to the Langendorff method. After reaching maximal pressure, 
hearts were paced at 320 bpm and allowed to reach a steady state for 10 min prior to the perfusion 
with 1 μM Ang-(1-9) for 10 min. Time-matched perfused hearts presented in Figure 4-9 served as 
control. (A) Example left ventricular pressure (LVP) trace of Ang-(1-9) perfusion in a paced rat 
heart. (B) left ventricular developed pressure (LVDP), (C) dP/dtmax, (D) dP/dtmin and (E) tau were 
measured using a fluid filled balloon connected to a pressure transducer and changes were 
expressed as percent-change compared to steady state. Data are presented as mean ± SEM. n= 5 
for control and n= 6 for Ang-(1-9). *p<0.05 vs. control (Student’s t-test). 
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To assess the role of the AT1R and AT2R in this process, rat hearts were pre-
perfused with 10 μM of the AT1R antagonist losartan or 1 μM of the AT2R 
antagonist PD123319 as outlined in protocol 3 in Figure 2-9 B (Figure 4-11).  
Pre-perfusion with PD123319 significantly reduced LVDP and dP/dtmin compared 
to control but dP/dtmax and tau were unaffected (Table 4-3). In the presence of 
PD123319, Ang-(1-9) induced a significant increase in LVDP within 2 min of 
perfusion (control 99.64 ± 0.45 % vs. PD123319+Ang-(1-9) 107.04 ± 0.63 %, n= 5, 
p<0.05) which was sustained throughout the perfusion period (Figure 4-11 A), 
similar to what has been observed with Ang-(1-9) alone (Figure 4-10 A). In a 
similar manner, dP/dtmax was significantly increased within 2 min of Ang-(1-9) 
perfusion (control 100.03 ± 0.64 % vs. PD123319+Ang-(1-9) 105.96 ± 0.75 %, n= 5, 
p<0.05) and remained elevated for the remaining perfusion period (Figure 4-11 
B). In contrast, dP/dtmin and tau were unaffected by perfusion with Ang-(1-9) in 
the presence of PD123319 (Figure 4-11 C-D).  
Pre-perfusion with losartan significantly reduced tau but LVDP, dP/dtmax and 
dP/dtmin were unaffected (Table 4-3). In the presence of losartan, Ang-(1-9) did 
not induce significant changes in LVDP, dP/dtmax and tau while dP/dtmin was 
significantly decreased to 96.97 ± 0.95 % and 96.31 ± 1.03 % after 4 and 6 min of 
perfusion, respectively (p<0.05) (Figure 4-11 A-D).  
To further elucidate the effect of losartan and PD123319 in Ang-(1-9)-induced 
inotropy, LVDP, dP/dtmax and tau measured after 6 min of perfusion (where most 
significant changes occurred with Ang-(1-9)) were directly plotted against Ang-
(1-9) and their respective controls and assessed by one-way ANOVA (Figure 4-11 
E–G). Ang-(1-9) significantly increased LVDP to 103.40 ± 0.97 % (p<0.05) and this 
was unaffected by PD123319. However, losartan fully blocked the increase in 
LVDP by Ang-(1-9) (p<0.05) (Figure 4-11 E). In a similar manner, dP/dtmax was 
increased by Ang-(1-9) and while this was unaffected by PD123319, losartan 
blocked the Ang-(1-9) induced increase in dP/dtmax (Ang-(1-9) 104.02 ± 1.07 %, 
PD1233319+Ang-(1-9) 102.63 ± 1.40 %, Losartan+Ang-(1-9) 99.22 ± 1.24 %, n= 5–6, 
p<0.05) (Figure 4-11 F). Tau was significantly increased to 114.08 ± 2.58 % by 
Ang-(1-9) and this was abolished equally by both PD123319 and losartan (p<0.05) 
(Figure 4-11 G).  
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Table 4-3. Baseline parameters of inhibitor treated paced rat hearts prior to perfusion with 
Ang-(1-9).  
 
n LVDP (mmHg) dP/dtmax (mmHg/s) dP/dtmin (mmHg/s) Tau (ms) 
Control 5 127.17 ± 2.02 3812.20 ± 117.94 -2653.23 ± 121.55 26.05 ± 0.81 
PD123319 5 102.97 ± 4.78* 3557.98 ± 191.40 -2208.50 ± 113.26* 26.95 ± 1.39 
Losartan 5 119.09 ± 5.81 4046.77 ± 262.62 -2840.65 ± 167.14 21.68 ± 1.23* 
H89 5 118.30 ± 2.98* 3734.58 ± 57.16 -2436.91 ± 95.29 25.74 ± 0.67 
K93 5 119.39 ± 3.91 4056.90 ± 92.32 -2613.40 ± 144.28 22.95 ± 1.18 
*p<0.05 vs. control; LVDP= Left ventricular developed pressure; dP/dtmax/min= rat of left ventruclar 
pressure rise and fall; Tau= exponential decay of left ventricular pressure fall 
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Figure 4-11. Role of Angiotensin receptors in paced Ang-(1-9)-perfused rat hearts 
Rat hearts were perfused according to the Langendorff method. After reaching maximal pressure, 
hearts were paced at 320 bpm and allowed to reach a steady state for 10 min and pre-perfused 
with 10 μM losartan or 1 μM PD123319 for 10 min prior to the addition of 1 μM Ang-(1-9). Time-
matched perfused hearts presented in Figure 4-9 served as control. (A) left ventricular developed 
pressure (LVDP), (B) dP/dtmax, (C) dP/dtmin and (D) tau were measured using a fluid filled balloon 
connected to a pressure transducer and changes were expressed as percent-change compared to 
steady state. (E) LVDP, (F) dP/dtmax and (G) tau measured after 6 min of perfusion were directly 
plotted against Ang-(1-9) and their time-matched control (control 1 for Ang-(1-9), control 2 for 
PD123319 and losartan). Data are presented as mean ± SEM. n= 6 for Ang-(1-9) and n= 5 for 
control, PD123319+Ang-(1-9) and losartan+Ang1-9. *p<0.05 vs. control. † p<0.05 vs. Ang-(1-9) 
(ANOVA with Tukey’s post-hoc analysis).  
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4.3.2.3 Role of CaMKII and PKA in Ang-(1-9)-perfused hearts 
Next to assess the downstream pathways that may play a role in the inotropic 
response induced by Ang-(1-9), the role of CaMKII and PKA were assessed due to 
their role in the regulation of EC coupling and previous evidence demonstrating 
CaMKII and PKA activation by Ang II (Wagner et al., 2014) (Figure 4-12). Rat 
hearts were perfused with 1 μM H89 or 2.5 μM K93 for 10 min prior to the 
addition of Ang-(1-9) to inhibit PKA, and CaMKII, respectively (protocol 4, Figure 
2-9 B). These doses have previously been found to be effective in inhibiting the 
activity of these kinases (Salas et al., 2010, Gonano et al., 2011, García-Villalón 
et al., 2011, Robinet et al., 2005).  
Pre-perfusion with H89 significantly reduced LVDP while all other parameters 
were unaffected (Table 4-3). K93 did not alter cardiac contractile parameters 
(Table 4-3). In the presence of K93, Ang-(1-9)-induced a significant increase in 
LVDP peaking at 4 min with 104.23 ± 1.13 % (p<0.05) (Figure 4-12 A). Similarly, 
dP/dtmax was significantly increased within 2 min peaking at 8 min with 104.09 ± 
1.24 % (Figure 4-12 B). dP/dtmin and tau were unaffected by perfusion with Ang-
(1-9) in the presence of K93 (Figure 4-12 C-D). In contrast, in the presence of 
H89 Ang-(1-9)-did not modulate LVDP and, in contrast, LVDP was significantly 
reduced after 10 min (control 97.51 ± 0.92 % vs. H89+Ang-(1-9) 92.54 ± 0.83 %, 
n= 5, p<0.05) (Figure 4-12 A). Similarly, Ang-(1-9)-did not alter dP/dtmax or tau in 
the presence of H89 (Figure 4-12 B-D). However, dP/dtmin was significantly 
reduced after 6 min of perfusion with a maximum reduction of 6.94 % (p<0.05) 
(Figure 4-12 C).  
To further elucidate the above observations with H89 and K93, LVDP, dP/dtmax 
and tau measured at 6 min perfusion were plotted directly against Ang-(1-9) and 
assessed by one-way ANOVA (Figure 4-12 E–G). K93 did not significantly alter the 
significant increase in LVDP induced by Ang-(1-9). However, this was completely 
abolished in the presence of H89 (Ang-(1-9) 103.40 ± 0.97 % vs. H89+Ang-(1-9) 
95.38 ± 1.00 %, n= 5-6, p<0.05) (Figure 4-12 E). Similarly, H89 blocked the Ang-
(1-9)-induced increase in dP/dtmax while K93 had no effect (Ang-(1-9) 104.02 ± 
1.07, H89+Ang-(1-9) 97.22 ± 1.47 %, K93+Ang-(1-9) 103.09 ± 0.96 %, n= 5–6, 
p<0.05) (Figure 4-12 F). Both, H89 and K93 blocked the Ang-(1-9)-induced 
increase in tau (Ang-(1-9) 114.08 ± 2.58, H89+Ang-(1-9) 102.89 ± 2.09 %, 
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K93+Ang-(1-9) 100.81 ± 1.25 %, n= 5–6, p<0.05) (Figure 4-12 G). Overall, this 
data suggests that PKA and to a lesser extent CaMKII may play a role in 
mediating Ang-(1-9)-induced positive inotropy and negative lusitropy.  
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Figure 4-12. Role of CaMKII and PKA in Ang-(1-9) perfused rat hearts. 
Rat hearts were perfused according to the Langendorff method. After reaching maximal pressure, 
hearts were paced at 320 bpm and allowed to reach a steady state for 10 min and pre-perfused 
with 1 μM H89 (for PKA) or 2.5 μM K93 (for CaMKII) for 10 min prior to the addition of 1 μM Ang-(1-
9). Time-matched perfused hearts presented in Figure 4-9 served as control. (A) left ventricular 
developed pressure (LVDP), (B) dP/dtmax, (C) dP/dtmin and (D) tau were measured using a fluid 
filled balloon connected to a pressure transducer and changes were expressed as percent-change 
compared to steady state. (E) LVDP, (F) dP/dtmax and (G) tau measured after 6 min of perfusion 
were directly plotted against Ang-(1-9) and their time-matched control. n= 6 for Ang-(1-9) and n= 5 
for control, H89+Ang-(1-9) and K93+Ang-(1-9). Data are presented as mean ± SEM. *p<0.05 vs. 
control. † p<0.05 vs. Ang-(1-9) (ANOVA with Tukey’s post-hoc analysis).  
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4.3.3 PKA activity in rat hearts and adult mouse cardiomyocytes 
PKA is activated by increases in cyclic AMP (cAMP) formed by adenylate cyclase. 
Two cAMP molecules bind to each of the two regulatory subunits of PKA inducing 
their dissociation and thereby activating PKA catalytic activity (Dulin et al., 
2001). However, PKA has also been shown to be activated in a cAMP-
independent pathway by Thr-197 phosphorylation of the catalytic subunit 
(Adams et al., 1995, Dulin et al., 2001). Therefore, phosphorylation of PKA in 
response to Ang-(1-9) was assessed by Western immunoblot in Langendorff-
perfused rat hearts with Ang-(1-9) or PD123319+Ang-(1-9) (Figure 4-13).  
Compared to control hearts, PKA phosphorylation was 89.94 ± 8.77 % and 87.21 ± 
6.59 % in Ang-(1-9) and PD123319+Ang-(1-9)-perfused hearts, respectively and 
not significantly different from baseline PKA phosphorylation (Figure 4-13 A-B). 
Additionally, PKA phosphorylation was assessed in isolated adult mouse 
cardiomyocytes where it has previously been shown that Ang-(1-9) increases Ca2+ 
transients via the L-type Ca2+ channel (Fattah et al., unpublished) (Figure 4-13 
C-D). Mouse cardiomyocytes were treated with 1 μM Ang-(1-7) and Ang-(1-9) for 
20 min with Forskolin (which activates adenylate cyclase and leads to cAMP 
generation) serving as control and phosphorylation of PKA measured by Western 
immunoblot (Figure 4-13 C). Ang-(1-9) tended to increase phosphorylation of PKA 
to 104.22 % compared to control, however, this did not reach significance. In 
contrast, Ang-(1-7) had no effect on PKA phosphorylation while forskolin tended 
to decrease phosphorylated PKA to 90.48 % (Figure 4-13 D).  
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Figure 4-13. PKA phosphorylation in rat hearts and mouse cardiomyocytes. 
(A) Representative Western blot of phosphorylated PKA (pPKA) in homogenates of Langendorff-
perfused rat hearts treated with 1 μM Ang-(1-9) (n= 6), 1 μM PD123319+Ang-(1-9) (n= 5) or a 
solvent control (n= 6). (B) PKA phosphorylation was expressed as a ratio to total PKA and 
normalised to control. GAPDH served as loading control. (C) Adult mouse cardiomyocytes were 
stimulated with 1 μM Ang-(1-7) or Ang-(1-9) for 20 min and pPKA was assessed by Western blot. 
Forskolin served as control. Representative Western blot of pPKA in adult mouse cardiomyocytes. 
(D) pPKA was expressed as a ratio of total PKA and normalised to control. GAPDH served as 
loading control. Results were confirmed in three independent experiments. 
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4.3.4 Angiotensin receptor expression 
The expression of the angiotensin receptors AT1R, AT2R and Mas were 
determined by qPCR in control-perfused rat hearts. Expression was normalised to 
expression of the stable housekeeper Ppib and are reported as ΔCt (Figure 4-14). 
Expression of all receptors could be detected in rat hearts. The AT1R and Mas 
were expressed at similar levels (AT1R: 6.52 ± 0.13; Mas: 6.64 ± 0.25) while 
expression of the AT2R was substantially lower with a ΔCt of 10.85 ± 0.55 (Figure 
4-14). 
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Figure 4-14. Angiotensin receptor expression in rat hearts.  
RNA was extracted from control-perfused rat hearts and gene expression of AT1R, AT2R and Mas 
was assessed by qPCR and normalised to expression of the stable housekeeper Ppib as ΔCt. n= 4 
for AT2R and n= 6 for AT1R and Mas. 
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4.4 Discussion 
Here, the effects of Ang-(1-9) and Ang II on the isolated spontaneously beating 
and paced Langendorff-perfused rat heart were investigated. The results 
demonstrated that Ang II mediated little direct effects on cardiac contractility 
whereas Ang-(1-9) mediated a positive inotropic effect by increasing LVDP, 
dP/dtmax and dP/dtmin. The positive inotropic effect by Ang-(1-9) was attenuated 
by the AT2R antagonist PD123319 and abolished by the AT1R antagonist losartan. 
Furthermore, inhibition of PKA abolished the positive inotropic effects of Ang-(1-
9) in the isolated rat heart. The results are summarised in Table 4-4. 
Table 4-4. Summary of effects of Ang II and Ang-(1-9) in Langendorff-perfused rat hearts. 
 Spontaneously beating Paced 
 HR LVDP dP/dtmax dP/dtmin tau LVDP dP/dtmax dP/dtmin tau 
1 µM Ang II  — —    — — — 
1 µM Ang-
(1-9) 
    —   —  
PD123319 
+ Ang-(1-9) 
  — — —   — — 
Losartan + 
Ang-(1-9) 
Not investigated 
— —  — 
H89 + Ang-
(1-9) 
 —  — 
K93 + Ang-
(1-9) 
  — — 
/= sustained increase/decrease; /= transient increase/decrease. 
Here, it was identified that the contractile response of isolated rat hearts to Ang 
II and Ang-(1-9) infusion was partially influenced by whether the hearts was 
paced or allowed to beat spontaneously. Experimental design usually dictates 
whether hearts will need to be paced or are allowed to follow their natural 
rhythm during Langendorff perfusion. When the heart is allowed to beat 
spontaneously, it usually adopts a HR lower than observed in vivo due to the loss 
of nervous input (Bell et al., 2011). Slowing of the HR intrinsically alters cardiac 
contractile function as described in the force-frequency relationship (FFR), also 
called Bowditch staircase and may complicate interpretation of results regarding 
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their relevance in vivo (Ross et al., 1995). The FFR is an intrinsic mechanism of 
cardiac reserve during physiological stress and dictates that increases in 
frequency lead to an increase in contractile force (Ross et al., 1995). This effect 
is due to an increased Ca2+ loading of the SR due to the high frequency of Ca2+ 
influx and a shorter time for Ca2+ extrusion by NCX (Bers, 2000). In large 
mammals, this relationship is biphasic with peak contractility at physiological 
frequencies before contractility declines at supraphysiological rates (Taylor et 
al., 2004). A drug with chronotropic actions may alter cardiac function through 
the FFR and at high heart rates this can mask direct effects of the drug on 
cardiomyocyte contractility (Derumeaux et al., 2008). In contrast, allowing the 
hearts to beat spontaneously may uncover unknown effects of a given drug on 
HR. For example, Masaki et al. (1998) demonstrated that Ang II increases HR in 
isolated Langendorff-perfused mouse hearts but this effect was absent in vivo 
(Masaki et al., 1998). Removing HR as a variable through pacing is beneficial 
when assessing drugs with known chronotropic actions to uncover direct drug 
effects on the myocardium. Additionally, this allows a physiological preparation 
mimicking in vivo heart rates which does not suffer deterioration of HR over 
lengthy perfusion protocols.  
In this study it was observed that Ang II mediates contrasting responses in 
spontaneously beating hearts and hearts maintained at a constant HR. In 
spontaneously beating hearts, Ang II mediated a positive chronotropic effect 
accompanied by a transient increase in dP/dtmax, dP/dtmin and a decrease in tau. 
This suggests an increase in inotropy and lusitropy while LVDP remained 
relatively unaffected. In contrast, in paced hearts, Ang II transiently increased 
LVDP but this was preceded by a decrease in dP/dtmax, dP/dtmin and an increase 
in tau collectively indicating a negative inotropic effect.  
How Ang II mediates its positive chronotropic actions is still controversial. In the 
pithed rat the positive chronotropic actions of Ang II were similar to those 
observed in animals with intact autonomic control (Li et al., 1996) confirming 
that the positive chronotropic actions of Ang II are largely independent of 
central actions. However, it is yet unclear whether Ang II predominantly 
mediates its chronotropic effect by altering Ca2+ and other ionic fluxes in 
ventricular cardiomyocytes or sinoatrial pacemaker cells. In isolated ventricular 
cardiomyocytes, Ang II has been shown to increase the frequency of spontaneous 
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contractions and L-type Ca2+ channel current in the mouse (Liang et al., 2010, 
Masaki et al., 1998), rat (Allen et al., 1988, Touyz et al., 1996b), chicken (Bkaily 
et al., 2005) and cat (Aiello and Cingolani, 2001, Salas et al., 2001) in an AT1R-
dependent manner. Similarly, in rat and mouse right atrial preparations, the 
location of the SA node, Ang II mediated positive chronotropy by binding the 
AT1R receptor (Mori and Hashimoto, 2006, Li et al., 1996) and direct injection of 
Ang II into the canine sinus node artery increased HR in a manner involving the 
AT1R and L-type Ca2+ channels (Lambert, 1995). In contrast, however, in guinea 
pig and rabbit SA pacemaker cells, Ang II was reported to decrease spontaneous 
firing by inhibiting the L-type Ca2+ channel current suggesting that species-
specific differences exist (Habuchi et al., 1995, Sheng et al., 2011). Since in 
Langendorff perfusion, both, the SA node and ventricular cardiomyocytes are 
equally exposed to Ang II in the perfusate and the organ bath, it is likely that 
Ang II activates both SA node cells and cardiomyocytes which may contribute to 
the positive chronotropic and ultimately pro-arrhythmic effects of Ang II 
(Wagner et al., 2014). 
Previous studies of Ang II have presented controversial data on the inotropism of 
Ang II in various heart preparations. While it has been suggested that Ang II is a 
positive inotrope in rabbits and pigs via a mechanism that involves the AT1R and 
phosphoinositide hydrolysis (Ishihata and Endoh, 1995, Broomé et al., 2001), 
others have shown that, for example in mice and humans, Ang II acts as a 
negative inotrope or has no effect at all (Holubarsch et al., 1993, Sekine et al., 
1999, Sakurai et al., 2002). The contrasting observations are most likely due to 
species specificity and experimental differences and therefore make direct 
comparisons difficult. Ishihata & Endoh (1995) previously demonstrated that in 
ventricular muscle preparations from dogs, rats and ferrets but not rabbit, Ang II 
failed to induce an inotropic effect despite its ability to mediate 
phosphoinositide hydrolysis which is linked to PKC activation and stimulation of 
Ca2+ transients via the L-type Ca2+ channel (Ishihata and Endoh, 1995, Kamp and 
Hell, 2000, Aiello and Cingolani, 2001, Salas et al., 2001). Similar observations 
have also been made in human atrial and ventricular preparations (Holubarsch et 
al., 1993). Interestingly, it was previously demonstrated that the inotropic 
response to Ang II switches during development and while Ang II significantly 
increased cardiac contractile force in right ventricular heart strips from neonatal 
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mice it decreased in the adult (Sekine et al., 1999). In contrast to neonatal 
cardiomyocytes stimulated with endothelin-1, in adult rat cardiomyocytes no 
changes in intracellular Ca2+ were observed with Ang II stimulation and this was 
concomitant with observations on cell shortening which remained unaltered with 
Ang II stimulation (Lefroy et al., 1996, Touyz et al., 1996a).  
The positive chronotropic and vasoconstrictive actions of Ang II in organ 
preparations are well established and given the evidence on a lack of positive 
inotropic actions of Ang II in the rat demonstrated here and by others (Ishihata 
and Endoh, 1995), it can be hypothesised that Ang II mediates very few direct 
effects on the rat myocardium and the majority of contractile effects by Ang II 
are due to its effects on HR and coronary vascular dynamics. Therefore, in the 
spontaneously beating heart, evidence suggests that while HR may drive an 
increase in cardiac contractile function, this is offset by the vasoconstrictive 
effects of Ang II. As discussed previously, in isolated heart and ventricular 
preparations, increases in stimulation frequency lead to an increase in 
contractile force, the FFR. In rats and mice whose HR is intrinsically high and 
whose contractile force is primarily governed by Ca2+ release from the SR 
(Monasky and Janssen, 2009), negative FFR has been observed (Narayan et al., 
1995, Morii et al., 1996) but a positive or unchanged FFR is evident in 
physiological preparations (Layland and Kentish, 1999, Taylor et al., 2004, 
Georgakopoulos and Kass, 2001). The mean intrinsic rate of rat hearts in this 
study corresponds to a frequency of 4.6 Hz which increases to approximately 
5 Hz upon Ang II perfusion and these frequencies are on the positive staircase of 
the rat FFR (Layland and Kentish, 1999, Joulin et al., 2009). Increases in HR with 
Ang II perfusion in spontaneously beating hearts occur within 2 min before 
reaching steady state at 4 min at which point cardiac contractility and 
relaxation, measured by dP/dtmax, dP/dtmin and tau, respectively, is increased. 
Contractile changes in response to HR may take up to 3 min to reach steady 
state (Layland and Kentish, 1999) and it therefore can be assumed that the rise 
in cardiac contractility and lusitropy at 1 μM Ang II may be direct function of Ang 
II-induced increases in HR. The transient nature of this observation may be 
explained by the effects of Ang II on the coronary vasculature which offset the 
effects of HR and the FFR: Ang II is a potent vasoconstrictor and when applied to 
the isolated heart mediates a significant reduction in coronary flow peaking at 
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Ang II concentrations of 1 μM (Liang et al., 2010, van Esch et al., 2006, van Esch 
et al., 2010, Aplin et al., 2007). While HR usually increases coronary flow to 
increase oxygen and nutrient delivery (Heusch, 2008), vasoconstriction and the 
resulting decrease in blood flow decrease cardiac contractile function. As such, 
in Langendorff-perfused spontaneously beating mouse hearts, Ang II was 
observed to induce a significant reduction in coronary flow despite a peak 
increase in heart rate by 71 bpm (Liang et al., 2010). Since LVDP and cardiac 
contractile function are in part governed by coronary flow (Opie, 1965), Ang II 
mediated vasoconstriction may therefore counteract the FFR by reducing cardiac 
contractile performance before reaching a new steady state of vasodilation after 
longer perfusion periods induced by the release of vasodilators and Ang II 
receptor desensitisation (Pörsti et al., 1993).  
In line with this hypothesis, in hearts maintained at a constant HR, Ang II-
mediated changes in cardiac chronotropy are prevented and therefore, force-
frequency mediated changes in cardiac contractility are removed. This would 
suggest that in paced hearts, Ang II-mediated changes in cardiac contractility 
are largely dependent on coronary vascular dynamics. Although vascular 
autoregulation is overridden in constant flow Langendorff preparations and 
therefore does not allow flow adaptations to changes in workload and ischaemia, 
the coronary vascular dynamics in response to vasoactive drugs such as Ang II can 
be assessed by measuring coronary perfusion pressure (Bell et al., 2011). In 
isolated constant-flow perfused rabbit hearts, Ang II mediates a biphasic 
response in cardiac contractility with an initial decrease in LVDP that is 
concomitant with an increase in coronary perfusion pressure (i.e. a reduction in 
coronary flow) followed by a period of vasodilation and increase in LVDP that 
returned to near basal levels after 9 min of perfusion (Pörsti et al., 1993). This 
response shares some similarity with the response observed here in paced rat 
hearts where a transient increase in LVDP was preceded by a significant 
reduction in cardiac contractility and relaxation although a decrease in LVDP 
was not observed. A similar response to Ang II has also been observed in 
spontaneously beating mouse hearts albeit over a different time-course (Liang et 
al., 2010) and therefore, it can be assumed that the vascular effects of Ang II 
contribute significantly to the response observed in paced rat hearts. Coronary 
dynamics have not been assessed in this study by measuring perfusion pressure 
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and therefore it cannot be directly verified that in the rat, Ang II modulates the 
coronary microvasculature in a similar manner to the rabbit and this would be of 
interest for future studies.  
In hearts perfused with Ang-(1-9) a positive inotropic response was observed and 
the nature of this response was dependent on HR. In spontaneously beating 
hearts, perfusion with Ang-(1-9) induced a transient positive inotropic effect 
peaking at 4 min of perfusion. This effect was partially inhibited by the AT2R 
antagonist PD123319 but this led to a significant increase in HR. In contrast, in 
hearts maintained at a constant HR, Ang-(1-9) induced a sustained inotropic 
effect that was resistant to AT2R inhibition by PD123319 but could be blocked by 
the AT1R antagonist losartan. These contrasting observations suggest a complex 
interaction between Ang-(1-9) and the AT1R and AT2R.  
As previously discussed, investigations in spontaneously beating hearts are often 
complicated and confounded by drug effects on HR. While Ang-(1-9) itself 
induced a transient decrease in HR and only increased HR after longer perfusion 
times, in the presence of PD123319, Ang-(1-9) significantly increased HR within 
2 min. This suggests that in the presence of an AT2R antagonist, Ang-(1-9) may 
bind to the AT1R to mediate positive chronotropic effects similar to Ang II. As HR 
can significantly alter cardiac contractile parameters and high HRs have been 
shown to confound changes in cardiac contractility (Derumeaux et al., 2008, 
Taylor et al., 2004), the modulation in HR by Ang-(1-9) in the presence of 
PD123319 may result in the contrasting observation of AT2R blockade in paced 
and spontaneously beating hearts.  
On a molecular level, two possibilities exist for modulation of EC coupling by 
angiotensin receptors: Alterations in intracellular Ca2+ haemodynamics or 
modulation of myofilament proteins. The former include modulations of ion 
channels and receptors involved in intracellular Ca2+ homeostasis and include the 
L-type Ca2+ channel, the RyR, SERCA and phospholamban. The latter includes 
modulation of cross-link formation and the Ca2+ sensitivity of myofilaments 
targeting troponin I and myosin light chain. While the AT1R can modulate cardiac 
contractility by activation of PKC, as previously discussed, little is known about 
the role of the AT2R in cardiac contractility. The AT2R is an atypical GPCR and is 
not linked to activation of any G-protein but rather mediates activation of cGMP, 
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NO and protein phosphatases such as PP2A and SHP1. PP2A, like PP1, is a major 
phosphatases regulating EC-coupling and its targets include the L-type Ca2+ 
channel, RyR, NCX and cardiac troponin I (Lei et al., 2015). PP2A activity is 
usually associated with a decrease in inotropy and lusitropy exemplified by the 
attenuation of β-adrenergic signalling via dephosphorylation of the L-type Ca2+ 
channel as well as the myofilament proteins troponin I, myosin-binding protein C 
and myosin light chain 2 (Kirchhefer et al., 2014, Davare et al., 2000). The net 
effect is a decrease in Ca2+ transients alongside an increase in myofilament Ca2+ 
sensitivity, decreasing contraction and relaxation (Kirchhefer et al., 2014, 
Davare et al., 2000). Additionally, dephosphorylation of the RyR by PP2A 
stimulates Ca2+ release and decreases SR Ca2+ content (Terentyev et al., 2003). 
In contrast, the effects of cGMP and NO in the heart are complex (Massion et al., 
2003). While NO may increase cardiac contractility indirectly by increasing 
coronary flow, endogenous and exogenous NO in cardiomyocytes exhibits a 
bimodal effect on cardiac contractility (Mohan et al., 1996, Pellegrino et al., 
2009) . At physiological concentrations, NO acts as a positive inotrope possibly 
by increasing cardiac Ca2+ transients via cGMP-dependent inhibition of cAMP 
phosphodiesterases, while at high concentrations, NO is a negative inotrope by 
shortening twitch duration and contractile force via cGMP-PKG pathways (Mohan 
et al., 1996, Pellegrino et al., 2009). Barouch et al. (2002) demonstrated that in 
cardiomyocytes, NOS1 selectively associates with the RyR to facilitate SR Ca2+ 
release (Barouch et al., 2002). In contrast, NOS3 is associated with the L-type 
Ca2+ channel where it negatively regulates β-adrenergic inotropy suggesting that 
NO signals in microdomains and the final outcome is dependent on selective 
activation of NOS isoforms (Barouch et al., 2002). cGMP has largely been 
associated with negative inotropic effects (Layland et al., 2002, Flesch et al., 
1997) and an increase in cellular cGMP decreases spontaneous contractile 
frequency in isolated cardiomyocytes (Balligand et al., 1993), in similarity to the 
transient fall in HR observed here with Ang-(1-9). While this may suggest an 
involvement of AT2R mediated signalling pathways in the inotropic response of 
Ang-(1-9), given the complex nature of the data and observations that 1) AT2R 
activation was demonstrated to counteract Ang II-induced inotropy (Masaki et 
al., 1998, Castro-Chaves et al., 2008) and 2) the AT1R and AT2R can 
heterodimerize to form a signalling network (AbdAlla et al., 2001, van Esch et 
al., 2006), further experiments, including dual blockade of the AT1R and AT2R, 
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and assessment of EC coupling in isolated cardiomyocytes are needed to 
definitively elucidate the receptors and signalling pathways mediating the 
positive inotropic actions of Ang-(1-9). 
In paced hearts, it was identified that Ang-(1-9) mediates its positive inotropic 
actions by interacting with the AT1R. Ang-(1-9) can bind the AT1R and AT2R with 
equal affinities but its affinity for the AT1R is 100-fold lower than Ang II (Flores-
Muñoz et al., 2011). The data here shows that in rat hearts, the expression of 
the AT1R is nearly 2-fold higher than the AT2R corresponding with the low 
expression of the AT2R in the adult. In support of the observation that Ang-(1-9) 
is acting through the AT1R is the observation that in the presence of Ang II, Ang-
(1-9) failed to elicit an increase in inotropy seen during Ang-(1-9) application 
alone in spontaneously beating hearts suggesting that Ang-(1-9) is competing 
with Ang II for receptor occupation and Ang II in this instance may be acting as a 
competitive inhibitor. If Ang-(1-9) is acting through the AT1R, this raises the 
question as to why, despite engaging the same receptor, Ang II and Ang-(1-9) 
mediate contrasting effects on cardiac contractility. There are two possibilities 
that stand to reason: biased agonist activity/ functional selectivity or receptor 
modulation and dimerization. The potential of ligands to stabilise a given 
receptor in certain conformations eliciting distinct signalling pathways, called 
biased agonism or functional selectivity, has been explored increasingly 
(Rajagopal et al., 2010). As discussed previously in Section 1.3.5 biased agonism 
at the AT1R has also been characterised. Full activation of the AT1R by Ang II is 
particularly governed by interactions of Asp1, Tyr4 and Phe8 with the receptor 
and modifications of these amino acids to Sar1, Ile4, Ile8 (SII) prevents G-protein 
and Ca2+ mobilisation by the AT1R while selectively engaging β-arrestin signalling 
(Miura and Karnik, 1999). Selectively engaging the AT1R with SII increases 
inotropy and lusitropy in isolated mouse cardiomyocytes distinct from Ang II and 
independent of Ca2+ mobilisation and PKC activation (Rajagopal et al., 2006). In 
a similar manner, the synthetic peroxisome proliferator-activated receptor γ 
agonist troglitazone has been characterised as a biased agonist at the AT1R, 
mediating an increase in FS in isolated mouse cardiomyocytes in a β-arrestin2-
depedent and Gq-independent pathway (Tilley et al., 2010). This has been 
extrapolated to in vivo observations where the two synthetic peptides 
TRV120023 and TRV120027 increased cardiac contractility while simultaneously 
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decreasing BP, contrasting normal ARBs which negatively affected cardiac 
contractile function (Violin et al., 2010). Specifically, the positive inotropic 
actions of TRV120023 in a model of dilated cardiomyopathy were due to an 
increase in the phosphorylation of myosin light chain 2 increasing cardiac output 
and stroke work despite no change in LVDP (Tarigopula et al., 2015). These 
observations suggest the potential of Ang-(1-9) to show functional selectivity at 
the AT1R. The possibilities of selective modulation of a receptor range from 
allosteric modulation to function as a dualsteric ligand (Smith et al., 2011). One 
example of allosteric modulation by Ang-(1-9) is the re-sensitisation of the 
bradykinin receptor by allosteric modulation of the ACE active domains 
interacting with the B2 receptor (Deddish et al., 1998, Marcic et al., 1999, Chen 
et al., 2005). Ang-(1-9) is an inhibitor of ACE (Kokkonen et al., 1997) and in a 
similar manner to the B2 receptor may allosterically modulate the AT1R via an 
interaction with ACE stabilising the AT1R at the plasma membrane and 
preventing de-sensitisation (Chen et al., 2005). Interestingly, the AT2R has 
previously been shown to inhibit cardiac fibrosis by stimulation of bradykinin 
release while bradykinin itself can act as a positive inotrope (Munch and 
Longhurst, 1991). Both, the AT2R and AT1R form heterodimers with the B2 
receptor and especially AT1R-B2 dimerisation has been shown to significantly 
enhance AT1R signal transduction (Abadir et al., 2006, AbdAlla et al., 2000). 
Whether such interactions also occur in the heart needs to be established and 
their potential in modulating the cardiac effects of Ang II and Ang-(1-9) 
investigated. Overall, this evidence highlights the complexity in the signalling of 
angiotensin peptides which make direct assessments of RAS signalling in isolation 
using specific receptor antagonists difficult. Future studies are needed to assess 
the potential of Ang-(1-9) to act as a biased agonist on the AT1R by assessment 
of activated signalling pathways, G-protein and β-arrestin dependency and 
tracing of ligand-receptor interactions. Furthermore, the contributions of 
bradykinin, and receptor interactions by formation of homo- and heterodimers in 
this process should be investigated. 
Using perfusion with H89, it was shown that the positive inotropic effects by 
Ang-(1-9) are due to PKA-mediated changes in EC-coupling. PKA is a holoenzyme 
consisting of two catalytic subunits bound by 2 regulatory subunits that inhibit 
PKA enzymatic activity. The canonical pathway of PKA activation involves the 
Chapter 4   218 
 
 
activation of the stimulatory G protein Gs which stimulates adenylate cyclase to 
increase production in cAMP. The binding of cAMP to the regulatory subunits of 
PKA leads to their dissociation and subsequent activation of PKA (Dulin et al., 
2001). This PKA pathway is classically activated by β1-adrenergic stimulation in 
cardiomyocytes mediating positive inotropic and lusitropic actions (Kamp and 
Hell, 2000). Here, Ang-(1-9) was shown to mediate its positive inotropic actions 
via a pathway involving the AT1R and PKA but not its proposed receptor the 
AT2R. The AT2R is an atypical GPCR linked to the activation of phosphatases such 
as PP2A, NO release as well as cGMP formation and PKG activation, all of which 
have been shown to counteract target activation by PKA (Nouet and Nahmias, 
2000, Kamp and Hell, 2000), confirming that it is unlikely the mediator of PKA 
activation in cardiomyocytes. The AT1R classically has been shown to couple to 
the G proteins Gq/11, Gi and G12/13 but not Gs and hence would be unable to 
activate PKA via the canonical pathway but instead has the ability to inhibit 
adenylate cyclase and cAMP formation (Higuchi et al., 2007). In line with this, 
ample evidence suggests that in cardiomyocytes, activation of the AT1R is linked 
to the G-protein Gq activating PKC which mediates the inotropic effects in 
response to Ang II binding (Kamp and Hell, 2000, Salas et al., 2001, Liang et al., 
2010). However, it has been shown that PKA can be activated in Gs and cAMP-
independent pathways involving G13 and AKAP110 or Nox2 (Niu et al., 2001, 
Wagner et al., 2014). Additionally, it has been shown that vasoactive peptides 
such as Ang II and ET-1 can activate PKA in a cAMP-independent mechanism 
involving degradation of IκB in VSMC (Dulin et al., 2001) suggesting that the AT1R 
has the potential of activating PKA in cAMP independent pathways. In 
cardiomyocytes, the phosphorylation targets of PKA include the L-type Ca2+ 
channel, RyR, phospholamban and troponin I, all of which collectively mediate 
an increase in Ca2+ transient amplitude and extrusion resulting in positive 
inotropy and lusitropy. Ang-(1-9) stimulation mediated positive inotropy as seen 
by an increase in LVDP and dP/dtmax, however, the rate of relaxation was less 
affected and indeed, isovolumetric relaxation time, tau, tended to increase 
suggesting impaired relaxation. This corresponds to observations made with β2-
adrenergic stimulation where PKA–mediated phosphorylation of phospholamban 
and troponin I cannot be observed resulting in slower relaxation time (Xiao and 
Lakatta, 1993, Kuschel et al., 1999). A J-shaped relationship between changes in 
LVP (due to increased afterload) and tau have previously been observed in the 
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dog and mouse where tau begins to exponentially increase after reaching an 
inflection point of LVP increase while contraction time tended to increase 
(Leite-Moreira and Gillebert, 1994, Yang et al., 2013a). This corresponds to 
observations made here where tau increased concomitant with LVDP in response 
to Ang-(1-9). An increase in isovolumetric relaxation time suggests a decrease in 
the mechanism of Ca2+ extrusion including SR Ca2+-reuptake by SERCA and 
sarcoplasmic Ca2+ extrusion by NCX (Bers, 2002). In cat myocytes Salas et al. 
(2001) previously demonstrated that Ang II via the AT1R mediates negative 
lusitropy by elongation of the action potential and a decreased extrusion of Ca2+ 
by NCX. The increase in tau was equally blocked by PD123319, losartan, K93 and 
H89 suggesting a complex interplay between the AT1R, AT2R, CaMKII and PKA. 
The AT1R and AT2R have previously been shown to form dimers and can also 
signal in a complex with the Mas receptor (Castro et al., 2005). Indeed, interplay 
of the AT1R, PKA and CaMKII mediating Ang II-induced arrhythmias has recently 
been demonstrated (Wagner et al., 2014). In this study, Ang II mediated the 
cAMP-independent activation of PKA and CaMKII via Nox2 resulting in an increase 
in the Ca2+ and Na+ current and RyR-dependent diastolic Ca2+ leak, respectively 
which may also collectively lead to a decrease in Ca2+ extrusion and slower 
relaxation time (Wagner et al., 2014).  
Recent data from our group suggests that in isolated mouse cardiomyocytes, 
Ang-(1-9) increases Ca2+ transient amplitude via an increase in L-type Ca2+ 
current (Fattah et al, unpublished). In line with this, the L-type Ca2+ channel has 
been shown to be phosphorylated by PKA on its α1c (Ser1928) and β2a (Ser459, Ser 
478, Ser479) subunit which increase the available fraction and opening 
probability of channels during depolarisation (Kamp and Hell, 2000, Bünemann 
et al., 1999). Ang II has already been shown to increase L-type Ca2+ current in 
various animal models mainly by the activation of PKC (Salas et al., 2001, Aiello 
and Cingolani, 2001, Liang et al., 2010). Furthermore, enhanced coupling of the 
AT1R with L-type Ca2+ channels has been reported in the aortas of diabetic rats 
(Arun et al., 2005) confirming a functional link. More recently, Ang-(1-7) was 
also shown to activate the L-type Ca2+ current in a PKA-dependent manner when 
applied intracellularly in rat ventricular cardiomyocytes (De Mello, 2015) and in 
cardiomyocytes from rats with HF (Zhou et al., 2015). This suggests that the 
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activation of the L-type Ca2+ channel and PKA may be a mechanism that is global 
to peptides of the RAS albeit with different outcomes on cell behaviour.  
Thr-197 phosphorylation is required for optimal PKA enzyme activity (Adams et 
al., 1995). However, here no significant difference was found in Thr-197 
phosphorylation of PKA in cardiomyocytes stimulated with Ang-(1-9) and 
similarly, forskolin did not alter PKA phosphorylation. PKA is a unique enzyme as 
it is assembled as an active enzyme with a fully phosphorylated activation loop 
and is regulated by holoenzyme formation dependent on cAMP. The catalytic 
subunit is always found fully phosphorylated when purified from mammalian 
tissue and hence suggests that although no changes in PKA phosphorylation were 
detectable, this is not a direct measure of PKA activation (Moore et al., 2002). 
PKA activity can be assessed by PKA substrate antibodies or specifically by the 
phosphorylation of vasodilator-stimulated phosphoprotein (VASP) in an 
electrophoretic mobility shift assay (Dulin et al., 2001) and this would be of 
interest to verify PKA activity in response to Ang-(1-9). 
4.5 Summary 
Ex vivo Langendorff perfusion is the gold standard for the assessment of cardiac 
contractile function in the absence of systemic effects. Perfusion of isolated rat 
hearts with Ang-(1-9) conveyed positive inotropy with an increase in LVDP, 
dP/dtmax and dP/dtmin. This effect was mediated by both, the AT1R and AT2R 
with activation of PKA. In contrast, Ang II and Ang-(1-7) had little effect on 
cardiac contractility. These results suggest a direct effect of Ang-(1-9) on the 
heart distinct from the related peptides Ang II and Ang-(1-7) which may 
contribute to the beneficial effects of Ang-(1-9) in the heart.  
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Chapter 5 – Characterisation of EndMT in Ang II-
induced cardiac remodelling in vivo and its role 
in TGFβ-induced EndMT in vitro 
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5.1 Introduction 
5.1.1 Endothelial-to-mesenchymal transition 
ECs form the inner lining of blood vessels separating the blood from the 
underlying VSMCs and therefore have an important gate-keeping function. ECs 
are characterised by the expression of cluster of differentiation (CD) 31 [also 
known as platelet endothelial adhesion molecule-1 (PECAM-1)] and vascular 
endothelial (VE)-cadherin both of which are crucial for the transduction of 
changes in blood flow to the endothelial cytoskeleton to mediate endothelial 
alignment with the flow of blood (Tzima et al., 2005). Endothelial plasticity is 
important for the maintenance of normal vascular function to facilitate changes 
in blood flow. One extreme form of endothelial plasticity is EndMT which has 
been demonstrated to play a crucial role in cardiac development and disease. 
EndMT describes the process during which ECs transdifferentiate into 
mesenchymal cells such as fibroblasts and VSMCs (Garside et al., 2013). During 
this process, ECs delaminate from the layer of ECs and infiltrate the underlying 
tissue. This is accompanied by a loss in cell-cell junctions, cell polarity and 
changes in cytoskeletal dynamics eliciting increased motility (Yoshimatsu and 
Watabe, 2011). On a molecular level, cells lose expression of EC-specific 
markers such as CD31 and VE-cadherin (Frid et al., 2002). Parallel to these 
changes, cells also gain expression of mesenchymal markers such as FSP1, αSMA, 
calponin and smooth muscle (SM)22-α (also known as transgelin) which are part 
of the contractile apparatus of smooth muscle and other mesenchymal cells. 
This process is predominantly governed by TGFβ signalling (Goumans et al., 
2008). EndMT is a specific form of epithelial-to-mesenchymal transition (EMT) 
which has been extensively studied both on a molecular level and in 
physiological and pathological settings (Lamouille et al., 2014). Physiological 
EndMT is primarily involved in the formation of the cardiac valves and the 
interventricular septum during cardiogenesis (Garside et al., 2013). Pathological 
EndMT has been demonstrated in various fibrotic diseases including renal and 
hepatic fibrosis, cancer and CVDs (Zeisberg et al., 2007a, Zeisberg et al., 2007c, 
Zeisberg et al., 2008, Zeisberg et al., 2007b).  
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5.1.2 EndMT in cardiovascular disease 
In the past experimental efforts focussed on the understanding of EndMT in the 
embryo and it was thought that EndMT in the adult was very rare (Piera-
Velazquez et al., 2011). The first pioneering study demonstrating the occurrence 
of EndMT in adult endothelium was demonstrated by Arciniegas et al. in 1992 
(Arciniegas et al., 1992) who cultured bovine aortic ECs for up to 20 days in the 
presence of TGFβ1. At the end of the protocol up to 90 % of ECs were found to 
have irreversibly lost their EC phenotype, be αSMA positive and had 
differentiated into mature contractile SMC. This was further corroborated by 
Frid et al. (2002) who used fluorescence activated cell sorting to obtain a pure 
culture of bovine aortic EC and when maintained in culture, these cells were 
found to spontaneously transition to mesenchymal cells with a differentiated 
smooth muscle phenotype (Frid et al., 2002). This phenotypic switch was found 
to be dependent on TGFβ1 and only occurred in cells cultured on tissue plastic 
but not on denatured collagen, suggesting that the matrix is inhibitory to 
mesenchymal transition. The phenotypic switch could however be activated by 
addition of TGFβ1 to the culture (Frid et al., 2002). Similarly, Ishisaki et al. 
(2003) provided evidence that ECs from the venous system retain the potential 
to transform into smooth muscle like cells. In this study, they deprived human 
umbilical vein ECs of fibroblast growth factor 1 (FGF-1) which can be routinely 
added as a growth supplement to EC cultures. After several weeks in culture 
they identified that ECs switched on a mesenchymal gene expression profile with 
increases in calponin and SM22-α and were able to contract collagen gels when 
stimulated with ET-1 (Ishisaki et al., 2003). This spontaneous transition was 
thought to be mediated by increases in activin A, a member of the TGFβ 
superfamily, and highlights the plasticity of ECs to adjust to changes in their 
environment which may also occur during disease development. 
An increasing body of evidence now suggests that EndMT can also occur 
postnatally as a feature of various pathologies such as fibrosis and cancer 
(Zeisberg et al., 2007a, Zeisberg et al., 2008). Similar to the embryonic gene 
expression program activated during cardiac hypertrophy, it has been postulated 
that pathological EndMT in the adult, recapitulates the embryonic 
developmental process. As discussed in detail in Section 1.4.2 tissue fibrosis is 
characterised by the disordered and excessive deposition of ECM by persistently 
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activated fibroblasts which results in the disruption of normal tissue architecture 
and ultimately leads to organ dysfunction. In a hallmark study, Zeisberg et al. 
(2007b) provided evidence that EndMT significantly contributes to cardiac 
fibrosis in the pressure-overloaded heart (Zeisberg et al., 2007b). Using 
endothelial lineage tracing by employing Cre-lox technology under the Tie1 
promoter which encodes for a vascular endothelium specific receptor tyrosine 
kinase involved in angiogenesis (Korhonen et al., 1994), they identified that up 
to 30 % of fibroblasts positive for either FSP1 or αSMA in the fibrotic heart were 
derived from endothelial origin. This was found to be partially due to signalling 
through the TGFβ1-SMAD3 axis and could be prevented by administration of BMP7 
(Zeisberg et al., 2007b). Since then, EndMT as a source of fibroblasts has been 
confirmed in several other models of cardiac fibrosis. In a model of 
streptozotocin-induced diabetes, EndMT was found to contribute to the increase 
in perivascular cardiac fibrosis and a reduction in myocardial capillary density 
where up to 20 % of the S100A4-positive fibroblast population was found to also 
express CD31 (Widyantoro et al., 2010). This phenotype was abolished by 
endothelial-specific deletion of ET-1 and could be recapitulated in human ECs 
cultured in high glucose conditions in vitro by ET-1 knockdown. This was found 
to be due to the reciprocal increase of ET-1 and TGFβ in high glucose conditions 
leading to phosphorylation of SMAD3 and Akt activation which could be abolished 
by TGFβ neutralising antibodies (Widyantoro et al., 2010). Furthermore, EndMT 
was shown to contribute to the pathogenesis of endocardial fibroelastosis, a rare 
disorder usually occurring in young children characterised by the aberrant 
deposition of fibrous tissue in the endocardial layer leading to thickening of the 
ventricular wall and impairment of cardiac contractile function (Xu et al., 2015). 
Dyssynchronous contraction of the ventricles due to contraction delay is a 
common phenomenon of HF. In a model of canine dyssynchronous HF, Mai et al. 
(2015) recently showed that the increases in cardiac fibrosis especially in the LV 
lateral wall were partially due to an increase in EndMT which could be modelled 
in vitro by exposing ECs to cyclic stretch correlating to previous reports on the 
role of fluid shear stress on EndMT (Egorova et al., 2011, Moonen et al., 2015, 
Mai et al., 2015). Interestingly, cyclic stretch synergistically acted with TGFβ1 to 
induce EndMT and caused a greater transition than either of the factors alone 
(Mai et al., 2015) suggesting a self-perpetuating axis of cardiac fibrosis in vivo. 
More controversially, EndMT was also present in aged mice with a genetic 
Chapter 5  225 
 
 
deficiency of plasminogen activator inhibitor-I (Ghosh et al., 2010) but its 
clinical relevance still needs to be determined. Interestingly, despite the widely 
accepted notion of a pathological role for EndMT in cardiac fibrosis, EndMT was 
shown to be activated during granulation tissue formation following MI 
(Aisagbonhi et al., 2011) suggesting its involvement in neovascularisation and 
scar formation following the ischaemic insult. Partial EndMT with the loss of cell-
cell contacts and cell polarity and the gain of a migratory phenotype is 
associated with neovascularisation and angiogenesis (Welch-Reardon et al., 
2015), suggesting that EndMT may act as a double-edged sword in cardiac 
remodelling.  
5.1.3 The RAS in EndMT and EMT 
The role of Ang II has been extensively assessed in renal EMT and its potent 
inductive role is well characterised. Ang II infusion in rats by osmotic minipumps 
leads to EMT within the renal tubules and can be replicated by in vitro 
stimulation of renal proximal tubular cells (HK2) with Ang II (Carvajal et al., 
2008). Ang II induces EMT in a time-and dose dependent manner and was able to 
downregulate E-cadherin and upregulate αSMA mRNA expression in NRK52E cells 
within 6 h of exposure (Yang et al., 2009). This was correlated with a decrease 
in E-cadherin and increase in αSMA protein expression after 1 and 3 days of Ang 
II exposure, respectively and linked to the induction of CTGF by Ang II via SMAD3 
(Yang et al., 2010) which could be attenuated by CTGF antisense oligonucleotide 
(Chen et al., 2006). Similarly, in an in vitro model of high glucose induced EMT 
using a renal proximal tubular epithelial cell line, exposure to high glucose for 
24 or 48 h resulted in significant upregulation of components of the RAS 
including angiotensinogen, ACE and AT1R which increased the secretion of Ang II 
into the cell culture medium (Zhou et al., 2010). The AT1R antagonist losartan 
blocked the phenotypic switch in the epithelial cells characterised by increases 
in vimentin, fibronectin and TGFβ1 secretion and a reduction in E-cadherin (Zhou 
et al., 2010). Furthermore, Ang II has been demonstrated to be involved in EMT 
in other organs. For example, in a model of dermal fibrosis, Ang II infusion 
caused skin fibrosis at the site of subcutaneous infusion and co-localisation 
studies with VE-cadherin and FSP1 confirmed EMT was present in the skin lesions 
(Stawski et al., 2012). This could be replicated by stimulating human dermal 
microvascular ECs with Ang II for 96 h (Stawski et al., 2012). In cancer research, 
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Ang II was associated with increasing EMT in intrahepatic cholangiocarcinoma by 
activating the stromal cell-derived factor-1/CXCR4 signalling axis (Okamoto et 
al., 2012) and in a recent abstract published by Oh et al. (2015), AT1R 
overexpression in the MCF7 breast cancer cell line increased cell proliferation, 
migration and invasion which was accompanied with a mesenchymal cell 
phenotype (Oh et al., 2015). Overall, these results indicate a potent role of Ang 
II in EMT in various diseases settings in vitro and in vivo. 
In contrast, the role of Ang II in EndMT is less well understood. Recent advances 
in elucidating the contribution of the RAS in EndMT have been made by the use 
of AT1R receptor antagonists. In human aortic ECs, high glucose conditions have 
been demonstrated to induce EndMT by elevating αSMA and FSP1 gene and 
protein expression (Tang et al., 2010). This was associated with a significant 
increase in Ang II secretion. Inhibition of Ang II signalling with irbesartan 
reduced Ang II secretion and blocked mesenchymal gene expression, suggesting 
that Ang II mediates high glucose-induced EndMT (Tang et al., 2010). This was 
further corroborated in an in vivo model of streptozotocin-induced diabetes in 
rats where administration of irbesartan not only reduced diabetes-induced 
adverse cardiac remodelling but also decreased the number of cells double-
labelled for CD31 and FSP1 (Tang et al., 2013). More recently, it has been 
demonstrated that the AT1R antagonist losartan inhibits TGFβ1-induced EndMT in 
mitral valve ECs by inhibition of ERK phosphorylation while high concentrations 
of Ang II directly induced αSMA protein expression in valvular ECs which was 
linked to TGFβ production (Wylie-Sears et al., 2014). More recently, it was 
demonstrated that endothelial-specific overexpression of Nox2 promotes ECs to 
undergo EndMT in response to Ang II stimulation in vivo and in vitro thereby 
contributing to Ang II-induced cardiac fibrosis in vivo (Murdoch et al., 2014). 
This suggests that ROS may play an important role in mediating EC 
transformation in various models of EMT and EndMT involving TGFβ1 and Ang II. 
Overall, these results demonstrate a role of Ang II in several models of EndMT, 
however, the direct effects of Ang II on mesenchymal gene expression in ECs has 
so far not been investigated in detail.  
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5.2 Aims 
 Assess capillary density and EndMT in mice with Ang II-induced cardiac 
remodelling. 
 Assess the role of the counter-regulatory RAS axis peptide Ang-(1-9) on 
myocardial capillary density and EndMT in Ang II-infused mice in vivo.  
 Develop and characterise an in vitro model of EndMT to determine the 
role of Ang II in this process and identify signalling pathways that are 
modulated by Ang II. 
5.3 Results 
5.3.1 Capillary density in Angiotensin II-infused mice 
Changes in the cardiac microvasculature have previously been described in 
patients with HHD (Mohammed et al., 2015). To assess the state of the 
microvasculature in Ang II-dependent hypertension, cardiac capillary density was 
assessed in Ang II-infused mice from Section 3 by CD31 immunostaining and 
quantified as capillary density (capillaries/mm2) and capillary/cardiomyocyte 
ratio (Figure 5-1, Table 5-1).  
In control mice capillary density ranged from 2161 ± 111 capillaries/mm2 at 4 
weeks to 2894 ± 119 capillaries/mm2 at 6 weeks with an estimated 
capillary/cardiomyocyte ratio between 1.1 ± 0.1 to 0.8 ± 0.1. Infusion of 
24 μg/kg/hr Ang II for 2 weeks tended to reduce capillary density (control 2518 ± 
209 vs. 24 μg/kg/hr Ang II 1775.0 ± 364, n= 6, p= 0.11) and 
capillary/cardiomyocyte ratio (control 1.1 ± 0.1 vs. 24 μg/kg/hr Ang II 0.7 ± 0.2, 
n= 6, p= 0.06) (Figure 5-1 B-C). After 4 weeks, microvascular rarefaction was 
apparent as a significant reduction in myocardial capillary density (control 2161 
± 111 vs. 24 μg/kg/hr Ang II 835.0 ± 132, n= 4, p<0.05) and 
capillary/cardiomyocyte ratio (Control 0.8 ± 0.1 vs 24 μg/kg/hr Ang II 0.3 ± 0.1, 
n= 4, p<0.05) and this was maintained until week 6. Infusion of 48 μg/kg/hr 
Ang II for 6 weeks tended to exacerbate microvascular rarefaction compared to 
the low dose of 24 μg/kg/hr Ang II (Table 5-1, Figure 5-1 B-C). At 2 weeks, 
capillary density tended to correlate with cardiac hypertrophy measured as 
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HW/TL (R2= 0.24, p= 0.11) and at 4 weeks, there was a strong correlation 
between capillary density and cardiac hypertrophy with an overall R2= 0.91 
(p<0.05). This correlation was lost after 6 weeks with an R2= 0.02 (p>0.05). 
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Figure 5-1. Capillary density in Ang II-infused mice. 
(A) Capillary density was assessed by CD31 immunohistochemistry in mice infused with H2O 
(control), 24 μg/kg/hr Ang II (24 μg Ang II) or 48 μg/kg/hr Ang II (48 μg Ang II) for 2–6 weeks. 
Capillaries were counted and expressed as (B) capillaries/mm2 and (C) capillaries/cardiomyocyte. 
n= 6 and 4 at 2 and 4 weeks, respectively and n= 11, 10, 3 for control, 24 μg/kg/hr and 48 μg/kg/hr 
Ang II, respectively at 6 weeks. Histological sections for animals at 2 weeks were provided by Dr 
Monica Flores-Munoz. Data are presented as mean ± SEM.Scale bar: 100 μm. *<0.05 vs. time-
matched control (Student’s t-test and ANOVA with Tukey’s post-hoc analysis).   
Table 5-1. Microvascular characteristics in hearts of Ang II-infused mice after 6 weeks 
 Capillaries/mm2  Capillaries/cardiomyocyte 
 
MEAN SEM n 
p-
value 
 MEAN SEM n 
p-
value 
Control 2894 119 11   1.09 0.10 11  
24 μg/kg/hr 
Ang II 
2023 197 10 <0.01  0.70 0.06 10 <0.01 
48 μg/kg/hr 
Ang II  
1597 206 3 <0.01  0.47 0.06 3 <0.01 
p-value vs. control 
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5.3.2 Endothelial-to-mesenchymal transition in mouse hearts 
To investigate the occurrence of EndMT in the hearts of Ang II-infused mice 
which may contribute to the loss in capillary density, cardiac sections from a 
subset of Ang II-infused mice from Section 3 were stained for the EC marker 
CD31 and the fibroblast markers S100A4 (FSP1) or αSMA (Figure 5-2). Co-
localisation was assessed using Pearson’s coefficient R and Mander’s coefficients 
M1 and M2 which provide a measure of the linearity and ratio of overlap of the 
two channels, respectively (Table 5-2, Table 5-3).  
At 4 weeks, co-expression of CD31 and S100A4 was apparent in the hearts of Ang 
II-infused mice (Figure 5-2 A) and this was reflected in a significant increase of 
Pearson’s coefficient R which significantly correlated with the decrease in 
capillary density during Ang II infusion (R2= 0.59, p<0.05). Similarly, Mander’s M1 
and M2 ratios of co-localisation between CD31 and S100A4 were significantly 
increased (p<0.05) (Table 5-2). In contrast, αSMA only partially co-localised with 
CD31 and no significant increase in Pearson’s and Mander’s coefficients of co-
localisation was detected (Figure 5-2 A, Table 5-2). Following 6 weeks of Ang II 
infusion, co-expression of CD31 and S100A4 was still apparent (Figure 5-2 B) and 
reflected in an increase in the coefficients of co-localisation (Table 5-3). 
Infusion with a high dose of Ang II (48 μg/kg/hr) significantly increased the co-
expression of CD31 and S100A4 or αSMA as measured by Pearson’s R (Table 5-3). 
However, 24 μg/kg/hr AngII infusion did not induce significant co-expression of 
CD31 with either S100A4 or αSMA after 6 weeks (Table 5-3).  
  
Chapter 5  231 
 
 
 
Figure 5-2. EndMT in hearts of Ang II-infused mice 
Cardiac sections of mice infused with H2O (control), 24 μg/kg/hr Ang II (24 μg Ang II) or 48 μg/kg/hr  
(48 μg Ang II)for (A) 4 or (B) 6 weeks were dual stained for CD31 (green) and S100A4 or αSMA 
(red) and co-localisation was assessed. Nuclei were counterstained with DAPI. Arrowheads 
indicate co-localisation. The inset represents a magnification of the area within the white square. 
Magnification: 40x. Scale bar 50 μm. 
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Table 5-2. Co-localisation analysis of CD31 with S100A4 and αSMA in hearts of Ang II-infused mice after 4 weeks 
 
 
Pearson's coefficient R  Mander's coefficient M1  Mander's coefficient M2 
 
 
MEAN SEM n p-value  MEAN SEM n p-value  MEAN SEM n p-value 
C
D
3
1
 &
 
S
1
0
0
A
4
 
Control 0.029 0.015 4 
 
 0.023 0.005 4 
 
 0.062 0.010 4 
 
24 μg/kg/hr 
Ang II 
0.199 0.044 4 0.011  0.126 0.030 4 0.015  0.305 0.058 4 0.006 
                
C
D
3
1
 &
 
α
S
M
A
 Control 0.104 0.020 4 
 
 0.148 0.014 4 
 
 0.157 0.016 4 
 
24 μg/kg/hr 
Ang II 
0.121 0.014 4 0.518  0.157 0.035 4 0.816  0.175 0.020 4 0.504 
p-value vs. control (Student’s t-test). 
Table 5-3. Co-localisation analysis of CD31 with S100A4 and αSMA in hearts of Ang II-infused mice after 6 weeks 
 
 
Pearson's coefficient R  Mander's coefficient M1  Mander's coefficient M2 
 
 
MEAN SEM n p-value  MEAN SEM n p-value  MEAN SEM n p-value 
C
D
3
1
 &
 
S
1
0
0
A
4
 Control 0.132 0.031 4 
 
 0.104 0.038 4 
 
 0.203 0.055 4 
 
24 μg/kg/hr Ang II 0.227 0.033 4 >0.05  0.139 0.036 4 >0.05  0.335 0.071 4 >0.05 
48 μg/kg/hr Ang II 0.291 0.022 2 n.a.  0.192 0.046 2 n.a.  0.409 0.012 2 n.a. 
                
C
D
3
1
 &
 
α
S
M
A
 Control 0.103 0.018 4  
 0.209 0.033 4 
 
 0.075 0.011 4 
 
24 μg/kg/hr Ang II 0.134 0.015 4 >0.05  0.190 0.035 4 >0.05  0.118 0.023 4 >0.05 
48 μg/kg/hr Ang II 0.192 0.028 3 <0.05  0.205 0.003 3 >0.05  0.182 0.075 3 >0.05 
p-value vs. control (ANOVA with Tukey’s post-hoc analysis). 
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5.3.3 Ang-(1-9) in Ang II-induced microvascular rarefaction and 
EndMT in vivo 
Ang-(1-7) and Ang-(1-9) have previously been shown to counteract the actions of 
Ang II (Flores-Munoz et al., 2012). To assess whether Ang-(1-9) can also 
counteract the actions of Ang II on the microvasculature in vivo, capillary 
density and EndMT was assessed in the Ang-(1-9) infusion models outlined in 
Section 3.3.2 & 3.3.3.  
Ang-(1-9) infusion over 6 weeks did not significantly affect capillary density and 
the co-localisation of CD31 with either S100A4 or αSMA (Table 5-4). Similarly, 
when Ang-(1-9) was infused for 2–4 weeks following an initial 2 week infusion of 
48 μg/kg/hr Ang II (Section 3.3.3), Ang-(1-9) did not affect the Ang II-induced 
reduction in capillary density (Figure 5-3 A-B) and co-localisation of S100A4 and 
αSMA with CD31 (Figure 5-3 C-D, Table 5-5, Table 5-6).  
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Table 5-4. Capillary density and co-localisation analysis of CD31 with S100A4 and αSMA in hearts of Ang-(1-9)-infused mice. 
 Capillaries/mm2  Capillaries/cardiomyocyte   
 MEAN SEM n p-value  MEAN SEM n p-value   
 3296 216 4 0.11  1.03 0.04 4 0.57   
            
 Pearson's coefficient R  Mander's coefficient M1  Mander's coefficient M2 
 MEAN SEM n p-value  MEAN SEM n p-value  MEAN SEM n p-value 
CD31 & S100A4 0.148 0.034 4 0.73  0.050 0.018 4 0.25  0.322 0.034 4 0.11 
               
CD31 & αSMA 0.152 0.041 4 0.32  0.228 0.063 4 0.80  0.126 0.018 4 0.05 
p-value vs. control (presented in Table 5-3) (Student’s t-test) 
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Figure 5-3. EndMT in Ang II-infused mice after reversal with Ang-(1-9) 
Cardiac sections of mice infused with H2O (control), 48 μg/kg/hr Ang II or 48 μg/kg/hr+Ang-(1-9) for 
(A) 4 or (B) 6 weeks were stained for CD31 and (A) capillaries/mm2 and (B) capillaries/ 
cardiomyocyte determined. n= 6 and 8 for 4 and 6 weeks, respectively. Data are presented as 
mean ± SEM. *p<0.05 vs. control (ANOVA with Dunnett’s post-hoc analysis). Cardiac section of 
mice infused for (C) 4 and (D) 6 weeks were dual stained for CD31 (green) and S100A4 or αSMA 
(red). Nuclei were counterstained with DAPI (blue). Arrowheads indicate co-localisation. The inset 
represents a magnification of the area within the white square. Magnification: 40x. Scale bar 
50 μm. 
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Table 5-5. Co-localisation analysis of CD31 with S100A4 and αSMA after 2 weeks reversal with Ang-(1-9) 
 
 
Pearson's coefficient R  Mander's coefficient M1  Mander's coefficient M2 
  MEAN SEM n p-value  MEAN SEM n p-value  MEAN SEM n p-value 
C
D
3
1
 &
 
S
1
0
0
A
4
 Control 0.144 0.029 5 
 
 0.106 0.034 5 
 
 0.084 0.040 5 
 
Ang II 0.255 0.040 3 >0.05  0.432 0.106 3 <0.05  0.165 0.045 3 >0.05 
Ang II+Ang-(1-9) 0.315 0.070 4 >0.05  0.305 0.083 4 >0.05  0.246 0.085 4 >0.05 
                
C
D
3
1
 &
 
α
S
M
A
 
Control 0.018 0.015 5 
 
 0.086 0.020 5 
 
 0.028 0.010 5 
 
Ang II 0.163 0.011 3 <0.05  0.335 0.101 3 <0.05  0.138 0.036 3 >0.05 
Ang II+Ang-(1-9) 0.149 0.051 4 >0.05  0.184 0.069 4 >0.05  0.134 0.048 4 >0.05 
p-value Ang II vs. control, Ang II+Ang-(1-9) vs. Ang II (ANOVA with Dunnett’s post-hoc analysis) 
Table 5-6. Co-localisation analysis of CD31 with S100A4 and αSMA after 4 weeks reversal with Ang-(1-9) 
 
 
Pearson's coefficient R  Mander's coefficient M1  Mander's coefficient M2 
  MEAN SEM n p-value  MEAN SEM n p-value  MEAN SEM n p-value 
C
D
3
1
 &
 
S
1
0
0
A
4
 Control 0.090 0.077 5 
 
 0.064 0.055 5 
 
 0.119 0.096 5 
 
Ang II 0.283 0.032 4 >0.05  0.251 0.074 4 >0.05  0.281 0.044 4 >0.05 
Ang II+Ang-(1-9) 0.308 0.035 5 >0.05  0.216 0.041 5 >0.05  0.270 0.060 5 >0.05 
                
C
D
3
1
 &
 
α
S
M
A
 
Control 0.042 0.022 5 
 
 0.098 0.030 5 
 
 0.052 0.030 5 
 
Ang II 0.108 0.042 3 >0.05  0.159 0.030 3 >0.05  0.144 0.066 3 >0.05 
Ang II+Ang-(1-9) 0.159 0.037 4 >0.05  0.085 0.045 4 >0.05  0.113 0.050 4 >0.05 
p-value Ang II vs. control, Ang II+Ang-(1-9) vs. Ang II (ANOVA with Dunnett’s post-hoc analysis) 
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5.3.4 In vitro model of EndMT  
The potential of TGFβ1 and TGFβ2 to induce EndMT in ECs has already been well 
established (Maleszewska et al., 2013, Arciniegas et al., 1992, Frid et al., 2002). 
To assess whether Ang II can induce mesenchymal marker expression in ECs, Ang 
II was assessed in an in vitro model of EndMT based on previous protocols 
(Maleszewska et al., 2013) where HCAEC were stimulated with 1 μM Ang II for 5-
15 days (Figure 5-4). TGFβ1 and TGFβ2 served as positive controls. Gene 
expression of mesenchymal markers (ACTA2, S100A4, Col1A1, CNN1, TAGLN) was 
assessed by qRT-PCR, normalised to the housekeeper GAPDH and expressed as 
relative quantity (RQ) compared to time-matched control cells.  
After 5 days of stimulation, TGFβ1 and TGFβ2 significantly increased expression 
of ACTA2 whereas Ang II had no effect (RQ: TGFβ1 5.33 ± 1.10, TGFβ2 10.99 ± 
0.28, Ang II 1.77 ± 0.28, n= 3, p<0.05) (Figure 5-4 A). S100A4 remained 
unchanged with TGFβ1 and TGFβ2 whereas Ang II significantly down-regulated 
S100A4 mRNA (RQ: TGFβ1 0.74 ± 0.07, TGFβ2 0.82 ± 0.21, Ang II 0.36 ± 0.04, n= 3, 
p<0.05) (Figure 5-4 B). After 15 days, ACTA2 expression was significantly 
increased by TGFβ2 (RQ: 2.11 + 0.62, p<0.05) and trended to be increased with 
TGFβ1 (RQ: 1.50 + 0.15) and Ang II (RQ: 1.48 + 0.37) but did not reach statistical 
significance (Figure 5-4 C). In contrast, Col1A1 was significantly elevated by 
TGFβ1 and TGFβ2 whereas Ang II had no significant effect (RQ: TGFβ1 4.94 ± 
0.82, TGFβ2 14.97 ± 4.52, Ang II 2.01 ± 0.35, n= 4, p<0.05) (Figure 5-4 D). 
Similarly to 5 days, S100A4 expression remained unchanged by TGFβ1 and TGFβ2 
but AngII significantly reduced S100A4 expression (RQ: TGFβ1 0.89 ± 0.26, TGFβ2 
0.76 ± 0.05, Ang II 0.33 ± 0.12, n= 4, p<0.05) (Figure 5-4 E). This was in contrast 
to protein expression assessed by dual-immunofluorescence for CD31 and 
S100A4. S100A4 was undetectable in control cells, but expression was visibly 
increased by TGFβ1, TGFβ2 and Ang II (Figure 5-4 F), suggesting a mismatch 
between gene and protein expression. When cell morphology was assessed 
microscopically, control cells appeared with a characteristic cobblestone shape 
whereas cells treated with TGFβ1, TGFβ2 and Ang II presented with a loss of cell-
cell contacts and elongated cell shape characteristic of fibroblasts and SMCs 
(Figure 5-4 F). Overall these results indicate that both, TGFβ1 and TGFβ2 induce 
EndMT in HCAEC with TGFβ2 being more potent. Even after 15 days exposure, 
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Ang II alone had only mild effects on mesenchymal gene expression, affecting a 
subset of genes induced by TGFβ1 and TGFβ2. 
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Figure 5-4. Effects of Ang II on mesenchymal gene expression in HCAEC 
HCAEC were stimulated with 10 ng/mL TGFβ1 or TGFβ2 or 1 μM Ang II and gene expression for 
ACTA2, S100A4 and Col1A1 was assessed following (A, B) 5 and (C, D, E) 15 days. Gene 
expression was normalised to the housekeeper GAPDH and expressed as relative quantity (RQ) to 
time-matched controls cells which were set at RQ= 1. Data are presented as RQ+ rqmax. n= 3 and 
4 individual biological repeats per group for 5 and 15 days, respectively. Experiments were 
repeated on two independent occasions. *p<0.05 vs. control (ANOVA with Dunnett’s post-hoc 
analysis). (F) After 15 days of stimulation, HCAEC morphology was assessed by light microscopy 
and were then fixed and dual stained for CD31 (red) and S100A4 (green). Black arrowheads 
indicate changes in EC morphology. Magnification: 25x (immunofluorescence), 10x (light 
microscope), Scale bar: 100 μm. 
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5.3.5 Assessing the role of angiotensin II in TGFβ1-induced 
EndMT 
Various molecules have previously been reported to act synergistically with TGFβ 
to induce EndMT in ECs from various origins (Maleszewska et al., 2013, Rieder et 
al., 2011). Since Ang II alone only had mild effects on mesenchymal markers in 
ECs and Ang II and TGFβ1 have previously been reported to act in a signalling 
network in vivo (Rosenkranz, 2004), the role of AngII in TGFβ-induced EndMT 
was assessed. EndMT was established in HCAEC as described in Section 2.3 by 
stimulation with 10 ng/mL TGFβ1 in the presence or absence of AngII (100 nM or 
1 μM). Gene and protein expression were assessed after 3 (Figure 5-5) and 10 
days (Figure 5-6) to capture acute and chronic changes in gene expression.  
5.3.5.1 Day 3 
After 3 days of stimulation, gene expression of the EC markers PECAM1 (CD31) 
and CDH5 (VE-cadherin) were not significantly altered by any treatment 
compared to the time-matched control (Figure 5-5 A-B). However, compared to 
TGFβ1, the co-addition of AngII significantly increased CDH5 and PECAM1 gene 
expression. Whereas TGFβ1 alone did not significantly alter ACTA2 gene 
expression, the co-addition of Ang II dose-dependently increased ACTA2 mRNA 
compared to control and TGFβ1 (RQ: TGFβ1 1.29 ± 0.13, 100 nM Ang II 1.75 ± 
0.06, 1 μM Ang II 1.96 ± 0.17, n= 4, p<0.05) (Figure 5-5 C). Similarly, Ang II dose-
dependently exacerbated Col1a1 gene expression by 6.69 ± 0.81 and 10.61 ± 
1.44-fold, respectively (p<0.05) (Figure 5-5 D). In contrast, gene expression of 
S100A4 trended to be decreased by TGFβ1 which was further decreased by 
addition of AngII in a dose-dependent manner with a significant 0.39 ± 0.03-fold 
reduction with 1 μM AngII (Figure 5-5 E). Further gene expression analysis of 
CNN1 (calponin) and TAGLN (transgelin, SM22α), mesenchymal markers that have 
been shown to be expressed early during mesenchymal transition and associated 
with immature SMCs, revealed no significant up-regulation with TGFβ1 alone but 
the addition of Ang II significantly up-regulated CNN1 (RQ: TGFβ1 1.12 ± 0.15, 
1 μM Ang II 1.89 ± 0.13, n= 4, p<0.05), whereas TAGLN remained unchanged 
(Figure 5-5 F-G). Similar to its gene expression data, protein expression of CD31 
was not significantly changed by any treatment compared to control (Figure 5-5 
H-I). Unlike the increase in the αSMA gene expression, αSMA protein expression 
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could not be detected with any treatment and was only expressed in a human 
fibroblast control suggesting a mismatch between gene and protein expression 
during the early stages of EndMT.  
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Figure 5-5. Role of Ang II in acute TGFβ1-induced EndMT  
Plated and quiesced HCAEC were stimulated with 10 ng/mL TGFβ1 in the presence or absence of 
100 nM or 1 μM Ang II for 3 days. qPCR gene expression analysis for (A) CDH5, (B) PECAM1, (C) 
ACTA2, (D) Col1a1, (E) S100A4, (F) CNN1 and (G) TAGLN was normalised to the housekeeper 
GAPDH and expressed as relative quantity (RQ) to time-matched controls cells which were set at 
RQ= 1. Data are presented as RQ+ rqmax. (H) Protein expression analysis of CD31 and αSMA 
after 3 days by Western blot was normalised to the housekeeper GAPDH. Normalised protein 
expression was expressed as fold change in (I) CD31 compared to time-matched control cells. 
Experiments were performed with n= 4 individual biological repeats (for gene expression) and n= 3 
individual biological repeats (for protein expression) per group and confirmed in three independent 
repeats *p<0.05 vs. control, † p<0.05 vs. TGFβ1 (ANOVA with Tukey’s post-hoc analysis).  
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5.3.5.2 Day 10 
After 10 days of stimulation, gene expression of CDH5 and PECAM1 was not 
significantly altered by any treatment (Figure 5-6 A-B). Expression of ACTA2 and 
Col1A1 were significantly up-regulated 1.76 ± 0.11 and 9.16 ± 1.45-fold by TGFβ1 
alone, respectively (Figure 5-6 C-D). Addition of AngII significantly increased 
ACTA2 (RQ: 100 nM AngII 3.04 ± 0.69, 1 μM AngII 4.31 ± 0.26, n= 4, p<0.05) and 
Col1a1 (RQ: 100 nM Ang II 19.58 ± 3.49, 1 μM Ang II 30.17 ± 3.34, n= 4, p<0.05) 
gene expression compared to control cells and TGFβ1 alone in a dose dependent 
manner. Similar to its expression at day 3, S100A4 was reduced by co-stimulation 
with TGFβ1 and AngII despite not being significant (RQ: TGFβ1 0.77 ± 0.18, 
100 nM AngII 0.50 ± 0.20, 1 μM AngII 0.48 ± 0.06, n= 4, p>0.05) (Figure 5-6 E). 
CNN1 was significantly up-regulated 2.25 ± 0.22-fold by TGFβ1 alone and this was 
significantly exacerbated to 6.09 ± 0.74-fold by 1 μM AngII (Figure 5-6 F). In 
contrast, TAGLN was not modulated by TGFβ1 alone but addition of AngII 
significantly up-regulated TAGLN 1.89 ± 0.23-fold (Figure 5-6 G). Protein 
expression analysis of CD31 showed a trend to decrease with the combination of 
TGFβ1+Ang II reducing CD31 levels to 0.69-fold compared to time-matched 
control cells (Figure 5-6 H-I). αSMA expression was detected in cells that had 
been treated with TGFβ1+AngII whereas expression in cells treated with TGFβ1 
alone was negligible (Fold: TGFβ1 1.81, 100 nM AngII 2.84, 1 μM AngII 8.40, 
p<0.05). αSMA was not detected in time-matched control cells and cells 
harvested at the beginning of the protocol (Figure 5-6 J-H)  
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Figure 5-6. Role of Ang II in chronic TGFβ1-induced EndMT 
Plated and quiesced HCAEC were stimulated with 10 ng/mL TGFβ1 in the presence or absence of 
100 nM or 1 μM Ang II for 10 days. qPCR gene expression analysis (A) CDH5, (B) PECAM1, (C) 
ACTA2, (D) Col1a1, (E) S100A4, (F) CNN1 and (G) TAGLN was normalised to the housekeeper 
GAPDH and expressed relative quantity (RQ) to time-matched controls cells which were set at 
RQ= 1. Data are presented as RQ+ rqmax. (H) Protein expression analysis of CD31 and αSMA by 
Western blot after 10 days was normalised to the housekeeper GAPDH. Normalised protein 
expression was expressed as fold change in (I) CD31 and (J) αSMA compared to time-matched 
control cells. Experiments were performed with n=4 individual biological repeats (for gene 
expression) and n=3 individual biological repeats per group (for protein expression) and confirmed 
in three independent repeats *p<0.05 vs. control, † p<0.05 vs. TGFβ1 (ANOVA with Tukey’s post-
hoc analysis).  
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5.3.5.3 Role of AT1R and AT2R 
To investigate the receptor by which Ang II mediates the observed exacerbation 
of TGFβ1-induced EndMT, losartan and PD123319 were used to block the AT1R 
and AT2R, respectively.  
Preliminary data shows that following 10 days of stimulation, inhibition of either 
AT1R or AT2R significantly exacerbated the expression of ACTA2, Col1A1, CNN1 
and TAGLN compared to TGFβ1+Ang II (Figure 5-7 A-D). This suggests that Ang II 
mediated effects are independent of the AT1R and AT2R. 
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Figure 5-7. Role of AT1R and AT2R in Ang II-induced EndMT 
Plated and quiesced HCAEC were treated with 1 μM losartan and 500 nM PD123319 15 min prior 
to stimulation with 10 ng/mL TGFβ1 and 1 μM Ang II. Mesenchymal gene expression of (A) ACTA2, 
(B) Col1a1, (C) CNN1 and (D) TAGLN was assessed by q-PCR normalised to the internal 
housekeeper GAPDH and expressed as relative quantity (RQ) to time-matched control cells. Data 
are presented as RQ + rqmax. Experiments were performed once with n=4 individual biological 
repeats per group. *p<0.05 vs. control, † p<0.05 vs. TGFβ1+Ang II (ANOVA with Dunnett’s post-
hoc analysis). 
  
Chapter 5  247 
 
 
5.3.6 Signalling pathways activated during EndMT 
TGFβ1-induced SMAD2/3 signalling is indispensable for EndMT (Cooley et al., 
2014). To assess the role of the SMAD pathway in mediating TGFβ1 and Ang II-
induced EndMT, HCAEC were treated with the ALK5 (TGFβRI) inhibitor SB525334 
which specifically blocks the activation of SMAD2/3. 
HCAEC treated with the ALK5-inhibitor in addition to TGFβ1 and Ang II over 10 
days visibly retained their EC morphology whereas TGFβ1 alone or in combination 
with Ang II induced a fibroblast phenotype (Figure 5-8 A). Further, gene 
expression analysis showed that SB525334 prevented the induction of gene 
expression for Col1a1, CNN1 and TAGLN (Figure 5-8 B-D).  
To assess whether the expression of components of the SMAD signalling pathway 
are altered during EndMT, gene expression of the SMAD-induced transcription 
factors SNAI1 (Snail) and SNAI2 (Slug), the SMAD2/3 co-factor SMAD4 and the 
inhibitory SMAD7 were assessed. TGFβ1 reduced expression of SNAI1 which was 
reversed by the addition of Ang II (RQ: TGFβ1 0.82 ± 0.04 vs. TGFβ1+Ang II 1.11 ± 
0.06; p<0.05) (Figure 5-8 E). In contrast, expression of SNAI2, SMAD4 and SMAD7 
were unaltered over the course of EndMT in HCAEC (Figure 5-8 F-H).  
To assess whether AngII differentially regulates SMAD2 phosphorylation 
compared to TGFβ1 alone or in combination, pSMAD2 was assessed over a time-
course of 60 min by Western blotting. Phosphorylation was expressed as a ratio 
of phosphorylated SMAD2 to total SMAD2 and then normalised to unstimulated 
control cells. Stimulation with TGFβ1 induced phosphorylation of SMAD2 in a 
time-dependent manner with an initial 2.16 ± 0.18-fold increase observed at 
15 min that increased to 3.23 ± 0.50-fold at 30 min and peaked at 5.25 ± 1.43-
fold after 60 min (Figure 5-9 A-B). In contrast, Ang II did not induce any 
significant SMAD2 phosphorylation with a maximum increase in pSMAD2 of 1.79 ± 
0.57-fold at 60 min. Co-stimulation with TGFβ1+Ang II did not alter TGFβ1-
induced SMAD2 phosphorylation (Figure 5-9 A-B).  
ERK1/2 has previously been shown to mediate EndMT in bovine valvular ECs 
(Wylie-Sears et al., 2014). Given that Ang II did not affect TGFβ1-induced SMAD2 
phosphorylation, the role of ERK1/2 was assessed. TGFβ1 and Ang II alone 
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induced phosphorylation of ERK1/2 in a time-dependent manner which peaked at 
30 min with a 1.80 ± 0.01- and 1.98 ± 0.03- fold increase, respectively, and was 
not significantly different between the two treatments (Figure 5-9 C-D). The 
combination of TGFβ1+Ang II did not significantly alter ERK1/2 phosphorylation. 
However, there was a trend towards an increase in pERK1/2 at 30 min that was 
reproducible in independent repeats.  
Overall, these results show that inhibition of the SMAD2/3 pathway can block 
TGFβ1 and Ang II induced EndMT. However, Ang II neither modulates gene 
expression of members of the SMAD signalling pathway nor does it alter TGFβ1-
induced activation of SMAD2 and ERK1/2. 
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Figure 5-8. Role of SMAD pathway in Ang II-induced EndMT 
Plated and quiesced HCAEC were stimulated with 10 ng/mL TGFβ1 in the presence or absence of 
1 μM Ang II for 10 days. For inhibition of SMAD2/3, HCAEC were pre-treated with 1 μM SB525334 
for 30 min. (A) Light microscopy images of HCAEC phenotype after 10 days of stimulation with 
TGFβ1±Ang II in the presence or absence of SB525334. TGFβ1 and TGFβ1+Ang II-treated HCAEC 
are visibly larger and have lost their cobblestone morphology. Mesenchymal gene expression of 
(B) Col1A1, (C) CNN1 and (D) TAGLN was assessed by qPCR normalised to the internal 
housekeeper GAPDH and expressed as relative quantity (RQ) to time-matched control cells. 
*p<0.05 vs. control, † p<0.05 vs. matched treatment (ANOVA with Tukey’s post-hoc analysis). In a 
different set of cells, (E) SNAI1, (F) SNAI2, (G) SMAD4 and (H) SMAD7 gene expression was 
determined. *p<0.05 vs. control, † p<0.05 vs. TGFβ1 (ANOVA with Tukey’s post-hoc analysis). 
Data are presented as RQ+ rqmax. Experiments were performed once with n= 4 individual 
biological repeats per group.  
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Figure 5-9 Effects of AngII on cellular signalling pathways during EndMT 
Plated and quiesced HCAEC were stimulated with 10 ng/mL TGFβ1, 1 μM Ang II or in combination 
for 5–60 min, lysed and assessed for (A, B) pSMAD2 and (C,D) pERK1/2 by Western blotting. 
Phosphorylation was expressed as ratio of phospho-protein against total protein and normalised to 
unstimulated control cells. Data are presented as mean ± SEM. Experiments were performed with 
n= 2 individual biological repeats and confirmed in three independent repeats.  
  
Chapter 5  251 
 
 
5.3.7 The role of ROS in Ang II-induced EndMT 
ROS were previously demonstrated to contribute to TGFβ-induced EndMT 
(Montorfano et al., 2014, Boudreau et al., 2012, Rhyu et al., 2005). Ang II has 
previously been associated with the activation of Noxs in ECs which has been 
linked to its pathological actions mediating EC dysfunction (Li et al., 2004, 
Landmesser et al., 2002). To assess whether Ang II may exacerbate TGFβ1-
induced EndMT through the activation of Noxs and generation of ROS, quiesced 
HCAEC were stimulated with TGFβ1, Ang II or their combination for 1–30 min and 
O2- production was measured by lucigenin assay (Section 2.3.2). Mean 
absorbance was normalised to protein content and O2- generation was expressed 
as fold-increase compared to unstimulated HCAEC.  
TGFβ1 did not induce significant O2- production in HCAEC and peaked with a 1.33 
± 0.24-fold increase after 30 min (Figure 5-10 A). In contrast, Ang II induced a 
rapid 1.49 ± 0.26-fold increase in O2- following 1 min which decreased to control 
levels within 5 min. Co-stimulation with TGFβ1 and Ang II only induced a small 
1.17 ± 0.15-fold increase after 1 min. TGFβ1 was previously shown to only 
activate Nox4 mediating H2O2 production (Dikalov et al., 2008). Therefore, to 
assess which Nox is responsible for the rapid Ang II-induced increase in O2-, 
HCAEC were pre-treated with the Rac1/2 inhibitor EHT1864 (which inhibits, 
Rac1/2-dependent Nox1 and Nox2) (Shutes et al., 2007), the Nox1 inhibitor 
ML171 (Gianni et al., 2010) and the dual Nox1/4 inhibitor GKT137831 (Aoyama et 
al., 2012) (Figure 5-10 B). All inhibitors tended to decrease Ang II-induced O2- 
production to below basal levels with ML171 and GKT137831 being the most 
effective (Fold: Ang II 1.49 ± 0.26, EHT1864 0.96 ± 0.12, ML171 0.78 ± 0.08, 
GKT137831 0.76 ± 0.10, p<0.05). Given that Rac1/2 inhibition prevents Nox1/2 
activation and that ML171 and GKT137831 specifically target the O2- generating 
Nox1, this suggests that Nox1 is the major source of O2- in Ang II-stimulated 
HCAEC.  
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Figure 5-10. Ang II-induced oxidative stress in HCAEC 
Plated and quiesced HCAEC were stimulated with 10 ng/mL TGFβ1, 1 μM Ang II or their 
combination for 1–30 min, lysed and assayed for O2- production using the lucigenin assay. O2- 
production was normalised to protein content and expressed as fold-increase compared to 
unstimulated control cells. (A) Time-course of O2- production with TGFβ1, Ang II and TGFβ1+Ang II 
over 30 min (n= 8 for control, 7 for 1 min, 4 for 5 min, 5 for 30 min). (B) HCAEC were pre-incubated 
with 10 μM EHT1864 (n= 3), 1 μM ML171 (n= 3) or 1 μM GKT137831 (n= 3) for 30 min prior to 
stimulation with 1 μM Ang II for 1 min (n= 8 from A) and O2- was measured. Data are presented as 
mean ± SEM. *p<0.05 vs. control, † p<0.05 vs. Ang II (ANOVA with Dunnett’s post-hoc analysis).  
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5.4 Discussion 
Here, it was shown that following Ang II infusion over 2–6 weeks, myocardial 
capillary density progressively decreased leading to significant microvascular 
rarefaction. This coincided with the presence of EndMT in the hearts of Ang II-
infused mice which may contribute to the loss in myocardial capillaries. In 
contrast, co-infusion of Ang-(1-9) did not reverse Ang II-induced loss in capillary 
density or EndMT. This highlights that microvascular rarefaction and EndMT are 
Ang II-driven processes to which Ang-(1-9) does not contribute either when 
infused alone or in established Ang II-induced cardiac remodelling. 
In the heart, EC: cardiomyocyte interactions are important for the maintenance 
of normal cardiac function which demands a constant supply of oxygen and 
nutrients in order to maintain cardiac contractile output (Brutsaert, 2003). 
Adequate delivery of oxygen and nutrients is crucially dependent on 
cardiomyocyte/capillary ratio and intercapillary distance and is facilitated by a 
high density of capillaries in the myocardium (Brutsaert, 2003). Capillary density 
in the adult mammalian heart is estimated between 2000–5000 capillaries/mm2 
(Shiojima et al., 2005, Banerjee et al., 2009, Zentilin et al., 2010, Ikeda et al., 
2009) with capillary/cardiomyocyte ratios usually ranging from 0.9–1.12 but 
ratios as high as 1.8 have been reported (Messaoudi et al., 2009). With an overall 
mean capillary density of 2647 ± 106 capillaries/mm2 and a 
capillary/cardiomyocyte ratio of 1.04 ± 0.06 in control mice, the data fits well 
within the range of reported capillary densities in the heart.  
It is already well established that clinically, hypertension is associated with a 
reduction in myocardial capillary density (Mohammed et al., 2015) and this is 
replicated in animal models of hypertension: In the SHRSP, myocardial capillary 
density was shown to decrease by 57 % with a 62.5 % increase in arteriolar 
density (Pu et al., 2003). Similarly, capillaries were decreased by 60 % in rats 
with renovascular hypertension (Kobayashi et al., 1999) and in the Goldblatt 
1K1C model, capillaries were decreased by 12 % while arterioles increased by 
27 % (Levy et al., 2001). Here, a loss in myocardial capillary density following 
Ang II infusion was already apparent after 2 weeks with further reductions after 
4 and 6 weeks and confirms previous studies in mice and rats where Ang II 
infusion led to a 16–30 % reduction in capillary density (Sabri et al., 1998, 
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Belabbas et al., 2008, Graiani et al., 2005). Previously, myocardial capillary 
density has been shown to increase in the compensated phase of cardiac 
remodelling following TAC but then rapidly decline during decompensation (Sano 
et al., 2007). A similar trend in pro-angiogenic gene expression with Ang II 
infusion has been observed where vascular endothelial growth factor (VEGF) and 
Hif-1α peak after 7 days of Ang II infusion (Zhao et al., 2004) suggesting that Ang 
II may have a dual effect on cardiac capillary density. During the initial 
compensated phase of cardiac remodelling Ang II induces angiogenesis but as the 
heart progressively decompensates, Ang II signalling contributes to a reduction in 
capillary density. This dual effect is supported by the controversial observations 
that Ang II can promote angiogenesis through VEGF signalling either via the AT1R 
or the AT2R (Munk et al., 2007, Tamarat et al., 2002, Walther et al., 2003) 
whereas others have reported that each receptor is anti-angiogenic (Benndorf et 
al., 2003, Lakó-Futó et al., 2003, de Boer et al., 2003). Since in the data 
presented here, capillary density was already decreased after 2 weeks of low 
dose Ang II infusion which correlates with reduced pro-angiogenic gene 
expression observed previously (Zhao et al., 2004), this suggests that the heart is 
beginning to decompensate with a mismatch between cardiac growth and 
microvascular density. In fact, in the present study, it was shown that the 
relationship between capillary density and cardiac hypertrophy is a dynamic 
process as correlation of capillary density and hypertrophy increases during the 
progression of capillary loss within the heart.  
The mechanism by which Ang II decreases capillary density is still largely 
unknown. It has previously been shown that Ang II reduces the proliferation of 
coronary ECs following 2 week infusion of Ang II in rats (McEwan et al., 1998) 
and EC apoptosis was evident following 4 week delivery of Ang II relating to the 
progressive loss of ECs in vivo (Graiani et al., 2005). Furthermore, Ang II was 
shown to enhance ischaemia-induced HCAEC apoptosis in vitro (Li et al., 1999) 
and to induce senescence of endothelial progenitor cells participating in 
angiogenesis (Kobayashi et al., 2006) suggesting multifactorial effects of Ang II 
that collectively contribute to microvascular rarefaction. More recently, it was 
demonstrated that Ang II infusion in Nox2 overexpressing mice results in EndMT 
of myocardial ECs (Murdoch et al., 2014) and for the first time demonstrated 
EndMT in Ang II-infused mice. Here, we extended this finding and provide 
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evidence that EndMT is present in wildtype mice infused with low and high doses 
of Ang II. The increase in EndMT may contribute to the observed net loss in 
capillary density. Importantly, EndMT has previously shown to contribute to up 
to 30 % of the myofibroblast population following TAC (Zeisberg et al., 2007b) 
highlighting its significant contribution to myocardial collagen deposition and 
fibrosis. 
Here, an in vitro model of EndMT was developed by comparing the effects of 
TGFβ1 and TGFβ2 on mesenchymal marker expression in HCAEC over a time-
course of up to 15 days. Models of EndMT have been developed in a variety of 
ECs with varying protocols differing in their time of stimulation and cell culture 
conditions (Cooley et al., 2014, Rieder et al., 2011, Maleszewska et al., 2013, 
Wylie-Sears et al., 2014, Zeisberg et al., 2007b). Hence, no uniform protocol for 
EndMT exists which makes direct comparisons difficult. In the present study, it 
was shown that TGFβ2 is more potent in inducing mesenchymal gene expression 
than TGFβ1. This corroborates a previous study of Maleszewska et al. (2013) who 
showed that TGFβ2 was twice as potent as TGFβ1 in inducing SM22α (transgelin) 
gene expression in human umbilical vein ECs after 96 h stimulation (Maleszewska 
et al., 2013). Furthermore, similar to the results presented here, a study by 
Rieder et al. (2011) did not identify any changes in EC markers and phenotype in 
human intestinal microvascular ECs that had been stimulated with TGFβ1 for up 
to 30 days (Rieder et al., 2011). In in vitro models of EMT, TGFβ1 has been 
shown to induce mesenchymal transformation in mammary gland and renal 
tubular epithelial cells (Brown et al., 2004, Carvajal et al., 2008, Yang et al., 
2010). However, a systematic review of human and murine epithelial cell lines 
has shown that despite responsiveness to and necessity of TGFβ1, only few cells 
lines actually undergo TGFβ1-induced EMT (Brown et al., 2004, Scheel et al., 
2011) highlighting the differing potential across ECs to respond to TGFβ. Despite 
its minor role in EndMT and reduced potency compared to TGFβ2, TGFβ1 was 
chosen to assess EndMT in HCAEC to mimic myocardial capillary loss in vivo. This 
is based on observations that TGFβ1 acts in a network with Ang II (Rosenkranz, 
2004) and plays a key role in the pathogenesis of CVDs and cardiac remodelling 
with direct effects on myofibroblast differentiation (Cucoranu et al., 2005) and 
cardiomyocyte growth (Schultz et al., 2002). Increased TGFβ1 expression has 
been demonstrated in CVD models such as pressure overload (Kuwahara et al., 
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2002) and myocardial infarction (Dewald et al., 2004) and similarly cardiac-
specific overexpression of TGFβ1 directly induces cardiac fibrosis and cardiac 
hypertrophy (Rosenkranz et al., 2002).  
In the present study it was demonstrated that Ang II alone only marginally 
affects mesenchymal gene expression in HCAEC but that it exacerbates TGFβ1-
induced EndMT in vitro. This correlates with previous observations on 
inflammatory cytokines which only induce EndMT in ECs when co-stimulated with 
TGFβ1 and that this exacerbated the response by TGFβ1 alone (Maleszewska et 
al., 2013, Rieder et al., 2011). This suggests that TGFβ1 is needed as an 
inductive signal for a mesenchymal switch in ECs before Ang II can significantly 
modulate mesenchymal gene expression. In this context, Ang II has previously 
been shown to directly alter mesenchymal gene expression in cells of 
mesenchymal origin. For example, in rat VSMC, Ang II increases the expression of 
calponin in vivo and in vitro (di Gioia et al., 2000, Castoldi et al., 2001) whereas 
in fibroblasts and mesothelial cells, Ang II stimulates the secretion of collagen, 
fibronectin and laminin (Kawano et al., 2000, Kiribayashi et al., 2005).  
Previous studies have already shown that HCAEC express AT1R and AT2R (Li et 
al., 2000) and other RAS components such as renin and ACE (Hokimoto et al., 
1996, Xiao et al., 2000). Despite its well defined role in mediating organ fibrosis, 
the role of Ang II in EC transformation only started to be investigated very 
recently and in contrast to this study, has only been assessed indirectly by the 
use of receptor antagonists. As such, irbesartan was demonstrated to inhibit high 
glucose-induced EndMT in vivo and in vitro (Tang et al., 2010, Tang et al., 
2013). Furthermore, losartan abolished TGFβ1-induced EndMT in bovine valve 
ECs while supra-physiological doses of Ang II (50 μM) directly increased 
expression of αSMA (Wylie-Sears et al., 2014). Overall these studies suggest a 
role of Ang II in EndMT. However, here it was investigated whether Ang II plays a 
direct role in mediating EndMT and demonstrated that Ang II significantly 
exacerbates TGFβ1-induced mesenchymal transition in HCAEC. The effects of 
Ang II could not be blocked by inhibition of either AT1R or AT2R by losartan and 
PD123319, respectively and this is in contrast to the studies outlined above 
where AT1R antagonism was able to prevent EndMT in high glucose conditions. 
However, these studies investigated Ang II as part of another 
pathology/mechanism rather than directly as a causative factor suggesting that 
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model-specific differences exist. Furthermore, in a model of EMT in renal 
tubular epithelial cells it has previously been demonstrated that Ang II mediates 
EMT through a pathway involving the ACE2/Ang-(1-7)/Mas-axis which was 
resistant to blockade of either the AT1R or AT2R (Burns et al., 2010) 
strengthening the observation that Ang II-induced EndMT in HCAEC may be 
mediated via AT1R and AT2R-independent pathways. Further investigations are 
required to verify the role of the AT1R, AT2R and Mas in Ang II-induced EndMT. 
An inductive role for Ang II in EMT is already well established and in cell culture 
models of EMT, stimulation of epithelial cells with Ang II induces a mesenchymal 
phenotypic switch within as little as 24 h (Carvajal et al., 2008, Yang et al., 
2009, Yang et al., 2010, Zhou et al., 2010). This is in direct contrast to 
observations made here where similar doses of Ang II alone were not able to 
robustly induce a mesenchymal phenotype in ECs even after 15 days of 
stimulation. This may be linked to fundamental differences in cell environment 
and physiology. For example, kidney epithelial cells are exposed to 100 x higher 
Ang II concentrations than ECs (van Kats et al., 2001) and due to their key role in 
mediating fluid balance, kidney epithelial cells may be more sensitive to Ang II 
stimulation activating differential signalling pathways. In this context, SMAD3 
signalling and the induction of CTGF have been identified as a central pathway 
in Ang II-induced EMT mediating the early TGFβ1-independent induction of 
mesenchymal gene expression (Chen et al., 2006, Yang et al., 2009, Yang et al., 
2010). In contrast, here SMAD3 signalling could only be detected very weakly in 
HCAEC in response to Ang II stimulation. 
Activation of the SMAD pathway has been shown to be essential for EndMT and 
EMT (Zeisberg et al., 2007b, Li et al., 2010, Cooley et al., 2014). The present 
study demonstrates that TGFβ1 induced a time-dependent increase in SMAD2 
phosphorylation which is in line with previous observations on rapid SMAD 
activation by TGFβ which can be sustained over hours and days (Wylie-Sears et 
al., 2014, Kim et al., 2008, Yang et al., 2009). In contrast, it was observed that 
Ang II did not induce SMAD2 phosphorylation even after 60 min. This is in 
contrast to previous studies which have demonstrated that Ang II induces the 
TGFβ-independent activation of SMADs within 15-20 min in cardiac fibroblasts, 
VSMC and renal epithelial cells (Hao et al., 2000, Rodríguez-Vita et al., 2005, 
Carvajal et al., 2008). During EMT, especially Ang II-induced SMAD3 
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phosphorylation has been linked to the induction of mesenchymal gene 
expression in epithelial cells via the expression of CTGF (Chen et al., 2006, Yang 
et al., 2009, Yang et al., 2010). Here, SMAD3 activation in HCAEC could only be 
detected very weakly following stimulation with Ang II or TGFβ1 and suggests 
overall no significant role of Ang II in the early activation of the SMAD2/3 
pathway during EndMT. However, preliminary results show that inhibition of 
SMAD2/3 abolishes most transcriptional changes induced during EndMT in HCAEC 
suggesting a critical role of the SMAD pathway in the long-term effects of TGFβ1 
and Ang II. Although not investigated here, delayed phosphorylation of SMAD2 by 
Ang II after 2 days has been observed in the transformation of adipose 
mesenchymal stem cells to SMC and has been linked to MAPK-mediated TGFβ 
secretion and activation of the TGFβ–SMAD pathway (Kim et al., 2008). This 
suggests that Ang II may enhance chronic TGFβ1-induced SMAD2 phosphorylation 
by activation of the MAPK pathway.  
Investigation on the role of the ERK1/2 pathway showed that both, TGFβ1 and 
Ang II activate ERK1/2 in a time-dependent manner and that TGFβ1 and Ang II 
co-stimulation of HCAEC tends to enhance ERK1/2 activation acutely following 
30 min stimulation. Rapid activation of ERK1/2 by TGFβ1 and Ang II is already 
well established (Yang et al., 2009, Wylie-Sears et al., 2014) and it has already 
been found to be indispensable for Ang II induced EMT in renal epithelial cells by 
activation of downstream signalling pathways involving SMAD2/3 (Carvajal et al., 
2008, Yang et al., 2009) and RhoA (Rodrigues-Díez et al., 2008). Furthermore, 
losartan was found to inhibit EndMT in mitral valve EC by inhibition of ERK1/2 
(Wylie-Sears et al., 2014). Whereas these results suggest a crucial role for the 
cross-activation of ERK1/2 and SMAD pathways by TGFβ1 and AngII in EndMT, 
results presented here suggest that it is unlikely that alterations in these 
pathways by Ang II are responsible for the exacerbated response in TGFβ1-
induced mesenchymal gene expression by Ang II. This is supported by no 
detectable changes in the gene expression of members of the SMAD pathway 
during EndMT in HCAEC suggesting actions of Ang II independent of SMAD and 
ERK1/2 signalling pathways.  
Here, it was shown that HCAEC significantly increase O2- production in response 
to Ang II stimulation which could be abolished by inhibition of Nox1 and Rac1 
suggesting an important role for Nox1 in Ang II-induced EC dysfunction. In 
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agreement with this, it has previously been shown that Ang II stimulation of ECs 
leads to a significant increase in O2- production mediated via the AT1R and AT2R 
(Zhang et al., 1999) which is due to the induction of Nox1 and Nox2 gene 
expression and promotion of their assembly via p47phox phosphorylation (Li and 
Shah, 2003, Higashi et al., 2003, Dikalov et al., 2008). Ang II-induced O2- was 
shown to peak after 1 h in human umbilical artery ECs (Zhang et al., 1999) and 
after 10 h in human umbilical vein ECs (Rueckschloss et al., 2002) whereas in 
HCAEC presented here O2- production peaked after 1 min suggesting different 
kinetics in O2- production dependent on EC origin and activated Nox isoforms. 
Interestingly, it has been widely noted that Ang II regulates Noxs in a dose-
dependent manner with doses < 1 μM substantially increasing O2- formation and 
Nox expression whereas doses ≥ 1 μM have very little to no effect (Zhang et al., 
1999, Rueckschloss et al., 2002) and may therefore explain the acute response in 
O2- formation observed in HCAEC in this study. Here, TGFβ1 stimulation did not 
induce any O2- production in HCAEC and supports previous observations that 
TGFβ preliminarily activates the H2O2 generating Nox4 which has been linked to 
TGFβ-induced angiogenesis (Peshavariya et al., 2014) and myofibroblast 
differentiation (Cucoranu et al., 2005).  
ECs have been shown to express Nox1, Nox2, Nox4 and Nox5 which are 
constitutively active at low levels (Drummond and Sobey, 2014, Li and Shah, 
2003). Although Nox expression in HCAEC used here was not assessed, it has 
already been shown previously that HCAEC express Nox1, Nox2 and Nox4 mRNA 
as well as mRNA for the essential subunits p22phox, p47phox, p67phox and Rac1 
(Sorescu et al., 2002, Yoshida and Tsunawaki, 2008). With the observation that 
Ang II significantly increases Nox1-dependent O2- production in HCAEC it can be 
hypothesised that Nox1 may contribute to the exacerbation of TGFβ1-induced 
EndMT by Ang II in HCAEC. This is supported by previous observations in 
epithelial cells and ECs where overexpression of Nox1 and Nox2 predisposed cells 
to undergo EMT and EndMT, respectively (Murdoch et al., 2014, Liu et al., 2012).  
5.5 Summary 
In summary, this study has shown that Ang II infusion in mice leads to the 
dynamic loss of capillaries that coincided with the presence of EndMT in the 
hearts of Ang II infused mice, an effect not blocked by co-infusion with Ang-(1-
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9). Investigations of Ang II in an in vitro model of EndMT revealed that Ang II 
exacerbated TGFβ1-induced EndMT and that Ang II stimulation of HCAEC induces 
oxidative stress which may contribute to the underlying mechanism. Overall, 
these results present a novel pathway by which Ang II can mediate cardiac 
capillary loss and contribute to cardiac fibrosis in vivo. 
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Chapter 6 – Determination of Ang II in fibroblast-
derived microvesicles and its role in 
cardiomyocyte hypertrophy 
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6.1 Introduction 
In the last decades, the actions of cellular microvesicles (MVs), fragments of the 
plasma membrane shed by cells, in cellular communication has been reported as 
a novel method of intracellular communication within any living organism 
(Ibrahim and Marbán, 2015). The presence of MVs in blood has been known since 
1946 when Chargaff & West (1946) explored a thromboplastic lipoprotein that 
sedimented at high centrifugal forces while remaining in solution at low spinning 
speeds (Chargaff F and West, 1946). Wolf (1967) was the first to isolate these 
particles and image them using electron microscopy (Wolf, 1967). The term 
exosomes was first used by Johnstone et al. (1987) to describe the MVs derived 
from reticulocytes during their maturation to erythrocytes in vivo and in vitro 
(Johnstone et al., 1987). The characteristics of these vesicles were similar to the 
cell membrane of the reticulocytes they derived from and were enriched in 
acetylcholinesterase and transferrin which was lost during erythrocyte 
maturation (Johnstone et al., 1987). While it was then thought that the 
secretion of MVs was part of the cells waste management, the use of proteomics 
and genomics identified MVs as major carriers of DNA, RNA and proteins 
revealing MVs as a major pathway for intracellular communication (Waldenström 
et al., 2012, Pisitkun et al., 2004). The production of MVs has been confirmed 
for eukaryotes ranging from amoebas, plants to animals and humans and it is 
now accepted that MVs function as autocrine, paracrine and endocrine signalling 
systems to convey cell specific messages within an organism (Ibrahim and 
Marbán, 2015). A single cell releases a variety of different vesicles that overlap 
in their size distribution, membrane profile and function (Heijnen et al., 1999). 
These include apoptotic bodies (1–5 μm), MVs (100–1000 nm) and exosomes (20–
150 nm). The role of apoptotic bodies is purely the removal of damaged cells 
whereas MVs and exosomes have both been shown to participate in cellular 
communication (Sluijter et al., 2014). MVs are derived from shedding of the 
plasma membrane and closely reflect the plasma membrane of the cell of origin 
and may be enriched in cell lineage markers as well as MMPs (Lee et al., 2011) 
(Figure 6-1). In contrast, exosomes are derived via the endosomal pathway and 
the formation of multivesicular bodies (MVB) and have been found to be 
enriched in tetraspanins CD63, CD9 and CD81 all of which are involved in 
intracellular MVB formation. However, because these markers are not mutually 
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exclusive over the MV populations (Ibrahim and Marbán, 2015), MVs and 
exosomes are largely discriminated by their intracellular origin and so far it has 
been difficult to attribute the mechanistic effects to either vesicle population as 
current isolation protocols are unable to distinguish between the two 
populations. 
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Figure 6-1. Biosynthesis of exosomes and microvesicles.  
Exosomes in the extracellular space and membrane proteins are endocytosed into endosomes 
(left). Intraluminal vesicles bud of the endosomal membrane, incorporating ubiquitinated proteins 
as well as other membrane and cytoplasmic components to form multivesicular bodies (MVB). 
MVBs eventually fuse with the plasma membrane to release exosomes into the extracellular space. 
Alternatively, endosomes can fuse with lysosomes for degradation. Microvesicles (MV) are 
released by budding of the plasma membrane (right). This involves the clustering of the molecular 
cargo at the plasma membrane and subsequent maturation and budding of the MV. For re-uptake, 
MVs may then fuse with the plasma membrane of the cells, incorporating into the membrane and 
release its content into the cytoplasm (bottom right). Alternatively, MVs can be taken up by 
endocytosis into endosomes. Apoptotic bodies are released from cells undergoing apoptosis and 
contain intracellular organelles which are subsequently removed by macrophages. Schematic 
adapted from Cocucci and Meldolesi (2015). 
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6.1.1 Microvesicle Biosynthesis 
Exosomes 
Exosomes are MVs that are derived via the endosomal pathway involving the 
formation of MVB that fuse with the cell membrane (Figure 6-1). In the first step 
of exosome formation, the molecular cargo laterally segregates along the 
delimiting membrane of the endosome which then invaginates and pinches off 
releasing the vesicle into the endosome, creating MVBs (Raposo and Stoorvogel, 
2013). The machinery involved in the formation of MVBs comprises the family of 
endosomal sorting complex responsible for transport (ESCRT) proteins 0–III 
(Wollert and Hurley, 2010). ESCRT complex 0 recognizes ubiquitinated proteins 
marked for lysosomal degradation and sequesters them to the delimiting 
membrane on the endosome. ESCRT complexes I and II then induce the budding 
of the membrane while the ESCRT complex III mediates the fission of the 
endosomal membrane into the endosome (Wollert and Hurley, 2010). Although 
the ESCRT complex has been shown to be involved in the generation of 
exosomes, cells with silenced ESCRT complexes are still able to form MVBs, 
secrete exosomes and load non-ubiquitinated proteins suggesting ESCRT 
independent mechanisms of MVB and exosome formation (Colombo et al., 2013, 
Stuffers et al., 2009). In this aspect, sphingomyelinase was shown to be involved 
in the formation of exosomes in oligodendroglial cells and this corresponds with 
the high content of ceramide in exosomes (Trajkovic et al., 2008). Following 
MVB formation, endosomes are either destined for degradation in the lysosomal 
pathway or fusion with the cell membrane and evidence suggests that this is in 
part governed by the composition of MVBs. In line with this, intraluminal vesicles 
of MVB that were secreted as exosomes were found to be rich in cholesterol 
while vesicles associated with lysosomes were cholesterol-poor (Möbius et al., 
2002). Fusion of MVBs requires exocytosis, however, the machinery involved in 
the fusion of MVB with the plasma membrane is only starting to be uncovered 
and a role for the small GTPases Rab11, Rab27 and Rab35 as well as the classic 
tSNARE–vSNARE system employed in the release of synaptic vesicles has been 
suggested (Cocucci and Meldolesi, 2015). Exosome release usually occurs several 
minutes after stimulation and this is in line with the requirement of exocytosis 
of MVBs to release vesicles into the extracellular space (Qu et al., 2009).  
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Microvesicles 
MVs other than exosomes do not require exocytosis but rather are thought to 
originate from the regulated outward budding of the plasma membrane. Release 
of MVs can occur instantly following stimulation (Baroni et al., 2007, Pizzirani et 
al., 2007); however, the mechanisms involved in the formation of MVs are 
largely unknown. Recently it has been shown that post-translational 
modifications such as palmitoylation and myristoylation as well as binding sites 
for PIP2 and PIP3 are sufficient to anchor cytoplasmic proteins to the plasma 
membrane and lead to their incorporation in MVs (Shen et al., 2011). While it 
has been shown that activation of PKC and increases in intracellular Ca2+ can 
induce and sustain the release of MVs (Pizzirani et al., 2007, Stratton et al., 
2015), the ESCRT complex has also recently been shown to be involved in the 
loading of proteins into MV and the budding off the plasma membrane (Nabhan 
et al., 2012) suggesting that despite their different spatial origins, the 
biogenesis of MVs and exosomes share common pathways. Interestingly, in 
contrast to the release of exosomes, vesicle shedding in erythrocytes was shown 
to be facilitated by depletion of cholesterol (Gonzalez et al., 2009). 
MVs and exosomes released into the extracellular space can act either as an 
autocrine or paracrine signal to the surrounding cells within the tissue or enter 
the blood stream, lymph or cerebrospinal fluid to navigate to target tissue in an 
endocrine fashion (Caby et al., 2005, Luketic et al., 2007). MVs do not arbitrarily 
bind with any cell but show target selectivity. For example, MHCII-positive B-cell 
derived exosomes show a high specificity for the MHCII negative follicular 
dendritic cells and bind only weakly to macrophages and plasma cells (Denzer et 
al., 2000). Similarly, exosomes derived from a luciferase reporter expressing 
B16BL6 melanoma cell line were shown to preferentially bind to hepatic and 
splenic macrophages and pulmonary endothelial cells when administered in vivo 
(Imai et al., 2015). Similar to the binding of immune cells to activated 
endothelial cells, MVs initially roll over the cell surface before attaching to the 
plasma membrane by cell surface receptors (Tian et al., 2013b). The MVs can 
then either directly fuse with the plasma membrane to release their contents 
into the cytoplasm or be taken up by a form of endocytosis, including clathrin 
mediated endocytosis and phagocytosis (Tian et al., 2013b, Denzer et al., 2000, 
Montecalvo et al., 2012). In other cases, MVs may not be internalised and 
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instead activate intracellular signalling pathways on their binding to the plasma 
membrane (Vicencio et al., 2015, Lyu et al., 2015) while other MVs can break 
upon their release thereby liberating their contents into the extracellular space 
which is then free to interact with receptors on nearby cells (Cocucci and 
Meldolesi, 2015, Pizzirani et al., 2007).  
6.1.2 Microvesicles in cardiovascular disease 
The concept that exosomes participate in the propagation of disease has 
developed in recent years in particular with the identification of the crucial role 
of exosomes and MVs in cancer progression and metastasis. CVD is commonly 
associated with cardiac remodelling including cardiac hypertrophy and fibrosis 
and increasing evidence suggests a role of exosomes/MVs in mediating 
pathological signalling in the heart, giving them the name pathosomes (Ibrahim 
and Marbán, 2015). Cardiomyocytes have previously been shown to secrete MVs 
(cardiosomes) that contain DNA and RNA and modulate the transcriptome of the 
recipient cells (Waldenström et al., 2012, Gennebäck et al., 2013). 
Cardiomyocytes exposed to hypoxia as it occurs during myocardial ischaemia 
double their secretion of MVs and exosomes within 2 h of hypoxia (Gupta and 
Knowlton, 2007). The released vesicles are enriched in the molecular chaperone 
heat shock protein (Hsp) 60 which applied extracellularly has been associated 
with the activation of toll like receptor 4 (Tlr4) and concomitant production of 
TNFα and inflammatory cytokines contributing to cardiomyocyte dysfunction and 
death (Tian et al., 2013a). In contrast, plasma derived exosomes rich in Hsp70 
were shown to protect the rat myocardium against ischaemia-reperfusion injury 
by activation of Tlr4 and the cardioprotective Hsp27 (Vicencio et al., 2015) 
highlighting that the source of MVs strongly affects the signals they elicit in their 
target cells. Cardiac fibroblasts have previously been shown to mediate 
cardiomyocyte hypertrophy by soluble mediators (Cartledge et al., 2015). 
Recently, two independent groups have presented evidence that exosomes/MVs 
play a role in transfer of pro-hypertrophic messages from fibroblast to 
cardiomyocytes. Bang et al. (2014) showed that fibroblast derived exosomes 
were enriched in miR-21* and transfer of miR-21* to cardiomyocytes induced 
cardiomyocyte hypertrophy via the silencing of Sorbin And SH3 Domain 
Containing 2 (SORBS2) and PDZ And LIM Domain 5 (PDLIM5) in cardiomyocytes 
(Bang et al., 2014). In particular, miR-21* was further increased in the exosomes 
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from fibroblasts stimulated with Ang II and in the exosomes derived from the 
pericardial fluid of animals following TAC suggesting a role in disease 
propagation (Bang et al., 2014). In an independent study, Lyu et al. (2015) also 
reported pro-hypertrophic actions of cardiac fibroblast-derived exosomes on 
isolated cardiomyocytes via the activation of the cardiomyocyte RAS (Lyu et al., 
2015). This was dependent on the activation of intracellular signalling pathways 
including ERK1/2, JNK and Akt by extracellular exosomes and was independent 
of the activation of cardiac fibroblasts by Ang II or TGFβ (Lyu et al., 2015). More 
recently, it has been demonstrated that following pressure overload, 
cardiomyocytes release exosomes enriched with functional AT1R and by targeting 
cardiomyocytes, skeletal muscle and resistance vessels can modulate vascular 
responses thereby potentially contributing to CVD development (Pironti et al., 
2015).  
6.2 Aims 
 Assess the release of MVs from cardiac fibroblasts and characterise the MV 
population. 
 Determine whether Ang II is present in fibroblast-derived MVs and MVs 
isolated from blood in animal models of hypertension and cardiac 
remodelling. 
 Assess the effects of fibroblast-derived MVs in cardiomyocyte 
hypertrophy.  
6.3 Results 
6.3.1 Microvesicle characterisation 
MVs were purified from conditioned media from untreated or Ang II-stimulated 
fibroblasts and characterised using NTA (Figure 6-2). Over a period of 48 h, a 90–
100 % confluent monolayer of NRCF cultured in a 150 cm2 flask released 
approximately 108–1010 MVs with a modal particle size between 100–200 nm 
(Figure 6-2 A-B). There was no difference in the number of MVs secreted by 
control or Ang II-stimulated fibroblasts [MV no. (x108): Control 7.46 ± 0.48 vs. 
Ang II 9.33 ± 0.78, n= 3, p>0.05] (Figure 6-2 C).  
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Figure 6-2. NRCF secrete microvesicles.  
(A) Example image of microvesicles captured by nanoparticle tracking analysis (NTA). (B) 
Representative graph of microvesicle size distribution measured by NTA. (C) Representative graph 
of the mean number of MVs purified from a confluent monolayer of NRCF in a 150 cm2 tissue 
culture flask. n= 3. Data are presented as mean ± SEM.  
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6.3.2 Angiotensin II in microvesicles 
Since it has previously been shown that exosomes can contain ACE and ACE2 
(Gonzales et al., 2009, Pisitkun et al., 2004), next, it was assessed whether MVs 
released from fibroblasts also contained Ang II. For this, MVs were purified from 
control NRCF or NRCF stimulated with 1 μM Ang II for 48 h. Conditioned media 
was prepared in triplicate from NRCF at passage 2, 3 and 4. Purified MVs were 
sonicated and Ang II levels were determined in MVs and MV-depleted 
supernatant using the Angiotensin II EIA ELISA (Section 2.4.7.1, Figure 6-3).  
Ang II was present at low concentrations in the MV-depleted supernatant of 
control NRCF and this was significantly increased following the treatment of 
NRCF with 1 μM Ang II for 48 h (control 1.46 ± 0.51 pg/mL vs. Ang II 29.95 ± 
5.31 pg/mL, n= 9, p<0.05) (Figure 6-3 A). Ang II was also detected at low 
concentrations of 3.42 ± 0.85 pg/mL in MVs isolated from control NRCF. Ang II 
stimulation of NRCF increased Ang II content in MV to 7.81 ± 2.05 pg/mL (p= 
0.06) (Figure 6-3 A). 
To further confirm the presence of Ang II in MVs, DiI-labelled NRCF were treated 
with FAM-labelled Ang II and the purified MVs were tracked on H9c2 cells which 
are a rat cardiomyoblast cell line, by confocal imaging (Figure 6-3 C). After 
30 min, MVs had settled onto the H9c2 cells and were bound to the cell 
membrane. DiI signal could be detected in H9c2 cardiomyocytes treated with 
MVs from unstimulated NRCF. In contrast, in H9c2 cardiomyocytes treated with 
MVs from FAM-Ang II stimulated NRCF, the red DiI signal co-localised with green 
FAM-Ang II signal (Figure 6-3 C). This was confirmed by a corresponding 
significant increase in the co-localisation coefficients Pearson’s R, Mander’s M1 
and M2 (Table 6-1) and confirms packaging of exogenous Ang II into MVs by 
cardiac fibroblasts. 
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Figure 6-3. Ang II is located in microvesicles 
Microvesicles were purified from conditioned medium of untreated or Ang II-stimulated neonatal rat 
cardiac fibroblasts (NRCF). Ang II concentration was measured in (A) microvesicles and the 
microvesicle-depleted supernatant. A sample of predetermined Ang II concentration (15 pg/mL) 
was used as positive control. n= 9 for each group. *p<0.05 vs. control (Student’s t-test). (C) H9c2 
cardiomyocytes were incubated with microvesciles from DiI labelled unstimulated or FAM-Ang II-
stimulated NRCF for 30 min and microvesicles were imaged for DiI (red) and FAM-Ang II (green) 
using confocal microscopy. The inset represents the magnified area in the white square. 
Magnification: 40 x. Scale bar: 100 μm.  
Table 6-1. Co-localisation coefficients of FAM-Ang II in DiI-labelled microvesicles 
 
Pearson's coefficient R Mander's coefficient M1 Mander's coefficient M2 
 
MEAN SEM n p MEAN SEM n p MEAN SEM n p 
Control 0.028 0.014 6 
 
0.003 0.002 6 
 
0.084 0.063 6 
 
Ang II 0.348 0.045 8 <0.0001 0.203 0.038 8 0.0007 0.762 0.106 8 0.0003 
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6.3.3 Fibroblasts and cardiomyocyte communication by MVs 
It has previously been shown that fibroblasts and cardiomyocytes can exchange 
exosomes (Lyu et al., 2015, Bang et al., 2014). To verify MV exchange between 
NRCF and H9c2 cardiomyocytes, NRCF were labelled with DiI (Figure 6-4 A) and 
plated in the top chamber of a 0.4 μm transwell while H9c2 cardiomyocytes 
were plated in the bottom (Figure 6-4 B). DiI exchange was visualised by 
confocal microscopy in H9c2 cardiomyocytes after 48 and 96 h of co-culture 
(Figure 6-4 C) and supporting the assertion that MVs were transferred between 
NRCF and H9c2 cardiomyocytes.  
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Figure 6-4. Fibroblasts and cardiomyocytes communicate via microvesicles 
(A) Neonatal rat cardiac fibroblasts (NRCF) were labelled with Vybrant DiI for 30 min and plated on 
glass coverslips. DiI labelling of NRCF was examined by confocal microscopy after 48 h in culture. 
(B) DiI-labelled NRCF were plated in the top chamber of a 0.4 μm pore size transwell while H9c2 
cardiomyocytes were seeded in the bottom. Microvesicle exchange was allowed for 48–96 h prior 
to fixation of H9c2 cardiomyocytes. DiI transfer via NRCF-derived microvesicles was assessed by 
confocal microscopy (C). The inset represents the magnified area within the white square. DiI: red, 
DAPI: blue. Magnification: 40x. Scale bar: 100 μm.  
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6.3.4 Microvesicles in cardiomyocyte hypertrophy 
To assess whether the Ang II contained in the MVs is biologically active, H9c2 
cardiomyocytes were incubated with MVs derived from control and 1 µM Ang II-
stimulated NRCF for 96 h to induce cardiomyocyte hypertrophy. Cells were then 
stained with phalloidin to outline cell boundaries and their cross-sectional area 
measured. Stimulation with 100 nM Ang II served as a positive control (Figure 
6-5) 
MVs from 1 µM Ang II-stimulated NRCFs induced significant 64% (p<0.05) increase 
in H9c2 cardiomyocyte size compared to cells treated with MVs from 
unstimulated NRCFs (Figure 6-5 A-B). The increase in cross-sectional area was 
similar to hypertrophy achieved by direct stimulation with 100 nM Ang II (Control 
3575.45 ± 123.77 μm2 vs. AngII 6151.49 ± 281.35 μm2, n= 109-194, p<0.05). This 
confirms that the Ang II contained in MVs from Ang II-stimulated fibroblasts is 
biologically active and is as potent as direct stimulation with Ang II.  
To further verify that this response was not limited to H9c2 cardiomyocytes, 
primary NRCM were treated with MVs derived from unstimulated and 1 µM Ang II-
stimulated NRCF (Figure 6-5 C-D). MVs from Ang II-stimulated fibroblasts induced 
a 94 % (p<0.05) increase in NRCM cross-sectional area. Similarly, direct 
stimulation with Ang II induced a 51 % (p<0.05) increase in NRCM size (Figure 6-5 
D) confirming that the pro-hypertrophic effect of MVs derived from Ang II-
stimulated fibroblasts can be observed in cell line models and primary 
cardiomyocytes.  
Due to the different Ang II concentrations used for the stimulation of NRCF to 
generate MV-conditioned medium and H9c2 cardiomyocytes to induce cell 
hypertrophy, it was assessed whether stimulation of NRCF with 100 nM Ang II 
also led to loading of Ang II into MVs to transfer a pro-hypertrophic effect onto 
H9c2 cells (Figure 6-5 E-F). MVs from NRCF stimulated with 100 nM Ang II 
induced a 25 % increase in cell size (p<0.05) and this was significantly smaller 
than the 55 % increase in cell size observed with direct stimulation (p<0.05) 
(Figure 6-5 F). This suggests that loading of Ang II into MVs is dose-dependent.  
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Figure 6-5. Microvesicles induce cardiomyocyte hypertrophy. 
Microvesicles (MVs) were isolated from the conditioned medium of unstimulated and 1 µM Ang II-
stimulated neonatal rat cardiac fibroblasts (NRCF). H9c2 cardiomyocytes were either treated with 
100 nM Ang II or purified NRCF MVs for 96 h. Cells were then stained with (A) phalloidin and (B) 
cell area was determined (n= 109–194). (C-D) In a similar manner, NRCM were treated with MVs 
from control and Ang II-stimulated NRCF and cells size determined (n= 160–221). (E-F) MVs were 
purified from the conditioned medium of unstimulated or 100 nM Ang II-stimulated NRCF and H9c2 
cardiomyocyte size was determined (n= 110–167). Data are presented as mean ± SEM. 
Experiments were performed in triplicate and repeated on three independent occasions. Scale bar: 
100 μm. *p<0.05 (Student’s t-test). 
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6.3.5 Effects of Brefeldin A and Proteinase K 
To verify that the pro-hypertrophic effect of MVs from Ang II-stimulated 
fibroblasts is specific to the release of MVs and not a paracrine factor, MV 
release was inhibited by BFA. BFA is an inhibitor of the endosomal secretory 
pathway (Islam et al., 2007) but due to its global effect on cellular secretion, its 
application is limited by its effects on cell viability and only allows stimulation 
for a maximum of 24 h.  
BFA significantly reduced the number of MVs released from NRCF in a 24 h period 
by approximately 50 % (p<0.05) which were then incubated on H9c2 
cardiomyocytes (Figure 6-6 A). While it was confirmed that even after only 24 h 
stimulation with Ang II, MVs derived from Ang II-stimulated NRCF induced 
cardiomyocyte hypertrophy, treatment of NRCF with BFA abolished the pro-
hypertrophic effect of the purified MVs when added to cardiomyocytes (control 
3731.66 ± 106.78 μm2, Ang II 4993.07 ± 215.14 μm2, Ang II BFA 3811.01 ± 105.58 
μm2, n= 153-224, p<0.05) (Figure 6-6 B-C). 
Secondly, to verify that the pro-hypertrophic effect of NRCF-derived MVs was 
due to Ang II encapsulated in MVs and not a factor attached to the vesicular 
membrane, MVs were treated with Proteinase K (Figure 6-6 D-E). Proteinase K is 
a serine protease that can cleave proteins over a broad spectrum and allows the 
breakdown of proteins contained on the vesicular surface while leaving proteins 
contained in the vesicular lumen intact (Shelke et al., 2014, Gupta and 
Knowlton, 2007). Treatment of MVs with proteinase K did not alter their pro-
hypertrophic effect (control 2980.39 ± 86.01 μm2  vs. Ang II 4891.256.71 μm2, n= 
166-215, p<0.05) (Figure 6-6 D-E). This confirms that the effect of NRCF-derived 
MVs is specific to vesicular release and Ang II packaged within rather than 
attached to the outside of MVs.  
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Figure 6-6. Effects of BFA and Proteinase K on microvesicle-induced hypertrophy. 
Neonatal rat cardiac fibroblasts (NRCF) were stimulated with 1 μM Ang II in the presence or 
absence of 5 μg/mL BFA for 24 h and microvesicles (MVs) were purified from the conditioned 
medium. (A) MV concentration was quantified by nanoparticle tracking analysis (NTA) (n= 3 for 
each treatment). (B) Isolated MVs were incubated on H9c2 cardiomyocytes for 96 h and stained 
with phalloidin and (C) mean cell size was determined (n= 153–224). (D) Example images of 
phalloidin stain of H9c2 cardiomyocytes treated with 100 nM Ang II or MVs from 1 µM Ang II and 
unstimulated NRCF that were treated with 500 μg/mL Proteinase K at 37 ºC for 1 h. (E) Mean cell 
size of H9c2 cardiomyocytes treated with Proteinase K treated MVs (n= 136–219). Data are 
presented as mean ± SEM. Experiments were performed in triplicate and repeated on three 
independent occasions. Scale bar: 100 μm. *p<0.05 (Student’s t-test and ANOVA with Tukey’s 
post-hoc analysis). 
  
Chapter 6  278 
 
 
6.3.6 Role of angiotensin receptors  
Next, to assess whether the Ang II contained in MVs is mediating pro-
hypertrophic changes via the classical AT1R signalling pathway, the AT1R was 
blocked by the addition of losartan (Figure 6-7).  
Losartan fully blocked cardiomyocyte hypertrophy induced by direct application 
of 100 nM Ang II (p<0.05) (Figure 6-7), confirming an AT1R mediated effect. In a 
similar manner, Losartan prevented the increase in cell size induced by MVs from 
Ang II-stimulated NRCF (control 3490 ± 107.51 μm2, Ang II 6101.65 ± 297.64 μm2, 
Ang II+Losartan 3547.93 ± 112.23 μm2, n= 134–225, p<0.05) (Figure 6-7). This 
confirms that the Ang II contained in MVs is mediating cardiomyocyte 
hypertrophy in an AT1R dependent pathway similar to stimulation with free Ang 
II.  
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Figure 6-7. Effect of Losartan on microvesicle-induced hypertrophy.  
H9c2 cardiomyocytes were treated with 100 nM Ang II or microvesicles (MVs) of untreated or Ang 
II-stimulated neonatal rat cardiac fibroblasts (NRCF) in the presence or absence of 1 μM Losartan. 
(A) Example images of phalloidin stain in the different treatment groups. (B) Mean cell size 
quantified by phalloidin stain (n= 134–225). Data are presented as mean ± SEM. Experiments were 
performed in triplicate and repeated on three independent occasions. Scale bar: 100 μm. *p<0.05 
(ANOVA with Tukey’s post-hoc analysis).  
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Since it has previously been shown that fibroblast-derived exosomes can induce 
cardiomyocyte hypertrophy by transfer of miR-21* (Bang et al., 2014) and by 
activation of cardiomyocyte RAS (Lyu et al., 2015), gene expression of miR-21* 
and RAS components was assessed by qPCR in NRCF-derived MVs and H9c2 cells 
treated with MVs, respectively (Figure 6-8). Expression of miR-21* in NRCF and 
NRCF-derived exosomes was below the detection limit of the Taqman assay. 
Preliminary results show that H9c2 cardiomyocytes, express mRNA for AT1R, 
AT2R, Mas and ACE. Stimulation of cardiomyocytes with exogenous Ang II did not 
modify mRNA levels of the AT1R but treating cells with MVs irrespective of Ang II 
treatment tended to increase AT1R expression (RQ: Ang II 1.15 ± 0.43, control MV 
2.51 ± 0.45, Ang II MV 2.63 ± 3.56, p>0.05) (Figure 6-8 A). AT2R gene expression 
in H9c2 cells was significantly increased 4-fold by treatment with control MVs 
compared to untreated H9c2 cardiomyocytes (p<0.05) (Figure 6-8 B). There was 
no difference in AT2R expression between treatment with control or Ang II MVs 
(p>0.05). Expression of the Mas receptor was not changed (Figure 6-8 C). 
Similarly, ACE gene expression was unaffected by treatment with control MVs or 
Ang II MVs (Figure 6-8 D).  
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Figure 6-8. Gene expression of RAS components following MV treatment. 
H9c2 cardiomyocytes were treated with 100 nM Ang II or microvesicles (MVs) purified from 
unstimulated or Ang II-stimulated neonatal rat cardiac fibroblasts (NRCF) for 96 h. Gene 
expression of (A) Agtr1a , (B) Agtr2, (C) Mas and (D) ACE was assessed by qPCR, normalised to 
the housekeeper Ppib and expressed as relative quantity (RQ) compared to untreated control cells 
which was arbitrarily set as RQ= 1. Data are presented as RQ + rqmax. n= 4 individual biological 
repeats for each group. *p<0.05 (ANOVA with Tukey’s post-hoc analysis) 
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6.3.7 Angiotensin II in microvesicles isolated from blood 
Since Ang II was localised in MVs isolated from NRCF in culture, it was 
determined next whether Ang II is also present in circulating blood MVs from two 
animal models of hypertension, a murine model of Ang II infusion hypertension 
(Section 3) and the SHRSP (Doggrell and Brown, 1998) (Figure 6-9). MVs were 
isolated from the serum of control mice and mice infused with Ang II and the 
plasma of 21-week old WKY and SHRSP rats (at this age hypertension is fully 
developed). MVs were quantified using NTA and Ang II content was measured by 
ELISA.  
On average, there were 15.56 ± 3.95 x 107 MVs/μL serum in control mice (Figure 
6-9 A). This was unchanged by the infusion of either 24 or 48 μg/kg/hr Ang II 
(x107 MVs/μL: 24 μg/kg/hr Ang II 9.61 ± 2.45, 48 μg/kg/hr Ang II 15.96 ± 4.36, n= 
3-6, p>0.05) (Figure 6-9 A). Ang II was detected in the serum MVs from all 
treatment groups with an average of 0.36 ± 0.15 pg/mL per 109 MVs in control 
animals (Figure 6-9 B). This was unchanged by low dose Ang II infusion. However, 
the high dose of Ang II tended to increase Ang II content in MVs to 2.08 ± 1.50 
pg/mL/109 MVs, although this did not reach significance (Figure 6-9 B). 
Interestingly, Ang II concentration in the MV depleted serum was decreased by 
Ang II infusion (control 179.20 ± 8.20 pg/mL, 24 μg/kg/hr Ang II 71.55 ± 22.60 
pg/mL, 48 μg/kg/hr Ang II 93.33 ± 41.50 pg/mL, n= 3-6, p>0.05) (Figure 6-9 C).  
In the plasma of WKY rats there were on average 1.86 ± 0.36 x 108 MVs/μL 
plasma and this was not different in the SHRSP (2.96 ± 0.32 x 108 MV/μL, n= 3, 
p= 0.08) (Figure 6-9 D). Ang II was present in the plasma MVs from both, WKY 
and SHRSP rats and levels were unchanged by the development of hypertension 
in SHRSP (pg/mL/1010 MVs: WKY 15.86 ± 4.59 vs. SHRSP 10.32 ± 2.88 , n= 3, 
p>0.05] (Figure 6-9 E). 
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Figure 6-9. Ang II is located in blood MVs. 
(A) MVs were isolated from serum of mice infused with either H2O (control, n= 6), 24 μg/kg/hr Ang 
II (24 μg Ang II, n= 3) or 48 μg/kg/hr Ang II (48 μg Ang II, n= 6), quantified using nanoparticle 
tracking analysis and expressed as MVs/μL serum. (B) Ang II was measured in serum MVs and 
Ang II content per 109 MVs was determined. (C) Ang II concentration was measured in the MV 
depleted serum of Ang II infused mice. (D) MVs were isolated from the plasma of 21-week old 
WKY (n= 3) and SHRSP (n= 3) rats, quantified by NTA and expressed as MVs/μL. (E) Ang II was 
measured in the plasma MVs of WKY and SHRSP rats and expressed as Ang II per 1010 MVs. 
WKY and SHRSP serum was provided by Dr Delyth Graham. Data are presented as mean ± SEM.  
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6.4 Discussion 
Here it was shown that fibroblasts secrete MVs and when stimulated with Ang II, 
Ang II localises to MVs and could be detected fluorescently and by ELISA. MVs 
derived from Ang II-stimulated fibroblasts stimulated cardiomyocyte hypertrophy 
in the H9c2 cardiomyoblast cell line which was prevented by the AT1R specific 
antagonist Losartan. Inhibition of exosome biosynthesis with BFA and treatment 
with proteinase K confirmed that the pro-hypertrophic effect of MVs derived 
from Ang II-stimulated NRCF was specific to Ang II located in MVs. Additionally, 
Ang II was found to be present in MVs circulating in the serum and plasma of 
healthy mice and rats and Ang II content may increase with the development of 
hypertension in Ang II-infused mice.  
Components of the RAS have previously been shown contained in exosomes. In a 
large scale proteomic analysis of urinary exosomes ACE and ACE2 were shown to 
be contained in the vesicles shed by the renal tubules and urinary tract 
(Gonzales et al., 2009, Pisitkun et al., 2004) and more recently, it was shown 
that cardiomyocytes release exosomes enriched with AT1R during pressure 
overload (Pironti et al., 2015). However, so far the presence of angiotensin 
peptides has not been explored and these results presented here demonstrate 
the presence of Ang II in MVs. Lyu et al. (2015) recently showed that cardiac 
fibroblast-derived exosomes can activate the cardiomyocyte RAS and thereby 
mediate a pro-hypertrophic effect (Lyu et al., 2015). However, they did not 
detect Ang II in fibroblast-derived exosomes after Ang II stimulation, in direct 
contrast to the results presented here. However, previously only the exosome 
population of fibroblast-derived MVs was investigated (Lyu et al., 2015) while 
here a fibroblast-derived MV population with a particle size between 100–200 nm 
was investigated which does not fit exosome criteria. This data may therefore 
suggest that Ang II is preferentially packaged into vesicles other than exosomes. 
This is indirectly supported by observations of MV secretion in platelets which 
differentially increase secretion of exosomes or MVs in a stimulus-dependent 
manner and when comparing exosome and MV content, it was observed that they 
only have 13 of the 267 detected proteins in common (Aatonen et al., 2014). 
Additionally, experimental differences may account for the observations. For 
example, here it was shown that Ang II in MVs is present at low levels and ranges 
between 1–20 pg/mL out with the detection range of the ELISA employed 
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previously (Lyu et al., 2015). Furthermore, fibroblasts were stimulated in the 
presence of serum and it was previously demonstrated that the presence of 
serum influence MV release and vesicular cargo (Li et al., 2015).  
The serum and plasma levels of circulating free Ang II are estimated to range 
between 5–15 pg/mL and 60–200 pg/mL in healthy human subjects and rodents, 
respectively even though levels as high as 1000 pg/mL have been reported (Roig 
et al., 2000, Cervenka et al., 1999, dos Santos et al., 2014, Zou et al., 2014, 
Yang et al., 2012). Levels of Ang II determined here in MV-depleted serum from 
control mice fits within the range of reported values. The finding that Ang II 
circulates in MVs from serum and plasma may have important implications in 
disease development where circulating levels of Ang II are increased as shown 
here in the Ang II-infusion model. As shown here with proteinase K treatment, 
the vesicular cargo and therefore Ang II is protected against the degradation by 
peptidases and protease. While the half-life of free Ang II in the circulation is 
estimated to be approximately 30 s (van Kats et al., 1997), packaging of Ang II 
into MVs may increase its half-life by protecting it from cleavage by ACE, ACE2 
and other peptidases. Previously, MVs in lymph nodes have been shown to be 
stable for at least 3 days in vivo (Luketic et al., 2007) and in isolated plasma, 
MVs remained intact for up to 30 days at physiological temperatures (Kalra et 
al., 2013). This will be important to assess further in future studies to determine 
the pharmacological impact of packaging Ang II into MVs. 
The mechanism by which Ang II is loaded into MVs still remains unclear. On 
binding of Ang II to the AT1R or AT2R, the AT1R is subsequently internalised and 
recycled in a β-arrestin dependent manner while the AT2R remains at the plasma 
membrane (Hein et al., 1997, Anborgh et al., 2000). Recently, Pironti et al. 
(2015) showed that this pathway is involved in the enrichment of exosomes with 
AT1R during osmotic stress and pressure overload in cardiomyocytes suggesting 
that this pathway may also play a role of Ang II loading into MVs (Pironti et al., 
2015). Using fluorescently-labelled Ang II, the recycling of the Ang II–AT1R 
complex has been visualised in HEK293 cells revealing that the complex was 
trafficked into early endosomes as well as recycling endosomes which is 
dependent on the activation of PI 3-kinase (Hunyady et al., 2002, Hein et al., 
1997). Inhibition of PI 3-kinase by wortmannin induced the formation of large 
MVB-like vesicles that contained the AT1R and Ang II in small internal vesicles 
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(Hunyady et al., 2002) providing a functional link between receptor recycling 
and MV formation. It has been demonstrated that the AT1R but not the AT2R is 
involved in the plasma clearance of Ang II and thereby contributes to the 
increase in intrarenal Ang II levels which can be prevented by AT1R blockers 
highlighting that Ang II must be accumulated intracellularly (Zou et al., 1996, 
Zou et al., 1998). In support of this, a study by Wang et al. (1995) has previously 
shown that bovine medullary adrenal cells internalise exogenous Ang II by 
receptor mediated endocytosis and process it via the endosomal pathway prior 
to its renewed secretion in its intact form or as biologically active Ang II 
fragments (Wang et al., 1995). Indeed, renal endosomes were shown to contain 
Ang II as well as Ang II receptors and ACE and renal endosomal Ang II was 
increased in rats fed on a high salt diet or receiving Ang II infusion (Imig et al., 
1999, Zhuo et al., 2002) providing a potential link between the loading of Ang II 
into MV and the increases in serum MV Ang II levels seen during high dose Ang II 
infusion. 
Whilst it was previously shown that stimulation of cardiac fibroblasts with Ang II 
leads to the enrichment of miR-21* in exosomes to mediate cardiomyocyte 
hypertrophy (Bang et al., 2014), here miR-21* could not be detected in MVs 
derived from Ang II-stimulated fibroblasts. In contrast, recently Lyu et al. (2015) 
showed that MVs from unstimulated cardiac fibroblasts mediated cardiomyocyte 
hypertrophy by activating the cardiomyocyte RAS and increase the autocrine 
secretion of Ang II in cardiomyocytes (Lyu et al., 2015). In this setting, 
stimulation with Ang II did not modulate the pro-hypertrophic effect and is in 
contrast to the results here where MVs from unstimulated fibroblasts did not 
affect cardiomyocyte cell size. While activation of the cardiomyocyte RAS has 
not been fully investigated here, a similar increase in the mRNA for the AT1R and 
AT2R was detected in H9c2 cells treated with MVs from cardiac fibroblasts 
irrespective of Ang II treatment. This receptor upregulation did not translate 
into a pro-hypertrophic effect with control MVs and was also not induced by 
stimulation with exogenous Ang II. This is in line with the observation that Ang II 
stimulation, either exogenously or via MVs, tended to decrease ACE mRNA. It is 
therefore plausible that the increase in AT1R and AT2R gene expression may be a 
result of the exosomal transfer of AT1R and AT2R as previously demonstrated 
(Pironti et al., 2015). Nevertheless, these results demonstrate that induction of 
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cardiomyocyte hypertrophy by fibroblast-derived MVs is likely to be due to a 
multitude of factors and pathways that converge on the hypertrophic signalling 
pathways within cardiomyocytes.  
Here, it was demonstrated that AngII packaged into fibroblast-derived MVs 
mediates cardiomyocyte hypertrophy in an AT1R dependent manner. However, 
given results previously discussed, the location of these AT1R remains elusive and 
there are several possibilities. MVs can either adhere to the cell membrane 
inducing outside-in signalling extracellularly or they can fuse with the plasma 
membrane releasing their cargo into the recipient cells or get internalised by 
endocytosis (Cocucci and Meldolesi, 2015). Additionally, some vesicles may 
break and release their contents into the extracellular space thereby freeing up 
Ang II to bind extracellular AT1R (Cocucci and Meldolesi, 2015). An intracellular 
action of Ang II is supported by the observation that the AT1R can be localised 
intracellularly in endosomes as part of its recycling process as well as in the 
nucleus and other yet unidentified cellular compartments (Li and Zhuo, 2008, 
Brailoiu et al., 1999, Hein et al., 1997). By binding to its receptors, intracellular 
Ang II has previously been shown to induce TGFβ1 and MCP1 gene expression by 
binding nuclear AT1R (Li and Zhuo, 2008) and to mediate VSMC contraction by 
mediating Ca2+ influx (Brailoiu et al., 1999). However, intracellular Ang II also 
demonstrated AT1R-independent effects including the mobilisation of 
intracellular Ca2+ and the stimulation of cell growth as well as cardiomyocyte 
hypertrophy (Baker et al., 2004, Baker and Kumar, 2006, Zhuo et al., 2006). 
Although Losartan has been demonstrated to be taken up and transported by 
epithelial cells, in cardiomyocytes extracellularly applied losartan failed to cross 
the cell membrane to inhibit intracellular Ang II signalling (Soldner et al., 2000, 
De Mello, 1998). It is therefore unlikely that Ang II contained in MVs is released 
into the cytosol to mediate intracellular effects. While Pironti et al. (2015) have 
demonstrated that the AT1R is enriched in exosomes (Pironti et al., 2015), the 
presence of Ang II regulated signalling molecules such as PLA2, phospholipase D, 
Akt and PKC-α in MVs has also been confirmed (Subra et al., 2010, Nazarewicz et 
al., 2011). This raises the possibility that instead of the transfer of single 
molecules and peptides by MVs, MVs have the potential to transfer an entire 
“signalosome” to its recipient cells to modulate cell behaviour.  
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6.5 Summary 
In summary, this study has shown that cardiomyocytes and cardiac fibroblasts 
can communicate via MVs and that cardiac fibroblasts stimulated with Ang II load 
Ang II into MVs. MVs loaded with Ang II mediated cardiomyocyte hypertrophy in a 
similar manner to exogenous Ang II which was dependent on binding to the AT1R 
(Figure 6-10). Treatment with Brefeldin A and Proteinase K to inhibit MV release 
and digest membrane associated proteins, respectively, confirmed that the 
hypertrophic response was specific to Ang II loaded into MVs and therefore 
represents a novel pathway for cardiac fibroblasts to alter cardiomyocyte 
behaviour during cardiac disease. Moreover, Ang II was found to be present in 
circulating MVs from the serum and plasma of different animal models of HHD. 
Overall, these results demonstrate the presence of Ang II in MVs derived from 
isolated cardiac fibroblasts in vitro and serum and plasma in vivo which has 
important implications for our understanding of the RAS in cell–to-cell 
communication in health and disease. 
  
Chapter 6  289 
 
 
 
Figure 6-10. Schematic of fibroblast-derived MV-induced cardiomyocyte hypertrophy. 
Stimulation cardiac fibroblasts with Ang II leads to the internalisation of Ang II, potentially via the 
AT1R. Ang II is subsequently loaded into MVs via a yet unidentified pathway and secreted back into 
the extracellular fluid where the fibroblast-derived MVs interact with cardiomyocytes. Ang II 
contained in MVs interacts with AT1R of yet unknown location to initiate cardiomyocyte growth.  
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7.1 Overall summary 
Activation of the RAS plays a key role in the development of hypertension and its 
associated adverse cardiac remodelling during HHD which eventually results in 
HF (Brooks et al., 2010, Berk et al., 2007). Understanding the underlying 
molecular mechanisms in Ang II-mediated structural remodelling in the heart is 
essential for the development of novel therapeutics targeting adverse cardiac 
remodelling. Activation of the counter-regulatory RAS has emerged as a 
potential novel therapeutic objective to treat adverse cardiac remodelling and 
maintain cardiac function in CVDs (McKinney et al., 2014). The primary aim of 
this thesis was to investigate the potential therapeutic effects of the counter-
regulatory peptide Ang-(1-9) in reversing chronic Ang II-induced cardiac 
remodelling and contractile dysfunction. Additionally, this thesis aimed to 
elucidate whether Ang II-induced cardiac remodelling involves the process of 
EndMT and cell-to-cell communication via MVs.  
Initially, a mouse model of chronic Ang II infusion was characterised for 
structural and functional changes by infusion of either a low or high dose of Ang 
II for 6 weeks. Echocardiographic analysis revealed that low dose Ang II infusion 
resulted in a gradual decline in cardiac contractile function with dysfunction 
being evident after 4 weeks of infusion. In contrast, high dose Ang II infusion 
resulted in acute cardiac contractile dysfunction as early as 2 weeks after 
treatment. Cardiac hypertrophy and fibrosis were evident in the hearts of Ang II-
infused mice which was not significantly different between either concentration. 
Gene expression analysis revealed no changes in components of the RAS but 
infusion of a high dose of Ang II exacerbated the expression of pro-fibrotic and 
pro-hypertrophic markers. The structural and functional changes occurring 
during chronic low dose infusion of Ang II closely mimic the development of 
hypertension in humans (Simon et al., 1995) while high dose infusion provides an 
ideal model to study acute cardiac dysfunction. The Ang II-infusion model is 
therefore an ideal model to study the therapeutic potential of Ang-(1-9) in 
reversing Ang II-induced cardiac disease.  
Next, the cardiovascular actions of Ang-(1-9) infusion in healthy normotensive 
mice were assessed. Ang-(1-9) infusion for 6 weeks did not significantly alter 
cardiac function and had no effect on cardiac remodelling processes. In the next 
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study, cardiac dysfunction and remodelling was induced by minipump infusion of 
a high dose of Ang II for 2 weeks before minipumps were replaced and Ang-(1-9) 
was co-infused with Ang II for a further 2-4 weeks. Ang-(1-9) did not significantly 
modulate Ang II-induced increases in BP. However, the addition of Ang-(1-9) 
significantly improved cardiac FS after 2 weeks of infusion before a further 
decline after 4 weeks. The recovery of FS by Ang-(1-9) after 2 weeks was 
independent of an effect on Ang II-induced cardiac remodelling and similarly, no 
differences were found after 4 weeks suggesting that Ang-(1-9) mediates direct 
effects on cardiac contractile function.  
To investigate the transient effect observed for Ang-(1-9) on cardiac function in 
the in vivo reversal study, next its effects were assessed in the isolated 
Langendorff perfused rat heart in comparison to Ang II and Ang-(1-7). Perfusion 
of Ang-(1-9) in the isolated paced or spontaneously beating heart resulted in a 
significant increase in LVDP and dP/dtmax suggesting that Ang-(1-9) acts as a 
positive inotrope. In contrast, both Ang II and Ang-(1-7) had little to no effects 
on cardiac contractile function. The effects mediated by Ang-(1-9) were found 
to potentially be mediated by the activation of PKA but not CaMKII. Investigation 
into the receptor by which Ang-(1-9) mediates its effect was performed using 
the specific antagonists Losartan and PD123319 for the AT1R and AT2R, 
respectively. It was demonstrated that the effects of Ang-(1-9) were only 
partially mediated by the AT2R and could be fully abolished by AT1R blockade. 
This suggests a novel mechanism of Ang-(1-9) action and warrants further 
investigation.  
Next, novel pathways that may contribute to Ang II-induced cardiac remodelling 
were investigated. EndMT has emerged as an important mechanism in the 
development of cardiac fibrosis (Zeisberg et al., 2007b). The role of TGFβ1 in the 
induction of pathological EndMT is already well described (Yoshimatsu and 
Watabe, 2011). Here it was hypothesised that Ang II could contribute to 
microvascular rarefaction in vivo by the induction of EndMT. Microvascular 
density in the hearts of Ang II-infused mice was significantly reduced following 
the infusion of Ang II for 4-6 weeks. Furthermore, EndMT could be detected in 
the myocardium by significant co-localisation of endothelial and fibroblast 
markers via immunofluorescence (Murdoch et al., 2014). To further elucidate 
the role of Ang II, a cell culture model of EndMT using HCAEC was established. 
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Stimulation of HCAEC with Ang II alone only marginally altered mesenchymal 
gene expression, however, when cells were co-stimulated with Ang II and TGFβ1, 
it was found that Ang II significantly exacerbated TGFβ1-induced expression of 
mesenchymal markers. The activation of SMAD2/3 and ERK1/2 are key mediators 
of TGFβ-induced EndMT (Li et al., 2010, Cooley et al., 2014, Wylie-Sears et al., 
2014). To further elucidate a possible signalling pathway underlying the effect of 
Ang II, the acute activation of SMAD2/3 and ERK1/2 was assessed by Western 
immunoblot. AngII did not modulate TGFβ1-induced activation of either SMAD2/3 
or ERK1/2. Measurements of superoxide production however revealed that Ang II 
significantly increased superoxide production in HCAEC through activation of 
Nox1. Further studies are required to elucidate whether Nox1 contributes to the 
exacerbation of TGFβ1-induced EndMT by Ang II in vitro and in vivo.  
Extracellular vesicles have emerged as important paracrine mediators of cellular 
signalling and a role of MVs and exosomes has also been demonstrated in the 
cardiovascular system (Sluijter et al., 2014). Because components of the RAS 
have previously been demonstrated in MVs (Gonzales et al., 2009, Pisitkun et 
al., 2004, Pironti et al., 2015), a further study aimed to examine whether Ang II 
is present in fibroblast-derived MVs and their role in Ang II-induced 
cardiomyocyte hypertrophy. Measurements of Ang II concentration by ELISA 
revealed that fibroblast-derived MVs contain detectable amounts of Ang II which 
increased when fibroblasts were stimulated with Ang II suggesting that 
fibroblasts load exogenous Ang II into MVs. MVs from Ang II-stimulated fibroblasts 
were found to induce cardiomyocyte hypertrophy while control MVs from 
unstimulated fibroblasts had no effect. This pro-hypertrophic effect was 
maintained after proteinase K digestion of MVs to remove MV surface proteins 
but could be abolished by treatment of fibroblasts with BFA to inhibit endosomal 
trafficking. Identification of the receptor by which the fibroblast-derived MVs 
mediate their pro-hypertrophic effect was investigated using the ARB Losartan. 
It was found that Losartan fully blocked the pro-hypertrophic response to MVs 
from Ang II-stimulated fibroblasts. However the location of this receptor still 
needs to be determined. To further investigate the relevance of Ang II packaged 
into MVs, MVs were isolated from the serum and plasma of AngII-infused mice 
and SHRSP rats, respectively and Ang II content measured. Results demonstrate 
that MVs from control mice and WKY rats contain Ang II. Ang II content tended to 
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increase with Ang II infusion but was not significantly different in the SHRSP rat. 
The presence of Ang II in serum and plasma MVs correlates with the increased 
presence of ACE, ACE2 and the AT1R in MVs in CVD (Pironti et al., 2015, Pisitkun 
et al., 2004, Gonzales et al., 2009). However, the physiological and 
pharmacological importance of these observations needs to be established in 
future studies.  
7.2 Considerations and future perspectives 
This study is the first study to present evidence that the actions of Ang-(1-9) in 
cardiac pathology are dependent on its time of administration with it having no 
effect in normotensive healthy mice but beneficial when given to mice with 
established cardiac disease.  
Here it was shown that when administered to mice with established Ang II-
induced contractile dysfunction, Ang-(1-9) transiently improved cardiac 
contractile function by a direct effect on the heart. This was independent of an 
effect on cardiac remodelling and therefore suggests a direct effect of Ang-(1-9) 
on cardiac contractility. Transient improvement could be explained by a 
mismatch in cardiac energy demand/ nutrient supply. Thus, the increased 
cardiac energy demand due to the positive inotropic actions of Ang-(1-9) is not 
met by the significantly reduced myocardial capillary density while uncontrolled 
hypertension further favours adverse cardiac remodelling. It can therefore be 
hypothesised that if BP were controlled, Ang-(1-9) may mediate more favourable 
long-term effects on cardiac contractile function. This is demonstrated in 
another study which demonstrated the cardioprotective effects of Ang-(1-9) in a 
model of diabetic cardiomyopathy (Zheng et al., 2015). This model lacks a 
hypertensive phenotype and when Ang-(1-9) was administered over 4 weeks it 
improved cardiac contractile function and reduced adverse cardiac remodelling 
(Zheng et al., 2015). Therefore, it would be of interest to assess the functional 
effects of Ang-(1-9) in the Ang II-infusion model when BP is controlled with anti-
hypertensive therapy. This provides a more clinical setting as it is appreciated 
that most hypertensive patients would be receiving at least one anti-
hypertensive medication. Because both ARBs and ACE-I interfere with the RAS 
and therefore with AngI II and Ang-(1-9) metabolism, an alternative anti-
hypertensive such as a diuretic which has been shown to lower BP without an 
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effect on cardiac remodelling (Kim et al., 1995) would be the drug of choice to 
elucidate the direct effects of Ang-(1-9) on Ang II-induced cardiac dysfunction in 
the absence of hypertension.  
Another process that has been suggested to be a key event in the early stages of 
Ang II-induced cardiac remodelling is the occurrence of myocyte apoptosis which 
has been demonstrated to occur within 3 days of Ang II-infusion (Tan et al., 
1991, Campbell et al., 1995). Although this has not been assessed here per se, 
replacement fibrosis is clearly evident in Ang II infused mice after 4 and 6 
weeks. Although there is so far no evidence linking Ang-(1-9) to apoptosis or 
necrosis, a role for the AT2R has been clearly demonstrated in a variety of cell 
types, including cardiomyocytes, where activation of the AT2R counteracted Ang 
II mediated stimulation of growth pathways resulting in inactivation of Bcl-2 and 
subsequent apoptosis (Yamada et al., 1998b, Yamada et al., 1996, Horiuchi et 
al., 1997, Goldenberg et al., 2001). Hence, Ang-(1-9) may directly contribute to 
cardiac dysfunction by exacerbating cardiomyocyte apoptosis. This could be 
assessed by Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling 
(TUNEL) staining of cardiac sections to identify apoptotic cells (Goldenberg et 
al., 2001). However, cell necrosis is more difficult to determine because so far 
no distinct biochemical marker has been identified and cells may proceed from 
apoptosis into necrosis (Krysko et al., 2008). Thus, identification of cell necrosis 
requires a combination of morphological and biochemical techniques including 
light microscopy, electron microscopy and Western blotting. Because apoptotic 
and necrotic cell death with Ang II infusion has been demonstrated to peak at 3 
days before subsiding (Fiordaliso et al., 2000) these investigations should be 
carried out at early time points rather than at 4 and 6 weeks where cardiac 
remodelling is well established and cardiomyocyte apoptosis will be very low 
which may lead to a false negative result. Another important aspect to consider 
is that if Ang II induces the loss of cardiomyocytes and Ang-(1-9) prevents Ang II-
induced fibrosis (Flores-Munoz et al., 2012), this will result in impaired wound 
healing where the dead myocytes are not equally replaced by a collagenous scar 
therefore altering cardiac ultrastructure and predisposing the myocardium to 
myocyte slippage resulting in contractile and electrical dysfunction.  
The direct effect of Ang-(1-9) leading to improved contractile function was 
corroborated in the ex vivo Langendorff-perfused rat heart where Ang-(1-9) 
Chapter 7  296 
 
 
mediated positive inotropic effects. This was in contrast to Ang II and Ang-(1-7) 
which had little to no effect and therefore provide evidence that Ang-(1-9) 
elicits its positive inotropic actions independent of its breakdown to either Ang II 
or Ang-(1-7). It is noteworthy that ex vivo studies were performed in rat hearts 
whereas in vivo assessments of Ang-(1-9) were performed in mice. Although rats 
and mice share similar mechanisms of EC coupling and Ca2+ homeostasis that 
differ from rabbits and humans (Berk et al., 2007), it has been demonstrated 
that Ang II only mediates an increase in cardiac contractility in mice but not in 
rats (Masaki et al., 1998, Lefroy et al., 1996). Hence, despite similar molecular 
mechanisms, species differences may exist and it would therefore be of interest 
to corroborate the effects of Ang-(1-9) perfusion also in the ex vivo mouse heart. 
A previous study has already identified that Ang-(1-9) increases Ca2+ transient 
amplitude and fractional cell shortening in isolated mouse cardiomyocytes 
(Fattah et al., 2014) and this supports the hypothesis that Ang-(1-9) has direct 
positive inotropic actions in the mouse heart. Additionally, it would be of 
interest to investigate this finding in more detail in vivo by employing pressure-
volume (PV-loop) analysis. Using PV-loop analysis it has already been 
demonstrated that bolus infusion of Ang II leads to an acute increase in LV end 
systolic and end diastolic pressure and volume and an increase in dP/dtmax  
(Broomé et al., 2001, Cheng et al., 1996). However, the effects of chronic (>2 
weeks) Ang II infusion on PV-loop parameters are relatively unknown (Murdoch et 
al., 2014). PV-loop analysis would therefore provide invaluable information on 
the underlying pathophysiology of Ang II-induced contractile dysfunction 
(independent of pre-/afterload and how this is modulated by the infusion of Ang-
(1-9).  
The present study did not use receptor antagonists to determine the receptor by 
which Ang-(1-9) mediates its effect in vivo. However, previous evidence has 
demonstrated that Ang-(1-9) mediates its anti-hypertrophic, anti-fibrotic and 
more recently cardiac effects via the AT2R (Flores-Muñoz et al., 2011, Flores-
Munoz et al., 2012, Flores-Munoz et al., 2013, Zheng et al., 2015) and it can be 
assumed that in this study Ang-(1-9) mediates its effects via the AT2R. While this 
may hold true for the anti-remodelling effect of Ang-(1-9) which was not 
demonstrated here, the data presented here in the isolated rat heart suggests 
that Ang-(1-9) is mediating its cardiac actions via the AT1R. Although Ang-(1-9) 
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can bind the AT2R and the AT1R with equal affinities, this is the first report of 
Ang-(1-9) binding to the AT1R to mediate its biological actions. It would be of 
interest to confirm these observations in vivo and assess whether the recovery in 
cardiac contractile function by Ang-(1-9) is indeed mediated via the AT1R in 
vivo. This could be accomplished by the co-infusion of the receptor-specific 
antagonist Losartan and PD123319 for the AT1R and AT2R, respectively which 
have been employed successfully in previous studies (Flores-Munoz et al., 2012, 
Ocaranza et al., 2014, Zheng et al., 2015). However, concerns have been raised 
about the specificity of PD123319 and off-target effects have been reported for 
example in Ang II-induced abdominal aortic aneurysms where PD123319 
enhanced Ang II-induced aneurysm formation to a similar degree in wild type and 
AT2R-null mice (Daugherty et al., 2013). The AT2R-null mice would therefore 
provide an ideal tool to investigate the contribution of the AT2R in mediating the 
cardiac effects of Ang-(1-9). However, it has to be noted that AT2R-null mice 
have been shown to respond differently to Ang II infusion and are protected 
against Ang II-induced cardiac hypertrophy (Senbonmatsu et al., 2000, Ichihara 
et al., 2001) and therefore care must be taken when interpreting results.  
The identification that Losartan fully blocks the positive inotropic actions in the 
paced rat heart although Ang II itself has no direct cardiac actions allows the 
speculation that Ang-(1-9) acts as a biased agonist at the AT1R. Previously, it has 
been demonstrated that Ang-(1-9) mediates its beneficial effects on cardiac 
remodelling via the AT2R but not the AT1R (Flores-Muñoz et al., 2011, Flores-
Munoz et al., 2012) and the current results suggest a new tissue specific role for 
Ang-(1-9) in cardiomyocytes. Biased agonists at the AT1R have previously been 
demonstrated to mediate an increase in cardiac contractility by selectively 
engaging the β-arrestin-MAPK pathway strengthening the notion that Ang-(1-9) 
may activate β-arrestin signalling at the AT1R (Violin et al., 2010). Identification 
of Ang-(1-9) as a natural biased agonist at the AT1R would have important 
implications for its therapeutic potential as synthetic biased AT1R agonists are 
currently in development to harness the beneficial effects of AT1R signalling via 
β-arrestin pathways while blocking the detrimental effects of Ang II-mediated G 
protein activation (Violin et al., 2010, Kim et al., 2012, Boerrigter et al., 2011, 
Boerrigter et al., 2012). Such biased agonism could be investigated in, for 
example, Chinese hamster ovary cells (which do not intrinsically express the 
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AT1R) selectively expressing the AT1R stimulated with Ang-(1-9) and 
subsequently probing for the activation of ERK1/2, Ca2+ mobilisation as well as 
measuring [35S]GTPγS binding and β-arrestin recruitment to the AT1R (Wei et al., 
2003, Rajagopal et al., 2006). 
Using specific inhibitors, it was demonstrated that the positive inotropic effect 
induced by Ang-(1-9) in the isolated rat heart requires PKA but not CaMKII. 
However, phosphorylation of PKA was found to be unchanged in response to Ang-
(1-9) stimulation. PKA is a unique enzyme which is fully phosphorylated in vivo 
and in vitro and is mainly regulated by binding of cAMP (Moore et al., 2002). 
Hence PKA phosphorylation is not a prerequisite for PKA activation. It would be 
of interest to further confirm PKA activation via other experimental approaches. 
As such, commercial PKA activity assay kits are available employing a specific 
synthetic substrate for PKA the phosphorylated from of which can then be 
detected by a specific polyclonal antibody. One such PKA target is VASP which 
has been employed previously to probe for specific PKA activation (Dulin et al., 
2001). Alternatively, cAMP generation could be measured by ELISA to give an 
indirect measure of PKA activation. However, since neither the AT1R or AT2R 
have been linked to activation of the G protein Gs and instead it has been 
demonstrated that the AT1R can activate PKA via cAMP independent pathways 
(Dulin et al., 2001) it would not be unexpected if PKA activation occurs in the 
absence of cAMP generation when cardiomyocytes are stimulated with Ang-(1-9). 
Furthermore, it would be of interest to investigate the role of PKA in the 
positive inotropic effect in isolated cardiomyocytes. It has previously been 
demonstrated that Ang-(1-9) increases Ca2+ transient amplitude and fractional 
cell shortening via an increase in the L-type Ca2+ current (Fattah et al., 2014). 
Since the L-type Ca2+ channel is regulated by PKA phosphorylation (Bünemann et 
al., 1999, Kamp and Hell, 2000) it would be of interest to investigate whether 
PKA inhibition also abolishes this pathway in isolated cardiomyocytes stimulated 
with Ang-(1-9). Additionally, in this study, the phosphorylation of targets in the 
EC coupling machinery such as PLB, the L-type Ca2+ channel, RyR and SERCA 
were not investigated. Ang-(1-7) has previously been shown to stimulate PKA and 
enhance L-type Ca2+ currents in isolated cardiomyocytes while SERCA2A was 
found upregulated in transgenic mice with Ang-(1-7) overexpression in the heart 
(De Mello, 2015, Zhou et al., 2015, Ferreira et al., 2010). Phosphorylation of 
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these targets are the key mechanisms involved in the regulation of EC coupling 
on a beat-to-beat basis (Bers, 2002) and hence it would be important to 
investigate the phosphorylation and expression of these targets to better 
understand the molecular mechanisms by which Ang-(1-9) affects cardiomyocyte 
EC coupling and mediates positive inotropy.  
Here it was demonstrated that Ang II infusion led to a significant reduction in 
myocardial capillary density which correlates with the development of cardiac 
hypertrophy. It has previously been demonstrated that vascular growth is tightly 
coupled to myocardial growth (Brutsaert, 2003, Zhang and Shah, 2014). Thus, 
inhibition or stimulation of cardiac angiogenesis promoted the development of 
cardiac hypertrophy and cardiac contractile dysfunction (Giordano et al., 2001, 
Tirziu et al., 2010). This suggests that when there is dysregulation of the 
angiogenic program the result is cardiac hypertrophy. More importantly, it has 
been suggested that the transition from a compensated to a decompensated 
state is accompanied by a significant loss in myocardial capillaries (Izumiya et 
al., 2006, Shiojima et al., 2005). This correlates with the observations made in 
this study where the loss in myocardial capillary density at 4 weeks strongly 
correlated with cardiac hypertrophy at the stage of cardiac decompensation. 
Moreover, it has been demonstrated that ECs prevent cardiomyocyte 
dedifferentiation and re-expression of foetal markers such as βMHC and skeletal 
actin while endothelial ET-1 secretion mediates cardiomyocyte hypertrophy 
(Brutsaert, 2003, Adiarto et al., 2012) highlighting the importance of adequate 
endothelial-cardiomyocyte cross-talk which is lost in the progression of cardiac 
remodelling. Although evidence has shown that Ang II contributes to 
microvascular rarefaction during hypertensive cardiac remodelling the 
underlying mechanisms remain unclear (Sabri et al., 1998, Belabbas et al., 
2008). It has previously been suggested that Ang II reduces the proliferation of 
ECs and stimulates EC apoptosis (Graiani et al., 2005, Li et al., 1999). This was 
not investigated, however, Ang II induced EndMT in vivo and in vitro providing 
an alternative mechanism contributing to the loss in microvascular endothelium. 
Furthermore, this process contributes to the recruitment of activated cardiac 
fibroblasts in the heart participating in the extensive cardiac remodelling in 
response to Ang II infusion. In the pressure overloaded heart using endothelial-
lineage tracing mice, it was previously demonstrated that up to 30 % of 
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fibroblasts are sourced from EndMT (Zeisberg et al., 2007b). The total 
contribution of EndMT could not be quantified in the current study but it would 
be of interest to investigate Ang II-induced EndMT in endothelial lineage tracing 
mice to further delineate the contribution of EndMT to Ang II induced 
microvascular rarefaction and cardiac fibrosis.  
While stimulation of HCAEC with Ang II in vitro only partially induced EndMT, 
Ang II significantly exacerbated TGFβ1-induced EndMT. Although this process 
could be abolished by an inhibitor of the SMAD2/3 pathway, the pathway by 
which Ang II exacerbates TGFβ1-induced EndMT remains unknown. This study has 
demonstrated that Ang II selectively stimulates O2- production via the activation 
of Nox1 in HCAEC. To further investigate the link between Nox and EndMT it will 
be important to determine the direct involvement of Nox1 in Ang II-induced 
EndMT in vitro by employing the specific Nox1 inhibitors ML171 and GKT137831 
used in this study. Alternatively, to exclude potential off target effects of these 
inhibitors, siRNA against Nox1 may be used.  
MVs have emerged as important paracrine mediators of cell signals throughout 
the body and they have also gained much attention in the physiological and 
pathophysiological regulation of the cardiovascular system (Sluijter et al., 2014). 
Although members of the RAS have previously been demonstrated to be present 
in exosomes (Gonzales et al., 2009, Pisitkun et al., 2004) and that the RAS can 
modulate exosome secretion and vice versa (Lyu et al., 2015, Bang et al., 2014), 
this is the first report of the presence of Ang II in fibroblast-derived MVs which 
act as paracrine mediators to induce cardiomyocyte hypertrophy. Although the 
direct mechanism by which fibroblasts load Ang II was not investigated here, it 
has previously been demonstrated that cardiomyocyte-derived exosomes are 
enriched in AT1R during pressure overload in a β-arrestin dependent manner 
suggesting a role for the AT1R recycling pathway (Pironti et al., 2015). It would 
therefore be of interest to investigate whether loading of Ang II is dependent on 
binding to the AT1R and its subsequent internalisation and processing through 
the cellular endosomal pathway (Hein et al., 1997). This is supported by the 
observation that BFA treatment abolished the pro-hypertrophic effect of 
fibroblast-derived MV possibly by attenuating Ang II endosomal transport. If Ang 
II loading was dependent on the AT1R, then this should be inhibited by an AT1R 
antagonist such as Losartan. As such, an initial experiment should investigate 
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whether Ang II is loaded into fibroblast-derived MVs when they are stimulated 
with Ang II in the presence of Losartan. Further experiments could investigate 
the dependency on β-arrestin in this pathway by using siRNA to β-arrestin 1 and 
β-arrestin 2 (Wei et al., 2003). Since the experiments in this study have been 
performed in in vitro cell culture models it would be of interest to further 
evaluate the biological significance of Ang II in MVs. This could be assessed ex 
vivo by circulating Ang II-loaded MVs in the isolated Langendorff-perfused heart 
and measuring acute effects on cardiac contractile function (Vicencio et al., 
2015). It has to be noted however, that the rat heart would be unsuitable for the 
investigation due to the lack of a positive inotropic effect during Ang II infusion 
(Lefroy et al., 1996) and hence, the mouse heart would be a better suited 
model. Alternatively, this could also be assessed in vivo by measuring the acute 
BP response to a bolus injection of Ang II-loaded MVs. It would be of further 
interest to study the homing of these MVs in the circulation by injecting 
fluorescently labelled MVs (Luketic et al., 2007). This would not only help to 
identify whether these MVs preferentially accumulate in the heart but also to 
determine the approximate half-life of MVs in the circulation. 
7.3 Conclusion 
Overall, these studies demonstrate the potential therapeutic applications for 
Ang-(1-9) in the treatment of cardiac contractile dysfunction while highlighting 
the necessity to further elucidate Ang-(1-9) signalling in the heart. Furthermore, 
these studies provide insight into novel pathways contributing to Ang II-induced 
cardiac remodelling which may present a novel therapeutic target to treat 
adverse cardiac remodelling in hypertension. 
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